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Abstract
Building on Reynolds' and Gutman's (1988) assumption that is possible to
categorise consumers with respect to their values orientation, we argued
that it is possible to categorise Portuguese GPs according to their clinical
values. The exploratory phase of this research was therefore developed
in accordance with Means-End Chain Theory (Gutman, 1982) and the
related Laddering technique (Reynolds and Gutman, 1988). These tools
were useful in assessing Portuguese GPs' therapeutic cognitive structures.
Resulting hierarchical maps (which summarise the most frequently evoked
therapeutic means-end paths) were obtained with newly available software
(LadderMap) (Gengler and Reynolds, 1995). The results suggested that
Portuguese GPs' prescribing behaviour was based on different patient
typologies. These cognitive schemas were used to develop the patient
typology model (PTM). Subsequently, a self-administered questionnaire
was sent to 1,500 Portuguese GPs. Factor analysis and multiple logistic
regression were the statistical techniques chosen for the analysis of the 309
responses. This empirical phase of the research confirmed that the PTM
is a useful theoretical framework to categorise Portuguese GPs according
to the stepped-care approach and the liberal approach. The former uses
diuretics and P-blockers, while the latter prefers angiotensin-converting-
enzyme (ACE) inhibitors for the management of hypertension.
11
Declaration
I declare that no portion of the work referred to in
this thesis has been submitted in support of an
application for another degree or qualification of this
or any other university or institution of learning.
Reinaldo A. G. Proenca
III
Aknowledgments
I would like to acknowledge the contribution of several people to the
work contained in this thesis. Firstly, I would like to thank my tutor, Prof.
L. Moutinho for the effective guidance, advice and constructive criticism.
I am also very grateful to all members of the PhD Review Panel of the
University of Glasgow Business School for their helpful comments and
recommendations. Thanks are also due to Mrs. Andrea Douglas and Mrs.
Sylvia Kerrigan from the University of Glasgow Business School not
only for the provision of research facilities and administrative support,
but also, and, particularly, for their friendship. I want also to thank Doctor
Moira Fischbacher for her comments and time spent on the improvement
of the English of this thesis.
My gratitude also is due to the Portuguese Foundation of Science and
Tecnology for the sponsorship. My sincere thank is to the Portuguese
Health Authorities, particularly the North Health Region, Centre Health
Region and Lisbon and Tagus Valley Health Region, for their supports
and assistances during the data collection. I would also to thank all the
Portuguese GPs who were interviewed.
Finally, I am deeply grateful to my wife, Maria Jose, and my daughters
Cristina, Ines and Madalena, whose moral support, patience, and
encouragement have made it possible for me to submit this thesis.
iv
An important issue for both industry and academic consumer
researchers is the development of an understanding of how
consumers derive personally relevant meaning about products.
This meaning is the basis consumers use to shape their
decision criteria among competitive products and services.
Gengler and Reynolds, 1995.
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1 Chapter One Introduction
This Chapter begins with the scope of the thesis. The second part of the
chapter presents an overview of the thesis and the rationale for the two-
stage research approach undertaken. The Chapter concludes by
summarising the thesis structure.
1.1 Scope of the Thesis
Prescribing is one of the central medical fimctions of general practitioners
(Gilleghan, 1991) and it seems to have begun in 1542: "Prescribing has been at
the very core of general practice since an Act of 1542, the so-called "Quack's Charter",
permitted our forebears the apothecaries to supply simple herbal medicines to patients
legally" (Richards, 1996: Foreword). However, research into the prescribing
behaviour of general practitioners (GPs) dates from 1949 (Bradley, 1991). In
Portugal there is no academic research on GPs' prescribing behaviour,
The leading drugs prescribed by Portuguese GPs in early 1990's show how
trends and habits change because of the introduction of new effective drugs.
For example, the introduction of effective preparations for cardiac disorders,
particularly hypertension, caused "heart preparations" to go to the lead
(Infarmed1, 1996).
J In Portugal. the National Institute of Pharmacy and Medicines (INFARMED) is the Ministry of
Health's central structure that evaluates the entrance of medicinal and health products in the
reimbursement system. INFARMED follows up the evolution in the consumption patterns, spreading
information and promoting a rational use of medicinal products, aiming at a more rigorous
expenditure of the State's financial resources.
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Nowadays, primary care doctors in Portugal behave much like GPs in Britain:
they serve as doctors of first resort for nearly all medical problems and act as
gatekeepers for patients' access to pharmaceutical products (Green, 1997;
Agrawal and Calantone, 1995). Two thirds of consultations with GPs end
with the issuing of a prescription: "at least one prescription is given by a GP in two
out of three consultations and numerous repeat prescriptions are given to unseen
patients" (Fry, 1993: 59), and "each general practitioner prescribes, on average,
about 18000 items a year" (Harris, 1996: Introduction).
It has been widely accepted that GPs' prescribing behaviour is not easily
altered once established (Denig and Haaijer-Ruskamp, 1995; Taylor and
Bond, 1991; Harris et al., 1985; 1984). Nevertheless, Armstrong et al.
(1996) studied why doctors changed their prescribing behaviour over six
months and found that multiple factors were involved. For example, Chen
and Landefeld (1994) found that drug promotion developed by
pharmaceutical companies is one of the most important factors that
influence GPs' prescribing behaviour.
Devlin and Hemsley (1998) found that typical brand-based drug
companies themselves estimate that around the world they spend on
average 35% of sales on promotion. Such massive expenditure by the drug
companies is not only attached to research and development costs involved
in launching a new pharmaceutical brand but also to market conditions:
2
"pharmaceutical companies spend millions of pounds promoting their products,
particularly new medicines. The reason for this is not hard to understand. For
example, it is now estimated that the research and development costs involved in
launching a new medicine are in excess of £100 million. With a limited time available
under patent protection for exclusive marketing rights, i.e., before generic
alternatives erode profits, there is enormouspressure to exploit the potential market
for new drugs fully. As a result the companies need to win prescribers over to their
new treatments, which in some instances offer only minor advantages over established
drugs, or have not been adequately defined in terms of their appropriate place in
therapy" (Hough, 1996: 164).
During the 1980's, the positive impact that pharmaceutical manufacturers'
promotion activities can have on influencing GPs' prescribing behaviour
was questioned by a British researcher: "The drug industry spent £169m
promoting its products to doctors in 1983, and the estimated expenditure was almost
£200m for 1985. That works out at £2500 for each doctor, but almost 80% of the
expenditure (£160m) is on general practitioners - over £5000 is thus spent for each
general practitioner. In contrast, the NHS spends about £2m refunding expenses
incurred by general practitioners attending postgraduate education - less than £70
for each doctor" .(Smith, 1986: 905). Against this pharmaceutical
manufacturers' commercial pressure, research was developed by health
authorities to descnbe the types of drugs prescribed by GPs, the additions and
deletions made to doctors' repertory and the factors influencing these changes
(Gilleghan, 1991;Taylor and Bond, 1991).
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In most countries, the ongoing increase in prescribing costs is caused by
prescribing new and more expensive products (Denig and Haaijer-Ruskamp,
1995). Some researchers reported that doctors continue to prescribe trade-
name drugs when less expensive generics substitutes are available CAvery et
aI., 2000; Hellerstein, 1994). As new therapeutic categories become available
and older drugs are outmoded, the GP will change hislher personal list. The
reasons for making such changes are not clear. However, it is possible to
argue that GPs have a personal list of therapeutic categories which they
prescribe. Furthermore,
"consumers are said to be inmfficiently well informed to decide on the merits of products
(quite apart from the cost). Consequently, GPs decide on the efficacy and safety of
medicines and, to that extent, are the 'real' consumers. To make matters lrorse, doctors
do not maJce a price-conscious choice because payment is made by a third party (an
insurer or the government). Thus, the relationship between the consumer and producer is
very different from that in a typical market. The doctor typically decides whether a
product is worth prescribing, the patient takes it, and a third party pays. Normal market
disciplines do not operate" (Green, 1997: 1). As a result, spending on drug costs
has tended to rise:
"expendtture in Denmark, the Netherlands, Sweden and the UK is markedly below that
which might be expected but that in France, Greece and Portugal is markedly above"
(Burstall, 1997: 80).
4
During the 1990's, Portuguese health authorities, following British example,
identified prescribing in general practice as a particular area needing
attention (Infarmed, 1996). Portuguese National Health Service (NHS)
"revolution", particularly the adoption of international medical guidelines for
therapeutic decision-making imposes dramatic changes on prescribing. The
purpose of these guidelines is "to assist practitioners in clinical decision-making, to
standardize and improve the quality of patient care, and to promote cost-effective drug
prescribing" (Veterans Health Administration, 1996: 5). Guidelines for the
management of hypertension suggested that "the physician should tailor the choice
of drug to the individual patient" (World Health Organization (WHO) -
International Society of Hypertension (ISH), 1999: 168). In line with this
reasoning, Monane et al. (1995) suggested that patient characteristics such as
age, gender and race were important determinants of drug choice. Therefore,
considerable effort was devoted in the present research to the construction of
different patient typologies. The conviction that different patient typologies
require alternative therapeutic approaches was reinforced recently by
researchers who analysed the factors associated with antibiotic prescribing:
"Prescribing behaviour may have been a .function of patient-specific rather than general
beliefs about antibiotics" (Lambert et al., 1997: 1767). Because of the scarcity
of the research on this topic, the Means-End Chain theoretical framework
(Gutman, 1982) and its Iaddering procedure (Gengler and Reynolds, 1995;
Reynolds and Gutman, 1988) was initially used.
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Therefore, one of the novel features of the present research lies in the use of
a different approach to that employed previously. That is, the approach to
research differs from those who believe that the Expectancy-Value Theory
(Ajzen and Fishbein, 1980; Fishbein and Ajzen, 1975) can explain GPs'
prescribing behaviour. Consequently, the direction of this research - in both
theory and empirical work - was towards developing an understanding of
the GPs' clinical values that guide drug choice in Portugal. The emphasis on
the relationship between therapeutic categories and patient typologies
reinforces the importance of terminal values'- rather than instrumental
values: "terminal values determine choice at the product class level but instrumental
values at the brand choice lever' (Howard, 1989: 58). Previous
pharllUlCeutical marketing research focused on instrumental values at the
brand choice level. To our best knowledge, no research has previously
defined GPs' clinical terminal values towards first-line drug therapy. This
is the second major difference from previous research on GPs' drug
choice, which is particularly important when categorising GPs according to
their first-line drug therapy. Therefore, the aim of the present research is:
~ to conceptualise a new theoretical framework, The Patient Typology
Model (PI'M), in order to categorise Portuguese GPs in accordance
with their fll'St-line drug therapy to hypertensive patients.
2Howard (1989) defined two-level choice structure in which terminal values operate at the higher level
(i.e., product class) and instrumental at the lower level (i.e., brand).
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A number of objectives were defined to achieve the aim described earlier:
• to establish which sources of drug information are used by Portuguese
GPs to organise their first-line antihypertensive drug therapy; .
• to identify demographic and clinical characteristics of hypertensive patients
that influence Portuguese GPs' first-line antihypertensive drug therapy; and
• to analyse whether Portuguese GPs' practice and personal factors
influence first-line anti-hypertensive drug therapy.
1.2 Overview of the Thesis
It has been suggested that the doctor's prescribing behaviour may vary from
country to country and thus national studies are very important (Haaijer-
Ruskamp and Hemminky, 1993). Marked differences were found among the
major European countries in terms of patterns of prescribing (Stem, 1997;
Smith, 1991b; O'Brien, 1984). To date, no empirical work has been
presented to the academic community about patterns of prescribing of
Portuguese GPs. Therefore, the research in this thesis is mainly concerned
with the categorisation of Portuguese GPs in accordance with their first-
line antihypertensive drug therapy. In undertaking this research, it is
hoped to contribute to a better understanding of GPs' prescribing
decisions for patients with hypertension.
7
To obtain the desired objective, research design and methodology were
developed in two different stages:
Stage I: Qualitative Approach (seeChapters Fourand FIVe)
Individual interviews and focus group discussions with GPs were carried out
in order to improve the researchers' familiarity with the anti-hypertensive
therapeutic approach. Then, a national exploratory study was developed using
the Means-End Chain theoretical framework (Gutman, 1982).
The Means-End Chain Theory was used to identify the linkages between
pharmaceutical product attributes, consequences produced through
prescribing, and the clinical, personal values of doctors underlying their
decision-making processes. In order to retrieve the attribute-consequence-
value chain, a one-to-one in depth interview technique called "Laddering"
was used to understand the relevant excerpts of doctors' cognitive
structures (Gengler and Reynolds, 1995; Reynolds and Gutman, 1988).
Stage D: QlIIlIItitative Approach (see Chopters Six, Seven tuUl Eight)
Based on the findings from the qualitative exploratory phase, the Patient
Typology Model (PTM) was developed and a questionnaire was launched
on April 1998. In order to improve the response rate, a reminder and a second
wave of questionnaires were sent to those GPs not responding to the first
questionnaire.
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After a factor analysis was developed to simplify a complex set of data on
doctors' sources of drug information, a multivariate logistic regression
was performed in order to categorise the Portuguese GPs according to
their first-line drug therapy.
The methodology used in the present study is a combination of two
research methods used together for the first time. To the best of the
author's knowledge, this is the first time that the Laddering approach (i.e.,
a semi-qualitative technique) has been used in conjunction with
Multivariate Logistic Regression (i.e., a quantitative technique) to develop
the categorisation process of Portuguese GPs (see Appendix Four).
1.3 Thesis Structure
The conventional thesis structure, which entails a rigid demarcation
between Chapters with theoretical reasoning and empirical data, has been
followed. The main body of the thesis is arranged in two parts:
• part one, Chapters II to V, contains the background to the thesis and
for this reason is particularly related with the qualitative phase of the
present research;
• part two, Chapters VI to IX, based on the quantitlltive approach,
organise the categorisation process of Portuguese GPs and present the
managerial implications arising from this study.
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Chapters
• Chapter One, the present chapter, illuminates the scope of the thesis. An
overview of the thesis is also presented.
• Chapter Two discusses the crucial role of innovation and new product
development within the pharmaceutical market. The Chapter introduces the
reader to the importance of hypertension on doctors' prescribing behaviour.
In line with this reasoning, the Chapter presents the two opposing
philosophies of prescribing on the treatment of essential hypertension.
The Chapter finishes with the presentation of a flow chart representing
the study overview (Figure 2.2: Study Overview).
• Chapter Three presents a review of previous research on doctors'
prescribing behaviour and emphasises the most representative models
which provide the researcher with an understanding of the process by
which doctors make decisions and the factors that influence them.
• Chapter Four looks at the Means-End Chain Theory and Laddering
technique as the most appropriate theoretical framework for a study of
doctors' prescribing-relevant cognitive structure. The Chapter reinforces
that the central tenet of the theory is that product, service or behaviour
meaning structures stored in memory consist of a chain of
hierarchically-related elements.
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• Chapter Five encapsulates the results from the Means-End Chain
approach and reinforces the contribution of these findings to an
understanding of doctors' clinical values.
• Chapter Six discusses and develops the patient typology model (PTM)
as a useful tool to organise both the questionnaire and the entrance of the
explanatory variables into the multiple logistic regression equation.
• Chapter Seven is concerned with data collection and the research
methodology. The main goal of this Chapter is to explain the reasoning
behind the research design and methodology. The aim in this discussion
is therefore to justify the research approach and to show how various
considerations shaped the research design and methodology adopted in
the present study.
• Chapter Eight analyses the findings from the factor analysis and the
logistic regression analysis in terms of the categorisation process of
Portuguese GPs. In the first part of the Chapter, the model-building
approached is explained and the explanatory variables are presented. The
second part of the Chapter interprets the multiple logistic regression model
parameters in accordance with a number of different statistics. Based upon
this, the final multiple logistic regression model is presented. In the last part
of the Chapter, the selected 16exphmatory variables are used to classify
Portuguese GPs into stepped-care followers or liberal followers.
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• The concluding Chapter provides an overview of the main fmdings of
the research and their managerial implications for marketing strategists.
Specifically, Chapter Nine examines the interest of the Portuguese
GPs' first-line antihypertensive drug therapy in tenns of stepped-care
and liberal approaches to define marketing strategies. The fmal part of
the Chapter outlines the importance of the patient typology model
(PTM) as a useful tool to develop pharmaceutical marketing strategies,
as well as addressing the limitations of the study and providing
suggestions for further research.
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2 Chapter Two: The Pharmaceutical Industry and the Context of Research
2.1 Introduction
The initial part of the chapter distinguishes "ethical pharmaceuticals" from
"over-the-counter (OTe) and proprietary drugs". This is followed by an
examinationof the crucial role of innovationand new product development
within the pharmaceutical market, which has four different phases I. The
chapter then goes on to introduce the ways in which medical guidelines
influence drug choice. The purpose of the next part of the chapter is to
introduce the reader to the importance of hypertension on GPs' prescribing
behaviour and to discuss some of the issues which initially triggered the
researcher's interest in the therapeutic classes/categories used to treat
hypertensivepatients.
In the last part of the chapter, a recently developed approach to market
research is advanced as a way of understanding doctors' prescribing
behaviour. This new avenue of research that is introduced derives from the
medical guidelines that have been advanced by EU Members' health
authorities. The Chapter also presents the rationale for studying GPs'
prescribing decisions in Portugal. The chapter finishes by introducing the
flow chart of the present research.
1 Phase I trials involve 4-5 new chemical entities and examine pharmacokinetics and the tolerability in
healthy volunteel'S, smallest effective dose, dose/effect relationship, duration of effect. and side-effects.
Phase Il trials bring the first controlled exposure to patients and studies on bioavailability. Phase m trials
develop full-scale evaluation of treatment (substantial number ofpatientsldrug comparison with standard
treatment). Phase IV trials include Marketing/Post Marketing Surveillance (Taggart and Blaxter, 1992).
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2.2 The Pharmaceutical Industry
Pharmaceuticals/ produced and distributed commercially are generally
classified into one of two broad groups (Buzzell and Quelch, 1988):
• Ethical pharmtlCl!utica/s, available only through a doctor's prescription;
• Over-the-counter (OTC) and proprietary drugs, sold without prescription.
However, "it was difficult to draw an exact boundary between the two categories,
because drugs that were sold only on physicians' prescriptions in one country 'Were
available as OTC products in other countries. In addition, many products that had
formerly been classed as ethical drugs had, over time, evolved into OTe products."
(Buzzell and Quelch, 1988: 78-79). This exploratory study deals exclusively
with the ethical sector of the pharmaceutical industry, but does make some
mention of OTe products.
The pharmaceutical industry is one of the largest, powerful, wealthiest and
most internationally orientated industry sectors in the developed world
(Doyle and Monteiro, 1994; McGahan, 1994; Buzzell and Quelch, 1988).
However, the success of pharmaceutical industry is heavily dependent on its
ability to innovate (Taggart and Blaxter, 1992). This is not easy because
pharmaceutical industry's new product development is subject to extensive
governmental regulation in almost every country in the world (Green, 1997).
2In its broadest sense. the term "pharmaceuticals" includes all kinds of medicinal substances, even
medical herbs used as folk remedies. We will use the term "ethical pharmaceuticals/drugs" to distinguish
the products that can only be prescribed by doctors.
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2.3 The Pharmaceutical Industry's New R&D Strategies
European Union health authorities have progressively applied more rigorous
controls to the introduction of new ethical pharmaceutical brands (Infarmed,
2000a; Schwartz, 1998; Taggart and Blaxter, 1992). Often these controls
have been extended through time to cover stringent evaluations of established
products. Therefore, the time taken between the development and
commercialisation of a major, innovative medicine has lengthened, and a
gestation period of 10 up to 12 years is now assumed (Cearnal, 1992). As a
result, the R&D costs of developing a major innovative medicine are now in
excess of 125 million pounds (Waldholz, 1992). Although somewhat
unexpected, some pharmaceutical companies are countering low-cost
competition from the generics' with new defensive strategies:
"Because patents on many major drugs are scheduled to expire between 1994 and 2000,
leading companies may find integration into generics increasingly important to maintain
revenue" (McGahan, 1994: 117).
As a result, many pharmaceutical brands within mature product lines have to
face competition from low price generics, and low-cost competition with
established leaders is expected to rise (Hellerstein, 1994). Consequently,
competition in the market will increase and it will encourage competitors to
re-define their marketing strategies.
3
In order b • geaeric cIrus to be marlted, cbe Food IDd Drug Administration (FDA) requires cbat cbe geaeric 1lllllUtic:turc:r prove
its drug is virtually idcaticaI to its trado-oamc COIIIIk:rpert (Hdlcrstcin. 1994 I).
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2.4 A New Pharmaceutical Market Approach
2.4.1 New Pharmaceutical Marketing Strategies
It is of prime importance for pharmaceutical companies operating within
the ED market that they identify and understand how doctors develop their
"internal audil' and make their therapeutic decisions, and to identify what
factors influence prescribing behaviour. Meanwhile, they have powerful
and diversified tools to disseminate information and to communicate with
the doctors, in order to influence prescribing behaviour (Devlin and
Hemsley, 1998; Andaleeb and Tallman, 1996; Vicciardo, 1995).
It has been recognised that the industry has a good understanding of the
"nature of business", the importance of continual environmental scanning
and the dominance of the customer and his/her needs in any planning
process (Cortjens, 1991; Fletcher and Hart, 1990). However, some
researchers take the opposite view (Doyle and Monteiro, 1994). For
example, some researchers pointed out that to exploit the growth
opportunity of ethical products within the European market, pharmaceutical
manufacturers need to be far more consumer oriented (Dudley, 1994).
Since the mid 1970's pharmaceutical companies have become aware that
information directed towards doctors must be problem oriented, and must
carefully combine scientific and commercial aspects in order to influence
prescribing behaviour (Dittmer, 1975).
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Some pharmaceutical manufacturers have been developing customer
databases, ensuring that the sales force knows precisely what to
communicate, and developing a more targeted approach to their activities
according to those areas which offer the greatest potential for creating new
business. This new marketing approach relies on a good quality database of
existing customers that is instantly transmitted to the sales representatives
through information-based selling (Walsh, 1993). That is, pharmaceutical
manufacturers are becoming increasingly aware of how much they have to
learn from the behavioural sciences in order to remain competitive in the
new international arena (Doyle, 1994).
At the same time, however, the pharmaceutical market has been changing
dramatically, particularly during the last 10 years: "The attractiveness of the
industry began to deteriorate in the late 1980s and early 1990s as managed care
introduced price competition into some segments of the market" (McGahan, 1994:
117). Consequently, pharmaceutical manufacturers have once again been
"invited" to redesign their marketing strategies according to the changes in
the health care environment (Doyle and Monteiro, 1994; Buzzell and Quelch,
1988). That is, the reality of the "health care revolution" during the last
decade has produced unalterable events which have been shaping the
current and future pharmaceutical marketplace. These driving forces within
the health care context have market implications for pharmaceutical
manufacturers:
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"Health care reform, increasing competition, and overwhelming desire for higher-
quality health care at lower prices are all creating competitive pressures, which are
transforming our industry" (Nichols, 1994b: 106).
Changes in doctors' prescribing behaviour, particularly their approach to
cost-effective first-line therapy, represents an important dimension in this
new pharmaceutical environment.
Given the new competitive pharmaceutical environment, market research 4
and marketing research are crucial for the success of new drugs. Therefore,
a new approach to primary care in terms of pharmaceutical promotion is
required (Barton, 1993; Adams, 1992). General practitioners are now
subject to rational prescribing guidelines that impose fewer "degrees of
freedom" in terms of drug choice. Recent prescribing guidelines place
more emphasis than earlier reports on absolute risk and benefit and uses
risk stratification as part of the treatment strategy (WHO-ISH, 1999). The
development of new ethical products in accordance with these prescribing
guidelines is one possible strategic option, which requires accurate
research on GPs' prescribing decisions. In summary, pharmaceutical
companies can no longer just react to events around them; they must be
proactive and develop innovative marketing strategies.
"Although the two terms are often used interchangeably, it is useful to distinguish market research _
determination and assessment of the qualitative and quantitative dimensions of the market, from
marketing research - analysis of the effects of the various marketing activities of a firm and its
competitors.
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2.4.2 New Link between Medical Guidelines and Doctors' Clinical Values
The huge amount of investment in new product development reinforces the
importance of accurate research on GPs' prescribing decisions. Better
information on first-line drug choice may have the capacity to reduce the
cost of new drug development because it provides a framework that helps
to reduce the probability of unpromising compounds being tested in Phase
Il and Phase ill trials. Changes in the pharmaceutical market environment
suggest that a drastic shift in the pattern of analysis of new compounds
tested in Phase ill is critical to pharmaceutical manufacturers. These new
compounds must be developed according to the specific characteristics of
patients that have been described within different medical guidelines. For
example, in preparing medical guidelines for the management of
hypertension, the WHO and the ISH were "keenly aware that there are marked
differences between individual patients with similar levels of hypertension, which have
important implicationsfor decisions concerning treatment. hypertensive patients differ
with respect to age, blood pressure elevation, organ damage and concomitant risk
factors and diseases, and they live in societies in which cardiovascular risk and
economic resources also differ widely" (WHO-ISH, 1993: 905). Thus, new drug
development according to the specific characteristics of hypertensive patients
means less investment on new compounds inPhase illtrials.
Recent medical guidelines suggest that the GP "should tailor the choice of the
drug to the individualpatient" (WHO-ISH, 1999: 168).
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With information obtained from medical guidelines, it is possible to
improve the efficiency of communication strategies m terms of cost-
effectiveness: "As resources grow scarce and money gets tight, pharmaceutical
companies are seeking more cost-effective ways to educate, communicate with, and
conduct market research with physicians" (Vicciardo, 1995: 33). Therefore, it is
critical to increase innovative market research to understand not only what
is happening in the European health care market, but also why it is
happening: "The value we created is by emphasizing the why of the findings, not just
what the findings are. More open-ended questions are being added than in the past,
resulting in more combined quantitative and qualitative market research studies"
(Lawson, 1997: 255). It seems certain, however, that both clinical context
and values, particularly doctors' clinical values, intervene between content
and outcome: "values (of doctors and of patients) and the context in which
consultation takes place affect the needs priortttsed and the process of the care which
follows" (Howie, 1998: 1022). That is, the link between medical guidelines
and doctors' clinical criteria may be used to explain and/or predict GPs'
first-line drug therapy. However, to educate, communicate with, and
conduct market research with doctors, it is necessary to identify doctors'
compliance with those medical guidelines (Hutchinson, 1998). Having a
better understanding of how doctors develop their prescribing behaviour
may help to define more appropriate marketing strategies for influencing
drug choice according to recent "institutional" medical guidelines.
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It is, therefore, not surpnsmg, that the patient's clinical context and
doctors' clinical values in terms of theirfirst-line drug therapy represent a
new avenue of research concerningGPs' decision-making processes.
Interest in this disease management approach was recently pointed out by
pharmaceuticalresearchers:
"Disease management was one of the areas we talked about. The top management of our
company viewed this as an important strategic marketing initiative (Lawson, 1997:
257) ... "Disease management becomes the stepping stone to creating offocused health
care conglomerates" (Boscheck, 1996:640).
However, doctors who are responsible for primary care maintain a strong
influenceover the whole process of the drug therapeutic approach:
"physicians still retained essentially complete latitude to prescribe as they wished, but
they felt an increasing responsibility to respect the financial burden of their prescribing
decisions" (Kossman, 1994:70).
Nevertheless, drug manufacturers have realised that all the changes
described above represent a historic shift (Schwartz, 1995). The new
pharmaceutical market constraints are less a "blip", than a new set of
conditions to which they had to adapt, particularly continued cost-cutting,
price erosion, and even exclusion from the purchasing lists (Koberstein,
1995).
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2.5 The Rationale for Studying GPs' Prescribing Decisions in Portugal
Primary care is diverse in its development, organisation, and funding, such
that there is a "considerable variety in consulting patterns by general practitioners
throughout the European Union" (Evans, 1994: 645). To reduce this variety of
therapeutic approaches, a significant investment has been made in primary
care medical education, and Portugal is no exception within the EU:
"Growing value is placed on the role of the well educated and trained generalist at the
primary level. This is clear from developments in the United Kingdom, Holland,
Denmark, Sweden, Finland, Spain, and Portugal' (Evans, 1994: 645).
Health authorities in Portugal, particularly Infarmed", are aware that
"prescribing information should always be developed at the country level, with regard
to prevailing diseasepatterns ant the access of the target population to health services -
particularly to essential drugs" (Couper, 1995: 601). Furthermore, "the nature of
factors may vary from country to country and national studies are therefore needed"
(Hemminki, 1915a: 114), (a point recently reinforced by Haaijer-Ruskamp
and Hemminki, 1993). However, at the present time, the factors that
influence Portuguese GPs' prescribing decisions are unknown. To date,
no published studies in the area of drug prescribing have explicitly
examined factors that affect the use of Portuguese GPs' decision-making
processes. The present study opens this opportunity.
5 Infiumed is the National Institute of Pharmacy and Medicines (Instituto Nacional da Farouicia e do
Medicamento) is a public institution granted with administrative and financial autonomy, under tutelage
?f the Minister of Health. Its activity is mainly related to medicines for human and veterinary use, and
ISSUesopinions on regulations related to research, production, marketing and use of medicines.
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2.6 Why Hypertension?
Doctors' prescribing behaviour has been analysed within different clinical
contexts. However, the treatment of hypertensive patients has been found
particularly relevant to understanding and modelling doctors' therapeutic
decisions (Hui and Pasic, 1997; Doyle and Monteiro, 1994; Chinburapa
and Larson, 1992; 1988; Segal and Hepler, 1985; Zelnio, 1982). This
situation is mirrored in Portugal where antihypertensive therapy is the most
important class of drugs prescribed by GPs (Infarmed, 1996; 1995).
Furthermore, hypertension represents the medical problem most frequently
seen by GPs in Portugal, and it accounts for more practice visits and
prescriptions than any other disease (Jordao, 1995; Carrageta 1985). In
Portugal, more than 100 brand-name drugs are available to treat
hypertensive patients (Cris6gono, 1997). Two main reasons have been
advanced to explain the wide range of prescribed antihypertensive drugs:
1.Hypertension is the most common and dangerous cardiovascular
disorder, and affects around 20% of the adult population in many
countries. Furthermore, "More than half of thepopulation older than 65 years of
age has hypertension, the most important reversible risk factor for cardiovascular
complications such as myocardial infarction and stroke" (Monane et aI., 1995).
As a result, "High blood pressure of moderate or severe degree, even if
symptomless, carries a large risk of complications, particularly of stroke" (Evans
and Rose, 1971: 37).
23
2. To treat hypertension the doctor may choose from well over one hundred
drugs, encapsulated within five/six" major therapeutic categories:
"The six main drug classes used, world-wide,for blood pressure lowering treatment
are: diuretics, beta-blockers, calcium antagonists, ACE inhibitors, angiotensin II
antagonists, and alpha-adrenergic blockers" (WHO-ISO, 1999: 166); (see
Figure 2.1 and Appendix Two):
~ Diuretics: Increase the excretion of water and salt through the kidneys,
lowering blood volume and blood volume pressure, and relax blood
vessels. Thiazide diuretics were launched in 1957.
~ Beta Blockers: Slow the heart and reduce the force of its contractions.
Propanolol, the first appeared Beta Blocker, was launched in 1966.
» Calcium Channel Blockers (CCB): Relax blood vessels. Nifedipina
(Adalat) was the first category ofCCBs in the market in 1979.
~ Angiotensin Converting Enzyme (ACE) inhibitor: Relax blood vessels
by turning off production of angiotensin IL a chemical that causes the
arteries to constrict. Captopril (Capoten) was the first category of
Angiotensin Converting Enzyme (ACE) inhibitor in the market in 1981.
~ Angiotensin II Antagonists: Relax blood vessels by blocking the action
of angiotensin II. Losartan (Cozaar) was the first of Angiotensin II
Antagonists launched in the market in 1994).
6
The alpba-adrenegic blockers are also a therapeutic class that has been mentioned. However, these
drugs are not prescribed in Portugal.
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Figure 2.1: Antihypertensive Therapeutic Approach
~-Blockers
Some researchers argue that doctors' prescribing variation derives from the
variety of therapeutic categories which work by a different mechanism of
action, encapsulate many brand-name drugs, and differ significantly in
terms of cost: "The volume and cost of prescribing varies considerably between
practices. This variation is at least in part due to the prescribing behaviour of
individual doctors, who are often faced with a range of therapeutically equivalent
generic and brand-name drugs" (Roberts et aI., 1997: 13).
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To avoid vanances m the volume and cost of different patterns of
prescribing, various medical bodies in different countries have launched a
plethora of guidelines7 to provide advice to doctors treating high blood
pressure (WHO-ISO, 1999; WHO, 1996; WHO-ISO, 1993). However,
these medical guidelines do not avoid the marked differences that were
found among the major European countries in terms of patterns of
prescribing (O'Brien, 1984). Thus, established patterns of prescribing and
their variations have been analysed (Stern, 1997). Health authority
hypertension guidelines and medical opinion leaders' comments and
suggestions on those guidelines have provided an interesting dialectic
reflection on issues of drug choice. From this perspective, these guidelines
can be thought of as "philosophies of prescribing", which have encountered
support from somemedical opinion leaders and opposition from others.
The reading of several medical books for the practical management of
hypertension (Schachter, 1997; Birkenhager, 1996; Beevers and
MacGregor, 1995; Kaplan, 1994) Houston, 1992) suggests the existence of
two opposing philosophies of presctibing, which we will classify as:
• The Stepped Care approach; and
• The Liberal approach.
7 The purpose of the guidelines is to assist practitioners in clinical decision-making, to standardise and
improve the quality of patient care, and to promote cost-effective drug prescribing. These guidelines
attempt to define principles of practice which should produce high quality patient care (Veterans Health
Administration. 1996).
\
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The Stepped Care approach is mainly related to the pharmacological values
developed by the medical community during the 70's and early 80's, and at
the time "had the merit of introducing some system into the prevailing chaotic
approach to treating the hypertensive subject" (Birkenhager, 1996: 156). This
strategy of antihypertensive drug treatment postulates that therapy should
be simple, starting generally with a single drug, in most cases a thiazide
diuretic (Opie, 1998). That is, "efficacy, side effects, and cost considerations are
key components of decision making in prescribing an antihypertensive agent. Thiazide
and related diuretics have the longest and best-established track record of all
antihypertensive drugs" (Monane et aI., 1995: 1049). This therapeutic category
would be prescribed at a low dosage and only later, if necessary, would
progress to a more elaborate regime, such as beta blockers.
During the 80' s a range of new drug therapeutic categories, particularly
calcium antagonists and angiotensin converting enzyme (ACE) inhibitors,
became available.
In view of these expanded options, treatment guidelines were liberalised,
and in due course the stepped-care approach appeared to some members of
the medical community to be too rigid and patronising.
This liberal approach states that "A more pathophysiologic and individlllllised
approach to drug therapy for hypertension is recommended rather than the
traditional stepped care approach, which has emphasised predominantly diuretics and
P-blockers" (Houston, 1992: 1338).
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2.7 Patterns of Prescribing and Patient Characteristics
Examination during the last decade of prescribing patterns for hypertension
indicated that ACEIs represent the most important drug class with a 32%
share of prescriptions followed by calcium channel blokers (CCB) (24%)8
(see Appendix Three). While ACEIs and CCBs have shown significant
prescription growth over the last 10 years (Maclure et aI., 1998),
prescriptions for diuretics and beta blockers, as well as other conventional
drugs, have been on the decrease (Moser, 1998). This is consistent with the
current literature on patterns of prescribing which has shown a decreasing
reliance on diuretics and beta-blockers, and an increasing reliance on
ACEIs and CCBs (Nichol et at, 1997; Monane et al., 1995). Meanwhile,
investigators from the Gruppo Italiano di Farmacovigilanza nell' Anziano
(GIFA) reported that: "Inhibitors of angiotensin-converting enzyme (ACE) have
gained a leading role among antihypertensive drugs, whereas use of calcium-channel
blockers increased until to 1993 and had declined thereafter. Use of diuretics declined
between 1988 and 1991, did not change until 1995, and then rose to 41.5% in 1997,
compared with 42% and 39.5% for ACE inhibitors and calcium-channel blockers,
respectively. The frequency of use of beta-blockers was uniformly low (lncalzi et al.,
1998: 1557). Although Portuguese health authorities recommend the use of
beta blockers and diuretics for first-Une drug therapy, recent studies have
identified low levels of prescribing (McAlister et aI., 1997):
• Confidential data - Novartis, 1997.
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~ Only 12% of the patients with hypertension were given beta-
adrenegic blocking agents and this figure reduces to 11% on
patients receiving thiazide diuretics.
~ Of the patients who were prescribed an antihypertensive drug other
than a diuretic or beta-adrenegic blocking agent as first-line drug
therapy, less than half (43%) had a documented contraindication to
diuretics or beta-adrenegic blocking agents (BBs).
~ Although beta blockers have been known to reduce mortality and
coronary heart disease after myocardial infarction, their use has been
associated with a higher risk of side effects than other drug regimes.
Within Britain, diuretics and BBs, which have been available for more than
25 years, are the most commonly prescribed classes (Smith, 1991b). These
therapeutic categories have been found to be related to cost effective
prescribing practices and defined by medical guidelines as adequate quality
at a lower cost: "At present, for most hypertensive patients who require therapy
(including patients with type 2 diabetes), drugs other than diuretics or beta-blockers
should be selected infrequently (Cutler, 1999: 605). However, some medical
researchers argue that those guidelines are "compromised by a hidden
"political" agendo based on cost-oriented considerations" (Birkenhager, 1996:
156). Meanwhile, there is no doubt that "the choice of drug should be lIliIored to
the individual patient Factors to take into account include coexisting disease and
side-effects" (Mayor, 1994: 31). The presence of a concomitant disease that
can be improved or worsened by antihypertensive treatment, should be a
major consideration in the choice of initial drug (Incalzi et aI., 1998)
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2.8 Research Dimensions
The purpose of the previous discussion was to illustrate further the
relevance to an understanding of the major differences that can be found
on drug choice. The two main issues that clinicians are facing are, first,
what medical regimen to choose, and, second, what therapeutic class is
better to initiate the treatment", The answer is not easy because all five
therapeutic categories have specific advantages and disadvantages for
particular patient groups, and there is no evidence as yet that the main
benefits of any drug class are drug specific rather than related to the
reduction of blood pressure per se (Schachter, 1997).
According to the previous assumptions and by drawing upon the principal
ideas expressed earlier, two main dimensions of substantive research
interest are:
1. GPs' clinical values in the treatment of hypertensive patients; and
2. Antihypertensive "philosophies of prescribing".
The former determine the choice of the therapeutic category while the latter
give the patient's clinical structure that guides GP prescribing behaviour. It
is argued in this thesis that these two major dimensions have paramount
importance on doctors' first-line drug therapeutic approach. Therefore, l!!D!.
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represent a substantive area of research and a new roule 10 fill a gap
within the literature on doctors' prescribing behaviour. Furthermore, they
avoid the use of a 'patient scenario approach' which has been found not
the best solution for eliciting doctors' therapeutic cognitive structures
(Cbinburapa et al., 1993; Bradley, 1991).
2.9 Summary
In Portugal, medical treatment is often equated with drug-based therapy. Over
the years there has been considerable interest in the variations in patterns of
prescribing. Lack of consensus among doctors about the best way to treat
hypertensive patients may help to account for the unexplained variations as
general practice lacks accepted standards of appropriate prescribing.
The current emphasis on ensuring a scientific basis for drug choice bas been
directed at evaluating interventions such as educational inputs and clinical
guidelines, that attempt to change prescribing behaviour in Portuguese GPs
(Therapeutic Bulletin; 1998; 1997; Silva, 1997; Infarmed, 1996; 1995). As
a result, the Portuguese pharmaceutical business environment has changed
dramatically during the 1990's. In order to address the new, complex and
threatening Portuguese market conditions, particularly progressive
government controls on prescribing and reimbursement (INFARMEDb,
2000), pharmaceutical companies should move from a sales culture to a
customer-oriented culture (Doyle, 1994).
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That is, pharmaceutical marketing managers have to identify GPs'
philosophies of prescribing that derive from the new medical guidelines.
By tailoring the characteristics of new ethical drugs to sub-segments of a
specific disease, a pharmaceutical manufacturer could conceivably
differentiate its products and obtain price premiums. The achievement of
competitive advantage through this route requires not only the
accumulation of relevant and innovative information the clinical values that
guide first-line drug therapy, but also requires specific information on the
individual patient's characteristics that differentiate drug choice.
According to Portuguese antihypertensive guidelines, the first choice for
most patients with elevated BP, should be diuretics and beta blockers,
though doctors can use other classes of drugs if the first try does not work
(Therapeutic Bulletin; 1998; 1997).
As pointed out earlier, the total increase in expenditure in antihypertensive
drugs was mainly due to a shift in drug choice, from the already existing
drugs (i.e., diuretics and beta blockers) to the recently introduced ACE
inhibitors. Nevertheless, current recommendations have renewed emphasis
on the use of diuretics and beta blockers as first-line drug therapy, unless
there are special indications for other therapeutic categories. As a result,
two opposing philosophies of prescribing on the treatment of essential
hypertension were identified:
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• The stepped care approach; and
• The Liberal approach.
As EU Members experience different health care environments, the nature
of factors that influence GPs' prescribing decisions may vary from country
to country. Therefore, national studies on doctors' prescribing decisions
have been recommended (Haaijer-Ruskamp and Hemminky, 1993).
However, to date, no information has been published on the factors that
influence Portuguese GPs' prescribing decisions. As a result, empirical
work needs to be conducted in this particular in this EU Member. This
empirical work has two main dimensions of substantive research interest:
» GPs' clinical values in the treatment of hypertensive patients
» Antihypertensive "philosophies of prescribing"
GPs' clinical values are encapsulated within prescribing-relevant cognitive
structures, while philosophies of prescribing represent cognitive processes.
On the basis of this two-stage cognitive-oriented approach, we developed a
flow chart representing the study overview (see Figure 2.2).
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3 CHAPTER THREE REVIEW of the LITERATURE
This chapter presents the theoretical models that have been used to explain
drug prescribing. These models will be used to differentiate between the
different theoretical frameworks that embrace the drug prescribing
literature. The models are presented chronologically in order to understand
the influence of the consumer behaviour research on the prescribing field.
Particular attention will be given to those cognitive models that are always
present in any review of the drug prescribing literature.
The chapter, then, presents an evaluation and comparison of the different
theoretical models. In evaluating the models, the ten criteria proposed by
Zaltman and Wallendorf (1983) for what the desirable properties of a
consumer behaviour model should be are used.
In addition, decision-making processes; methods used to study decision-
making, and social networks affecting the use of various decision-making
strategies will be discussed in order to define the paradigmatic
assumptions that underpin the research on doctors' prescribing behaviour.
Finally, the chapter discusses previous studies' main deficiencies and
suggests a new research approach to study GPs' prescribing behaviour.
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3.1 Introduction
Several researchers have proposed models that attempt to explain the
decision-making process that leads a doctor to prescribe a particular drug
over another. Some of these models related external factors to doctor drug
prescribing, while others incorporated or considered the cognitive
processes underlying doctor prescribing decisions. As a result, the
literature review on drug prescribing offers 3 ways of looking at drug
choice:
1. as a "black box" with unknown processes going on within, about
which only associations of inputs and outputs can be learned;
2. as a consequence of a social system of influence and information
flow; and
3. as a consequence of a physician's active effort to make sense of
reality and solve clinical problems.
As models of therapeutic decision making, the three research approaches
overlap. The first is virtually amorphous (see Hemminki's model). The
second emphasizes how information gets to a prescriber (see Miller's
model). The third emphasizes how the doctor processes the clinical
information (see Cognitive models).
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There are areas of incompatibility, however. Neither the first nor the
second model acknowledges the individuality of of the prescriber. The first
is a fundamentally static view that attempts to explain the physician's
behaviour with a set of empirical associations, and that ignores differences
in prescribing-relevant cognitive structures and prescribing processes.
The second model views the GP as a passive receiver of information.
Finally, the cognitive approach acknowledges the active individuality of
the clinical problem-solving prescriber. These differences reinforce the
importance of the substantial amount of empirical research that has been
conducted concerning the factors and processes which are critical to
understanding drug prescribing. However, the factors and processes
influencing doctors' prescribing behaviour are diverse and sometimes
contradictory (Freeman et at, 1993). Given these contrasting findings, the
paradigmatic and theoretical assumptions that underpin the research on
doctors' prescribing behaviour have to be reviewed.
3.2 Paradigmatic and Theoretical Assumptions on Drug Choice
Research on doctors' prescribing behaviour is usually understood as a
problem-solving and decision-making sequence of clinical activities
(Bradley, 1991). However, other paradigms have been advanced. In line
with this reasoning, we would like initially to clarify the paradigmatic and
theoretical assumptions that support the different models on drug choice.
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3.3. Behaviourist Theoretical Models on Drug Prescribing
3.3.1 Hemminki's Model: A Behaviourist Model?
In her critical review of different factors that influence doctors' prescribing
behaviour, Hemminki (l975a) used some behavioural expressions. For
example, frequent reference to the "prescribing habits" of doctors may
indicate that drug choice is shaped and maintained by its consequences. It
follows, then, that the explanation of prescribing behaviour in terms of
contingencies of reinforcement (i.e., operant conditioning}, which is
externally controlled) would be distinct from that of the cognitive
psychology which has attracted some attention in drug choice research
(Lambert et al., 1997; Chinburapa et aI., 1993; Denig and Haaijer-
Ruskamp, 1992; Chinburapa and Larson, 1988; Denig et aI., 1988;
Mancuso and Rose, 1987; Segal and Hepler, 1982, 1985; Epsetein et aI.,
1984; Harrell and Bennett, 1974). However, Hemminky's (1975b) model
has no identifiable epistemological location, or theoretical background:
Hemminki proposed a complex model of prescribing which include many of the
influences known to operate and speculated in many others. However, she makes
no comment on whether she considers these influences to operate via cognitive or
behavioural type processes" (Bradley, 1991: 283).
J "In operant conditioning, the individual emits responses which are repeated at a rate determined by
their environmental consequences. Antecedent events do playa role, however, insofar as they signal
or set the occasion for the reinforcement contingent on the performance of a specific response"
(Foxall, 1993: 47).
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Almost twenty years later, Haaijer-Ruskamp and Hemminki (1993)
introduced a few alterations to Hemminki' s (197 5b) model whilst
maintaining the substantive theoretical approach.
However, the "new model" revealed the influence of Ajzen and Fishbein's
(1980) cognitive/ approach to consumer behaviour. The influence of other
health professionals on doctors' decision-making and consequent
prescribing behaviour was a further indication that the initial behavioural
model (Hemminki, 1975b) was incomplete. In line with this reasoning,
Hepler et al. (1981) pointed out that "No studies of prescribing that used a
behaviorist model have appeared, although some terminology (prescribing habits)
suggesting a behaviorist view is occasionally seen and implicitly behaviorist
interventions are commonplace" (Hepler et al., 1981: 34).
3.3.2 Hemminki's (1975b) model
Hemminki (1974) considered that doctor's prescribing behaviour IS
influenced by several factors, which can be divided into two groups:
2 Cognitive psychology tends to de-emphasise the role of the environment as a source of stimuli of
behaviour. Whilst not denying the envirooment as the inevitable source of external stimuli, cognitive
psychologists place more stress OD and devote a greater proportion of their effort to the investigation
of internal stimuli, i.e. those intra-personal, mental events and processes which are consequent upon
environmental inputs, through which the recipient individual's experience is constructed and by
which contingent responses are initiated. "The underlying model viewed the mind as an internal realm
of operations and computations, to be revealed by experimentation and the systematic manipulation
of specifiable inputs and outputs to the cognitive 'black box'" (Gillett, 1995: 112).
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1) Factors easily modified by administrative measures, such as
pharmaceutical promotional activities, education and extent of control; and
2) Factors not easily modified by administrative activities such as the
characteristics of patients and doctors, and the doctor-patient relationship.
Based on these two sets of influences on doctors' prescnbing behaviour,
which were described on her studies (Hemminki 1974; Hemminki 1975a),
Hemminki (1975b) developed a model to analyse whether the prescription
of drugs displaced other forms of therapy.
Adopting the method of behaviour simulation (Hemminki, 1975b), a
questionnaire was sent by post to a sample of 100, randomly selected GPs.
Doctors were requested to provide their therapeutic choices regarding the
hypothetical patients described in the questionnaire sent to them. From
these 100 GPs, 72 presented their prescribing solution. Although most of
these standard patient cases were formulated in such a way that they could
be easily treated without any drug, most of them were received a drug-
based solution. In accordance with these findings, the researcher stressed
that no alternative form of treatment was suggested. The obvious
conclusion was that the role of prescriptions in therapy displaces more
adequate and casual therapeutic approaches (Hemminki, 1975b). These
results reinforced her conviction that research and pressures developed by
the pharmaceutical companies were the major influences on doctor's
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prescribing behaviour. Nevertheless, Hemminky (197 5b) suggested that
the level of influence of the pharmaceutical companies would depend not
only on doctors' personal characteristics and their working conditions, but
also on their therapeutic opportunities. Hemminky (1975b) pointed out that
these findings were in line with her previous review of the literature on the
factors affecting drug prescribing in Western countries (Hemminki,
1975a). In this review, she suggested that the role of pharmaceutical
industry on doctor's prescribing behaviour was particularly important, and
was wide-spread through different sources of information. Factors like
education, advertising, colleagues, control and regulation measures,
demands from society and patients' and doctors' characteristics were
found to perform a decisive role in decisions about drug therapy. The
Hemminki (I 975a) approach to contextual factors (i.e., factors easily modified
by administrative measures), such as phatmaceutical advertising, medical
education and extent of control, was particularly interesting when assessing
prescribing behaviour and suggesting prescribing interventions.
Based on previous studies (Hemminki 1975a, b; Hemminki 1988), Haaijer-
Ruskamp and Hemminki's (1993) model was organised around two types
of factors: the condition and the influence/actors.
Haaijer-Ruskamp and Hemminki (1993) argued that the medical care
process was influenced at the macro-level by the national health care
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system (conditioning factors). These social scientists defmed four main
conditioning factors:
a) The tradition and education of the population, which may mould both
the expectations of the patients and the views of the physicians;
b) Medical teaching and professional thinking, which define the concepts
of health and illness and thus determine the use of physicians services;
c) The level and distribution of wealth in a country and the ideology and
power of the state, since these can affect the organisation, regulation and
availability of both professional care and drug supply; and
d) The power and vitality of the pharmaceutical industry.
Haaijer-Ruskamp and Hemminki (1993) suggested that the condition
factors may act on the influence factors from time to time and from country
to country. These condition factors were also found to have an overall
influence at the micro-level. Three major individual factors that penetrate
to the micro-level to influence drug choice were reported:
1. The demands and expectations of pressure groups and society at large;
2. The influence of the pharmaceutical industry and research results; and
3. The control measures and regulations imposed by the health authorities.
Haaijer-Ruskamp and Hemminki (1993) suggested that the power, the
influence, and the penetration of these three major pressure groups on the
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factors influencing doctors' prescribing behaviour was exercised mainly
through intermediaries. Their influence was particularly relevant during pre
and pos-graduate medical education, as indicated in a previous study
(Hemminki, 1976). Some opinion leaders as colleagues, consultants and
other health professionals were also mentioned as sources of influence on
doctors' drug choice. However, at the micro-level, the influence factors on
doctors' prescribing behaviour were mainly related to doctors' therapeutic
decision making.
Cultural values and beliefs about health and illness were also found to
influence the micro-level (Haaijer-Ruskamp and Hemminki, 1993). In their
model, the individual patient's personal characteristics, demands and
expectations were important to the therapeutic approach. These
researchers suggested that these factors represent direct biunivocal
influences. That is, the factors were found to mould doctors' therapeutic
approach, but at the same time the social context in which they were
developed and where they are active, also determines values and beliefs
about health and illness.
Haaijer-Ruskamp and Hemminki (1993) concluded that the nature of the
factors may vary from country to country and thus national studies are
needed.
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3.3.3 Miller's (1974) Model
Miller's (1974) model derived from Coleman et al.'s (1966) work on new
drug adoption, particularly in relation to the sequence of sources of drug
information, Three major divisions were proposed inMiller's model:
Box 3.1 :Miller's Model
1 - Antecedents: 2 - Process: 3 - Results:
Factors present ID the The process through which The confirmation of the new
situation prior to the an individual passes from drug as a first-line drug
introduction of a new drug first hearing about an therapy, which can be
(i.e., the structural reality): innovation to actual continuously used
the doctor's identity and purchase or use of the discontinued at a later date,
the doctor's perception of innovation.
the situation.
indicates its market success.
1) Antecedents
The doctor's identity was subdivided in four main topics:
• Integration in social networks
• Personal characteristics: this item included different variables such as
age, community experience, medical school and orientation and
attitudes.
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or
• Practice characteristics: variables like type of practice, office sharing,
size of practice, patients' income, level of use of class of drugs and
medical staff membership were included in practice characteristics.
• Communication behaviour: it includes sources of drug information,
colleagues, and manufacturers' representatives.
The doctor's perception of the situation embraces three variables:
• Cultural and social variables
• Patient variables
• Organisational influence
2) Process
The process stage is divided into two main categories:
• Information Sources; and
• Attributes of Drug Innovations.
Miller (19731Part f-Ill) argued that sources of drug information and
characteristics of the innovation seem to be the most important variables
during the adoption process. Five major stages were defined:
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I) Awareness Stage
The awareness stage is the starting point from which a doctor simply
becomes aware that a new pharmaceutical product was introduced in the
market. If this new product is a radical drug innovation it is probable that
he/she will bypass the awareness stage and go directly to the adoption
stage. However, the awareness stage is mainly characterised by a lack of
motivation in terms of information about the new drug. The role of
different sources of information such as manufacturers' representatives,
journal advertising, medical journal articles, direct mail advertising,
samples, and meetings were considered very important in this stage.
However, "after initial awareness is created, professional sources of information
are used increasingly" (Miller, 1973: 494).
II) Interest Stage
If for any reason doctor becomes interested in the use of the new drug
he/she begins to actively seek information about it in order to decide
whether to adopt it or not. However, the doctor's personality and the
social network to which slbe belongs influences not only the choice of
drug information sources, but also how sources are used. Miller (1973)
pointed out that the manufacturer's representative, journal advertising,
journal articles, colleagues, and doctor's desk reference are relevant at this
stage as they increase the level of knowledge about the new drug.
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III) Evaluation Stage
The evaluation stage was considered important in deciding whether the
new drug will be prescribed. This fmal judgement may be reinforced by
the clinical opinion of colleagues or local consultants with whom doctors
exchange clinical information. The importance and influence of these
sources of drug information is supposed to increase if the doctors'
perception of the new drug risk is high.
Medical articles and clinical meetings are further sources of information
important in the evaluation stage.
Since most "new products" are introduced for purely commercial reasons
(Lumbroso 1981), doctors may decide not to prescribe the new drug
(Miller, 1974).
When doctors realise that a new drug is not a radical innovation, and only
small modifications were introduced, they usually weigh up the advantages
and disadvantages of discontinuing the older drug.
Undesirable effects of the old drug are judged against the advantages
offered by the new drug therapeutic approach. If the advantages are
considered important, doctors are then expected to initiate the trial stage in
a limited number of patients.
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IV) Trial stage
In the trial stage doctors actively seek information, particularly through the
physician's desk reference (PDR), journal advertising, house organs (i.e.,
journals that are published by pharmaceutical manufacturers), direct mail
advertising, and samples. Pharmacological characteristics such as side-
effects, daily dosage, and efficiency are evaluated in order to prescribe the
new drug to a small number of patients.
V) Adoption Stage
The adoption stage is the confirmation of an interest in the new drug as a
first-line drug treatment. The extent to which the drug therapeutic
approach will be enriched with this new compound depends on doctors'
perceptions of advantages and risks: "Patients previously given the new drug's
predecessors may or may not be switched to the new drug depending on the relative
advantages of the new drug and the risk involved in making such a change" (Miller,
1973: 494). To evaluate the new drug's advantages and risks Miller (1974)
noted that doctors preferred more scientific or professional sources of drug
information. Doctors' colleagues were found to be important in drug
adoption, particularly when called upon to treat difficult conditions in
which the effects of therapy are less clearly defined. Doctors sharing an
office with another peer were found to use the colleague as a source of
information for drugs not presently prescribed by the physician.
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3) Results
The confirmation of the new drug as a first-line drug therapy, which can be
continuously used or discontinued at a later date, indicates its market
success (Miller, 1974). If the new drug meets the doctor's needs and
expectations it will become a first-line drug therapy. If the opposite is true,
two options are faced: to reject or re-evaluate the situation. The re-
evaluation of the situation may transform non-adoption into later adoption
or into continued non-adoption.
Miller (1973; 1974) pointed out that the length of time that elapses
between first hearing about an innovation and adopting it, define
s the type of adopter. However, the rate of innovation diffusion was
reported to be dependent both on the antecedents and on the process
(Miller, 1974). The complexity of all the factors included within the
antecedents and process stages and their dynamic nature suggested that
"they are far from being the relatively simple mechanism that many people have
thought them to be" (Miller, 1974: 89).
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3.4 Cognitive Theoretical Models on Drug Prescribing
The concept of attitude has played a major role in both social psychology
and consumer behaviour studies because attitudes reflect how people are
perceiving and interpreting objects and events around them (Foxall and
Goldsmith, 1994). For this reason, attitude is probably the most basic and
widely accepted concept throughout the social sciences. Given the great
progress that has been made in the past two decades in understanding the
nature of attitude and its relation to behaviour (Ajzen and Madden, 1986;
Ajzen and Fishbein, 1980; Fishbein and Ajzen, 1975; Fishbein, 1967;
1963), this concept is of a particular interest to marketing strategists.
Knowing how consumers evaluate products, services, and promotional
campaigns is extremely important for marketing managers: "Measuring and
undel'Stllnding consumer attitudes allow marketers to develop the products
consumers want, promote these products effectively, and eva/illite their efforts at
promotion" (Foxall and Goldsmith, 1994: 93). Thus, through a knowledge
of consumer attitudes marketing managers can determine the best
segmentation of the market, the correct product positioning and the
appropriate communication strategy (Chisnal, 1985). One of the most
systematic and widely used approaches to attitude conceptualisation and
measurement in marketing has been The Theory of Reasoned Action
(TORA) (Ajzen and Fishbein, 1980; Fishbein and Ajzen, 1975).
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Following this trend, several researchers have proposed models that
attempt to explain doctors' prescribing behaviour (Knapp and Oltjen,
1972; Miller, 1974; Harrell and Bennett, 1974; Hemminki, 1975; Lilja;
1976; Epstein et al., 1984; Chinburapa et aI., 1987; Denig et aI., 1988;
Segal and Hepler, 1982; 1985; Denig and Haaijer-Ruskamp, 1992;
Chinburapa et aI., 1993; Lambert et aI., 1997). It was recognised that
"Most of the proposed cognitive models were generally based on the expectancy-
value theory that stated that a physician's drug choice is a function of the
subjective beliefs that certain outcomes will occur from various drug choices and
the values attached to those outcomes" (Chinburapa et aI., 1993: 1473). The
expectancy-value models', particularly TORA (Fishbein and Ajzen, 1975;
Ajzen and Fishbein, 1980), has been the preferred theoretical framework:
"Most published studies have attempted to model the internal processing of
physicians as they IIUlke prescribing decisiOns, and most have used expectancy-
value type models such as the theory of reasoned action" (Lambert et aI., 1997:
1768). For example, Harrell and Bennett (1974) developed a deep
discussion regarding the use of expectancy models in attitude measurement
to predict and understand drug choice. Some of these models related
external factors to drug choice, while others incorporated mainly the
cognitive processes underlying prescribing decisions.
3 "Expectancy-value models are designed to represent how people actually integrate multiple pieces
olin/ormation to arrive at an overalljudgement" (Bagozzi, 1982: 562-563).
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In line with the reasoning that has been advanced, it is possible to argue
that in the last two decades the Fishbein and Ajzen's (1975) and Ajzen and
Fishbein's (1980) theoretical framework relating the conceptualisation of
attitude influenced most of the research on doctor's prescribing behaviour.
This theoretical framework was considered particularly relevant to GP
prescribing research (Sampson and Palmer, 1973). Chisnall has the same
opinion: "The best results encountered had concerned a very spedfic problem, viz.
research among General Practitioners in connection with drugs for a particular
kind 0/ arthritis. In this particular case, there were/our/actors which contributed
to likely accurate behaviour prediction/rom attitudes: (a) homogeneous "involved"
popullltion, (b) high interest attitude object, (c) specifICsituation nominated, and
(d) more rigorous data collection methods (Chisnall, 1985: 83).
Given the importance ofTORA not only to prescribing behaviour research,
but also to purchase generic prescription drugs (Brinberg and Cummings,
1984), an initial presentation of this model of social behaviour is required.
3.4.1 The Theory of Reasoned Action
The theory of reasoned action (TORA) (Ajzen and Fishbein, 1980;
Fishbein and Ajzen, 1975) has been systematically and widely used in a
variety of experimental and naturalistic settings for more than two decades
(Foxall and Goldsmith, 1994; Ajzen and Madden, 1986). Its longevity and
acceptance for explaining social action have been recognised by
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prestigious researchers: "One mark of the success of any theory is its longevity. By
this measure, the theory of reasoned action (e.g., Ajzen and Fishbein 1980; Fishbein
and Ajzen, 1975) has achieved due recognition as afundamental modelfor explaining
social action" (Bagozzi, 1992: 178).
According to the theory, attitudes should be placed within a sequence of
linked cognitive constructs: beliefs, attitudes, intentions and behaviour.
The TORA model specifies not only relationships between these
motivational constructs, but also includes the social aspects of attitude
formation (Miniard and Page, 1984). Moreover, the approach implicit in
TORA has proved especially attractive as regards the problem of attitude-
behaviour consistency (Foxall, 1984a; b; c; 1983; 1981).
In the past, attitude items specified only the target object of the attitude.
As a result, Fishbein defined attitude as "the amount of effect for or against a
psychologic objecl' (Fishbein, 1967: 478). The Fishbein (1967) notion of
attitudes toward actions (act) as opposed to the more traditional attitude
focus on objects was an important revolution in the conceptualisation of
and distinction among variables. Furthermore, the "attitude toward the
act" was considered to be one expression of Fishbein's (1967) general
movement toward conceptual sophistication. Given this complex set of
concepts, an extension of Fishbein (1967) reflection was developed, and a
"new" theory was born: The Theory of Reasoned Action (Ajzen and
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Fishbein, 1980; Fishbein and Ajzen, 1975). Therefore, TORA has been
presented as an extension of earlier research on expectancy-value models
of attitude (Fishbein, 1967; 1963). A particular interest in rational,
volitional behaviour (i.e., behaviours that can be controlled by individuals)
can be found in Fishbein and Ajzens (1975) subsequent research. The
assumption that most actions of social relevance are under volitional
control is of particular interest because it enables these theorists to claim
emphatically that a person's intention to perform (or not perform) a
behaviour is the immediate determinant of the action. The behaviour under
volitional control was assumed to be dependent on an actor's attitude
towards the behaviour.
Another revolution in conceptualisation was the redefinition of the usual
cognitive component of belief: which was assumed to be "the subjective
probability of a relotion between the object of the belief and some other object,
value, concept, or attribute" (Fishbein and Ajzen, 1975: 131). The conative
component of attitude was termed behavioural intention, defined as "a
person's location on a subjective probability dimension involving a relation between
him and some action" (ibiden, p.288). The importance of the separation of
the components of attitude was developed in order to obtain a causal chain
involving attitude, intention and behaviour. Fishbein and Ajzen (1975)
claimed that there is a strong relationship between behaviour and
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behavioural intent only when a very explicit situation-specific intention is
present. In this way, behaviours (i.e., volitionally controlled behaviours)
were assumed to be a consequence of behavioural intention, which in turn
was a function of attitudes towards the acts in question, and influenced by
normative beliefs. This social-normative factor represents "one's judgements
about the expectations of particular signifICant others and one's motivation to
comply with those expectations" (Fishbein and Ajzen, 1975: 302). That is, in
addition to providing a model which focuses on attitudes toward actions
and resultant consequences, Fishbein and Ajzen's (1975) model includes a
measure of the social consequences (i.e., the subjective norm). In line with
this reasoning, the researchers argued that attitudes were functionally
linked to beliefs.
The conceptual sophistication of Ajzen and Fishbein (1977) model
assumed that attitudes and behaviours are realities "consisting of four
dijJe,ent elements: the action, the target at which the action is di,ected, the context
in which action is performed, and the time at which is performed' (Ajzen and
Fishbein, 1977: 889). The major conceptual argument supported by Ajzen
and Fishbein (1977) was that attitudes should predict behaviours best
under conditions of high correspondence. That is, the elements constituting
attitude and behaviour should be the same (Ajzen and Fishbein, 1980).
Furthermore, these elements should be defined at the same level of
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specificity for high correlations to appear empirically. These authors
assumed that behaviours were items just like those contained in attitude
scales. Thus, any particular behaviour should be subjected to psychometric
analysis. Researchers who investigated the Fishbein and Ajzen's (1975)
theoretical framework argued that "the model has been shown to have predictive
validity in a rea/-world marketing application" (Ryan and Bonfield, 1980: 92).
Generally speaking, the TORA embraced the assumption that individuals
are usually quite rational and make systematic use of the information
available to them. Such reasoning strengthens the Fishbein and Ajzen's
(1975) argument that people consider their actions before they decide to
engage or not engage in a given behaviour. That is, the behaviour is
assumed to be a consequence of the intention to act. As a result, the
model recognised that behavioural intention was a function of:
(1) Probability beliefs about outcomes of behaviour;
(2) The subjective desirability of the outcomes; and
(3) Normative beliefs (i.e., beliefs about the social acceptability of a
behaviour).
The pre-behavioural posture results from a person's attitudes toward
performing the behaviour in question and the person's subjective
perception of the norm concerning the behaviour.
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Figure 3.1: The Theory of Reasoned Action
So"",,, : Derived from Filhboin, II. and I. Ajzen (1g75~ s.1;.r, Alllfude, Inlenlion, and 8e11I.iour: An In_uclion 10Theory Ind R•• _ ,Re.ding, MA: Mdil.r>-W .. loy
That is, the behavioural intention is a function of two basic determinants,
one personal in nature and the other reflecting social influence. Thus, the
person's intention to behave in a certain manner was represented by a
linear regression function of two main dimensions:
a) attitude toward the target behaviour (personal in nature); and
b) normative pressures that regulate behaviour (social in nature).
At the most basic level of explanation, it could be argued the TORA
embraces behaviour as a function of salient information, or beliefs,
relevant to the behaviour. Two kinds of beliefs were distinguished,
behavioural beliefs and normative beliefs. The former were assumed to
influence attitudes toward the behaviour, while the latter was faced as the
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underlying determinants of subjective norms. The TORA faces each
behavioural belief as a bridge between behaviour and a certain outcome.
Fishbein and Ajzen (1980) pointed out that individual external variables
such as personality traits, intelligence and demographic characteristics, or
social external variables such as status and the level of socialisation were
not necessarily related with behaviour. Nevertheless, these external
variables were assumed to be important in terms of the influence they have
on the person's beliefs or on the relative importance attached to attitudinal
and normative considerations. Thus, the effect of these external variables
on behaviour was assumed to be a function of its influence on the
determinants of that behaviour. That is, the TORA "stresses the importance
of antecedents of attitudes and subjective norms, which in the final analysis
determine intentions and actions" (Ajzen and Madden, 1986: 454).
In line with the reasoning that has been advanced, it is possible to stress
that the theory of reasoned action "deals moinly with the factors that intervene
between extemal variables and behaviour (Ajzen and Fishbein 1980: 9). For
this reason, the theory's validity does not depend on support for
hypotheses concerning the effects of external variables but on empirical
support for the relationships and the relative importance of attitudinal and
normative considerations as determinants of intentions. Thus, each of the
two components of intention to behave can be further specified.
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The beliefs that underlie people's attitudes toward the actual performance
of the behaviour (behavioural beliefs) depend upon what the person
believes will happen if he or she performs the behaviour. This also takes
into account the individual's evaluation of the consequence:
• Attitude toward performing the behaviour = The belief that the
behaviour leads to a specific consequence (i.e., the individual's
evaluation of that consequence)
Symbolically, AB = I: biei, where "b" is the belief that performing
behaviour "B" leads to consequences or outcome "i","e" is the person's
evaluation of outcome "i", and "L" is the number of beliefs the person
holds about performing behaviour "B".
The SUbjective norms are also a function of beliefs, but beliefs of a
different kind, which take into account how motivated a person is to
comply with that reference group's norms. These normative beliefs
embrace the person's beliefs that specific individuals or groups think he or
she should perform the behaviour in question. Thus:
• The Subjective norm concerning the behaviour = The normative beliefs
about the behaviour (i.e., the individual's motivation to comply with
those norms).
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Symbolically, SNB = 2: bi.m i., where "bi" is the normative belief (i.e.,
the person's belief that reference group or individual "L" thinks he or she
should or should not perform behaviour "B", "mi" is the motivation to
comply with the referent" i", and "2:" is the number of relevant referents.
Both the two sets of external factors can be known and be stable across
the range of behaviours which are to be explained. Therefore, it is possible
to argue that the intention to assume a particular course of action is a
function of the sum of the motivations weighted with the strengths of the
beliefs. Facing a new situation, with some particular characteristics, the
individual activates a subset of beliefs from his/her cognitive structure.
Along with the consequent motivations to comply with the opinion/advice
of the main referents, this will determine a certain behavioural intention or
preference and behaviour. These .two conceptually independent
components of intention, the attitude toward the behaviour and the
subjective perception of the norm are responsible for the final behaviour.
The former refers to the degree to which a person has a favourable or
unfavourable evaluation of the behaviour in question, while the latter
predictor of intention is a social factor, which is responsible for the
perceived social pressure to perform or not to perform the behaviour.
When any situation of conflict between the attitude toward the behaviour
and the subjective norm occurs, the relative importance of each factor will
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determine the behaviour. The outcome will be a function of the context.
For some behaviours the attitude someone has towards performing that
behaviour will be more important than the subjective perception of the
norm concerning that behaviour and will carry more weight in determining
the behavioural intention. For other behaviours the subjective perception of
the norm will be more important.
In short, expectancy-value models, particularly Fishbein and Ajzen (1975)
and Ajzen and Fishbein's (1980) theory of reasoned action, have been
extensively applied to consumer behaviour, and its presence in several
studies on doctor's prescribing behaviour is confirmation of its high level
of importance for pharmaceutical marketing. According to this view,
doctors process information and consequently form beliefs about an object
or the consequences of some action; associated with each belief is the
individual's evaluation of the information, and the two are combined
together to arrive at an overall judgement. Depending on one's school of
thought, this judgement is either synonymous with the person's attitude, or
is distinct from, but causally related to the attitude, and represents the
cognitive structure upon which it is based. Therefore, it is of relevance to
the research community on doctors' prescribing behaviour, that this
literature review was able to distinguish clearly between the TORA and
other expectancy-value models.
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3.4.2 Knapp and Oeltjen's (1972) Model
Knapp and Oltjen (1972), in an experimental study of benefit-to-risk
assessment in drug selection among GPs and specialists used an
"expectancy-value" model to analyse doctors' prescribing behaviour.
According to this theoretical framework, the prescription of a particular
drug would be a function of doctors' perceptions of:
I) The expectancy that a beneflcial effect would occur in the patient if the drug
wereprescribed;
2) The amount of the beneficial effect to be gained;
3) The expectancy of possible side effects; and
4) The ItUlgnitudeof these side-effects.
The relative weight given to the four factors was assessed under different
levels of severity of hypothetical cases of essential hypertension. Knapp
and Oltjen's (1972) study suggested that prescribing decisions were based
on subjective expectations about benefit (efficacy), risks (side-effects), and
other factors relating to the severity of the illness. The results derived from
this analytic framework indicated that doctors' characteristics,
particularly their speciality, and the severity of the illness were major
considerations in drug choice. Other variables such as a doctor's status,
age, practice site, and prescribing rate were not significantly related to
his/her perception of the benefit-to-risk ratio of any particular drug.
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3.4.3 Harrell and Bennett's (1974) Model
Harrell and Bennett (1974) were the first researchers to use Fishbein's
Behavioural Intention model to understand doctors' prescribing behaviour.
These researchers developed their study based on an unpublished paper
from Fishbein (1970) which was entitled "An Investigation of Relationships
Evalutive Beliefs, Affect, Behavioural Intention and Behaviour" (Harrell and
Bennet, 1974). Two versions of the expectancy-value model were tested.
The classic swnmative technique which follows Fishbein exactly and is
represented by the formula n, == RxI = f [ Bi a, ] WI + [ (NB) (Mc) ] W2
was used:
R, = prescribing behaviour regarding a specific brand;
RxI = behavioural intention to prescribe a particular brand in a specific
situation;
B, = belief about the outcomes of the behaviour (i.e., the probability that
each outcome is related to the behaviour);
a, = the evaluative aspect of the possible outcome (i.e., the relative
desirability of each outcome);
NB = the normative belief (i.e., the doctor beliefs about what his/her
colleagues would advise them to prescribe in that clinical situation;
Mc =motivation to comply with norms (i.e., doctors desire to comply with
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what colleagues would advise);
Wi = Beta weights (i.e., standardised partial correlation coefficients)
derived from multiple regression;
n = the number of relevant outcomes or consequences to the prescribing
act; and
f = L as in the Fishbein model, symbolising the extended disagregative
form in which each B, a, provides a separate independent variable in the
multiple regression equation.
This approach incorporated two dependent measures, behavioural intention
(RxI), which was measured by a seven-point bipolar scale, and prescribing
behaviour (Rx). As both actual behaviour (Rx) data and attitudinal
information (RxI) were available, it was possible to avoid considerable
alterations of the situation for each measurement.
Harrell and Bennett's (1974) attempted to create a clinical situation in
which, for a given patient with diabetes mellitus, drug choice was analysed
and a questionnaire was developed to collect the data. The questionnaire
encapsulated a comprehensive list of possible drug outcomes and side
effects which had been obtained during a prior group discussion. A
statement with the most typical prescribing situation for diabetes patients
was also introduced into the questionnaire. This instrument was used to
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understand and measure doctors' pharmaceutical brand preference. In
addition to the questionnaire, secondary data were obtained from a
prescribing panel was also used to test the Fishbein Behavioural Intentions
model. The different data were useful to evaluate:
1) The desirability of those outcomes;
2) The probabilities that those outcomes would be attached to five
pharmaceutical oral hypoglycemics brands; and
3) The medical, professional acceptability of that drug therapeutic
approach.
As mentioned earlier, Harrell and Bennett's (1974) research tested two
forms of the expectancy value model:
a) The summative technique which follows Fishbein's three variable
model: VD = (Summed Attributes) Wo + (Normative Factors) Wh
where VD = behaviour intent or actual behaviour.
b) The second form followed the alternative disaggregative model, which
is represented as a seven-variable model:
VD = (Attribute 1) WI + (Attribute 2) W2 + (Attribute 3) W3 +
(Attribute 4) W4 + (Attribute 5) Ws + (Attribute 6) W6 +
(Normative Factors) W" or
RxI= f [B, ail (Wi) + [(NB) (MC)] + (W,).
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In both formulae, attributes were not the physical attributes of the product,
but were factors derived from beliefs about the outcomes of performing the
act ( BI) and the evaluation of those beliefs ( aj ).
These researchers advocated that the second model was more practical for
marketing managers. This conviction was based on the advantage of a
better interpretation regarding the relative importance of each attribute as a
predictor of the dependent variable. Furthermore, the seven-variable
disaggregated form of the expectancy value model produced stronger
results than its summed form: "As such, it is a model with some direct
application to such mIlrketing decisions asproduct design, product positioning, and
the development ofpromotionai appeals (Harrell and Bennett, 1974: 277).
Although a strong relationship was expected, the authors concluded that
the relationship between actual behaviour and behavioural intention was
not strong (average correlation coefficient being only 0.40). As said
earlier, Fishbein's model can be expected to obtain strong correlations
between behavioural intention and behaviour when a very explicit situation
is defined. Otherwise, it is neither possible to measure attitudes toward
that specific action, nor to measure the beliefs and evaluations of the
specific outcomes attached to that action. In terms of the doctor's drug
choice, "prescriptions for the same drug might be for two different patients and
for somewhat different patient conditions" (Harrell and Benett 1974: 270). As
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a result, a specific patient profile is required in order to attempt to control
patient variation. To overcome this problem, these researchers presented
doctors with a clinical problem which guided their behaviour: "One way to
attempt to control for this variation is to present the respondent with a situation-
specific problem for which the behaviour is directed" (Harrell and Benett 1974:
270). The patient description provides a specific clinical context which is
relevant to the theoretical, cognitive premise that attitudes toward specific
actions and not towards brands would provide the best predictors of drug
choice. However, this strategy was insufficient for improving the
correlation between behavioural intention and actual behaviour. This was
reinforced by the significance level, which was an empirical indication that
a relationship was present, but that it was rather weak. Therefore, the
model was not able to explain a significant amount of the variance in the
dependent measure: "Aswith most research in buyer behaviour, however, a large
portion of the variance in the dependent measure is not explained by the mode!'
(Harrell and Benett, 1974: 273). These researchers pointed out that multi-
brand use and substantial brand switching by doctors over time may
partially justify the difference between actual behaviour and behavioural
intention. Additionally, they suggested that some specific characteristics of
the diabetic prescribing situation helped to explain these weak results.
Normative factors were also found unimportant in this study. Their
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fmdings also suggested that "patient conditions vary and often suggest the use
of particular brands; the "most typical" patient description situation did not
account for this ••• different patients often respond differently to different brands,
the favored brand might not match the patient's physio-chemical makeup ... the
averagephysician sees approximately six diabetics per month, a number too small
to randomize the effects of several variables such as concomitant diseases unlisted
on the patient description" (Harrell and Bennett, 1974: 276). Nevertheless,
Harrell and Bennett (1974) stressed that the model was very useful for
explaining and predicting drug choice.
3.4.4 Lilja's (1976) Model
In a study for the Swedish government in 1973, Lilja (1976) tried to
identify the overall attitude of doctors regarding ten different drugs for
treating both diabets and pneumococcal pneumonia. The goal of his
research was to understand the doctors' attitude towards pharmaceutical
brands. Therefore, the relationship between anyone drug and its particular
outcomes, under a particular patient description, was analysed.
Data collection regarding antidiabetic and antibiotic prescribing was
conducted using a mail questionnaire to a sample of 180 doctors. Bipolar
scales were use to evaluate drug interest. One expert group for each
disease under investigation was selected in order to evaluate doctors'
decision making, as described in Figure 3.2: The Lilja (1976) Model.
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The outcome of the treatment in terms of its curative effect, side effects,
and cost was evaluated in accordance with the Swedish health authorities'
suggestion. The relative importance of each of these treatment outcomes
was defmed by multiple regression analysis. Lilja (1976) found that the
curative effect of antidiabetic medication was the best predictor for new
drug adoption. The low level of side-effects was the second most
important attribute of drug choice. Drug cost however was found to be of
little importance to antidiabetic prescribing. Yet was considered more
important than side effects when the doctor has to choose an antibiotic to
treat pneumococcal pneumonia. As long as the number of satisfactory
results with the drug is high, the drug therapeutic approach was found to
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follow a habitual choice approach. Lilja (1976) pointed out that non-
habitual choice is better for understanding doctors' new drug prescribing
behaviour. However, some unsuitable prescribing was found. Doctors'
knowledge about drugs and their disposition was found to be important to
a rational drug therapeutic approach. External information was also
considered important for moulding expectations about drug outcomes.
In the diabetic case, the older doctors differed from the expert group. The
researcher pointed out that in this case doctors who read more than two
professional journals were found to differ more with the expert group than
those doctors who read fewer journals. This surprising result was justified
by the fact that clinical trials of this type of drug seldom appear in Swedish
professional journals. In the pneumonia case, the number professional
journals read had the opposite effect, and doctors with a low number of
visits by patients were found to have a similar prescribing behaviour to that
of the expert group.
In Lilja's (1976) study a positive relation was also found between the
attitudes of doctors towards information from pharmaceutical
manufacturers' representatives and information from governmental health
pamphlets. The same positive relationship was true of the number of
professional journals read and attendance at professional meetings. Three
main implications were derived from Lilja's (1976) study:
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1. More scientific information was required to communicate the relative
advantage of different drugs to doctors.
2. Although important, other criteria besides curative effect were necessary
for determining drug prescribing decision-making. In the case of drugs
with the same therapeutic effect, comparative drug cost is an example.
However, it was found important to involve the doctor in decision-
making prior to establishing any type of criteria, otherwise the doctor's
acceptance of this decision would be low.
3. Providing price information as a means of influencing drug choice was
inappropriate because of the low weight cost it was found to have in the
decision process. The results suggested that the curative effect of the
drug was a stronger attribute for influencing doctors' drug choice.
3.4.5 Segal and Hepler's (1982; 1985) Models
In their review of drug prescribing, Hepler et al (1981) argued that doctors
"may exchange infomudion with colleagues in a group, but in the psychological
view he or she acts alone to choose drugs" (Hepler et al., 1981: 33). These
researchers considered that a cognitive framework would be most suitable
for understanding doctors' prescribing behaviour because it allows the
interplay of variables to be observed within subjects. In line with this
reasoning, Hepler et al. (1981) concluded that doctors' prescribing
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behaviour was an active, conscious problem solving process, based on an
individual's beliefs and values which they derive from the clinical context.
They argued that the problem- solving approach began with a description
of a hypothetical patient followed by the therapeutic approach in which
several drug choices are linked with their outcomes, and with the values
doctors place on these outcomes. Based on Hepler et al.' s (1981) review,
Segal and Hepler (1982) developed a cognitive model of doctors'
prescribing behaviour. In this model, behaviour was the result of an active
and conscious problem solving activity. Segal and Hepler (1982) extended
Knapp and Oeltjen's (1972) theory of drug prescribing to include the
opinions expressed by doctors' colleagues as an important influence on
doctors' prescribing behaviour.
Segal and Hepler's (1982) approach was in line with Harrell and Bennett's
(1974) and Lilja's (1976) perspectives on therapeutic outcomes derived
from drug prescribing. These researchers argued that all the psychological
studies described formally in the literature (Knapp and Oeltjen 1972;
Harrel and Bennet 1974; Lilja 1976; Hepler, Clyne and Donta, 1982)
related prescriber cognitions (eg. believes about drug effects) to actual or
intended drug choices, with some models including prescriber attitudes.
Segal and Hepler (1982) pointed out that according to the cognitive-based
theories of behaviour, a person's cognitions (i.e., conscious knowledge,
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and beliefs) are evoked by a stimulus and are enacted prior to the person's
behaviour. Consequently, behaviour is the result of active, conscious
problem solving, and a prescribing decision depends on the interaction of:
1) The prescriber's beliefs about the probabilities that certain outcomes
would result from various treatment choices for a specific patient (i.e,
instrumentalities); and
2) The personal value of those outcomes to the prescriber (i.e., valences).
Segal and Hepler (1982) also argued that two types of belief were
considered in these theories:
• Expectancy - related to the person's set of subjective probability
estimates that various levels of effort in "working up" a patient may
result in a well-founded diagnosis or a well-developed treatment plan,
which is important for initial success .
• Instrumentality - resulting from a subjective belief (such as well-
developed treatment plan), and a consequent outcome, (such as patient
cure or doctor's duty of good medical practice).
The researchers assumed that the instrumentalities (i.e., beliefs about drug
effects and other outcomes of the therapy such as cost-effectiveness; low
side-effects; etc) of each alternative treatment and valences (i.e., the
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personal value attached to those outcomes by the prescriber) for each
outcome could be obtained through the use of a questionnaire since
prescribing behaviour was assumed to be a problem-oriented process with
three different stages:
• Stage I - Analysis of data about the patient clinical context and
consequent diagnosis;
• Stage II - Therapeutic plan; and
• Stage ill-Patient outcomes.
Segal and Hepler's (1982) theoretical framework of doctors' prescribing
behaviour encapsulated two cognitive models that explain and predict
different stages of the clinical decision-process:
1) Data-Gathering Model; and
2) Drug-Choice Model.
According to the Data-Gathering Model (Segal and Hepler, 1982), clinical
decisions at the Stage I are influenced by three main considerations:
• nonpsychological circumstances;
• the prescriber's clinical methods, particularly method of interviewing;
• the interaction of the doctor's expectations and valences.
Although the Data-Gathering Model was not investigated, the Drug-
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Choice Model incorporated its influences, particularly the importance of
the clinical context data. In the Drug-Choice Model, which addresses only
stages II and III, the formulation of a "Therapeutic Plan" was found to be
influenced by:
• The data about the patient coming from stage I (facts);
• The prescriber's valences for perceived outcomes that may occur in
stage III; and
• The instrumentality of each alternative therapeutic plan.
Six main drug-treatment outcomes were identified by Segal and Hepler:
1) Control of disease state;
2) Patient compliance with a treatment;
3) Side effects of a treatment;
4) Treatment expense (cost) to a patient;
5) Satisfying a demand for a particular treatment by a patient; and
6) Criticism from colleagues.
After identifying and listing the common outcomes associated with drug
therapy through interviews with twelve physicians, the authors used a
questionnaire to test their drug-choice model. A questionnaire called the
Prescribing Perceptions Instrument (PPI) was developed to obtain:
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(I) The probabilities of use three different drugs for each of the six pre-
selected outcomes;
(2) Doctor's personal value of each outcome (valences); and
(3) Instrumentalities.
The questionnaire was submitted to a sample of fifty resident or staff
family practice physicians, who were given a hypothetical description of a
hypertensive patient and three treatment choices, in order to collect the
data. In a fmal open question, doctors were also asked to define what they
assumed to be the correct drug treatment for the hypothetical hypertensive
patient. Forty-six usable questionnaires were returned.
As the first step to test the power of the Drug-Choice Model (DCM) to
predict a prescriber's attitude towards drug therapy, alternative treatments
were defined. The analysis was based on "theequation: Cj=L VkIjk' where
• Cj is the prescriber's valence of an alternative treatment j ;
• Vk is the prescriber's valence of outcome k; and
• Ijk is the doctor's belief about the instrumentality of treatment j for
outcome k.
The model's prediction of drug prescribing intention was based on the
treatment alternative with the highest Cj score.
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Control of the disease state was defmed by the prescribers in this sample
as being the most important outcome, followed by compliance with the
therapeutic regimen, side effects, cost, demand, and criticism from
colleagues. These fmdings confirmed earlier studies by, for example,
Knapp and Oltjen (1972) and Lilja (1976), where instrumentalities and
valences were found important predictors of drug choice. However, it
must be noted that the relatively large standard deviations of outcome
valence scores suggest that the generalis ability of these fmdings is risky.
As a result, inferences cannot be made about the importance of the validity
of these outcomes in other medical practices. Furthermore, different
doctors may assume other outcomes that were not identified.
In a later study Segal and Hepler (1985) tested the DeM under clinical
conditions. Their goal was to obtain a theory of drug prescribing that
would support and guide various prescribing intervention strategies. Two
extensions of Segal and Hepler's (1982) findings were studied:
I) The doctor's prescribing intentions (or the doctor's prescribing
behaviour) were a function of the highest calculated utility of all the
alternative pharmaceutical products; and
2) The doctor's general beliefs about drug therapeutic effects with
reference to typical hypertensive or diabetic diagnoses can be used to
predict their prescribing behaviour and prescribing intention.
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A questionnaire was designed to identify the doctor's guidelines for
selecting first-line drug therapy for hypertension and diabetes mellitus.
Forty doctors were given two fictional clinical case histories and SIX
disguised case histories of patients they had recently treated for
hypertension or diabetes mellitus in order to defme:
• the beliefs about the probability that seven treatment-related outcomes
would result from the prescribing of several alternative treatments; and
• the values placed on each outcome.
The doctors were also asked, in an open-ended question, how they would
treat the patient described in the case.
For each patient visit, the researchers defined three different measures:
1. the actual prescribing (pSA);
2. the prescribing intention (psi); and
3. the patient-specific beliefs connecting several prescribing alternatives
and drug treatment outcomes (Isjk).
Several utilities scores of treatment alternatives (Cj), one for each
alternative treatment, were calculated according to the equation below:
Cj = ~ Vk I Sj k,
where C] is the prescriber's utility for treatment j, Vk is the subjective
value of outcome k, and I Sj k is the prescriber's belief about the
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probability that prescribing treatment j would result in outcome k for a
specific patient. Segal and Hepler's (1985) prediction of the doctor's
actual prescribing behaviour, or the doctor's prescribing intention, was
then classified as either correct or incorrect by comparing the highest
calculated utility with PsA, or Psi.
To overcome the methodological problem of the questionnaire serving as a
temporary decision structure for the respondents, Segal and Hepler's
(1985) study data were collected from two sources:
1) Prescribers' interviews; and
2) Clinic records for patients of each participating prescriber.
This approach allowed researchers to "compare the model's predictive power
when prescribing intent was coUected either at the same time as outcomes values
and beliefs about treatment effects or one week later" (Segal and Hepler 1985:
968). As pointed out earlier, doctors were asked to read a case description
of a patient with either uncontrolled hypertension or diabetes mellitus.
Each prescriber was then asked:
• to rate the patient's disease severity according to his or her impression
of the untreated disease's effects on life expectancy and quality of life;
• to provide beliefs about the probability that certain drug treatment
outcomes would result from several alternative treatments. Seven drug
treatment outcomes were defined:
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1. Control of the disease state,
2. The patient's ability to pay for a treatment;
3. Criticism from colleagues;
4. Satisfying a patient's wishes;
5. Unwanted reactions to a treatment;
6. Patient taking the medication properly; and
7. Having good data to back up my treatment choice.
• to assume the best therapeutic approach for the patient described, via an
open-ended question.
Although the case description of a patient was presented as "hypothetical",
it was derived from the original patient visit. This strategy allowed
researchers to compare intended prescribing with the corresponding actual
prescribing for that specific patient's description.
The social norm, based on the concept of avoiding criticism from
colleagues, was found relatively unimportant in both studies (Segal and
Hepler 1982; 1985), and doctors, as a group, did not assume price as a
major consideration on drug choice (e.g., drug cost ranked fifth of seven in
the last study).
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Segal and Hepler's (1985) study found that prescribers highly valued
patient and disease-related outcomes both of antihypertensive and
antidiabetic therapies (controlling the disease; securing the patient's
compliance, avoiding side effects). The substantial predictive value of the
doctor's beliefs about treatment effects, which related these outcomes to
specific therapeutic choices, confirmed that clinical outcomes were
relevant to drug choice on hypertension and diabetes mellitus. These
findings were compatible with earlier research using psychological models
of doctors' prescribing behaviour (Knapp and Oeltjen, 1972; Harrell and
Bennett, 1974; Lilja, 1976). Segal and Hepler (1985) have also suggested
that knowing prescribers' cognitions of possible outcomes would allow the
prediction of doctors' therapeutic approaches. These researchers also
found that the choice of a specific drug, to obtain a particular drug
outcome, was mainly related with the patient's clinical characteristics:
"Finally, this study shows that some prescribers, at least the young resident
physicians in this study, see the usefulness of a particular drug for particular
outcomes differently for different patients" (Segal and Hepler, 1985: 975).
The drug choice model correctly predicted prescribing intentions in 81% of
the hypertension cases and in 87% of the diabetes cases.
Actual prescribing was correctly predicted in 76% of the hypertension
cases and in 70% of the diabetes cases (significant at p«O.OI).
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Segal and Hepler (1985) concluded that their cognitive model of drug
prescribing was a useful model for predicting doctor's drug choice.
However, the results should be carefully interpreted because they present
some limitations, especially with respect to sampling. This study (like its
predecessor) employed convenience sampling on a defined group of
American doctors. As a result, Segal and Hepler's (1985) findings were
derived from a sample that mayor may not be typical of a larger group.
3.4.6 Epstein et al: 's (1984) Model
Epstein et al. (1984) also used the Fishbein and Ajzen (1975) model to
study doctors' prescribing behaviour for anti-inflammatory medication. To
investigate the relationship between doctors' beliefs, attitudes and their
prescribing behaviour for anti-inflammatory drugs, 30 doctors in two
Veterans Administration clinics were surveyed by questionnaire, and 1,265
of their prescriptions were collected.
Doctors' beliefs regarding three drug attributes: efficacy, side-effects and
cost, and the relative importance of six drug attributes: efficacy, side-
effects, likelihood of compliance, placebo effects, cost, and the patient's
perception of doctors were measured.
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The doctors' beliefs were not found to be significantly related to
prescribing behaviour. However, the researchers concluded that the results
may be due to the small sample size (n=30) and the limited number of drug
attributes and beliefs that were measured: "First, our sample of physicians was
relatively small. With a Type I error of 0.05, our sample of 30 doctors gave us a
power of 83 percent to detect a real correlation of 0.4 was only 71percent. Second,
we did not control for case mix, either in collection of prescriptions or in our
questionnaire. The correlations we found may therefore be spuriously low. Third,
the beliefs we examined were limited to three elements; response rate, frequency of
side-effects and cost. We did not obtain any information on beliefs relating to
severity of side effects, likelihood of compliance, or other drug characteristics. It
may be that some of these beliefs are related to drug prescribing in this particular
situation. For these reasons, we are reluctant to conclude that beliefs are not
related to prescribing behaviour for these agents" (Epstein et al., 1984: 317).
Nevertheless, the study found that doctors' evaluations of the importance
of cost and placebo effects correlated significantly with prescribing
behaviour (p«O.05). However, Epstein and colleagues considered that
changes in prescribing behaviour that related to changes in drug beliefs
were easier to induce than changes in attitudes. Values or attitudes, on the
other hand, were found to be dependent on more complex patterns of
information including personal biases, habits and memorable experiences,
as well as drug knowledge.
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3.4.7 Denig et al. 's (1988) Model
Another interesting study of prescribing behaviour was conducted by
Denig et al. (1988). Although Denig et al. 's (1988) theoretical framework
used a derivative of the Fishbein and Ajzen (1975) Behavioural Intention
Model, their model presents substantial differences from the one proposed
by Segal and Hepler (1982; 1985).
Some researchers considered that the model represented in Figure 3.3 "is
more comprehensive than the one proposed by Segal and Hepler (1982)" (Agrawal
and Calantone, 1995: 100).
Figure 3.3: The Denig, Haaijer-Ruskamp and Zijsling's (1988) Model
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The DHZ's model is based on three main components:
1) Expectations and values about treatment outcomes;
2) The role of professional opinions, of expectations and values about the
professional acceptability of a particular drug therapeutic approach (i.e.,
subjective norm);
3) The doctor's personal clinical experience and value attached to it (i.e.,
prior behaviour).
The DHZ Model includes, in addition to expectancies and values about the
treatment outcomes, two additional components:
• Personal experience and value of personal experience; and
• Expectancies about opinions of social environment and motivation to
comply with environment.
Moderating factors such as the availability of the drug and the incidence of
the disease were also present in DHZ model, which was pioneering in
assuming that a doctor's personal clinical experience influenced their drug
choice. That is, prescribing is determined in part by past clinical
experience and the value attached to these experiences. Denig et al. (1988)
argued that we view "reality" through the mediation of our system of
concepts derived from prior behaviour. The interaction of "reality" and our
concepts makes up "experience". Thus, prior behaviour determines
experience, which in turn influences attitudes. However, attitudes were
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also found to be important predictors of behaviour. As a result, the idea
that behaviour exerts a reverse impact on attitudes, at least in certain
situations, suggests that through personal experience, consumers learn
which brands must be chosen to meet their needs and expectations.
Therefore, Denig et al.' s (1988) research found that prior clinical
experience with the drug was a major contributor to doctors' prescribing
behaviour. In the DHZ model, direct links were established between:
a) prior behaviour and target behaviour;
b) prior behaviour and behavioural intentions; and
c) attitude and target behaviour.
In DHZ model, attitude directly affects behaviour by means of its influence
on intention. As pointed out earlier, a second modification to Fishbein and
Ajzen's (1975) theoretical framework was the addition of prior behaviour
to the model: "Previous behaviour is postulated to affect both current intentions
and future behaviour, effects not predicted by the original FIShbein and Ajr.en
(1975) model (Fredericks and Dosset 1983: 502).
Denig et al. (1988), following Fredericks and Dosset's (1983) opinion,
considered that the Bentler and Speckart (1979) were right when they
considered that their approach was "the most theoreticaJ/y adequate causa/-
predictive system relevant to a variety of behaviour domains" (Bentler and
Speckart, 1979: 455). In line with this reasoning, Denig et al. (1988) and
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Fredericks and Dosset (1983) assumed that Bentler and Speckart (1979)
framework was better than Fishbein and Ajzen's (1975) model when
explaining consumer behaviour:
In the TORA, "formulation prior behaviour is not considered, hence intention
has no competitor. Bentler and Speckart, on the other hand operationalize both
prior and target behaviour via retrospective self-report" (Fredericks and Dosset,
1983: 511).
Fredericks and Dosset compared the Fishbein and Ajzen (1975) model
with Bentler-Speckart's (1979) modifications and concluded that their
study supports Bentler-Speckart's hypothesis that direct paths from prior
behaviour lead to both intention and target behaviour. However, a
significant direct path from attitude to subsequent behaviour was not
found. That is, information about prior behaviour and target behaviour
increased the predictability of target behaviour but the inclusion of attitude
variables did not. However, Denig et al. 's (1988) findings were neither in
line with this assumption, nor with Fredericks and Dosset's view that: "In
essence, once prior behaviour is included in the model, the effects of intention
become nonsignifICant; that is, unnecessary for the prediction of target behaviour
in these data" (Fredericks and Dossett 1983: 511). In contrast, Denig et al.
(1988), as well as Bentler and Speckart (1979), recognised that the effect
of intention on subsequent behaviour was relevant.
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The predictive power of the DHZ model and the role of its separate
elements were tested in two regions in the Netherlands where 169 GPs,
with an estimated practice size of more than 1250 patients, agreed to
participate. Data were collected during interviews in which doctors were
asked to estimate the components of the drug choice model for the
treatment of two disorders:
1. irritable bowel syndrome (lBS); and
2. renal colic.
The authors pointed out that the former was "a rather harmless disorder that
is seen approx. 3 times every week by the physicians" ..., while the latter is "an
acute disorder that is seen once to twice a month by the physicians" (Denig et aI.,
1988). For each disorder three commonly used drugs were selected from
different therapeutic classes. General practitioners were asked to give:
1. their expectations about the treatment outcomes of the three different
drugs per disorder;
2. the value they attached to these treatment outcomes;
3. their expectations about both the professional acceptability of the drugs
and patient demand for the drugs;
4. their motivation to comply with the professional environment and with
the patients;
5. prior experience with the drugs; and
6. the value they attached to their personal experience.
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Attitudes, personal clinical experiences, and subjective norms were found
to explain 45% and 60% of the variation in the overall preferences for IBS
and renal colic drugs, respectively. When the model was used to predict
doctors' first drug choice, it was found that 73.6% and 78% of the first
choices for IBS and renal colic, respectively, were correctly predicted by
the model. However, further analysis of the model using Kappa as a
measure of agreement between the model's prediction and drug choice,
found that there was only a high agreement between the predicted and
actual first drug choice for the treatment of renal colic. The Kappas
indicated a low agreement in the case of the predicted and actual drug
choice for ms. Further, discriminant analysis using the three factors in the
model (attitudes, subjective norms, and experience) was performed and
found that discriminant functions were significant only for the drugs used
in renal colic. The researchers argued that drug choice would be reliably
predicted by their model if a rational prescribing behaviour was developed
by the doctor, but the level of prediction would depend on the type of
disease. Denig et al (1988), for example, suggested that the drug choice for
IBS was less rational than drug choice for renal colic: "The results suggest
that in some fields of prescribing, physicians consciously weigh distinct pros and cons
before choosing a drug, while in other fields the drug choice is less reasoned. In the
latter case other - undiscemed -factors might be more relevant" (ibid: 1385).
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Although the influence of perceived patient demand on drug choice
appeared to be negligible in Denig et aI.' s (1988 ) study, the importance of
the professional environment (colleagues, specialists and pharmacists) on
doctors' therapeutic approach was relevant:
"For choosing a drug for renal colic, the professional environment is even more
important than the attitude towards the drug" (ibid: 1386). The influence of the
professional environment on drug choice was in line with Miller's (1973-
74) findings. Denig and colleagues, therefore, suggested that educational
programmes designed for groups would obtain better results than an
individual approach. Identical results were obtained by Chinburapa and
Larson (1987). These researchers, utilising Fishbein and Ajzen's (1975)
Behaviour Intention Model as a conceptual framework, found that the
subjective norm component was very important in explaining the doctor's
prescribing intention. Although an opposing view was expressed in Segal
and Hapler (1982; 1985) studies, Chinburapa and Larson (1987) pointed
out that doctors' beliefs about treatment outcomes, as well as the
SUbjectivenorm component (i.e., the social and professional factors), were
relevant for understanding the doctor's prescribing behaviour. In a similar
vein, Denig et al. (1988) pointed out that drug choice was a function of the
interaction between expectations and values about treatment outcomes
(i.e., attitudes), nonnative factors and personal experience.
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The importance of the subjective norm was determined by asking doctors
how far their colleagues would recommend a drug for a particular patient.
This result was then multiplied by the doctor's general motivation to
comply with those colleagues. The fmal score of the different treatment
alternatives would be obtained through the formula:
where Tx is the "Treatment Score", "(Ai x Bi) la" represents the attitude
towards the drug X based on treatment outcomes i, while "Cj x Dj I b" is
the subjective norm considering persons j, and finally E x F is the
experience component of the model, which defines the weighted
experience with the drug. "A" symbolises expectations about the treatment
outcomes, while "C" is the medical professional acceptability of the drug
therapeutic approach, and finally "E" represents doctors' personal
experience with the drug. ~~B","D", and "F" are the respective values for
the corresponding variables.
As Denig et al. (1988) stressed, a reliable prediction of a prescriber's first
drug choice using this theoretical framework depends on the type and
severity of the pathology in question.
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3.4.8 Denig and Haaijer-Ruskamp's (1992) Model
Denig and Haaijer-Ruskamp (1992) have handled the therapeutic decision
making of doctors somewhat differently from previous researchers. These
social scientists considered that general practice involves common clinical
conditions in which most disease states are neither irreversible nor life-
threatening. Consequently, most of the patient's health problems may be
encapsulated within a few clinical categories with well established patterns
of care that are rarely complex (Denig and Haaijer-Ruskamp, 1992). As a
result, the therapeutic approach is usually a simple process with two
different steps:
I. a small cluster of drugs come into the doctor's mind (i.e., the evoked
set) when they have to treat a patient.
2. A specific therapy is chosen for the treatment of a specific disease.
Denig and Haaijer-Ruskamp (1992) suggested that the "evoked set" has
just a few therapies, two to five possible drug alternatives depending upon
the diagnosis. However, these researchers were unable to explain" how the
decision is made to include a therapy in the evoked set" (Denig and Haaijer-
Ruskamp, 1992: 12). As soon as a therapy belongs to a doctor's "evoked
set", its prescription for an individual patient follows two different
approaches:
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• unreasoned process; or
• a rational and active problem solving.
I) Unreasoned Process
When choosing a specific therapy from a cluster of drugs, doctors may be
influenced by their experience and consequent habits regarding the
approach to disease states that frequently occurs in their clinical practice.
They may also use basic decision strategies to define the course of
treatment. These heuristics, or rules-of-thumb, may be derived from active
problem-solving or may have their origin in unreasoned processes:
"To what extent the final decision to adopt a new treatment is determined by trial and
error, simple persuasion, or by a reasoned weighing of pros and cons is unknown"
(Denig and Haaijer-Ruskamp, 1992: 12).
That is, the use of a drug from the "evoked set" is not always a reasoned
choice and may follow a heuristic process (Denig and Haaijer-Ruskamp,
1992). Accordingly, with this assumption the researchers recognised the
scarcity of studies about this specific point in the doctors' decision-making
process.
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2) Active Problem Solving (weighing pros and cons of the values and
expected outcome for each possible option)
This approach is based on the evaluation of expected outcomes, after
deciding which criteria are relevant to the decision. Outcomes are then
ranked, or valued, according to their importance. As a result, a few
potential therapeutic solutions will be chosen and one of them will be
selected from the evoked set. However, "if one wants to stimulate the use of a
certain treatment that is not included in the evoked set, physicians have to be
convinced that there is a need to change this evoked set. As long as the physicians
believe that their evoked set is suffICient, publications about the medical and
pha17lUlCeutica/properties of altematives are not likely to change the drug choices.
Acceptable reasons should be offered for changing the treatment options that are
considered' (Denig and Haaijer-Ruskamp, 1992: 13).
Doctors may choose different maximising strategies to decide the best
treatment in accordance with an analytical procedure which involves:
a) a set of procedures that doctors engage in when attempting to choose
between alternative prescribing courses of action; or
b) a decision rule that dictates how the results of the decision procedures
will be used to make the actual prescribing decision (Denig and Haaijer-
Ruskamp, 1992).
The set of procedures would be selected according to the patient's health
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context and some important criterion and would guide the decision rule. A
possible maximising strategy would be developed to choose the
therapeutic approach that performs best on that criterion. If a 'tie' occurs,
the second most important criterion would be chosen.
Doctors can also use the relevant criteria simultaneously. In this away,
doctors would obtain the expected utility of each therapeutic approach,
and would choose the treatment with the highest expected utility as the
most suitable approach. Mathematically this highest expected utility can be
described by the following equation:
EUj =L Vi • Oij,
where EU) is the expected utility oftreatmentj, Vi is the value assigned to
criterion i; and Oij is the expected outcome of treatment j with regard to
criterion i (Denig and Haaijer-Ruskamp, 1992).
To change doctors' unreasoned rules-of-thumb for prescribing, both
facilitative and restrictive strategies should be used. The former suggests
the use of guidelines, while the latter recommends the use of a formulary
or of financial restrictions. However, Denig and Haaijer-Ruskamp (1992)
proposed that before choosing an intervention strategy to improve doctors'
rational prescribing behaviour, health authorities should look at the nature
of the clinical problem in accordance with their model (see Figure 3.4).
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Figure 3.4: The Denig and Haaijer-Ruskamp's (1992) Model
1. Doctor is presented with a clinical PROBLEM. As a result, an
2. EVOKED SET comes into the doctor's mind, which is influenced by:
a) DETAILING/ADVERTISING
b) INFORMATIONIEDUCATION TRIALS
The evoked set is also influenced by:
a) knowledge about treatments
b) opinions of the environment
c) experience with treatment
which determine values and expectations.
The choice from the evoked set of a specific drug therapeutic approach for
an individual patient can either be based on
3. UNREASONED RULES or 4. ACTIVE PROBLEM-SOLVING
Active problem-solving involves the weighing of expected outcomes for
each possible option (i.e., reasoned ru/~s). Therefore, values as well as
expectations influence this process. However, the choice of therapy may
be adopted from an opinion leader without any reasoning by the doctor
himself. In this case, unreasoned rules guide the intentional choice oj
therapy.
5. CHOICE OF THERAPY
In some cases, this intention may differ from the actual prescribing due the
influence of external (contextual) factors (i.e., limitations due to external
factors).
6. PRESCRIBING
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3.4.9 Mancuso and Rose's (1987) Model
In the past decade, a substantial amount of research into decision-making
has focused attention on understanding the cognitive processes underlying
judgement and choice, and on the clinical context (Chinburapa et aI., 1993;
Chinburapa and Larson, 1992; Chinburapa and Larson, 1988; Mancuso
and Rose, 1987). However, these cognitive processes were found to differ
from the traditional compositional approach to attitude measurement such
as the TORA model. The expectancy-value framework, as hypothetic-
deductive analysis, has been used as the model that researchers proposed
in diagnostic decisions for clinical problem solving by the description of a
hypothetical patient. By structuring the patient observation, the clinical
situation can be disaggregated in sub-problems, which assume the form of
a decision tree. With this approach, the clinical events, the likelihood of
their occurrence, and the importance of the outcomes attached to different
drug choices (i.e., utilities), can be linked and the best therapeutic solution
found. However, Mancuso and Rose (1987) argued that doctors were not
seen to generate hypothesis regarding optimal treatment, nor did they
search the case for further data to support treatment choices or solve
clinical problems by growing a decision tree in their heads.
Focal composite analysis (Mancuso and Rose, 1987) (which is similar to
cognitive models based on expectancy-value theory and its consequent
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therapeutic decision-making process), determines the relevant clinical facts
selected during patient observation and evaluates them to defme the best
therapeutic approach. This change in the focus of research was because of
the complexity of the clinical context. Some researchers argued that
doctors' cognitive processes when making therapeutic decisions in a
complex clinical situation in which more than one drug treatment is
acceptable, were different from those that GPs face in primary care
(Mancuso and Rose, 1987). For example, the disaggregation of a patient's
clinical context (such as coronary heart disease) into sub-pathologic
realities so as to obtain a simplification of the problem, can be a complex
and time consuming process (Mancuso and Rose, 1987). Thus, the
doctor's clinical reasoning was understood as a decision making process
based on relevant clinical facts selected through patient observation. This
was termed/oeal composite analysis.
In Mancuso and Rose's study, eighteen internists were presented with
three hypothetical cases of patients with coronary heart disease and were
asked to explain their therapeutic approach. A technique of process tracing
was used to characterise the doctors' therapeutic decision making.
These researchers developed their cognitive model of therapeutic decision
making, the focal-composite model, with a hypothesis-generating study
in which the problem-solving strategy is done through narration at each
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step in the decision making process. They concluded that doctors arrived
at therapeutic decisions by selecting and evaluating focal points, one
element at a time, in order to reduce the amount of information that
accompanies a case history. The first step in the process looked for the
most important facts, a few focal points, which were evaluated with
respect to treatment options. Then, the value of each focal point was
evaluated as a function of other focal points and the patient's clinical story.
The final step was characterised by the assessment of the total sum of
focal points in order to decide the best therapeutic decision for the patient.
The analysis of each focal point was done with a knowledge of the
relevant literature on the field and with physicians' clinical experience of
similar cases, in order to identify the most important factors that would
ultimately influence the treatment decision. These arguments suggested
that one way doctors simplify complex problem-solving by focusing on
attributes that are particularly informative and predictive in terms of the
patient therapeutic approach. Other researchers also considered that "The
cognitive method for clinical decision making under uncertainty appears to be
incremental,subdividing the overall decision into sub-problems solved on the basis of
a few attributes" (Moskowitz et al., 1988: 443). Mancuso and Rose pointed
out that the attributes that were considered central to a pathology's
correlational structure, and for this reason correlate with many other
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attributes, were more diagnostic than less central attributes. The values
attached to each central attribute would determine the power to predict the
best prescribing solution and would be assumed as focal points. Rather
than searching for a universal and exhaustive taxonomy of factors that are
important to a therapeutic solution, focal composite analysis requires to
isolate only those focal points that doctors use when simplifying a complex
clinical problem. These focal points were chosen following a heuristic
process that simplifies the way doctors deal with clinical information in
order to select a limited set of drugs options: "Physicians, guided by their own
sets of heuristics, chose factors they considered most important. For example, a
frequently used heuristic was to recognize having managed similar cases in the past"
(ibidem: 1284). This approach offers a better short cut to a therapeutic
decision: "By contrasting actual decision making with decision analysis, physicians
would be able to make better and better justified therapeutic decisions" (ibid:
1284). However, doctors' personal clinical values were found to have an
important role in drug choice:
"Because therapeutic choices must often be made without a "state-of-the-art"
standard,physicians implicitly or explicitly incorporate their own personal values in
theformulation" (ibidem: 1284).
Mancuso and Rose suggested that further research was needed to clarify
the importance of these personal clinical values.
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3.4.10 Chinburapa and Larson's (1992) Model
Chinburapa et al. (1987), utilising the Fishbein and Ajzen (1975)
behaviour intention model as a conceptual framework, found that the
subjective norm component (i.e., the social factor) was significant in
explaining doctors' prescribing intentions. In the following study,
however, the role of peers was found to be relatively unimportant
(Chinburapa and Larson, 1988). In contrast with the initial study,
Chinburapa and Larson's subsequent (1988) study used conjoint analysis"
for predicting prescribing intention and assessing drug attribute importance
for a hypothetical case of a patient with essential hypertension. This
method, in contrast with the expectancy-value theory, analyses the trade-
offs that doctors have to make when judging between multi-attribute
alternatives. Nevertheless, the relative importance of drug attributes
obtained from both methods was not significantly different. Effectiveness
and side-effects were considered the most important attributes. Dosage
schedule was found to be the third most important attribute. Based on
these findings, Chinburapa and Larson (1992) developed a multi-attribute
model which was considered relevant both for the pharmaceutical industry
and health authorities:
44 Conjoint analysis is a measurement technique "from the fields of mathematical psychology and
psychometrics that can aid the marlceting manager in sorting out the relative importance of a
product's multidimensional attributes" (Green and Wind. 1975: 108).
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"From a pharmaceutical marketing perspective, information about a physician's
perception of a product is useful to identify particular characteristics that can affect
the drug's position in the market place...From a health care administrator's
perspective, the information can be used to help design educational programmes to
influence drugprescribing" (Chinburapa and Larson, 1992: 334).
Their model represents the outcome of considerable reflection on doctors'
prescribing behaviour.
The purpose of Chinburapa and Larson's study was to assess the relative
importance to doctors of specific side effects and outcomes (i.e, the
control of disease, convenient dosing and cost) as they differentiate drug
products for hypertension, allergic rhinits, and gastroesophageal reflux. In
addition, the study examined whether the importance of particular
characteristics attributed to a drug varied across four types of practice:
• solo practice;
• group practice;
• institution; and
• government.
Cbinburapa and Larson reported a response rate of 22% (i.e., 527
responses from 2,400 surveys mailed).
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The effective control of disease was perceived to be the most important
outcome, followed by the avoidance of specific side effects, in all three
prescribing scenarios. This result is consistent with earlier prescribing
research (Chinburapa and Larson, 1988; Denig et al., 1988; Zelnio, 1982;
Lilja, 1976). The practice setting was neither important in terms of its
influence on beliefs, nor in terms of its influence on results in any of the
three prescribing scenarios. However, doctors in each setting were found
to have different intentions towards prescribing certain studied drugs: "For
hypertension the likelihood of prescribing the four drugs was higher among solo and
government physicians than institution-based and group practice physicians.
Furthermore, government physicians were more likely to prescribe different
antihistamine drugs than solo or group practitioners. In the gastroesophageal reflux
case, solo practitioners were more likely to prescribe different drugs than were
institution-based or government physicians", (Chinburapa and Larson, 1992:
340).
Based on their findings, the researchers concluded that professional peer
pressure had a strong influence on doctors' prescribing intentions. This
fmding was in line with Chinburapa et al.'s (1987) study, in which the
subjective norm component, as suggested by Fishbein and Ajzen (1975),
was measured by asking the respondent to indicate the likelihood that his
colleagues would recommend a drug for a particular patient and
multiplying by the doctor's general motivation to comply with colleagues.
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3.4.11 Chinburapa et al:~s(1993) Model
Substantial evidence has been found in the prescribing literature that
supports the importance of two different factors in the drug decision-
making process (Chinburapa et aI., 1993; Denig and Haaijer-Ruskamp,
1992):
a) Situational involvement; and
b) Task complexity.
Situational involvement was defined as "the ability of a situation to elicit
from individuals concern for their behavior in that situation" (Houston and
Rothschild, 1978: 184). The construct of 'involvement' has received
intensive and rapidly growing attention in consumer behaviour research
during the last decade (Broderick et aI., 1995). In terms of prescribing
behaviour, published empirical evidence suggests that a high involvement
subject requires a more careful decision-making process based on a clear,
systematic and analytic approach to the clinical situation. In contrast, a low
involvement subject is less demanding in terms of the structure of the
analytic framework in the decision-making process (Cbinburapa et aI.,
1993; Denig and Haaijer-Ruskamp, 1992).
Task complexity was defined as the amount of information processing
that subjects have to deal with to manage the task.
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Three different factors were reported to characterise task complexity:
• the number of alternatives in the evoked set;
• the number of attributes; and
• time constraints.
To reduce the information-processing demands and cognitive effort
derived from task complexity, consumers develop heuristic processes.
When individuals have to face tasks with several alternatives they use a
noncompensatory decision-making approach. However, if there are only a
few alternatives, the process is simpler and individuals assume a
compensatory decision-making process (Chinburapa et al. 1993).
Conjoint analysis was used by Chinburapa and colleagues to determine the
predictive accuracy of the linear compensatory model in predicting
doctors' drug choice. The interaction effect between the characteristics of
the decision task (i.e., task complexity) and the decision environment (i.e.,
the importance of making a correct decision and the need to justify the decision to
others) was also analysed. In addition, they attempted to understand the
factors that affect the use of various decision-making processes.
Noncompensatory processes, such as conjunctive and elimination by
aspect (see Figure 3.5 for details), which do not involve tradeoffs between
attribute values and which only consider a subset of available information
when making the decision, were chosen to analyse drug choice.
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Figure 3.5 : Compensatory and Noncompensatory Processes
Combination Process: A mix of compensatory and noncompensatory processes,
combined or "constructed" on the spot to adopt the environmental factors.
• Compensatory Processes
Multiattribute model: A perceived weakness or negative evaluation on one
criterion is compensated for by a positive evaluation on another criterion.
Separate evaluations for each choice alternative are combined (added or
averaged) to form the overall evaluation of each one. Then the highest-rated
alternative is chosen .
• Noncompensatory Processes
Conjunctive: The Consumer establishes a minimum acceptable level for each
choice criterion. The consumer accepts an alternative only if every criterion
equals or exceeds the minimum cut-otT level.
Disjunctive: The consumer establishes acceptable standards for each criterion. A
product is acceptable if it exceeds the minimum level for at least one criterion.
Lexicographic: The consumer ranks choice criteria from most to least important.
Slhe chooses the best alternative according to the most important criterion. If a
tie occurs, slhe selects the best alternative according to the second most
important criterion, and so on.
Elimination by aspects: The consumer establishes minimum cut-otTs for each
choice criterion. Slhe selects one criterion and eliminates all alternatives that do
not exceed the cut-otT level. Slhe continues eliminating alternatives until just one
alternative remains which slhe then chooses.
Source: Adapted from James R. Bettman (1979), An Information Theory
of Consumer Choice, Reading, Mass: Addison-Wesley.
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The decision-making strategies described above also differ in terms of the
cognitive effort required to use the strategies and in terms of their ability to
lead to the optimal decision (Chinburapa et aI., 1993). Compensatory
decision-making processes were considered to be more complex, to
require greater cognitive effort, and to be more difficult to apply than
noncompensatory processes. However, compensatory processes were
considered to be more likely to lead to the optimal decision than
noncompensatory processes which only examine a subset of available
information and are more likely to lead to inconsistency or intransitivity in
preferences.
A sample of forty-eight doctors were asked to indicate their preferences
and choices for hypothetical anti-infective drugs. Cbinburapa et al. (1993)
used a combination of a process-tracing and an analysis of final judgement
techniques to examine the effects of situational involvement and task
complexity on the doctors' decision-making process. The process-tracing
technique employed in their research was the analysis of information
acquisition behaviour. The importance of the decision and the level of
responsibility related with the decision were found to be directly
responsible for the selection of more analytic strategies of information
acquisition: i.e., more effort to process the information and more time to
make the decision. The total amount paid for making a correct decision
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would therefore increase. However, these researchers postulated that "the
decision strategy used in a given situation is a result of balancing the cost and
benefits" (Chinburapa et aI., 1993: 1474). In accordance with this
reasoning, the choice of any decision strategy was assumed to be closely
related with the characteristics of the decision problems, decision and task
environments, and with the characteristics of the decision maker. Given
this assumption it would be possible to extrapolate that situational
involvement would have a significant effect upon, and interaction with,
task complexity during the information acquisition and decision-making
processes: "the effect of task complexity on decision-making process depends on
the subject's level of situational involvement" (Cbinburapa et al., 1993: 1474).
For this reason high-involvement subjects were supposed to use a more
analytical decision-making process (i.e., compensatory processes) than
low-involvement subjects. However, Chinburapa et al's (1993) study did
not prove the existence of a significant effect of situational involvement
on the use of decision-making processes. The increase in task complexity
was found to have a major and direct influence on the amount of cognitive
strain and information overload, which in turn was responsible for the use
of fewer analytical strategies to simplify the decision task and reduce the
cognitive effort. Task complexity was found to have a strong effect on
information acquisition and decision-making processes. However, these
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processes were contingent upon the characteristics of decision tasks and
other factors, which support their contingency model based on the
costlbenefit framework. That is, the results of the study clearly indicated
that doctors shifted from using compensatory to noncompensatory
decision-making processes when task complexity increased. The results
also indicated that the relative importance of drug attributes varied under
differing levels of task complexity. Task complexity was therefore found
to be important for the clarification of specific drug attribute information.
This finding was assumed to be relevant for understanding and influencing
doctors' prescribing behaviour (Chinburapa et aI., 1993). The most
relevant findings, however, were not only the use of noncompensatory
processes in decision-making, but also that there were no trade-off
attribute values in certain clinical conditions: "The findings that physiscians
used noncompensatory processes and did not trade-off attribute values in certain
conditions indicated that only a few alternatives may be considered in decision-
making" (ibid: 1481). These findings are in line with Denig and Haaijer-
Ruskamp's (1992) study on the limited set of doctors' treatment options
(i.e., the evoked set), which were found to vary between two to five
depending upon the diagnosis. In line with this reasoning, Chinburapa et
al. (1993) suggested that it was important to accurately identify the few
attributes and alternatives as well as pre-existing beliefs about the
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attributes for drug alternatives in the evoked set. Such information was
considered critical to clinical decision-making processes and should
therefore be used to effectively design communication messages to
influence doctors' prescribing behaviour. Finally, Chinburapa and
colleagues considered it relevant to use a multi-method approach to
study doctors' decision-making processes:
"The use of a combination of methods enables researchers to gain insights into how
decision-making processes and choices are affected by decision contexts" (ibid:
1481).
Cbinburapa et al.'s (1993) study confirmed that there was no single,
context-free clinical decision-making process. Thus, expectancy-value
theory was not the best framework tor predicting drug choice. These
researchers criticised the foundations of the expectancy-value framework
in terms of its:
• linear, compensatory decision-making processes in which all relevant
drug attributes or outcomes are considered;
• tradeoffs among attribute values; and
• proposition that overall evaluation is formed independently on each
alternative and the alternative with the highest overall evaluation is
chosen.
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3.4.12 Lambert et al: 's (1997) Extension to the TORA
As pointed out earlier, the TORA (Ajzen and Fishbein, 1980; Fishbein and
Ajzen, 1975) has, over the years, been applied to doctors' prescribing
behaviour (Segal and Hepler, 1985; 1982; Epstein et aI., 1984). However,
recent research on a proportion of prescriptions written by 19 primary care
physicians over a three month period found that antibiotic prescribing was
not significantly related to doctors' general attitudes, SUbjective norms, or
stated prescribing intentions. Using Ajzen and Fishbein (1980) and
Fishbein and Ajzen's (1975) theoretical framework, Lambert et aI. (1997)
found that "attitudes, subjective norms, and prescribing intentions were related to
one another in predictable ways, but actual prescribing of the seven selected
antibiotics was not related to any of these psychological constructs" (Lambert et
aI., 1997: 1774). Surprised by these unexpected results, the researchers
argued that "antibiotic prescribing at the facility studied was, in some sense, not
under physicians' volitional control' (Lambert et aI., 1997: 1775). Three main
factors were advanced to justify this conclusion:
1. Treatment protocols;
2. Formularies; and
3. The corporate transformation of medicine and the rise of managed care
in recent years.
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Given these changes to doctors' prescribing autonomy, Lambert et al.
(1997) argued that the TORA was no longer the best theoretical
framework for modelling prescribing behaviour because it was unable to
capture the importance of non-volitional or partially volitional drug choice.
Therefore, a revised version of the TORA, known as the theory of planned
behaviour (Ajzen, 1985; Ajzen and Madden, 1986) was assumed a better
approach to modelling the non-volitional or partially volitional aspects of
doctors' therapeutic approach (Lambert et al., 1997). However, to
understand Lambert et al.'s (1997) critic of the use of the TORA on
doctors' prescribing behaviour, it is necessary to analyse the changes that
can be identified in the evolution of this theoretical framework. The
contribution of other prestigious researchers to this discussion is also
relevant (Bagozzi, 1992; 1982; Ajzen and Madden, 1986). Given its
simplicity and applicability to different consumer contexts, it is not
surprising that the TORA has been considered a fundamental model for
explaining social action: "As shown by its longevity, the theory of reasoned action
has considerable theoretical and practical appeal. From a theoretical point of view, it
is intuitive, insightful in its ability to explain behaviour, and parsimonious. From a
practical perspective, it has been applied successfully to contexts such as consumer,
health, voting, recreational, and organizational behaviors...It is easy to
operationalise and yields relevant policy implications in everyday settings"
(Bagozzi, 1992: 180).
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In spite of the importance and success achieved by the TORA, some
researchers have been arguing that some fundamental problems, related
primarily to the theory's boundary conditions, remained unresolved
(Bagozzi, 1992; 1982; Ajzen and Madden, 1986). Different studies that
have been dealing with attitude research on drug choice stressed the
importance of these conditions in the methodological transition from verbal
responses to actual behaviour (Segal and Hepler, 1982; 1985; Harrell and
Bennett, 1974). Segal and Hepler for example, used patient-specific
measures of both prescribing intention and prescribing behaviour in order
to obtain a strong correlation between these two components of the
TORA. Segal and Hepler (1985) pointed out that the use of a general
measure of intention to predict a specific measure of behaviour would
result in a weak relationship between the two constructs. Furthermore, the
application of the TORA to doctors' prescribing decision-making has also
been questioned because of the elapsed time between the intention to act
and the behaviour itself:
''OJ course, the time lags between BI and B measures may alter considerably the
situationfor each measurement" (Harrel and Bennet, 1974: 270).
In line with the reasoning that has been advanced, three main prerequisites
are necessary to obtain a strong correlation between intention and
behaviour (Ajzen and Madden, 1986):
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1. the measure of intention must correspond in its level of generality to the
behavioural criterion;
2. intention must not have changed in the interval between the time at
which it was assessed and the time at which the behaviour is observed;
3. the behaviour under consideration is assumed to be under volitional
control.
According to the third criterion, the TORA applies only to actions that are
under volitional control:
"People can easily perform these behaviors if they are inclined to do so" (Ajzen,
1985: 12).
A behaviour may be considered to be completely under a person's control
"if the person can decide at will to perform it or not to perform it" (Ajzen and
Madden, 1986: 455).
This key assumption was considered absent from the new U.S.A.
prescribing context (Schlegelmich et al., 1990), which is characterised by
increased surveillance of doctors' clinical freedom in terms of drug choice:
"formulary management and concurrent drug utilization review are now followed Up
by computerized prescribing profiles and recommended intervention protocols to
control costs, improve quality, and constrain what management considers to be
erratic physician behavior" (Lambert et al., 1997: 1775-76).
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A similar conclusion was obtained by Agrawal and Calantone (1995) two
years before:
"New drug adoption models also need to incorporate the effects of new gatekeepers -
the hospital administrators and the insurance companies - on a physician's decision
making process regarding a new drug" (Agrawal and Calantone, 1995: 108).
In line with the reasoning that has been advanced, Lambert et al. (1997)
argued that the erosion of doctors' clinical freedom that has accompanied
the rise of corporatisation and managed care requires a non-volitional or
partially volitional approach to prescribing behaviour.
The total control of any situation (i.e., volitional control) is only present in
a limited range of behaviours (Bagozzi, 1992; Ajzen and Madden, 1986).
Thus, strictly speaking, most intended behaviours are best considered
goals, whose attainment is subject to some degree of uncertainty (Ajzen,
1985). In line with this reasoning, one must face this problem in terms of
behaviour-goal units. As a result, intentions must be faced as plans of
actions towards behavioural goals (Ajzen, 1985). The degree of
uncertainty of these plans of action towards behavioural goals reinforces
the importance of the concept of perceived behavioural control, which is
defined as "the person's belief as to how easy or difficult performance of the
behaviouris likely to be" (Ajzen and Madden, 1986: 457).
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To explain behaviours not "completely" under volitional control, Ajzen
and Madden (1986) introduced the theory of planned behaviour (TOPB).
The TOPB is identical to the TORA except that a new antecedent to
intentions and behaviour - perceived behavioural control - has been
introduced. Therefore, the behaviour under explanation refers not to
actions totally under volitional governance as with the TORA. In this case,
the TOPB embraces actions subject to interference by internal and external
forces (Ajzen and Madden, 1986). Bagozzi and Edwards (1998) examined
the interaction between weight loss intentions and perceived behavioural
control over body weight, and argued that various personality factors may
moderate the effect of perceived behavioural control on behaviour.
Therefore, "To ensure accurate prediction of behaviour over which individuals have
only limited control, we must assess not only intention but also obtain some estimate
of the extent to which the individual is capable of exercising control over the
behaviour in question" (Ajzen and Madden, 1986: 456). In line with this
reasoning, a measure of perceived behavioural control, which represents
"the person's belief as to how easy or difficult performance of the behaviour is likely
to be" (Ajzen and Madden, 1986: 457) was developed.
According to the TOPB, the presence or absence of requisite resources
and opportunities were among the beliefs that ultimately determine the
conative posture. That is, the more that attainment of a behavioural goal is
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faced as being under volitional control, the stronger is the individual's
intention to develop the behaviour. As in the case of behavioural and
nonnative beliefs, it is possible to identify and measure these perceived
behavioural control beliefs, and treat them as partly independent
determinants of behaviour:
"Just as beliefs concerning consequences of the behaviour are viewed as determining
attitudes, and normative beliefs are viewed as determining subjective norms, so
beliefs about resources and opportunities may be viewed as underlying perceived
behavioural control" (Ajzen and Madden, 1986: 457).
These researchers concluded that like attitudes and subjective norms,
perceived behavioural control was related to an underlying set of salient
beliefs which provide useful information about the opportunities and
resources to perform the partially volitional behaviour. Thus, perceived
behavioural control was found to be an important predictor beyond
attitude, subjective norm, and intentions, which were the constructs
presented in the original TORA (see Figure 3.6 and Figure 3.7).
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Fig. 3.6: Theory of Reasoned Action
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Lbe Attitude
>;=1 Intention BehaviourIILsbme Subjective(Social) Norm
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Fig. 3.7: Theory of Planned Bebaviour
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Where: b = behavioural beliefs (likelihood) e = Evaluation (desirability)
sb = social referent belief (approval) me= Motivation to comply (Concem)
cb= control beliefs (do not need resources)
Ajzen and Madden (1986) schematically presented two possible models of
the theory of planned behaviour.
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The first version was based on the assumption that perceived behavioural
control had motivational implications for intentions. This direct causal
effect of perceived behavioural control on intention was the main
divergence from the TORA. Individuals who believe that "they have neither
the resources nor the opportunities to perform a certain behavior are unlikely toform
strong behavioral intentions to engage in it even if they hold favourable attitudes
toward the behaviour and believe that important others would approve of their
performing the behaviour" (Ajzen and Madden, 1986: 458). Thus, an
association between perceived behavioural control and intention should be
considered independent from attitude and the subjective norm in the sense
that was not mediated by either the former or the latter. Perceived
behavioural control was therefore found to correlate with attitude and
subjective norm, and was found to exert an independent effect on
behavioural intention (Ajzen and Madden, 1986). However, Ajzen and
Madden pointed out that it was not possible to assume an additive effect
which nature determines by itself as an intention to perform a behaviour.
According to this perspective, behavioural control was considered a
necessary, but insufficient, condition for the final behaviour. Such
reasoning, developed in the first version of the TOPB (Ajzen and Madden,
1986), reinforced the argument that perceived behavioural control affects
intention in interaction with attitude and a subjective norm.
119
In contrast, the second version assumed the possibility of a direct link
between perceived behavioural control and behaviour that was not
mediated by intention (see Figure 3.7). However, the idea presented in the
second version of the model (Ajzen and Madden, 1986) was sufficiently
flexible to embrace the fact that attainment of behavioural goals was
dependent not only on intention but also on behavioural control.
According to this second version of the theory, behaviour could be
affected both by the direct and indirect influence of perceived behavioural
control. The former would influence behaviour by its capacity to become a
partial substitute for a measure of actual control, while the latter would do
so via intentions. Nevertheless, the direct connection between behavioural
control and behaviour is assumed to represent a nonvolitional
determination of action (Bagozzi, 1992).
Ajzen and Madden (1986) argued that two critical conditions should be
observed to validate the theory of planned behaviour:
1. the behaviour being predicted must not be under volitional control,
otherwise the concept of perceived behavioural control becomes largely
irrelevant to the prediction of behaviour and the theory of planned
behaviour reduces to the theory of reasoned action.
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2. it must be evaluated the level where perceptions of behavioural control
represent actual control in the situation, in order to be accurate. The
measure of perceived behavioural control was found to be relevant only
in situations where both perceptions of behavioural control and actual
control are almost identical. Furthermore, the interaction effect, which
was considered to be the result of a close relationship between intention
and control towards the performance of a behaviour, should also be
present when we assume that the effect of intention on behaviour
depends on perceived behavioural control.
In accordance with these two critical conditions that support the use of the
TOPB, it is clear that this model represents an extension of the TORA: "In
sum, the theory of planned behaviour complements the theory of reasoned action. The
latter applies only to behaviors totally under volitional control; the former addresses
behaviors under partial volitional control. Perceived behavioral control is thought to
take into account personal deficiencies or external obstacles that possibly might
thwart performance of an act" (Bagozzi, 1992: 181).
In their study of class attendance by college students, Ajzen and Madden
(1986) found the addition of perceived behavioural control to the classic
TORA greatly improved their model's predictive power: "Perceived
behavioral control had a strong effect on intentions to attend class, and effect not
mediated by attitude and subjective norm, and not dependent on the influence of past
behaviour" (ibid: 465).
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In accordance with later studies, Ajzen (1991) reinforced the conviction
that the TOPB was clearly preferable to the TORA.
Based on the results derived from a study of employees' attendance at a
training session, Fishbein and Stasson (1990) questioned the assumption
that the TOPB permitted more accurate prediction of intentions and goal
attainment than did the TORA.
Madden et al. (1992), however, found that TOPB had better accurate
prediction of intentions and goal attainment than did the TORA.
In line with Madden et al. (1992), Ajzen (1991) and Ajzen and Madden's
(1986) convictions about the predictive power of their model, Lambert et
al. (1997) proposed that the TOPB be used in a study of drug choice
within managed care settings:
"The widespread implementation of managed health care marks an historical point of
inflection after which it appears that the utilization of drugs will be dominated more
by management systems than by individual physician decision-makers. Models that
acknowledge this new reality may perform better than existing individualistic,
psychological models at predicting and explaining the utilization of antibiotics as well
as other classes of drugs" (Lambert et al., 1997: 1777).
Unfortunately, however, no empirical work was presented to evaluate the
interest of the TOPB on managed care settings.
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3.5 Evaluation and Comparison of the Most Representative Models
3.5.1 Definition of the Criteria to Evaluate the Models
Usually, consumer behaviour models represent a simplified description of
the complex decision-making process of consumers (Howard, 1989;
Chisnall, 1985; Zaltman and Wallendorf, 1983; Zaltman et aI., 1973). With
these simplified frameworks (usually presented diagramatically), the
marketer can be much more effective in predicting how consumers might
respond to hislher marketing effort. Thus, "models of buying behaviour have
two basic usesfor marketing managers:
1. They describe in simplifiedform the marketparameters or characteristics affecting
thepurchase of certain types of goods or services.
2. They allow predictions to be made of the likely outcomes of specific marketing
strategies" (Chisnall, 1985: 160).
The criteria from which the models are evaluated may vary according to
the researchers' goals: "A model can be evaluated on different criteria,
depending on who is doing the evaluation and what purposes and Junctions that
person believes the model should perform. For instance, the mathematician looks for
quantitativenessand precision. A social scientist evaluates a model on the basis of its
insight into human behaviour and its explanatory power. A practitioner, such as a
marketing manager or a public policy maker, looks for a model's applicability or
utility in decision making" (Zaltman and Wallendorf 1983: 622).
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For pharmaceutical marketing managers, the model's applicability depends
on its capacity to represent the needs or values that guide doctors'
prescribing decision-making (Corstjens, 1991). That is, the model has to
be "useful in specifying possible relationships between variables and in suggesting a
hypothesis which may be empirically tested' (Foxall and Goldsmith, 1994: 25).
If the relationships between variables were shown to be correct, with exact
sequences between them, and if cause and effect relationships were well
formulated, both the model's explanatory and predictive power will
increase (Agrawal and Calantone, 1995; Lilien et aI., 1981). Four main
characteristics have been identified in models with high predictive power.
Such models are able to (Lilien et aI., 1992):
1) identify and measure all major variables making up a behavioural
system;
2) specify fundamental relationships between the variables;
3) specify exact sequences and cause and effect relationships; and
4) permit sensitivity analysis in order to explore the impact of changes in
the major variables.
This framework, supplemented by criteria derived from existing work on
the philosophy and methodology of science such as the criteria proposed
by Zaltman and Wallendorf (1983) (see box 3.2 below), will be used to
evaluate the most representative models on doctors' prescribing behaviour.
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According to Zaltman and Wallendorf (1983) a model must have 10
desirable properties, which serve as a useful checklist for model building
and development. The properties are as follows:
Box 3.2 : Zaltman and Wallendorfs (1983) Criteria
1. capable of 2. general 3. high in 4. high in 5. internally
explanation as heuristic power unifying power consistent
well as prediction
6. original 7. plausible B. simple 9. supported by JO. testable,
facts verifiable
The explanatory and predictive capacity of a model is fundamental. The
capacity for explanation must guide the development of the model since it
allows good predictive power. In addition, in order to be used in several
different buying situations a model should be sufficiently general. The
heuristic power of the model will be important if new questions for future
research are to be posed, while its unifying power is determined by its
capacity to bring together previously unrelated areas of knowledge. Thus,
a good consumer behaviour model must be based on a "specific theory of
how people process the information that is provided in the behavioural cues and
how these motivate action" (Bagozzi and Dabholkar, 1994: 317).
To properly explain consumer behaviour, the model has to be free of
logical incongruities that diminish its internal consistency.
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The originality of a model is the researcher's contribution to science, and
to the state of the art. As science is a state of permanent evolution, the
plausibility of a model does not mean that it is conclusive in its
representation, but that the model should at least ensure its capacity to
make sense in terms of validity.
The model should introduce the complexity that it wants to explain in a
way that is understandable and useful for academic or professional
purposes, and for this reason it should be as simple as possible. Any
complexity that becomes irrelevant to explanations of the phenomena
under study must be avoided.
The facts presented in the situation under study must be encapsulated by
the model, and they should be obvious at the time of its development.
Although existing facts should not be denied, this does not mean that the
model is unable to refuse a particular explanation related to the facts.
Finally, the assumptions presented in the development of the model must
be testable and verifiable in order to evaluate the level of its precision in an
empirical study. Agrawal and Calantone (1995) purposed an additional
criterion, the relevance of the model to actual practice. In pharmaceutical
marketing, this additional criterion should signify the capacity of the model
to help to formulate and implement the marketing strategy.
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3.5.1 Comparison of the Models
3.5.2.1 Explanatory and Predictive Capacity
Most of the models presented so far have a comprehensive structure.
However, their explanatory capacity is not strong enough to define
interactions between the variables. As a result, it is not possible to identify
the changeable relations between the variables. For example, Segal and
Hapler's (1982; 1985) studies postulated that doctors' drug choice may
vary according to the severity of the illness. However, their drug choice
model neither explained how related variables interact with each other
when the severity of illness changes, nor evaluated the importance of each
of these variables in different patterns of illness. In a similar vein, Denig et
al. (1988) suggested that doctors' decision-making and consequent
prescribing behaviour were found to be related to the severity of the
patient's disease. Although important, the type or severity of the disease
were not components of the explanation offered by their behavioural
prescribing models. Furthermore, interactions between, for example, the
therapeutic category and the type or severity of disease should be
identified in order to improve the model's explanation and prediction
power. Nevertheless, Segal and Hapler (1982; 1985) and Denig et al.'s
(1988) models encapsulate new constructs that "appear to be important
elements in the overall appraisal of a drug. and it is encouraging that. in the studies
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both of Segal and Hepler (1985) and Denig et al (1988), the actual drug choice
could be predicted correctly" (Haaijer-Ruskamp and Hemminki 1993: 105).
A further drawback in terms of a model's explanatory and predictive
capacity is that it is difficult to say why the marketing strategy works or do
not work, if the model is not supported by a theoretical framework. This is
the case with at least one of the 'behavioural's models, the Hemminki
(197Sb) model. By neglecting to specify a concrete theory, Hemminki's
(l975b) simplified model of the factors that affect drug prescription has a
reduced marketing applicability. That is, it neither includes the cognitive
processes of the doctors' decision-making nor the needs and values that
guide prescribing behaviour.
Harrell and Bennett's (1974) model is very useful in explaining and
predicting what product attributes exert a stronger influence on drug
choice. However, no explanation was advanced as to why certain
therapeutic options were chosen against other possible alternatives with
the same product attributes. As pointed out earlier, substantial evidence
has been found in the prescribing literature to confirm that there is no
single, clinical context-free decision (Chinburapa et aI., 1993). Therefore,
explanatory and predictive capacity of any prescribing model is directly
linked to the type and severity of the disease, which in turn incurs a
, The asswnption was incorrect.
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therapeutic approach that is guided by doctors' clinical values. This line of
reasoning was partially present in Denig and Haaijer-Ruskamp's (1992)
study. Furthermore, the assumption that the adoption of a drug from a
specific "evoked set" may follow a heuristic process (Denig and Haaijer-
Ruskamp, 1992) is in accordance with the clinical task complexity, which
in tum was found to affect the doctors' information processing activity
(Chinburapa et aI., 1993). It has been postulated that increased task
complexity results in the use of various simplified decision strategies in
order to reduce information-processing demands and cognitive efforts on
goal setting and goal striving (Bagozzi, 1992). Researchers in the sub-area
of psychology that deals with attitudes have not considered goal setting
and goal striving within the clinical context. As a result, the explanatory
and predictive capacity of any prescribing model is diminished because the
theories of reasoned action and planned behaviour were found to be
unsuitable for goal setting and goal striving: "Understandably, the theories of
reasoned action and planned behaviour have been infrequently applied to the
achievement of outcome goals, and when they have, typically very small amounts of
explained variance result" (Bagozzi and Edwards, 1998: 594).
In line with the reasoning that has been advanced, it is possible to argue
that the explanatory and predictive capacity of any prescribing model is
also dependent on both its capacity to elicit the cognitive schemas of
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doctors in terms of type and severity of patients' diseases and its capacity
to derive the clinical goals relevant to these doctors. That is, to improve
the explanatory and predictive capacity of the prescribing model it is
necessary to use it as a tool to investigate the hierarchical cognitive
schemas of doctors with respect to their reasons for desiring to prescribe a
therapeutic category against other therapeutic categories for a specific
patient's type and severity of disease. In summary, a conjugation of
volitional, motivational, and behavioural processes have to be present in a
prescribing model to improve its explanation and prediction in terms of the
selection of therapeutic classes for a specific patient's type and severity of
disease. The model has to eliminate doubt about" how the decision is made to
include a therapy in the evoked set" (Denig and Haaijer-Ruskamp, 1992: 12).
Only two of the models of doctors' prescribing behaviour (Segal and
Hapler, 1982; Denig et aI., 1988) explicitly presented their predictive
power, with encouraging results showing that the actual drug choice could
be accurately predicted. All the other models neither evaluated the level of
prediction nor developed methods that would allows any observation of
predictive power.
Assuming a hypothetical, but realistic, description of a antihypertensive
drug, Knapp and Oltjen's (1972) research was undertaken to investigate
subjective expectations about benefit (efficacy) and risks (side effects).
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Although important, these drug pharmacological considerations are not
enough to explain drug choice. As a result, its predictive power is not
strong.
The Segal and Hepler (1982) model was assumed to have a high level of
prediction (72% of the cases examined), while Denig et al. (1988)
presented the best results (73 to 78% of the cases examined). However,
Denig et al. 's (1988) model neither defined a general patient scenario, nor
assumed behavioural intentions as a major construct. The former was a
restrictive and unrepresentative patient scenario based on two different
uncommon diseases (i.e., irritable bowel syndrome and renal colic), while
the latter has been assumed as a precondition for action. As a result, the
model's predictive power may be questioned because the patient scenario
is poor in terms of doctors' daily clinical activity, and intentions have been
found to be more effective predictors of behaviour as compared to overall
attitude towards a product.
Denig and Ruskamp's (1992) model may be thought of as a promising
future approach to doctors' prescribing behaviour. This new avenue for
future research is, however, beyond the scope of this thesis. Furthermore,
no empirical work has been conducted to test its predictive power.
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3.5.2.2 Generality
Hemminki's (l975b) model is the less generalisable. She introduced into
her doctors' prescribing model new dimensions such as the manufacturers'
influences on independent research, undergraduate and postgraduate
education, scientific journals and advertising, as well as control and
regulations from health authorities, health insurance systems, and
medicines committees. However, the model is not generalisable because
there are deep differences within the E.U's members health care systems.
The Segal and Hepler (1982) model has low generalis ability because the
model was only tested on a small sample of family practice residents and
staff doctors from just one practice site. Earlier evidence on differences
between doctors' outcome values (Segal and Hepler, 1982), was not
confirmed in their extended model (Segal and Hepler 1985). However,
these differences may be present in other clinical settings. Thus, the results
cannot be generalised to other types of prescribers or diseases, and
additional research must be developed to test the homogeneity of values
among different groups of doctors. All the other models have substantial
generalisability, particularly Harrell and Benett's (1974) model. Miller
(1974) and the Denig and Haaijer-Ruskamp's (1992) models should be
assumed to be the most generalis able because they can be applied to a
wide range of clinical contexts.
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3.5.2.3 Heuristic Power
By the time they were presented, Knapp and Oeltjen's (1972) and Harrell
and Bennett's (1974) models were interesting examples of high heuristic
power because they pioneered the use of expectancy-value theory on
doctors' prescribing behaviour. Their influence for stimulating new
questions concerning drug therapeutic approaches was strong and recent
studies on this field used a similar approach (Lambert et aI., 1997; Segal
and Hepler, 1982; 1985). The conflicting conceptual relationship between
behavioural intention and behaviour, as well as volitional and nonvolitional
behaviour presented in these studies are examples of such questions, and
were introduced into discussions about the accuracy and usefulness of the
TORA for predicting doctors' prescribing behaviour.
Although Miller's (1974) and Hemminki's (1975b) models did not present
a theoretical framework that supports their empirical work, both of these
models have a very high heuristic power, which is derived from their
capacity to generate new questions for future research. The former
introduces the Rogers' (1962) concept on innovative adoption in doctors'
prescribing behaviour, while the latter incorporates new, important
dimensions previously not included in drug adoption models. The same is
true for Denig and Haaijer-Ruskamp's (1992) model, which must be
regarded as a promising approach to drug choice.
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3.5.2.4 Unifying Power
Knapp and Oeltjen's (1972) model is a rare example of unifying power in
terms of the relationship between the clinical context and the therapeutic
approach, because their model connects, for the first time, the risk or
benefit of the drug with the severity of the illness.
Harrell and Bennett's (1974) model brings together and clarifies, for the
first time, the relationships among "attitudes", "beliefs", "behavioural
intentions", and "behaviour" in prescribing.
Several dimensions previously viewed as unrelated, were brought together
in both Hemminki's (l97Sb) and Haaijer-Ruskamp and Hemminki's
(1993) models. The unifying power of their model derives fundamentally
from the capacity to inter-relate various institutional, social, and
psychological variables. For example, control and regulations from health
authorities, health insurance systems, and medicines committees, as well
as demands and expectations of pressure groups and society at large, or
even doctors' personal characteristics were linked to dimensions that had
previously been found to be important to prescribing behaviour such as the
pharmaceutical manufacturers' influences on independent research,
undergraduate and postgraduate education, medical and scientific journals
and advertising.
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Miller's (1974) model has a strong unifying power that derives from its
capacity to link the antecedent variables in the structure of drug adoption
with the decision-making process and the therapeutic solution. Its unifying
power is reinforced by the relationship that is established between the
stages of adoption and the different sources of drug information, which
were the routes to Herruninki's (1975b) model.
The capacity to bring together different concepts like the doctor's clinical
past experience, professional environment and perceived patient demand
gives Denig et al. 's (1988) model an encouraging unifying power.
Denig and Haaijer-Ruskamp's (1992) model reveals a substantial unifying
power between two opposing paradigms of drug choice:
• rational problem solving; and
• unreasoned or heuristics processes.
3.5.2.5 Internal Consistency
The internal consistency of Miller's (1974) and Hemminki' s (197 5b)
models apparently seems to be less strong than other models because they
are general models that look for a simplified version of the panoply of
factors that were found to affect drug prescription. Furthermore, none of
them specify the direction or magnitude of the relationships between the
different constructs.
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The final version of Hemminki's (1975b) model (i.e., Haaijer-Ruskarnp
and Hemminki's, 1993 model) presents the same problem, which means
that the internal consistency is again not strong.
The Miller (1974) model may present some hidden inconsistencies related
to the different information sources that doctors were found to use in the
different stages of adoption of a new drug. All the other models seem to be
internally consistent.
3.5.1.6 Originality
In terms of the theoretical framework, both the Knapp and Oeltjen (1972)
and Harrell and Bennett (1974) are the most original models. The former
was the pioneering expectancy-value model, while the latter was anchored
to Fishbein's (1970) investigation of relationships among attitudes, beliefs,
behavioural intentions and behaviour, as they apply to drug choice.
In terms of constructs, both the Hemminki (l975b) model and its final
version (Haaijer-Ruskamp and Hemminki, 1993) can be regarded as the
most original since they propose the introduction of new dimensions to
embrace all the factors that were supposed to influence doctors'
prescribing behaviour. Control and regulations from health authorities,
health insurance systems, medicines committees and other health
professionals are some of the factors that affect individual physicians,
136
partially considered in some previous descriptive studies, but never
presented as structural constructs that provide a more systematic,
conceptual approach to drug choice. The important distinction between
factors that affect prescribing at the macro-level (so-called conditioning
factors) and factors that influence individual physicians (micro-level) is an
important step towards new approaches to drug therapeutic decision-
making.
The inclusion of personal clinical experience and the value attached to this
are two new major constructs presented in Denig et al.' s (1988) model,
which gives it a substantial construct originality.
Denig and Haaijer's (1992) theoretical drug choice model is quite original.
For the first time in the academic literature on drug choice, it was assumed
that the both reasoned and unreasoned decision-making processes may be
used by doctors when they prescribe a drug. However, "Conclusive evidence
in support one of these views over the other does not exist, and it seems possible that
more than one model is needed to represent the prescribing process" (Segal and
Hepler, 1982: 1892).
3.5.2.7 Plausibility
Although plausibility does not necessarily indicate that the model is
conclusive in its representation, it is necessary that it at least makes sense.
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All the models discussed above have a strong face validity since all of
them are the result of descriptive studies that have been developed to study
partial realities relating to doctors' therapeutic approaches.
3.5.2.8 Simplicity
Zaltman and Wallendorf (1983) suggested that the simplicity of a model
should be balanced with its capacity to include the main aspects of the
phenomenon that the researcher wants to explain or predict. With the
exception of Hemminki's (1975b) and Haaijer-Ruskamp's (1993) models,
it can be argued that all the models have a significant simplicity because
they are derived from Fishbein's (1970), Fishbein and Ajzen's (1975) and
Ajzen and Fishbein's (1980) classic work on attitude theory: "It is easy to
operationalize and yields relevant policy implications in everyday settings"
(Bagozzi, 1992: 180). This simplicity explains the reduced explanatory and
unifying power of the Knapp and Oeltjen (1972) model.
The introduction of constructs such as individual clinical experience in
Segal and Hapler's (1982; 1985) and Denig et al.'s (1988) models did not
alter their simplicity.
Lilja's (1976) model can be seen as moderately simple for an expectancy-
value model. The same is true for Denig and Haaijer-Ruskamp's (1992)
model.
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3.5.2.9 Supported by Facts
The literature relating drug adoption with drug choice covers a large
number of descriptive studies that suggest that most models were
supported by facts at the time they were developed.
3.5.2.10 Testable, Verifiable
As pointed out earlier, Segal and Hepler's (1985) and Denig et al. 's (1988)
prescribing models went further and integrated the role of opinions held in
the professional environment (by colleagues, specialists and pharmacists),
prior experience with the drug, and patient demand. Consequently, these
models encapsulate new constructs that were recognised as important
elements in understanding and explaining drug choice. In accordance with
this assumption, Segal and Hepler's (1985) and Denig et al. 's (1988)
prescribing models should be considered very testable and verifiable.
Harrell and Bennett's (1974) model, is also very testable and verifiable
because it derives from, perhaps the most comprehensive framework for
explaining consumer behaviour. The well-known work on attitude theory
developed initially by Fishbein (1970) gives Harrell and Bennett's (1974)
model a strong testable and verifiable capacity.
While Knapp and Oeltjen's (1972), Heminki's (1975b) and Haaijer-
Ruskamp and Hemminki's (1993) models can be quantified and therefore
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tested, Miller's (1974), Lilja's (1976), and Denig and Haaijer-Ruskamp's
(1992) models do not appear amenable to testing in their present form.
This is because of the structure of these models as they are more process
oriented than construct oriented.
3.5.2.11 Marketing Strategy Application
Harrell and Bennett's (1974) experimentation with Fishbein's (1970) work
on attitudes, intentions and behaviour was the first study presented to
pharmaceutical marketing managers. Other models of doctors' prescribing
behaviour had been developed to support health authorities' educational
programmes for improving "rational prescribing behaviour" or for defining
formulary list decisions (Freeman et al., 1993). Harrell and Bennett (1974),
following Fishbein's (1970) conceptual approach toward attitude, changed
the focus of attitudes toward objects to attitudes toward actions. This shift
of focus was important, and brought to pharmaceutical marketing new
conceptual considerations that were more congruent with actual
prescribing. Harrell and Bennett (1974) argued that there was a strong
intuitive support for measuring attitudes toward the act of prescribing, the
brand and the resultant consequences of prescribing. This approach was
considered better than the traditional view that assumes that knowing
attitudes toward a drug brand (i.e., the object) would enable prediction of
and explain underlying reasons for the purchase of that brand.
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Harrell and Bennett's (1974) fmdings were found to be important for
pharmaceutical marketing applications, particularly on "marketing decisions
as product design, product positioning, and the development of promotional
appeals" (Harrell and Bennett, 1974: 277).
Denig et al.'s (1988) model was suggested to be the most useful to
pharmaceutical marketing strategists because it is quite general (Agrawal
and Calantone, 1995). Furthermore, this model is based on an algebraic
formulation which provides marketing managers with the quantitative
information they need to support their decisions. However, no explanation
was advanced as to why the patient scenario was not representative of
doctors' daily clinical activity.
Besides their capacity to generate theory formulation, the structure of the
Hemminki (l975b) and Haaijer-Ruskamp and Hemminki (1993) models
did not present any empirical work whatsoever on drug choice.
Segal and Hepler's (1982; 1985) models provide quantitative information
which may be used for marketing strategy. However, they have an
identical problem to that described for Denig et al (1988).
Miller's (1974), Lilja's (1976), Denig and Haaijer-Ruskamp's (1992)
models have an interesting theoretical approach which can be used for
designing marketing strategies. This is not the case with the Knapp and
Oeltjen's (1972) model of risk-benefit assessment regarding drug choice.
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3.6 Information Exchange Networks
The sine qua non of prescribing decision making is information.
Accordingly, the doctor must seek information until (s)he knows what drug
to prescribe. Since the GP's information-seeking process can involve many
different information sources over an extended time, a research
framework is required to identify information exchange networks and
their relationship to drug choice. To accomplish this objective, we will
develop a literature review on doctors' social networks and their
influence on drug choice.
The primary goal of this study is to investigate GPs' prescribing behaviour.
Part of this broad goal is to be accomplished by evaluating the influence of
information exchange networks on drug choice. Successful marketing by
pharmaceutical manufacturers to doctors. is greatly determined by a good
understanding of the various social networks that influence their drug
choice. More specifically, it would be of benefit to pharmaceutical
marketers to ascertain to what extent drug choice is influenced by doctors'
social networks. Information exchange networks represent the contextual
environment within which the doctor operates. That is, drug choice is only
part of a more complex social network of drug use: "But, asa social act with
social consequences, drug prescribing is performed by doctors who are part of a
complex social network" (parish, 1974a: 215).
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In the primary care contextual environment, doctors as a group have
different preferences in terms of communication networks, but the
networks are the main vehicle for doctors to update their prescribing
behaviour (Linn et aI., 1972).
More recently, some researchers suggest that doctors practice within a
complex social and professional context that was found to influence and
to interact with their clinical activity (Lambert et aI., 1997; Peay and
Peay, 1994; Raisch, 1990a;b; Pendleton, 1984). For example, Raisch
pointed out that pharmaceutical manufacturers' representatives, opinions
of colleagues and scientific sources of prescribing information are thought
to influence prescribing decisions by influencing the thought process of the
physician. These social and professional structures are composed of
friendships and expert opinion or consultations (Eccles et aI., 1996), and
they comprise communication networks through which information,
influence, and innovation flow, particularly on new drug adoption:
"Hospitals, clinics and cardiologists have a significant impact on prescribing in
general practice. Physicians in primary care rank hospital recommendations as one
of the most important sources of information on new drugs" (Feely, 1999: 31).
Coleman et al.' s (1966) study identifies the importance and influence of
doctors' professional and social networks on drug prescribing and was
considered to be pioneering research, providing a fundamental and most
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suggestive understanding of the importance of professional and social
networks to innovative prescribing behaviour (Peay and Peay, 1994).
Pitt and Nell (1988) also showed that drug choice is influenced by
professional and social networks. Both the manufacturer's promotional
tools and interpersonal/organisational influences beyond marketers'
immediate control were cited. Interpersonal influences were seen as more
informal procedures by which doctors changed their opinions and
discussed prescribing with colleagues, consultants, associates andfriends.
Organisational influences were viewed as being somewhat more formal.
They were related to doctors' clinical experience with products in their
working situation, as well as hospital ward rounds and in-practice
discussions.
The adoption of a new antibiotic was found not to be an entirely individual
process because it existed in the context of ongoing interactions in the
professional environment with medical peers as well as interactions with
external influences (Coleman et aI., 1966). However, some studies on
drug innovation have also failed to replicate many of the findings from
the Coleman and colleagues' social networks perspective (peay and Peay,
1988; Christensen and Wertheimer, 1979). For example, doctors who were
highly integrated into social and professional networks did not adopt new
drugs earlier than their peers.
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Although the specific variables tested and the samples and settings used in
those studies varied, no evidence was found to support the relationship
between early adoption and participation in medical communication
networks or activities outside the doctor's practice. Neither was early
adoption associated with age (Peay and Peay, 1988), or the nwnber of
medical journals received (Weitz, 1981).
These fmdings were in line not only with the results of an earlier study
(Peay and Peay, 1984), but also with the Miller's (1974) work on new
drug adoption. For example, Christensen and Wertheimer (1979) found
that doctors used literature-based sources such as medical newsletters,
journal articles, medical texts and other written sources fOr general drug
information and colleagues for infOrmation on new drugs.
In summary, doctors have numerous social and professional sources of
drug information, To provide some structure four our literature review, we
arbitrarily classify'' the contextual clinical environment and its information
exchange networks as:
1. health authorities clinical information;
2. medical education and colleagues opinion; and
3. pharmaceutical industry promotion.
6 This classification scheme is not meant to be a scientific typology, but merely a convenience for
presentation.
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3.6.1 Health Authorities Clinical Information
There are many ways to gather drug information from the contextual
clinical environment, but doctors mostly were found to prefer and use
printed information sources such as medical journals and drug bulletins
(Denig et aI., 1990; Plumridge and Berbatis, 1989). For decades drug
bulletins have been produced by health authorities with the intention of
improving the standard of therapeutic decision and, more recently,
controlling drug expenditure. These drug bulletins are based on medical
guidelines and are "independent of the pharmaceutical industry, presented
attractively, and distributed efficiently and punctually to readers" (Plumridge and
Berbatis, 1989: 330). Again, studies of the impact of drug bulletins on
prescribing practices have reported conflicting results. Although the impact
of drug bulletins alone cannot be inferred, the interest of health authorities
in this source of therapeutic information suggests they have a significant
effect on rational prescribing. InPortugal, they were used for the first time
in 1998. The therapeutic information provided by these new
pharmacological source is based on medical guidelines developed by the
World Health Organisation (WHO). During the last decade, the WHO has
been involved in generating information on rational prescribing both for
specialists and GPs (Couper, 1995). Most of this information was
organised in accordance with medical guidelines for most common
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diseases (Ann strong, 1996; Pathman et al., 1996; Mant, 1994). Therefore,
these guidelines are considered the most recent influence on drug choice:
"guidelines perform a function for any professional group by helping to define the
bestpractice or 'the state-of-the-art:" (Newton et al., 1996: 513).
These considerations have stimulated the publication of guidelines to assist
physicians in the management of hypertension (Elliot, 2000). That is, these
medical guidelines were developed in an attempt to change the GPs'
inappropriate prescribing behaviour, particularly for the management of
hypertension (WHO-ISO, 1999; WHO, 1996; WHO-ISO, 1993).
A recent study which sought to determine what proportion of patients with
hypertension were managed in accordance with the guidelines established
by the Canadian Hypertension Society concluded that there is some
variation in the care of patients with hypertension (McAlister et al., 1997).
As a result, the researchers suggested that further studies were required to
determine the underlying reasons for doctors' non-compliance with the
evidence-based guidelines established by the Canadian Hypertension
Society. This was also suggested by Couper (1995) and Le Grand (1999).
Substantial variation between guidelines has also been pointed out: "The
international guidelines on the management of hypertension may use the same
evidence but they are not explicitly evidence linked and do not always agree on
recommendationsin important clinical areas" (Hutchinson, 1998: 1020).
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Guidelines have been developed for 3 main reasons (Newton et aI., 1996):
1. to define the best therapeutic approach or "the state of the art";
2. to evaluate medical practice in terms of drug prescribing against
standards; and
3. to improve efficiency.
The purpose of the medical guidelines on the management of hypertension
are identical: "The purpose of the guidelines is to assist practitioners in clinical
decision-making, to standardize and improve the quality of the patient care, and to
promote cost-effective drug prescribing. This guideline attempts to define principles
of practice which should produce high quality patient care. They are attuned to the
needs of a primary care practice but are directed to providers at all levels. The
guidelines also serve as a basis for monitoring local, regional and national patterns
of pharmacological care" (Veterans Health Administration, 1996: 5).
Wensing et al. (1998) considered that "the particular characteristics and
specific problems found in general practice can influence the implementation of
guidelines and innovations. For instance, the wide variety of symptoms and diseases
seen in general practice (as a result of the general accessibility of primary health
care) inhibits a strongfoeus on oneparticular guideline or innovation" (ibid: 991).
In the Netherlands, the perspectives of doctors who are being encouraged
or recommended to use guidelines in their every day work, were divided
into two categories (Grol, 1990):
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• general attitude towards clinical guidelines; and
• influence of clinical guidelines on drug prescribing.
Although Grol's (1990) study showed a generally positive attitude towards
clinical guidelines, the results suggested that GPs in the Netherlands did
not change their medical practice according to those clinical guidelines.
In a subsequent paper Grol (1992) described the barriers which may hinder
the process of implementation. Whilst some of these barriers were related
to the characteristics of guidelines themselves and the way they were
disseminated, others concerned the doctor's personal characteristics, in
particular age, clinical experience, self confidence, membership of
professional associations, and attitudes. In general, GPs preferred methods
for implementing medical guidelines that involved educational events and
discussions with colleagues (Feely, 1999; Braybrook and Walker, 1996).
Studies of the impact of drug bulletins on prescribing practices have also
reported conflicting results. For example, Watson et al. (1975) found that
drug prescribing by Western Australian GPs who were sent guidelines for
selected groups of drugs was more rational than prescribing by those who
did not receive them. This approach was extended by Evans et al. (1986)
who measured GPs' knowledge levels about hypertension before and then
four months after receiving a written education package of practice-
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oriented information. There was a statistically significant increase in
knowledge levels in the group who received the package compared with a
control group. However, a follow-up study conducted over 21 months
showed no lasting effects on GPs' knowledge levels about hypertension.
The authors of the study concluded that the use of drug bulletins in
institutional settings has a significant but short-term effect on
prescribing.
Other researchers hypothesised that printed information, such as in drug
bulletins, influences GPs' prescribing behaviour by changing their
knowledge of drug efficacy and adverse effects and their perceptions of
drug utility. Two different disorders (renal colic and irritable bowel
syndrome (IBS» were included. However, the results were not very
pronnsmg:
"It is suggested that the message concerning IBS was seen as difficult to implement
and perceived as less relevant. When this is the case, more intensive strategies are
probably necessary to change knowledge, perceived drug utility, and prescribing
behaviorof physicians" (Denig et aI., 1990: 92).
These findings were in line with a previous study which stated that:
"Although the factors that influence the success or failure of drug bulletins are still
being clarified, it is apparent that many bulletins fail to appeal to their target
audience" (plumridge and Berbatis 1989: 333).
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3.6.2 Medical Education and Colleagues Opinion
3.6.2.1 Medical Education
Almost twenty five years ago, Hemminki (1975a) expressed some concern
about the scarcity of studies on the influence of medical education on
doctors' prescribing behaviour. In her review of the literature, she noted
that relatively few studies were developed on the effects of medical
education on doctors' prescribing behaviour. Furthermore, she considered
that the pioneer studies on the influence of medical education on drug
prescribing reported different conclusions. Segal and Wang (1999)
suggested that new research on this topic was necessary. Following their
advice, some researchers pointed out that medical education and clinical
guidelines are supposed to provide doctors with the skills to practice
medicine during their professional career (Gill et al., 1999; Kinderman and
Humphris, 1995; Rimoldi, 1988; O'Hagan, 1984; Doran, 1984). These
skills were considered critical for the development of an accurate diagnosis
and subsequent therapeutic approach (Kinderman and Humphris, 1995).
Therefore, medical education was found relevant not only for medical
students, but also for post-graduate education on drug prescribing (Joyce
et aI., 1967). In their study of factors associated with cost and variation in
prescribing among GPs, earthy et al. (2000) suggested that medical
education is also important to reduce prescribing uncertainty.
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3.6.2.2 Colleagues Opinion
GPs have a personal list of drugs which they prescribe but "each general
practitioner guards jealously his personal list of drugs and may be sensitive about
discussing it". Nevertheless, "It can be assumed that the personal list has its roots
in the doctor's medical student career and is developed in early years in hospital
practice. Following entry into general practice the trainee doctor comes under the
direct influence of the patient in theprimary care settings and is heavily influenced by
the other doctors in the practice, particularly the trainer. It is easy to see that the
number of teachers and peers involved in the development of the personal list is high,
and these influences will continue to a lesser extent during the years as a principal in
generalpractice" (Gilleghan, 1991: 14).
With the advance of expectancy-value theory on consumer behaviour
(Fishbein and Ajzen, 1975; Ajzen and Fishbein, 1980), the importance of
collegial advice in terms of prescribing (i.e., the normative belief) became
relevant: "colleagues have significantly increased in importance as a source of
information about pharmaceuticals for physicians. Marketers should design
communications and marketing strategies to maximize word-oJ-mouthadvertising and
discussion amongphysicians" (Williams and Hensel, 1991a: 57).
Peay and Peay (1990) suggested that colleagues may play a relatively
minor role in the adoption process of a new drug. However, during the
drug adoption process, consultants and opinion leaders are an important
influence on their colleagues (Coleman et aI., 1966).
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In a more recently published study on GPs' attitudes towards drug
prescribing in times of economic pressure, Himmel et al. (1997) found that
continuing medical education and advice obtained from colleagues ranked
highest as information sources for drug selection. Therefore, doctors' drug
selection and its acceptance by peers was considered to be another
important factor which influences prescribing behaviour (Chinburapa et aI.,
1987; Segal and Hepler 1982; 1985; Zelnio, 1982). However, contrasting
findings have also been published:
"In contrast to an earlier study, the role of peers was found to be relatively
unimportant in this study. Chinburapa et al. (1987), utilizing the Fishbein Behaviour
Intention Model as a conceptual framework in studying physician prescribing, found
the subjective norm component (i.e., the social factor) to be significant in explaining
physician prescribing intentions" (Chinburapa and Larson, 1988: 15).
These contrasting results suggest that the influence ofGPs' colleagues on
drug prescribing may depend on the doctors' speciality (de Vries et al,
1996). For example, the adoption of high risk therapy and ongoing
therapeutic innovation among specialists was found to depend on
colleagues' advice (peay and Peay, 1994). However. the adoption process
of specialists differs markedly from the adoption process of GPs. In this
case, not only was the process of adoption different from that followed by
specialists, but the sources of influence on drug choice were also different.
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3.6.2.3 Pharmacists and Clinical Pharmacologists
In the early years of this century when medicines were often complex
mixtures, the pharmacist produced the medicine directly from its primary
constituents (Gilleghan, 1991). Since the pharmaceutical revolution which
followed the Second World War, the role of pharmacists has changed
dramatically and they no longer produce the medicines. They now buy the
finished products from the pharmaceutical industry. Meanwhile, GPs have
tended to work in primary health care teams which have not directly
involved community pharmacists, rather, the pharmacist has remained
isolated in his shop. Therefore, the influence pharmacists had in the 1950's
is no longer relevant (Caplow and Raymond, 1954; Winick, 1961). Even
in the 1960's and 1970's, doctors rarely used pharmacists as source of
drug information Williams and Hensel (l991a). During the 1980's,
however, the use of clinical pharmacists as drug therapy consultants to
doctors was a reality (Lipton et aI., 1992). Pharmacists and doctors once
again began working very closely together: "The responsibilities of today's
clinical pharmacist expand upon traditional functions and include assessing drug
response, identifying adverse drug effects and drug-drug interactions, monitoring
drug therapy and patient compliance, and conveying clinical information directly to
physicians and patients" (Lipton et aI., 1992: 647). Studies in the 1990's have
also reported an increasing role for pharmacists in influencing drug choice:
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a therapeutic substitution formulary "would guide pharmacists' judgements in
the selection of a less costly alternative drug therapy for that prescribed by a
physicianfrom within these therapeutic classes" (Pilkington and Dolinsky, 1991).
Researchers also reported that clinical information provided by
pharmacists to patients influences drug therapy (Bond, 2000; Morris et aI.,
1987). In the same vein, Roberts and Stokes (1998) demonstrated that the
extensive clinical training of pharmacists can contribute to the quality of
doctors' prescribing decisions. Even the introduction of patient
information leaflets (PILs) developed by clinical pharmacists may
influence drug choice: "From January 1, 1999, in accordance with EU legislation
(Council Directive 92197 EEC), medicines dispensed in the Union must be
accompanied by printed information writtenfor thepatient ...The introduction of PlLs
will have profound effects on prescribing (Collier, 1998: 1724). However,
"pharmacists are still unimportant as a source of pharmaceutical information for
physicians" (Williams and Hensel, 1991b: 35).
Boerkamp et al. (1992) argued that from a marketing point of view it was
important to know if and how the interaction between hospital pharmacists
and physicians influences their personal list of drugs. Since GPs' drug
personal list has its roots in the doctor's medical student career and is
developed in early years in hospital practice, pharmacists are assumed to
be an important source of drug information.
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3.6.3 Pharmaceutical Industry Promotion
The impact of drug manufacturers' commercial activities on drug choice
has been recognised by different researchers in this field, even by those
who are not in favour of such an influence (Couper, 1995; Gilleghan,
1991; Hemminki 1974; 1975a; 1976; 1988). For example, Hemminki
(I975a) found that there are two major influences on a doctor's therapeutic
approach: research and commercial activities developed by the
pharmaceutical companies. Unsuspicious reports also considered that "one
of the most potent influences on doctors' prescribing is the pharmaceutical industry,
which provides information at all levels and in many forms - written, verbal, and
audio-visual" (Gilleghan, 1991: 14). Furthermore, some members of the
WHO expressed a growing concern about the influence of the
pharmaceutical industry on doctors' prescribing behaviour: "It is a sad
reality, however, that in many countries, adequate information is not available even
at the highest level of the health care system, and doctors are largely reliant upon
promotional information from industry" (Couper, 1995: 599). The influence of
the pharmaceutical industry on therapeutic decision is not a recent
phenomenon. Some researchers reported this influence during the 1960' s
and 1970's: Wegner, 1960; Wilson et al. 1963; Coleman et aI., 1966;
Dunnel and Cartwright, 1972; Worthen, 1973) For example, Dunnel and
Cartwright found that GPs considered drug information from
pharmaceutical manufacturers as one of the most helpful sources.
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Wilson et al. (1963) also reported that the main source of influence on
doctors' prescribing behaviour was the process of communication
developed by the pharmaceutical industry. In some cases, doctors were not
aware of this influence:
"Although the vast majority of practitioners perceived themselves as paying little
attention to drug advertisement and detail men, as compared with papers in the
scientific literature, their beliefs about the effectiveness of the index drugs revealed
quite the opposite pattern of influence in large segments of the sample" (Avom et
aI., 1982: 7).
The fmdings indicated that over half of the doctors interviewed perceived
journal advertising (68%) and sales representatives (54%) to be of minimal
importance compared to scientific sources such as professional journals
and published clinical studies. However, the attitudes of doctors towards
the two groups of drugs were inconsistent with the information published
in scientific sources. Approximately half of the doctors who perceived that
they were not influenced by "commercial sources of influence" also
believed that these two drugs were very effective, as advertised by drug
firms. These findings indicated that doctors were unknowingly influenced
by advertising. Such reasoning strengthens the argument that doctors may
not be aware of the potential effect these commercial detailing techniques
can have on their prescribing practices (Roughead, 1998).
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In order to understand the complexity of doctors' professional and social
networks, some researchers initiated a debate on scientific versus
commercial sources of influence on doctors' prescribing behaviour (Chen
and Landefeld, 1994; Avorn et aI., 1982). By questioning doctors about
their beliefs regarding two drug groups (cerebral or peripheral
vasodilators), Avom and colleagues were able to conclude that the
"predominance of commercial rather than scientific sources of drug information
represents a problematic area in health care delivery" (Avom et aI., 1982: 7).
Gaither et al. (1996) pointed out that commercial sources were
particularly relevant for new drug information, while scientific sources
(e.g., medical journals, doctor colleagues, medical textbooks,
pharmacists) were cited for information on existing drugs and actual
prescribing decisions. Although drug promotion was found a powerful and
effective tool, some researchers argued that when a doctor prescribes
medication for a patient, the act is often shaped, to a large extent, by
different factors (Armstrong et aI., 1996; Gaither et aI., 1996). For
example, Gaither and colleagues argued that: "the number of other physicians
at the primary practice site, the number of patients seen daily, and the use of similar
drugs moderates the effects of attitudes and/or subjective norms to use non-
commercial sources of drug information (Gaither et aI., 1996: 1296/1297).
Nevertheless, doctors' colleagues, medical journals, and pharmacists have
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been the most common scientific sources of drug information that have
been reported in recent studies (Himmel et aI., 1997; Anderson and
Lexchin, 1996; Gaither et aI., 1996; Williams and Hensel, 1991).
Williams and Hensel (1991 a) reported significative changes, not only in
the sources and importance of various scientific/commercial activities, but
also on personal/nonpersonal information as they relate to doctors'
prescribing behaviour. For example, "commercial sources of pharmaceutical
information, specifically direct mail, journal advertising, and detailing, have declined
significantly" (Williams and Hensel, 1991a: 57). However, more recent
studies on the influence of different sources of drug information on drug
prescribing concluded that both scientific and commercial sources of drug
information were important (Wazana, 2000; Cryer and Hrsistodoulakis,
1998; Anderson and Lexchin, 1996; Gaither et aI., 1996; 1994).
Some authors pointed out that the use of drug information sources varied
according to the newness of the information sought (Gaither et at, 1996;
1994; Williams and Hensel, 1991a;b; Peay and Peay, 1994; 1990).
Nevertheless, not only were scientific sources of drug information such as
medical journals, medical text books, colleagues, and specialists
reported, but also commercial sources of drug information such as sales
representatives and symposia and conferences organised by the drug
industry (Wazana, 2000; Creyer and HrsistodouIakis, 1998).
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3.6.3.1 Pharmaceutical Manufacturers' Representatives
The typical pharmaceutical salesperson visits an average of eight doctors a
day, with meetings lasting from five to eight minutes each (Soumerai,
1990). Doctors see the pharmaceutical sales representative (PSR) "as an
important source of information, yet they feel they could get the needed information
without the PSR's assistance" (Andaleeb and Tallman, 1996: 87). "Although
many studies, including that of Coleman et al. (1966) have documented the
importance of the detail man in the adoption process, particularly in bringing first
news of the drug to doctor, they failed to jind a relationship between early innovation
and frequency of contact with detail men. However, they contend that the absence of a
relationship was due to the very high exposure of doctors to this information source
(Peay and Peay, 1994: 40). In a previous study, Peay and Peay (1988)
reported that frequent contact with the pharmaceutical representatives was
related to early drug adoption. However, different conclusions were
obtained some years later by the same authors when they investigated the
adoption of new drugs by specialists who treat serious disorders using
relatively high risk drugs with potential serious side-effects (peay and
Peay, 1994). They concluded that commercial sources were not important
for new drug adoption, nor did they exert much influence at the prescribing
stage. Nevertheless, these researchers suggested that "commercial sources
may serve the function of providing information about drugs which are not central to
the doctor's speciality, but that for drugs which are central, non-commercial sources
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are more important" (Peay and Peay, 1994: 50). They argued that the
adoption of high risk drugs was determined by two factors, preparedness
to prescribe the new drug and the presentation 0/ particular
circumstances which were appropriate/or its use.
Almost twenty five years ago, Hemminki (1975a) argued that the level of
influence of sales reps on drug prescribing depends on doctors' personal
characteristics, working situation, and therapeutic opportunities. Pitt and
Nel (1988) stressed that one of the most important findings of their study
to the pharmaceutical companies was the relatively low importance that
doctors placed upon the promotional work of sales representatives. GPs
became more critical towards information from pharmaceutical companies
(Ekedahl et aI., 1995) because sales reps present only selected, usually
positive, information about the products (Lexchin, 1997). Their activity
was even reported to have a negative impact on patient health: "Information
provided by sales reps affects the course of treatment prescribed by physicians, and
consequently, patients' health" (Creyer and Hrsistodoulakis, 1998: 36).
Therefore, GPs' intention to use sales reps as a source of drug information
has declined. Many industry observers are aware of the change, but not all
appreciate just how dramatic the shift has been: "From 1992 to 1994, the
number of sales representatives declined by 12percent ...But for the same time period,
meetings and events increased by 31percent" (Vicciardo, 1995: 33).
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3.6.3.2 Meetings and Event/
Pharmaceutical companies spent an estimated $500 million on meetings in
1994 (Vicciardo, 1995). Videoconferences and teleconferences accounted
for about 15% of meeting activity, nearly doubling from only 8% in 1993.
In the mix of traditional promotional activities, meetings and events are
obviously being used to meet somewhat different strategic objectives: "For
certain products and certain situations, personal selling is still the best way to
communicate, but budget constraints and staff cuts make it necessary to supplement it
with other promotional techniques. Survey results show that meetings and events are
one of the techniques companies are increasingly turning to in order to get their
messages across" (Vicciardo, 1995: 36).
3.6.3.3 Drug Advertisement in Medical Journals
Stimson (1977) takes the position that the problem with drug
advertisements as a source of therapeutic information is that they provide
hardly any therapeutic information:
"Analysis of drug advertisements indicate that they are limited as vehicles for
providing scientific information about the usefulness of drugs" (Stimson, 1977:
12).
7 The term "meetings and events" covers a wide range of promotional activities developed by
pharmaceutical companies. It can range from informal dinners with a small group of GPs to large
symposia or conferences attended by several hundred doctors.
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Nevertheless, drug advertisement m medical journals, meetings,
conferences and personal contacts developed by manufacturers' sales
representatives, were found to have a strong influence on drug choice
(Gemignani and Shaw, 1998; Gaither et al., 1996; Barton, 1993; Avom et
al., 1982). Printed advertisements, together with face-to-face visits by
representatives, were found to be the most important commercial
influences on prescribing (plumridge and Berbatis, 1989; Stimson, 1976),
particularly on new drug promotion: "Typically. the initial promotion of a new
drug is accompanied by extensive advertisement of its virtues - often a useful way of
bringing a product to physicians' attention" (Avom et aI., 1982: 7). In contrast,
Ring (1986) suggests that medical journals and scientific articles are the
major source of drug information and thus they are an increasing source of
competition for pharmaceutical manufacturers. Ring also noted that the
increasing number of medical publications in the early 1980's was a
consequence of this growing pressure on product advertising. Some
researchers pointed out that when an effective sales theme was employed,
medical journal product advertising was found to increase a product's
market share. Product advertising success was found to be dependent on
three different levels of campaign awareness (Ceamal, 1989):
I) Recognition of the advertisement;
2) Association of the product with the campaign; and
3) Association of the product with the sales theme.
163
The influence of drug advertisements in medical journals has been
questioned (Jones et aI., 1999). Some articles have suggested that
regulations developed to control drug advertisement were based on the
"notion that advertisers are capable of programming the minds of prescribers to
produce prescriptions for their product regardless of approved indications"
(Dickinson, 1992: 64). In a similar vein, Taylor and Bond's (1991) study
suggested that GPs were not unduly influenced by commercial sources of
drug information and their prescribing habits were found stahle and
conservative.
Identical conclusions were reported by Mackowiak and Gagnon (1985)
who found that pharmaceutical companies' promotional tools were not the
main and primary source of new drug information within the
communication networks. They studied the effects of detailing visits to
doctors and medical journal advertising on the primary and secondary
demand of diuretics and benzodiazepines. The number of new
prescriptions for a product was used as a measure of advertising
effectiveness. The study found no correlation between changes in detailing
or journal advertising expenditure and primary or secondary demand. For
this reason the authors concluded that drug manufacturers should evaluate
the effects of reductions in their promotional expenditures, changes in
promotional content, as well as seek alternative methods of advertising.
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In accordance with these fmdings, Mackowiak and Gagnon (1985)
suggested that pharmaceutical manufacturers would have to rethink their
communication strategies. However, this study had limitations concerning
the indicator used to measure advertising effectiveness. Even though the
ultimate (unction of the advertising is to increase sales. the intermediate
variables O.e.. doctors' beliefs and attitudes concerning the advertised
drugs) should also be measured in order to better determine advertiSing
effoctiveness.
Criticism of the scope of drug advertising usually focuses on its influence
on inappropriate prescribing. However, Smith (1977) reported that there
was unsubstantiated evidence that pharmaceutical manufacturers influence
doctors to prescribe drugs inappropriately through journal advertising.
Since journal advertising might influence drug prescribing in conjunction
with other factors (Jones et aI., 1999), it becomes difficult to study the
effect of drug advertising separately. Therefore, Smith (I977) argued that:
doctors "have excellent measures available to them as a defence against bad
advertising: (1) They need not read them, (2) they need not believe them, and (3) they
need not do what the advertisements suggest. Physicians who criticize drug
advertisingas the solo cause of poor prescribing seem very similar to thepeople who
complain about the quality or content of televisionprograms which they, nevertheless,
watchnight after night" (ibid: 1221).
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3.6.3.4 Product Characteristics/Attributes
Almost twenty-five years ago, pharmaceutical product characteristics such
as appropriateness, effectiveness, safety and economy (i.e., cost) were
considered the four most important criteria for rational prescribing (Parish,
1974). During the last 20-30 years, these criteria have also been used to
determine whether drug choice is in line with health authority guide-lines
(Audit Commission, 1995). However, "The values assigned to the decision
criteria may varyfor different physicians and different problems. For example, when
choosing a drug for a various serious disease, efficacy may be seen as the most
important criterion. For a self-limiting disease, adverse effects and costs might be
valued as more important" (Denig and Haaijer-Ruskamp 1992: 11). Recently,
however, product cost has became the major factor of analysis in terms of
doctors' prescribing behaviour because "Prescription drug prices have
increased two to three times faster than all consumer prices since 1981 and have
become a source of growing concern for policy makers, as well as individual and
institutional purchasers" (Lipton, 1988: 10). Therefore, "The major factor
promoting the assessment of prescribing by general practitioners is concern about the
rate of increase in the total bill in all European countries" (Buckley and Allen,
1995: 22). In a similar vein, Himmel et al. (1997) have provided evidence
showing that:
"In many European countries drug prescribing by primary care physicians has also
becomea matter of economic concern" (Himmel et at, 1997: 164).
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Several studies have been conducted on the influence of drug cost on
doctors' prescribing behaviour but they have had conflicting results
(Himmel et aI., 1997; Denig and Haaijer-Ruskamp (1995); Safavi and
Hayward (1992); Ryan et aI. (1991); Chinburapa et aI., 1987; 1988; Segal
and Hapler 1982; 1985; Zelnio 1982; Zelnio and Gagnon, 1979; Lilja
1976; Miller, 1973; Caplow and Raymond, 1954). For example, Safavi et
al. (1992) analysed the effects of price information on physician
prescribing patterns. The results suggested that doctors neither have
adequate knowledge of drug costs nor consider costs when prescribing.
German GPs, however, were found to have a drug cost oriented approach:
"Fewer drugs, less expensive drugs, fewer "patient-demanded" drugs, more generic
drug prescriptions" (Himmel et aI., 1997: 168).
During the 1980's, following health authorities' drug cost-effectiveness
information, doctors were reported to be aware and sensitive to the
importance of price as regards patient compliance with a therapeutic
regime (Lavizzo-Mourey et al., 1990). More recently, research on attitudes
towards, and knowledge of, GPs prescription drug costs revealed a
growing importance of drug costs in therapeutic decisions (Green, 1997;
Denig and Haaijer-Ruskamp 1995; Walzac et al., 1994; Ryan et al., 1991).
However, these studies recognised that doctors often made inaccurate
assumptions about the cost of the drugs they prescribe.
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Some researchers argued that "when a physician attaches a low value to
cost... information about cost will have little influence on the drug utility as perceived
by the physician" (Denig et aI., 1990: 87).
Elderly patients are willing to pay more for effectiveness and safety of
antihypertensive drugs: "Our pilot study indicates that elderly patients are
concerned about safety and effectiveness and are willing to pay more for these
qualities in their antihypertensive drugs" (Ferguson et aI., 1994: 61). In general,
it has been concluded that effectiveness and the importance of side-effects,
as well as the availability of dosage forms, dosage schedule, and ease with
which the drug can be administered were the most important attributes in
drug choice (Himmel et al., 1997; Chinburapa et aI., 1987; 1988; Segal
and RapIer 1982; 1985; Zelnio 1982; Zelnio and Gagnon, 1979; Lilja
1976; Caplow and Raymond, 1954). In Chinburapa and Larson's (1988)
study, the Side-effects of a drug was the most important attribute, followed
by effectiveness and dosage schedule. Cost, and acceptance by peers were
reported to have less influence on drug choice. With regard to the relative
importance of drug attributes in influencing prescribing intention,
Chinburapa et aI.' s (1988) findings were similar to previous research on
this topic, which suggested that side-effects and effectiveness/efficacy
were the two most important attributes in doctors' prescribing decisions
(Chinburapa et aI., 1987; Segal and Hepler, 1985; 1982; Lilja, 1976).
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For example, Chinburapa et al. (1987) studied the relative importance of
drug attributes among health maintenance organisation (HMO) and fee-for-
service (FFS) doctors with reference to the beta-blockers used to treat
hypertension and reported the same five characteristics in both cases. In
descending order of importance, these were:
1. patient compliance,
2. efficacy,
3. dosage schedule,
4. side-effects, and
5. source of drug information.
In a later study, Chinburapa and Larson (1992) determined the importance
of side effects and outcomes (i.e., the control of disease, convenient dosing
and cost) in doctors' differentiation of drug products used to treat
hypertension, alergic rhinitis, and gastroesophageal reflux. In addition, the
study examined whether the importance of particular characteristics
attributed to a drug varied according to the practice setting. They
concluded that the practice setting did not have a significant influence on
doctors' beliefs or on the importance of results in any of the three
prescribing scenarios. The effective control of disease was reported to be
the most important result in all the three prescribing scenarios, followed by
individual side effects. The difference between these findings and previous
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research on this topic (Chinburapa et al. 1987; Chinburapa and Larson,
1988; Denig et al. 1988; Lilja, 1976) was that "not all side effects are equally
important in their influence over drug preference and choice" (Chinburapa and
Larson, 1992: 341).
In the case of a new drug adoption, the product attributes that influence the
therapeutic decision making may be different. For example, Rao and
Yamada (1988) identified a number of product attributes that influence the
prescribing decision of a new drug:
• innovativeness as compared to substitutes
• effectiveness as compared to substitutes
• riskiness to the patient
• range of ailments for which appropriate
• seriousness of conditions for which prescribed
• frequency of prescription (by the physician)
The attributes selected also vary according to the type of disease. For
example, Freeman et al. (1993) suggested that adverse drug events such as
side-effects, drug interaction and risk for dependency influence general
and family practice physicians' prescribing behaviour on the treatment of
patients with panic disorder. The findings from the Freeman et al. (1993)
study reinforced the conclusion that after safety concerns are resolved,
doctors select drugs to treat panic disorder on the basis of the product's
ability to resolve the patient's complaints.
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3.7 Patients' Characteristics
Since a long time, drug prescribing was found to depend on the type of
illness the patient presents (Wilson et aI., 1963). These researchers pointed
out that GPs' first-line drug therapy varies according to the patient's type
of disease. They assumed that prescribing for patients with chronic and
severe diseases is different from patients with acute or common diseases.
As pointed out in Chapter Two, hypertension is a chronic and severe
disease. In a recent study, the seriousness of disease and the patient's
condition were also reported to be important predictors of doctors'
prescribing behaviour: "The results of the present study suggest that when the
patient's condition is serious and the drugs used to treat it have a relatively high level
of risk, drug "adoption" and "innovation" are qualitatively different processes from
those prescribed in traditional studies" (peay and Peay, 1994: 49). Therefore,
in the most unusual and risky clinical situations the drug is selected
according to the consultant or a peer colleague IS opinion. In contrast, in a
routine situation where the disease is not severe, the promotional efforts
of the pharmaceutical industry were considered to be the main influence
on drug prescribing. Identical findings were reported in studies developed
in Asia and South America, in which the doctors' perceptions about
pharmaceutical companies' promotion varied in accordance with the type
of disease or the therapeutic area (Liu, 1995; Zarate and Liosa, 1995).
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Wilson et al. (1963) argued that two doctors may learn to hold the same
attitude toward a given stimulus (i.e., the patient disease) but they may
assume different responses when facing the same problem, because of
previous clinical experiences. Although their attitudes towards the
patient's pathology may initially predispose them to behaving in the same
way (i.e., in accordance with common medical education for treating the specific
condition), the prescribing behaviours they ultimately come to exhibit may
differ. The therapeutic approach will in fact depend on the degree to which
their knowledge of the disease and its treatment has been reinforced by
clinical infOrmation they have received from the contextual environment.
In some studies patients were found to have only a slight influence on
doctors' prescribing behaviour (Worthen, 1973). In line with this
conviction, Pitt and Nel(l988) argued that patients exercise the role of
buyers and users, but they have little or no influence on drug prescribing.
The same opinion is shared by different researchers who argued that
patients have no importance whatsoever as a source of information or
influence on drug prescribing (Avom and Soumerai, 1983; Winick, 1961).
A later study confirmed the low influence of patients on drug choice
(Denig et aI., 1988). However, Freeman et al. (1993) refused to accept the
findings derived from the previous studies and suggested that the patient's
clinical characteristics were a major contribution to GPs' drug choice.
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In a similar vein, Benson's (1983) study provided evidence showing that:
• Patient characteristics (socio-demographics and clinical factors) were
found to be the most important variables across the three decision
stages.
• Clinical factors such as diagnosis and the level of impairment were
highly significant in the first two stages, whilst socio-demographic
characteristics (such as age) were the most important factors in the
third stage (drug dosage determination).
• The effects of practice setting characteristics on doctors' prescribing
behaviour were relatively low.
• Doctor characteristics (education, socio-demographic, and attitudes)
varied in importance across the decision stages. Doctors' attitudes were
significant in the first stage.
• Educational factors were highly significant during the first and third
stage, while doctors' socio-demographic factors had little effect across
the three stages of the decision process.
Patient age was also an important factor influencing drug prescribing
(Lipton et al. 1992; Lipton, 1988; Hadsall et at, 1982). Besides age,
gender was also an important factor in doctors' prescribing behaviour. For
example, Hartzema and Christensen (1983) studied the prescribing
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patterns of 80 family practitioners in a health maintenance organisation
(HMO) and found that the size and age composition of the patient panel
accounted for 45.7% of the variation in the prescribing rate. In addition,
female patients were found to prefer to see female doctors and older
physicians tended to have older patients than young doctors did. In line
with this reasoning, older doctors were assumed to have higher prescribing
rates because older patients generally have more chronic diseases and
require more drugs than younger patients. This assumption was
confirmed by Linn and Linn (1982) who assessed the effects of patient age
on doctors' prescribing behaviour. The study found significant differences
in the number of prescriptions given to young and old patients: " While use
of the medications did not differ between physicians for patients as a total group, they
did differ when age of the patient was taken into account' (ibid: 1531).
Rokstad et al. (1997) examined the prescribing patterns among GPs in
Norway in relation to the patients' age and sex and found that female
patients were receiving a greater number of items prescribed per patient
contact (male 0.76, female 0.83). Insomnia was the most frequently
recorded diagnosis for prescribing. Listed second were upper respiratory
tract infections (males) and anxiety (females). Hypertension was the third
most common diagnosis.
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Research focusing on gender differences in doctors' prescribing decisions has
found that doctors appear to be more likely to prescribe drugs of all types for
women than for men (Hohmann, 1989).
Ethnic and/or racial differences were also found to influence doctors'
drug choice (Hui and Pasic, 1997). By assessing the management of
hypertension in Asian Americans and comparing it with an age-and sex-
matched group of white patients with hypertension, these researchers
concluded that medication changes, dose reduction, and the experience of
side-effects were all more frequently recorded among American Asian
patients than among American white patients.
More than thirty years ago, Coleman et al. (1966) introduced the question
of the patients' income as an influence on drug prescribing. They reported
that those doctors who were more 'patient orientated' may consider price
as an important variable in drug choice. Their findings support the view
that doctors who have a relatively high proportion of higher income
patients prescribe more recently marketed and more expensive drugs than
those physicians with a relatively high proportion of lower income
patients. However, Lilja (1976), found, in his sample of Swedish
physicians, that drug cost was accorded little importance in antidiabetic
prescribing but was considered more important than side-effects in
choosing an antibiotic.
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3.8 Doctors' Personal Characteristics
Although the patient's clinical conditions have been described as relevant
to doctors' prescribing behaviour, influences other than the patient's
clinical conditions and the 'scientific' analysis of the treatment of the
patient's conditions are present in the GP's decision to prescribe a
particular medication (Armstrong et al., 1996). From a prescribing point of
view, GPs' personal characteristics have been reported as one of the most
important influences on drug choice (Steffensen et al., 1999).
Doctors differ not only in how much and how often they prescribe, but
also on what they prescribe (Joyce et al., 1967). This is because doctors
tend to have their own "educational programs" and also differ in terms of
methods and learning styles. Moreover, these "educational programs" are
often different from the medical institutions' stated programme. As a
result, individual cognitive styles. coupled with the various practices and
habits which students observe during clinical clerkships. provide doctors
with a specific therapeutic knowledge which may be different from that
contained in the curriculum fOrpharmacology or therapeutics.
Doctors' age and clinical experience were found to be responsible for the
great variety of prescribing patterns. For example, Stolley et al.' (1972)
study reported that younger doctors have a better quality of prescribing,
tended to consult more with their colleagues and placed a higher value on
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their profession. These young doctors were found to inform patients more
about drugs and treatments. These prescribers were more satisfied with
their formal medical training and more critical of pharmaceutical
manufacturer's promotional activities. They relied more on medical
sources of drug information, sought more data on drug contraindications,
and were more dissatisfied with existing sources of drug information.
Other researchers also agreed that young doctors have a different
prescribing behaviour than their older peers (Haayer, 1982; Hemminki,
1976; Miller, 1973, 1974; Coleman et al. 1966; Wilson, 1963; Menzel and
Katz, 1955). For example, Coleman et al. (1966), following Menzel and
Katz (1955), attempted to differentiate the innovators from later adopters
in order to define their personal characteristics. They argued that drug
prescribing by innovators was influenced by the social groups to which
they belonged. It was, therefore, relevant to define these social groups in
terms of demography, age and specialisation. Their study suggested that
the innovator is a professionally oriented, younger doctor with a broad
scope of attention to the medical world at large, yet one who participates
closely in his/her own medical community. Their work demonstrated the
complex role of social networks among doctors (both professional and
social) in the various stages of the new drug diffusion. For example, GPs
were found to consult colleagues (i,e., the innovators) more often in cases
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of chronic disease, which has many possible therapeutic approaches and
more ambiguous outcomes, than in acute cases. As a result, these
innovatorswere cited more frequently by colleagues as a professional or
social contact and were more likely to participate in out-of-town meetings,
and to visit out-of-town institutions. They found that important interactions
also occurred through shared offices, informal relationships with their
peers, institutional ties, and contact with manufacturers' salesmen.
These innovators also tended to subscribe to a larger number of medical
journals and to have more complex social and professional networks
(Menzel and Katz, 1955). In a similar vein, Haayer's (1982) study
suggests that rational prescribing depends on doctors' characteristics
rather than on patients' characteristics. Haayer assumed that there are
multiple factors influencing doctors' prescribing behaviour, but in
particularly their age. Younger doctors were more innovative and
prescribed drugs more rationally then older peers. However, doctors' age
was not an exclusive personal characteristic affecting drug prescribing. In
a similar vein, some researchers concluded that rational prescribers tended
to have more post-graduate medical education, but fewer years of
medical experience (Benson, 1983; Stolley et at, 1972).
Practice characteristics were also described as being an important
influence on drug prescribing (Gaither et at, 1996; Pharoah and Melzer,
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1995; Hemminki, 1975; Williamson, 1975; Becker et aI., 1972; Stolley et
aI., 1972). For example, Gaither and colleagues concluded that the number
of other doctors at the practice and the number of patients seen daily are two
important factors that "moderate physicians' patterns of usage of drug information
sources, and therefore influence drug prescribing" (Gaither, et aI., 1996: 1291).
Raynes (1980) found indications that some GPs develop particular routine
approaches to the patient, which they use regardless of the symptoms
presented. These routines were also important to drug choice. Raynes'
(1980) findings suggested that older doctors have more conservative
prescribing habits than their younger peers.
From Knapp and Oeltjen's (1972) point of view, both the severity of the
disease and the doctor's speciality are relevant when determining the
relative weighting of benefits and risks given to drugs used in the
treatment of hypertension. For example, for milder cases of hypertension,
the hospital doctor (i.e., internists) weighed the benefits of a drug more
heavily than the risks of the drug, while the GPs were more concerned
with the risks than benefits. For more severe hypertension cases, the
relationship was reversed. Internists weighed the risks of a drug more
heavily than the benefits, while the GPs were more concerned with the
benefits than the risks.
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3.9 Doctors' Philosophies of Prescribing
The type of disease was an important determinant of whether doctors took
a "conservative" or a 'risky' approach to prescribing. This was also
suggested by Rawlins (1984) who pointed out that pharmaceutical
companies categorise GPs as "conservatives or "risk takers" and have
different marketing strategies tor these two groups.
Linn et al., (1972) argued that beyond clinical experience, the general
philosophy of medication influences the therapeutic decision. Physicians
who prefer more professional sources of information (medical journals
and peers recommendation) would be more likely to express conservative
attitudes towards what constitutes legitimate drug use. Based on these
findings, Linn et al (1972) suggested that future investigations should
attempt to define and differentiate these philosophies of medication in
more detail. In line with these philosophies of medication, Mapes et al
(1977) proposed that doctors' prescribing behaviour was influenced by
their philosophical approach to medical practice. They supported the
view that there is both a "conservative prescribing" approach and an
"incautious prescribing" approach. The former was found to be
developed by older doctors, while the latter occurs most of the time with
younger innovative doctors, who were inclined to prescribe a new drug
more readily than their peers.
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3.10 Discussion
Most cognitive models described in the beginning of this Chapter were
based on the exctancy-value theoretical framework. No alternative
behavioural model has yet been proposed, though frequent reference to the
"prescribing habits" of doctors betrays behaviourist assumptions on the
part of some researchers in the prescribing field. However, "both schools of
psychology can account for quite complex behaviour of humans in situations of
choice, such as drug selection by doctors, and both run into difficulty accounting for
certain aspects of verbal behaviour. The truth of the matter may be that drug
selection by doctors is a mixture of rational or thought out behaviour and habit,
depending onfamiliarity of the problem or other such variables. Yet behind the habits
there may be poorly recalled or subconscious constructs which are essentially
rational. Likewise, behind the stated rationales there may be untested assumptions or
habits of thought" (Bradley, 1991; 283). Nevertheless, most researchers on
therapeutic decision making believe that the cognitive model, with
different research approaches, is the best paradigm! for predicting and
explain drug choice (Gaither et aI., 1996). Within this cognitive paradigm,
therapeutic decision making proceeds in an incremental way such that
clinical problem solving is broken down into a sequence of choices to be
made with simplification of the alternatives:
• We regard paradigms as established general models for doing research, without domain-specific
theoretical content. In contrast, research approaches includes both theoretical and methodological
guidelines that clearly limit issues of interest and the ways in which research is carried out.
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"By carefully studying expert physiscians solving a problem involving considerable
uncertainty and risk, we can infer properties of the underlying know/edge
representation and reasoning strategies they use to make difficult decisions. The
analysis focuses on two separate but related aspects of the knowledge representation:
• The strategy for imposing structure on the decision problem. to decompose it
into a set of manageable steps;
• The cognitive representation for likelihoods" (Kuipers et aI., 1988: 178).
In line with these considerations, Kuipers and colleagues recognised not
only the importance of prescribing-relevant knowledge structures, but
also the importance of cognitive processes.
Unfortunately, there has been little study of the contribution of personal
prescribing knowledge to therapeutic decision-making in general practice,
but antihypertensive medical guidelines suggests that it may be the most
important distinguishing feature. As we will see later, the expectancy-value
theoretical framework does not recognise the way prescribing-relevant
know/edge is stored and organised in doctors memory. Most published
studies have attempted to model the internal processing of doctors as they
make prescribing decisions (i.e, cognitive processes), and most have used
expectancy-value type models such as the theory of reasoned action.
Nevertheless, this theoretical framework, along with the social system of
influence and information flow, were very important to our research.
However, these studies suffer from some deficiencies:
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3.10.1 Practical Problems and Contradictory Findings
The contradictory findings in some studies were asswned to be linked to
difficulties in securing collaboration from doctors (Himmel et aI., 1997;
Lambert et aI., 1997; Haaijer-Ruskamp, 1990). This problem was also
identified by Hemminki (1976) who reported the following difficulties:
• prescription figures are not available;
• doctors are not very willing to talk about their prescribing behaviour;
• the drug industry, considered one of the most important influencers of
drug choice, is often unwilling to let outsiders study its activities.
• most pharmaceutical companies were found to be uncooperative in
giving information on prescribing behaviour; and
• the subject of the study requires both medical and pharmacological
knowledge, which non-medical researchers may not have.
In a similar vein, Haaijer-Ruskamp (1990) pointed out that "Besides the
methodological and theoretical problems to overcome, the researcher in this field is
faced with a number of practical problems •••One such problem is the privacy of
some data bases •• .A completely different type of practical problem that researchers
encounter is the importance of the often conflicting interests of those involved in
drug utilization. There are the policy-makers who decide on issues of public health,
the phantUlCeutical industry with its own interests, the pharmacists who at the one
hand want to be guardians of the quality of drug therapy, but on the other hand
have their ownfmancial interests, the physicians who often feel threatened in the;,.
autonomy and the patients who demand drugs" (Haaijer-Ruskamp, 1990: 95).
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Recently, Himmel et al. (1997) described difficulties with obtaining a
satisfactory response rate in Germany. Given these limitations, it is,
therefore, not surprising that in some of these studies several factors were
found to be valuable in predicting drug choice, while in others they were
unimportant: "These intervention programmes, however, show conflicting results"
(Denig and Haaijer-Ruskamp's, 1992: 9). "Serious disagreements in the
literature about what variables are actually correlated to adoption illustrate this
problem" (Hepler et aI., 1981: 30). Studies evaluating interventions aimed
at improving prescribing behaviour also reported contradictory fmdings (le
Grand et al., 1995). Furthermore, "the past 30 years of research in prescribing
have furnished descriptive data concerning the prescribing patterns and habits of
physicians, but a multi-dimensional analysis of prescribing behavior has not yet
appeared in the IlCIldemic literature" (Mackowiak and Gagnon, 1985: 1191).
3.10.2 Different Periods of Research
Gaither et al. (1996) pointed out that methods, materials and length of
investigation vary deeply among the most representative studies on the
sources of drug information that influence prescribing behaviour. A great
nwnber of them were performed during the 1970's and 1980's and for this
reason they do not reflect deep changes to the actual clinical context of
doctors' decision-making and their therapeutic approach (Freeman et aI.,
1993). As a result, no generalisations could be made from these studies.
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3.10.3 Different Clinical Realities Between Countries
Doctors' prescribing behaviour is influenced by several medical and non-
medical factors that are interrelated with the specific clinical context in
which prescribing occurs (WHO, 1999) and this may help to explain the
incoherent picture created from most of the previous research.
Bloor and Freemantle (1996) pointed out that in the Netherlands,
information is provided to prescribing physicians on the relative value of
drugs in practice. In France, a national contract has introduced national
medical guidelines for doctors with respect to diagnosis and treatments. In
Germany, budgetary restrictions were introduced in January 1993 that
placed a limit on drug costs. In this country, guidelines were introduced in
1995 to define the average prescription volume for each medical specialty
according to therapeutic use and category of drug. The guidelines were
formulated so that the total volume of prescriptions does not exceed the
regional budget and are therefore used as a means of budgetary control.
Physicians are reviewed on the basis of these guidelines, and if their
prescription level is more than 15% above the average they receive a visit
from pharmaceutical advisers to discuss their rates of prescription. In a
similar vein, individual general practice budgets have been introduced in
Britain (through the practice level fundholding and indicative prescribing
schemes) and are being considered in Italy. Several European countries
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have information feedback systems for physicians similar to the English
prescribing analysis and cost (PACT) scheme. However, most of these
strategies are not enforced, and information may be ignored. This is
thought to be the case in Portugal, where data on prescription costs in
relation to consultations are tracked and fed back to doctors to enable
them to monitor their own prescribing patterns. In Portugal, as in other
European countries, prescriptions are collated by a national authority and
information is fed back to general practitioners on a quarterly basis, either
in a simple "headline" format or in more detail when this is requested or
when a practice's costs are substantially greater than the local average
(Infarmed, 2000b).
3.10.4 Sample Size
There are several factors which affect the determination of sample size
(Moutinho et aI., 1998). If the target population is heterogeneous
demographically, but homogeneous with respect to a profession, questions
relating to professional conduct may be collected using a smaller
geographic sample frame. If the questions are attitudinal in nature,
however, a smaller geographic sample frame will not suffice, even if the
questions are related to the profession. When questions are attitudinal in
nature, however, as is the case with most of the studies on doctors'
prescribing behaviour, a large sample is required. In line with this
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reasoning, it is possible to argue that several different studies on doctors'
prescribing behaviour (Lambert et aI., 1997; Himmel et aI., 1997; Mancuso
and Rose, 1987; Segal and Hepler, 1982; 1985; Epstein et aI., 1984;
Harrell and Bennett, 1974) have an inappropriate sample size:
• Harrell and Bennett (1974) concluded that the sample used in their
research was not the most convenient;
• Bradley (1991) argued that the disappointing results obtained with
the Epstein et al. 's (1984) model were related with the sample size;
• Segal and Hepler's (1985) results contradicted Lilja's (1976)
conclusion about the little importance of drug cost in the treatment
of diabetes mellitus. This may have occurred because (like its
predecessor in 1982), Segal and Hepler's (1985) study presented
some sampling limitations. The former used a convenience sample
with only 55 respondents, while the latter collected information from
40 prescribers; and
• Mancuso and Rose's (1987) research is another example of
inappropriate sample dimension, as is Lambert et aI.' s (1997) study:
"although the sample was small, it was larger than that used in some
published studies of clinical decision-making (Mancuso and Rose, 1987), and,
more importantly, tests had sufficient power to detect effects of the expected
magnitude" (Lambert et al., 1997: 1772).
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3.10.5 Doctors as the Main Source of Information
Medicine has remained a prestigious profession based on scientific and
complex rules, managed by ancient and respectable institutions and which
provides medical education in a hermetically closed environment (Haaijer-
Ruskamp and Hemminki, 1993; Devlin, 1990). Doctors, as gatekeepers of
these values, are not necessarily reliable sources of information (Lomas et
aI., 1989) since the account they are willing to report may be influenced by
their assumption that prescribing behaviour is rational and scientific
because they want to preserve their image as competent technicians: "Of
course, whatphysicians say they'll do and what they actually end up doing can be two
different things. To get a clear picture of the payoff on event spending, better
measures than the physicians' words are needed' (Vicciardo, 1995: 34).
Otherwise, "the validity of using stated prescribing as a measure of actual
prescribing behaviour is questionable" (Bradley, 1991: 283).
Furthermore, pharmaceutical manufacturers' promotional activities
influence doctors' prescribing behaviour much more than most health
professionals realise (Rougheadet al., 1998; Orlowski and Wateska, 1992;
Pitt and Nel, 1988; Avorn et al., 1982). It may be due to the fact that
medical practitioners perceive pharmaceutical promotion as less influential
on their prescribing decisions than medical literature. For example, Pitt and
Nel (1988) asked doctors what other factors influenced their prescribing
188
and the most common answer to this question was the medical and
scientific literature. Avom et al. (1982) also pointed out that doctors are
reluctant to admit, and sometimes they are not aware of and deny the
relative importance of pharmaceutical manufacturers' influence on their
drug choice. That is, marketing is integral to a profit-driven industry that
spends hundreds of millions of pounds to develop and promote a new drug
(Wolfe, 1996). Pharmaceutical companies would not spend such massive
amounts on promotion if it were not effective at influencing prescribing.
And doctors do rely on it for information (Segal and Wang, 1999).
3.10.6 The Patient Scenario
To analyse drug choice, a written case scenario of a standardised patient
has been chosen by most researchers for its methodological simplicity, and
to exclude confusing variations in diagnoses (Chinburapa et aI., 1993;
Chinburapa and Larson, 1992; 1988; Mancuso and Rose, 1987; Segal and
Hepler 1982; 1985; Lilja, 1976; Hemminki, 1975; Harrell and Bennett,
1974; Knapp and Oeltjen, 1972). Furthermore, a simulated patient case
enables the researchers to experimentally control for the type and amount
of information in the decision environment and to study the effects of
selected independent variables on doctor clinical judgment and choice
processes. Most studies typically summarise the hypothetical case scenario
of patients with a single disease process, which requires rational
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prescribing: "researchers have attempted to create a situation in which,for a given
patient, the most effective, least expensive, easiest to use, safest drug is the drug most
frequently selected' (Lambert et aI., 1997: 1767). Recent evidence, however,
indicates that prescribing practice is often inconsistent with criteria for
safety and effectiveness (Anderson and Lexchin, 1996). That is, translating
the recommendations of clinical guidelines and the findings from research
studies into daily clinical practice remains a daunting challenge because
there are marked differences between individual patients. As a result, the
hypothetical case scenario does not represent most patients: "The doctor,
however, cares for individual patients who often differ in important ways from
patients described in those hypothetical case scenarios" (Pauker and Kassirer,
1987: 255). Other researchers also considered that the patient scenario
described in their study was too general: "Despite this attempt, the description
did not represent several situations" (Harrel and Bennet, 1974: 276).
As pointed out earlier, research in prescribing decision-making usmg
information processing (process tracing) of final judgments paradigms
have also used simulated patient cases to examine medical decision
making (Cbinburapa et aI., 1993; Mancuso and Rose, 1987). However,
Chinburapa et al. (1993) believe that the patient scenario may bias the
findings because it gives a hypothetical solution to the problem under
observation:
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"Another limitation concerns the use of a hypothetical case scenario and a well-
structured decision task in which all available alternatives and relevant drug
attributes were shown. This methodology may have provided subjects with part of the
solution to the choice problems" (ibid: 1481). In a similar vein, Bradley (1991 )
has noted, Segal and Hepler's (1982) study has obvious limitations "which
must make one remain cautious about accepting the model of drug choice proposed.
Firstly, it based only on a hypothetical case. Secondly, it is possible that the
questionnaire used actually encouraged doctors along a decision-making pathway
that was not their usual one" (ibid: 282).
The same methodological problem can be found m Chimburapa and
Larson's (1988) study. These researchers, usmg the first part of a
questionnaire, "described a hypothetical case of a patient with essential
hypertension. After reading the case, the respondents were asked to indicate the
degree of importance of each of the five attributes (effectiveness, incidence of side
effects, cost per day, dosage schedule, and acceptance by peers) in choosing an
antihypertensive drug for the described patient" (ibid: 9). However, the use of a
hypothetical patient scenano m the questionnaire for eliciting
instrumentality beliefs linking various drug choices and various outcomes
does not represent the respondent's cognitive structures and processes.
Furthermore, "Marry studies were not founded on actual clinical cases, but on
simulated cases or questionnaires for which there was no evidence of validity or
reliability" (Eisenberg, 1979: 962).
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On the other hand, the use of actual patient cases makes it difficult to
control for a large number of attributes and information that may be
presented or to compare results across doctors (Wigton, 1988).
Elstein et al. (1978) indicated two other limitations concerning the external
validity associated with the use of simulated patient cases or written case
presentation in medical decision-making research. First, hypothetical cases
can only include certain variables; thus other important variables that may
be crucial to the decision problem may be ignored. Examples of commonly
ignored variables are concomitant diseases and gender. Second, the use of
hypothetical cases may affect the responses given because doctors know
they are being observed in the study. However, the main limitation
concerns the findings obtained from simulated patient studies because the
results may not be generalizable to actual patients or actual clinical
environments inwhich decisions are less structured.
A final point to note here is that there is also evidence that the use of
different patient scenarios with different diseases such as renal colic,
hypertension, diabetes, or irritable bowel syndrome, may explain the
equivocal findings reported in Epstein et al. (I984) and Denig et al.' s
(1988) studies (Bradley, 1991). Denig et al. (1988) also suggested that
the contradictory findings of some of the studies on drug choice may be
explained by the diversity of patient scenarios that were used.
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3.10.7 Theoretical Framework and Research Methods on Drug Choice
3.10. 7.1 The Theoretical Framework
Although most studies of the factors that influence doctors' prescribing
behaviour were helpful in identifying and highlighting some particular
aspects of the therapeutic decision, they have tended to be largely
descriptive: "Many studies describing physicians' use of drug information sources
are descriptive, thus limiting our understanding of why specific sources are utilized.
In addition, these studies have lacked statistical rigor and a conceptual framework
in which to guide the Investigation" (Gaither et aI., 1996: 1291). In a similar
vein, Hepler et al. (1981) argued that most drug adoption studies "lack a
unifying theory. Serious disagreements in the literature about what variables are
actually co"eillted to adoption illustrate this problem. The studies tend to be
descriptive and to foliow the case-study approach" (Hepler et aI., 1981: 30).
Although such work has been helpful in identifying problem areas, "it has
tended to be largely descriptive, raising more questions than it answers about the
causes of the phenomena" (Haaijer-Ruskamp and Hemminki, 1993: 101).
Some models have, however, provided a more systematic conceptual
approach, which was based on recognised theoretical frameworks. For
example, some researchers argued that the theory of reasoned action was
an extensively researched cognitive model that has proven successful in
predicting and explaining behavioural intentions across a wide variety of
domains (Segal and Hepler, 1985; 1982). In line with this reasoning, it is
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possible to argue that during the 1970' sand 1980' s most of the research
on doctors' prescribing behaviour was influenced by Fishbein's (1967),
Fishbein and Ajzen's (1975), and Ajzen and Fishbein's (1980) theoretical
frameworks. During the 1990's, however, this approach was questioned
(Lambert et aI., 1997). Therefore, two different periods of research on
doctors' prescribing behaviour must be considered:
a) 1970's and 1980's
b) 1990's
In the first period, most studies on drug prescribing were based on the
expectancy-value theory. In accordance with this theoretical framework,
expectations about treatment outcomes and the value or desirability of
those outcomes were evaluated:
"All these studies directly or indirectly supported a view of prescribing as an active
problem-solving process directed at achieving outcomes consciously foreseen by
the prescriber" (Denig et aI., 1988: 1892).
All the researchers who used the TORA to explain drug choice assumed
that doctors' prescribing behaviour was determined by sets of beliefs
which are the cognitive component of attitude (Lambert et aI., 1997).
In one set of beliefs, courses of actions were linked to consequences of
those actions, and in another set, important social referents were linked to
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reactions to these courses of action. Attitudes and social values towards
prescribing behaviour were assigned to the decision-making process, and
were assumed to be the main descriptors for doctors' prescribing
behaviour. Behavioural intention was found to vary in accordance with the
sum of the weighted motivations and the strengths of beliefs. In terms of
methodological deficiencies, the traditional Fishbein and Ajzen (1975)
summated model has been criticised for assuming that each belief-product
makes an equal contribution to a simple uni-dimensional, or complex
multi-dimensional, expectancy-value attitude (Foxall, 1984a;b;c; Mazis,
1984; Bagozzi, 1982). If this assumption is violated, SUb-optimality IS
likely to be introduced into the measurement and prediction of attitude.
Since the early 1990's there has been a growing concern about these
assumptions (Lambert et aI., 1997; Bagozzi, 1992). Furthermore, the low
correlation that has been found between behaviour intention (BI) and
behaviour (B) is also explained by methodological problems. The time lags
between behaviour intention (BI) and behaviour (B) measures pose a very
important methodological problem because accurate prediction of
behaviour is only possible if intentions are stable. If this does not happen,
the problem is overcome by measuring behaviour intention (BI)
"immediately prior to the observation of the behaviour" (Ajzen and Fishbein
1980: 51).
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However, the influence of manufacturers' promotional activities, such as
representatives' calls, medical journal advertisements and conferences, or
interaction with another colleagues might intervene between BI and B, and
thus substantial brand switching may occur. Furthermore, prescribers are
usually questioned directly about their beliefs or behaviours (or
behavioural intentions). This raises the risk that doctors' attention may be
directed to facts that they might not notice or outcomes that they might not
consider during their daily clinical activity. Therefore, using Fishbein-type
scales inconveniently introduces prior definitions of doctors' therapeutic
cognitive structures. Besides these methodological deficiencies, the TORA
and its extension do not explain how, or which type of, cognitive processes
are responsible for the behaviour:
"It leaves unanswered the question of how prescribers' values and belieft are
formed, how stable they are and how they change" (Hepler et aI., 1981: 39).
It has been shown that attitudes, subjective norms, and past behaviour can
be used to predict doctors' intentions to prescribe different therapeutic
categories (Segal and Hepler, 1982; 1985), but specific antecedents to
decision-making in this context are generally unknown. An understanding
of the antecedents (i.e., prescribers' clinical values) is, however, needed in
order to more effectively influence the use of these therapeutic categories.
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Almost three decades ago, Vinar et al. (1971) tried to validate these
clinical values by looking into the pharmacologic and diagnostic patterns
of a group of doctors. During the last decade, however, it has become
increasingly clear that it is not possible to explain "how the decision is made
to include a therapy in the evoked set" (Denig and Haaijer-Ruskamp, 1992:
12). Recent research was also unable to identify how prescribers' values
and beliefs are formed (Lambert et aI., 1997).
In accordance with the previous assumptions, it is possible to argue that
the TORA (Ajzen and Fishbein, 1980; Fishbein and Ajzen, 1975) and its
extension (Lambert et aI., 1997) neither explains why certain values or
beliefs become relevant in the context of a particular choice, nor explains
how the motivations determining the impact of values or beliefs on
behavioural intention come about. Ajzen and Fishbein (1980) argued that
the characteristics of the choice situation will determine both which beliefs
become salient and which motivations will determine behaviour. This
assumption confirms that the process in which the individual analyses the
situation and activates a subset of beliefs from hislher cognitive structure is
not part of the theory (Grunert et aI., 1995). Therefore, an important
question remains unanswerable:
Why do doctors choose one therapeutic category over another, and what
are the decision-making processes that underlie this choice?
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3.10.7.2 Research Methods
Some researchers pointed out that most drug prescribing studies were not
entirely satisfactory in providing an explanation of the methods that can be
used to analyse decision making:
"Another limitation of past studies of drug prescribing concerns the method used to
study decision-making. Most previous drug prescribing studies have utilized an
analysis of final judgment or decision output such as ranking or rating and employed
statistical methods, mostly multiple regression, to test the fit of an algebraic model to
data in order to infer that a physician used a particular process in decision making.
However, relatively few studies directly observed or collect information regarding the
actual process used by physicians in making drug choice (Chinburapa et aI., 1993:
1474).
In line with the reasoning that has been advanced, it is possible to identify
two major approaches for understanding the cognitive processes
underlying medical problem solving and decision-making (Elstein et aI.,
1978; Newell and Simon, 1972).
The first approach involves a structural analysis of final judgment or
outcome of the decision processes such as choice, rankings, or ratings.
This method typically employs statistical models (e.g., multiple regression,
analysis of variance, etc.) to study the relationship between model input
such as attributes or cues and output such as choice.
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The other approach, referred to as process tracing, stems from the
information-processing approach to behaviour originated by Newell and
Simon (1972). The information-processing theorists rely heavily on verbal
reports to obtain data about the operations performed to solve a clinical
problem. Because is based on analysis of these protocols, the term process
tracing has also been applied. However, research in the process-tracing
tradition has been largely atheoretical, with the notable exception of the
substantial contribution of Newell and Simon (Elstein et aI., 1978).
In the following sections, each of the two approaches is discussed.
Structural Analysis of Final Judgment
Structural analysis of final judgment refers to methods that utilize decision
outputs to study the decision-making processes. As previously noted, this
approach employs algebraic or statistical methods to describe the
relationship between input (attributes, cues) and output (judgment, choice)
based on assumptions about how individuals use information to form
judgment or decision (Abelson and Levi, 1985).
Generally, alternatives that are used to elicit judgment or decisions from
subjects can be categorized into two types. The first type involves actual
alternatives that are known to subjects or those subjects have had prior
experience with.
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The other type involves hypothetical alternatives (i.e., patient scenarios)
that are described based on several attributes. The latter has been used in
most studies on doctors' prescribing behaviour.
Some of these models were developed to predict and improve judgment.
Through regression equations, researchers were able to "capture"
decision-makers' policies regarding variables involved in a decision. In
both approaches, subjects are presented with the alternatives and are asked
to indicate an overall rating or preference for each alternative, the weight
attached to each attribute, and for known alternatives, the beliefs or
evaluations for each attribute. The scale values for attributes are put into
mathematical equations based on hypothesized models to determine the
goodness of fit or the relationship with the subjects overall rating or
preference for alternatives.
As pointed out earlier, there are limitations associated with the use of
algebraic models to study drug prescribing. This method uses the degree of
fit of algebraic models to infer the decision-making processes and does not
directly observe or collect information about the actual processes used by
decision makers.
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Process-Tracing Techniques
A number of strategies or rules describing the processes doctors used to
make prescribing decisions have been identified in the literature in the last
decade (see Chinburapa et aI., 1993; Mancuso and Rose, 1987). These
studies follow Elstein et aI. (1978) and Newell and Simon's (1972)
information-processing theory of problem solving. The methods used in
these studies have also been in the spirit of their research approach:
verbalizations of doctors or medical students while solving medical
problems and subsequently reviewing their clinical performance. As
Newell and Simon pointed out, only the full complexity of verbal
behaviour, as captured in a verbatim transcript, can do justice to the
complexity of the medical knowledge representation.
Process-tracing techniques are data collection methods that trace the
information acquisition (Newell and Simon, 1972). Although collecting
and analysing the data using the process-tracing technique is time
consuming, this technique collects the data on pre-decisional behaviour to
identify what information attended to and how the information is processed
before the decision is made (Cbinburapa et aI., 1993). The process-tracing
approach was found particularly sensitive to the natural control structure of
the subject's problem-solving method (Kuipers et aI., 1988). In other
words, process-tracing techniques are data collection methods that are
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particularly suitable for understanding information acquisition. With this
qualitative approach, their efforts were clearly directed at development of
an information-processing model, which is practically nonmathematical.
Newell and Simon explicity pointed out that their theory of human
problem solving was intentionally nonexperimental and nonstatistical.
Thus, with a process-tracing technique, the researcher can usually
conclude that the information reported was actually in the subject's focus
of attention at the time but of course much of what the subject had in mind
necessarily goes unreported (Newell and Simon, 1972). This is
problematic because process-tracing data focus mainly on path-breaking to
identify presenting problems, gather background information and form and
test clinical hypotheses. The major concern of researchers in most process-
tracing investigations we have just summarized has not been to develop
prescribing decision-making theory. Rather, their aim has been to observe
the process of thinking and judgment within clinical settings that resemble
the actual task environment as closely as possible:
"The focus of the study is largely on the processes of diagnostic reasoning, although
questions of treatment selection and management are also addressed' (Elstein,
1978: 273).
Thus, information acquisition on the processes of diagnostic reasoning is
assumed particularly relevant on doctors' decision-making processes.
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The process-tracing technique employed in Chinburapa et al.' s (1993)
study was an analysis of information acquisition behaviour to examine
the effects of situational involvement and task complexity on doctors' pre-
decisional behaviour: "The method collects the data on pre-decisional behavior to
identify what information is attended to and how the information is processed before
the decision is made" (ibid: 1474). Chinburapa and colleagues found that the
process-tracing technique used in their study was able to obtain objective
and useful data regarding doctor information acquisition behaviour prior to
making prescribing decisions. A software system was used to monitor
information acquisition behaviour. Computer graphics were used to display
a set of drug classes in a form of alternative-by-attribute matrix:
"On a display screen, each column represents a drug alternative while each row
represents a drug attribute across all alternatives presented Each cell contains the
value of an attribute for the alternative that forms the cell. The values for alternatives
and attributes in the matrix are hidden behind the blank boxes" (ibid: 1475).
Besides the use of both a hypothetical case scenario (an acute
uncomplicated urinary tract infection) and hypothetical anti-infective
drugs, this methodology has a strong limitation as Chinburapa and
colleagues recognised:
"a well structured decision task in which all available alternatives and relevant drug
attributes were shown. This methodology may have provided subjects with part of the
solution to the choice problems" (ibid: 1481).
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Nevertheless, Chinburapa et aI.'s (1993) study on doctors' prescribing
behaviour was the first study to use a qualitative technique (i.e., process-
tracing) followed by a quantitative analysis (the analysis of final judgment
technique used in this research was conjoint analysis). This is critical for
future research on doctors' prescribing behaviour because a multimethod
approach is suggested for the first time: "the finding that the linear model
performed well in predicting drug choice even though the process-tracing technique
indicated that subjects used a noncompensatory decision-making process
demonstrates that a single model of studying decision-making is not sufficient if the
researcher's goal is to understand the process underlying decision making. A
mu/timethod approach should be used to study decision-making process. The use
of combination of methods enable researchers to gain insights into how decision-
makingprocesses and choice are affected by decision contexts." (ibid: 1481).
Mancuso and Rose (1987) recognised that "Medical problems differ from
many others traditionally used by psychologists to study problem solving, in that all
the information needed to solve the medical problem is typically unavailable at the
start" (Elstein et aI., 1978: 277). Nevertheless, Mancuso and Rose
explored doctors' cognitive processes with "a method used by cognitive
psychologists in which the problem-solving strategy is characterized from
verbalizations during each step in the decision-making process" (ibid: 1281). The
interviewer intervenes only with non-directive reminders to keep thinking
aloud.
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3.10.8 Medical Cues, Focal Points and Clinical Values
Mancuso and Rose's focal composite analysis designed the interview as a
'thinking aloud' experiment, in which the doctor is asked to report as
much as possible of what (s}he thinks about as (s}he solves a clinical
problem. From verbalizations during each step in the decision-making
process, only a few clinical focal points or pertinent facts are obtained.
This is also suggested by other researchers: "Among the skills necessaryfor the
practice of clinical medicine are the abilities to collect the pertinent facts about a
case and to use these facts intelligently in order to arrive at an appropriate
diagnosis" (Elstein et aI., 1978: 252). Thus, it is possible to assume a focal
point as a psychological tool to manage an enormous amount of clinical
information (Mancuso and Rose, 1987).
Similar to medical/clinical problem solving (Elstein et aI., 1978), the focal
composite model makes explicit that: ''focal points are valued, compared with
each other, and are the elements of the case around which individual decisions are
made" (Mancuso and Rose, 1987: 1284). However, this approach suggests
that doctors do not use the hypothetic-deductive method in arriving at
therapeutic decisions: "They were not seen to generate hypotheses regarding
optimal treatment nor did they search the case for further data to support treatment
choices" (ibid: 1284). Rather, doctors were found to be guided by their own
set of heuristics from which they make explicit the clinical facts (i.e., focal
points) selected and the values placed on them.
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Nevertheless, Mancuso and Rose recognised that: "The final choice could be
predicted solely by consideration of unweighted cues" (ibid: 1284). Again, cues
acquisition (i.e., focal points or personal clinical values in Mancuso and
Rose's terminology) represents one of the methods proposed by Elstein
and colleagues for understanding clinical problem solving: "Cue acquisition
refers to the process of collecting data in clinical problem solving ...Effective cue
acquisition proceeds according to a plan that permits and facilitates selective data
acquisition" (ibid: 277) ... "POSSible solutions to a diagnostic problem are
retrievedfrom a physician's long-term memory store via an associative process that
links cues to content stored in memory (ibid: 278).
Because drug prescribing decisions must often be made without a "state-
of-the-art" standard, it is possible to argue that the focal composite method
incorporates doctors' personal values in the decision-making process:
"In the focal composite method, such value judgments are expressed through the
choice of focal points and the importance placed on them. In addition, the model
allows the physician's personal values and assessments of clinical information to
be integrated Thus, the art of making a therapeutic decision has embedded within it
many small judgments, from those based on clinical science to those based on
personal values" (Mancuso and Rose, 1987: 1284).
In swnmary, "The choice of method appears to depend more on the structure of the
particular problem than on stylistic differences among physicians" (Elstein et aI.,
1978: 278).
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3.11 Main Conclusions
Prescribing is one of the most important roles of a GP. In fact, it is the
most common therapeutic approach taken when treating patients In
primary care and the number and potency of medicines available IS
increasing all the time. However, many GPs are reluctant to acknowledge
that drug marketing affects the way they practice medicine. That is, the
medical profession is exposed to many influences from outside their home
market through, for example, international guidelines, advertising in
international medical journals, conferences and other events. However,
local factors, senior peers and the influence these have during a GP's
traineeship play an important role in determining prescribing habits. Once
they are established, however, the decision to prescribe and what to
prescribe is influenced by several other national and regional factors:
• recent knowledge acquired about drug treatment through the
pharmaceutical manufacturers' promotion, through the medical
scientific literature, or more recently in Britain, as well as in other
European countries, through advice from the medical and
pharmaceutical advisers of the family health service authorities;
• each patient's lifestyle and background; and
• individual preference interacting with knowledge obtained from
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different sources of drug information.
In view of this, it is important to gain understanding of the backgrounds of
prescribers' therapeutic decision making. Two approaches have been used at
the prescriber's level:
• studies evaluating interventions aimed at improving drug choice; and
• studies explaining this prescribing behaviour.
The former, however, show conflicting results. The second type of studies
offers a further explanation. By building on the work of these researchers,
together with concepts of patient typology and medical guidelines, we find it
possible and desirable to develop a new taxonomy of clinical values useful for
research and pharmaceutical marketing practice on drug choice.
Understanding why specific prescribing behaviour prevails may clarify why
some intervention and marketing programmes fail.
In the drug choice process two steps were identified: firstly, the generation of
a small set of possible treatment options (i.e., an "evoked set") and, secondly,
the selection of a specific therapy for an individual patient. Whether a specific
therapeutic category or drug will become part of a GP's evoked set depends
on the education and information received. Changes will occur when a new
therapy is adopted by the GP. When introducing a new pharmaceutical class,
several effects are aimed at. Firstly, the need for a new product is stressed.
This need can be encouraged by campaigns that bring certain diseases or
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issues to the attention of the prescribers and patients. Secondly, doctors are
familiarized with the brand name by advertisements and mailings. Thirdly, a
positive brand attitude is created by building a good corporate image and by
providing objective positive information about the new product or drug class.
The latter is achieved by collaborating with independent research institutes,
and supporting and organizing meetings with a neutral outlook (i.e., meetings
focusing on a disease or a drug class rather than on one specific product).
Finally, the intention to prescribe the product is stimulated by offering GPs
acceptable reasons for introducing the new therapeutic category/brand or by
proving doctors with a chance to see for themselves (e.g., a seeding trial).
To explain the prescribing decisions of GPs, researchers often employ a
model or representation of the mental events and feelings of decision-makers.
In most of the models, researchers assume that action is initiated with a
processing of information, followed by an evaluation of the information and
the development of an attitude, and ending with the emergence of a intention
to act prior to performance of a particular behaviour. However, having
reviewed prescribing studies, one central question remains to be answered:
What are the clinical values derived from subsets of doctors' cognitive
structures that become behaviouralIv relevant to drug choice?
Based on the analysis to evaluate the described models it is possible to
conclude that it is necessary to build and develop a new model:
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"Most models not only ignore the effect of a number of important variables but also
fail to consider the interactions between the variables. In addition, few of these
models specify the relationships among the variables so as to facilitate the testing of
these models in some quantitativefashion. ..From the review and evaluation of the new
drug adoption models in thepharmaceutical literature, one can conclude that none of
the models are entirely satisfactory in providing a systematic and verifiable
explanation of the process by which physicians adopt new drugs" (Agrawal and
Calantone, 1995: 107-108). This difficulty appears to be related not only
to the theoretical framework chosen to study prescribing decisions, but
also to the research methods.
Mancuso and Rose's model embraces cues, focal points and personal
clinical values as interchangeable concepts with the same meaning. Thus,
the role of personal values as standard or criterion for influencing
evaluations or choices regarding pharmaceutical products suggests a
strong relationship between clinical values and therapeutic decisions. In
line with this reasoning, it is also clear that prescribing decision making in
primary care is strongly influenced by clinical values. These would have
to be taken into consideration in any study of drug choice in general
practice.
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4 Chapter Four Means-End Chain Theory and Laddering Technique
4.1 Introduction
As pointed out in Chapter Two, GPs' clinical values in the treatment of
hypertension and philosophies of prescribing (i.e., medical guidelines)
are two main dimensions of substantive research interest. These
dimensions represent a substantive area of research and a new route to fill
a gap within the literature on doctors' prescribing behaviour. Furthermore,
this line of inquiry distinguishes the present study from previous research.
As a result, the purpose of this chapter is to outline the theoretical/
conceptual basis of the study. The chapter will be organised in five parts:
• The first part of the chapter will be used for establishing the major
differences between the present study and previous research, followed
by an introduction to the research methodologies.
• Part two describes the Laddering Technique (Reynolds and Gutman,
1988). The importance of an Implication Matrix to the development of
an Hierarchical Value Map is also presented inpart two.
• Part three discusses the epistemological location of Means-End Chains
(MEe) Theory (Gutman, 1982), based on its roots and its contribution
to other theoretical approaches on consumer behaviour. Part two ends
with the definition ofMEC theoretical framework objectives.
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• The fourth part of the chapter presents the operationalisation of the part
two by describing a newly available algorithm to make the data analysis
(LadderMap) (Gengler and Reynolds, 1995). An overview of the stages
the researcher must go through, the important considerations at each
stage, and how these stages of computer analysis of Means-End data
can be facilitated using this software support tool are also presented.
• Some recent examples of the use of MEC theoretical framework and its
laddering approach are advanced in the fifth part of the chapter.
• A final issue with respect to MEC theoretical framework and Laddering
methodology concerns the impact of clinical values on drug choice. The
objective of the last part of the chapter is to clearly define the nature of
the values as conceptualised and measured by the researcher; comparing
this with alternative approaches. A micro research approach is defined
and its abstraction levels presented. Finally, the chapter highlights the
need to examine the implications derived from the researcher's values
conceptualisation and its influence on the interpretation of results.
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4.2 Major Differences from Previous Research
In attempting to understand how doctors defme their prescribing
behaviour, pharmaceutical marketing) researchers have concentrated their
efforts on GPs' attitudes, subjective norms and intentions towards brand
attributes. Until now, studies on prescribing behaviour have relied upon
the discovery of patterns of cause and effect in order to advance the
knowledge of which pharmaceutical brand attributes influence drug choice.
This study proposes a new theoretical framework and a different research
methodology to explain what values are derived from subsets of doctors'
cognitive structures that become relevant to drug choice:
"For some medical decisions, values and attitudes of physicians on how much
risk is acceptable or what levels of certainty are required for action can have a
substontial influence on what tests are ordered or which treatment is recommended
(Billings and Eddy, 1987: 23). That is, "The concept of 'value' replaces the
traditional concept of 'product' (Boerkamp et aI., 1992: 147). Because of the
scarcity of the research on this topic, the Means-End Chain theoretical
framework (Gutman, 1982) and its laddering procedure (Reynolds and
Gutman, 1988) was initiallyused.
I "PIIII11fUIUllticai mllrketing, lIS II slIbspeciaity of mllrketing, clln be defined lIS II process by wllich
'lie mllTketfor phllTmIlCellticai cllre is IIctlllllizetf' (Smith, 1991 a: 9).
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Therefore, one of the novel features of the present research lies in the use
of a different theoretical and empirical approach to that employed
previously.
Assuming that a GP's therapeutic approach is based on clinical values,
considerable effort will be devoted to the construction of different
hypertensive patient typologies. Segal and Hepler (1985) also suggested
that doctors' prescribing behaviour changes in accordance with the
patient's clinical context:
"The results show, however, that these prescribers changed their beliefs about
treatment effectsfrom patient to patient frequently" (Segal and Hepler, 1985:
974).
Therefore, in the present research, all the hypertensive patient typologies
will defined by Portuguese GPs in accordance with their daily clinical
activity. In this way, the therapeutic categories attached to those
hypertensive patient typologies will be used to categorise Portuguese GPs
according to their first-line drug therapy (see Chapter Two: Figure 2.2:
Study Overview).This is also other major difference from previous research
which defined a "patient scenario" to analyse drug choice. As a result, the
approach to this research diffors from those studies which believe that the
expectancy-value theory can explain GPs' prescribing behaviour.
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This conviction was reinforced recently by researchers who analysed the
factors associated with antibiotic prescribing:
"physicians' attitudes, subjective norms and intentions were not predictive of actual
antibiotic prescribing behaviour. Prescribing behaviour may have been a junction of
patient-specific rather than general beliefs about antibiotics" (Lambert et aI.,
1997: 1767).
That is, there is mounting evidence that prescribing is patient-oriented
rather than product-oriented and follows medical guidelines (Pathman et
al., 1996), which are an important tool concerning the promotion of the
rational use of medicines in Portugal (Andrade, 2000).
It is, therefore, not surprising, that "Research on clinical guidelines and
effectiveness is being undertaken to provide physicians and others with information to
assist in determining the type of care that should be rendered to a particular patient"
(Kay, 1990: 143).
Having said this, it should be added that this study follows not only
medical education guidelines (Schachter, 1997; Birkenhager, 1996;
Beevers and MacGregor, 1995; Kaplan, 1994; Hart, 1993; Houston,
1992), but also recent practical guidelines for the management of
hypertension (WHO-ISO, 1999; 1993; JNe VI, 1997; Veterans Health
Administration, 1996; WHO, 1996).
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The use of simulated patient' scenarios on medical training was also found
important to understand drug choice (Roberts et al., 1995; Baerheim and
Malterud, 1995). The emphasis on the relationship between therapeutic
classes and patient typologies reinforces the importance of terminal
values! rather than instrumental values:
"terminal values determine choice at the product class level but
instrumental values at the brand choice lever' (Howard, 1989: 58).
Previous research focused on instrumental values at the brand choice level.
To the best of our knowledge, there is no previous research that has
defined GPs' terminal values towards first-line drug therapy. This is the
third major difference from past published research on doctors'
prescribing behaviour.
The fourth major difference from past published research on drug choice
is attached to research design which encapsulates both qualitative and
quantitative data.
2 Simulated patients are role-players who pretend to be patients for medical students or doctors for
teaching, assessment or research purposes (Baerheim and Malterud, 1995: 410).
3 Howard (1989) defined a two-level choice structure in which terminal values operate at the higher
level (i.e., product class) and instrumental at the lower level (i.e., brand).
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4.3 Formulation of Research Design and Instruments
Following Chisnall's (1992) advice, this study uses both qualitative and
quantitative data:
"A central part of research activity is to develop an effective research strategy or
design. This will detail the most suitable methods of investigation. the nature of the
research instruments. the sampling plan. and the types of data. i.e., quantitative or
qualitative (or, ideally, both)" (Chisnall, 1992: 23).
Other researchers have provided evidence showing that "Qualitative
research is used for exploratory studies leading into more structured or
quantitative studies" (Hakim, 1987: 26). Surprisingly, no studies could be
found applying both methods to doctors' prescribing behaviour.
The variety of clinical contexts, the complexity of the problem and the
interdependence of influencing factors on doctors' prescribing behaviour
call for a diversity of conceptual approaches.
Basically, two major methodological schools of thought can be
distinguished: qualitative and quantitative (Gillett, 1995; Gabriel, 1990).
The former uses the participant observation, protocol studies or in-depth,
open-ended interviewing methods of data collection, while the latter is
intended to test hypotheses, generally relating to the causes of a particular
phenomena through a questionnaire (Henwood and Pidgeon, 1995).
217
Gill and Johnson (1991) suggest that qualitative data tend to be associated
with inductive reasoning, while quantitative data tend to be associated
with empiricist, positivist methods employing deductive reasoning and
testing of hypothesis (see Table 4.1 below).
For the reasons discussed above, research methods can be placed on a
continuum according to the type of reasoning they employ between
nomothetic methods at one end and ideographic methods at the other.
Table 4.1: Comparison of Nomothetic and Ideographic Methods
Nomothetic Methods Emphasise Ideographic Methods Emphasise
1. Deduction; vs Induction;
2. Explanation via analysis of causal vs Explanation of subjective meaning
relationships and explanation by systems and explanation by
covering-laws; understanding;
3. Generation and use of quantitative vs Generation and use of qualitative
data; data;
vs Commitment to research in
4. Use of various controls, physical or everyday settings, to allow access
statistical, so as to allow the testing of to, and minimise reactivity among
bypotheses; and the subjects of research; and
s. Highly structured research methodology vs Minimum structure to ensure 2, 3
to ensure replicability of 1,2,3,4. and 4 (and as a result of 1)
Laboratory Experiments, Quasi Experiments, Surveys, Action Research, Ethnography.
Source: replicated from Gill and Johnson (1991), pp: 36.
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As Gill and Johnson (1991) have noted, the choice of research strategy,
design and method is subject to a number of influences, philosophical,
social, political and practical. However, the intimate connection between
patient typology and drug choice that has been established within the
medical field, particularly antihypertensive medical guidelines, gives
priority to practical considerations. This reality suggests that there are
links between therapeutic categories (the 'means') and the consequences
these provide for the doctor in terms of therapeutic results, dependent on
the personal clinical values of that individual (the 'ends'). It is these end
values, rarely consciously considered, that play a major part in
determining the doctor's prescribing behaviour.
The in-depth laddering interview elicits these personal motivations by
encouraging respondents to revisit everyday, common place experiences
and to examine the assumptions and desires driving seemingly simple
choice behaviour.
In light of these assumptions, it became mandatory for us to use the in-
depth laddering interview (see section 4.6) as the most appropriate
technique for understanding how these clinical values determine drug
choice (see Decision Box 4.1 below).
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Decision Box 4.1: Formulation of Research Design and Instruments
~ Focus: The Relationship between Patient
Typology and Drug Choice
~ Theoretical Approach: Means-End Chain (MEC) approach and
Laddering technique (see this Chapter for specific details)
~ Design: In-Depth Interviews
(see Chapter Five for specific details)
~ Data type: Semi-Qualitative
Inductive, theory based analysis and~ Interpretation:
reasoning
~ Goal: To develop "The Patient Typology Model"
(see Chapter Six for specific details)
In some quantitative research, hypothetical case histories have been used
to analyse prescribing whereby the same case is presented to a series of
doctors and their views as to how they would prescribe for the patient in
question are recorded. One advantage of this method is that the case can
be purposefully constructed and each doctor is confronted with precisely
the same test situation. However, this approach has also one crucial
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disadvantage: it uses hypothetical case histories. To overcome this
problem, both the qualitative and quantitative approaches were used in
this research (see Decision Boxes 4.1 and 4.2). With the methodology
employed we were not creating hypothetical case histories. Instead, we
retrieved from GPs real cognitive excerpts in terms of the hypertensive
typologies that guide their first-line drug therapy (see Chapter Five).
These data were used to develop "The Patient Typology Model (PTM)"
(see Chapter Six) which involves the use of numeric data (see Chapter
Seven).
Decision Box 4.2: Formulation of Research Design and Instruments
~ Focus: Modelling and Categorisation of
Portuguese GPs' Prescribing Behaviour: The Case of Patients with
Hypertension
~ Theoretical Approach: Cognitive approach
~ Design: Positivistic, structured research design
~ Data type:
~ Interpretation:
(see Chapter VII for specific details)
Quantitative
Deductive
~ Goal: To categorise Portuguese GPs according to
their first-line drug therapy (see Chapter VIII for specific details)
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4.4 The Means-End Chain (MEC) Theory
Over the last decades there has been a growth of interest in the philosophy
of science to guide marketing theory and research (Brown, 1996; Gillett,
1995; Hunt 1993; 1992; 1983; Peter, 1992; Bagozzi, 1984; Deshpande,
1983). The ontological, epistemological, and methodological guidelines for
doing research have important consequences for the official ideology and
discourse through which the "facts" are constructed. However, "despite
advancing sophistication in the philosophy of science. the methodological debates
have proceeded for the most part separately from the empirical investigation of
marketingphenomena or the development of marketing theory" (Foxall, 1993: 46).
The dearth of theoretical frameworks to guide empirical investigations has
led to difficulties when linking marketing research and subsequent
marketing strategy (Reynolds and Craddock, 1988):
"Traditional marketing research does not have a framework by which the
understanding gained can be either (1) directly assessed for the development of
strategic options or can be (2) specified in a consumer-based strategy format. The
result of not having such a consumer-based strategy framework is undue subjectivity
in the translation process of research findings underlying the development of
advertisingstrategy" (Reynolds and Craddock, 1988: 53).
The vehemence with which Reynolds and Craddock made this point can
be found elsewhere in previous criticisms of the lack of correct
methodologies linking theoretical frameworks to empirical approaches.
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Foxall (1986), for example, pointed out that it is important to have: "a
frame of metatheoretical reference within which theory is derived, by which empirical
investigation is governed, and through which theory and observation are related in
the process of explanation" (Foxall, 1986: 28, 29). This assumption reinforces
the acceptance of the theory-laden nature of observation: "rather than a
data-driven process, science is being described more and more as a theory-driven
activity" (Bagozzi, 1984: 18).
The close relationship between theoretical assumptions and research
approaches is suggested to be an indirect consequence of the paradigm that
has been chosen, because it influences the way we move from the
language of theory (concepts) to the language of research (indicators). As
a result, the chosen paradigm and the theoretical framework within which
the empirical research is produced is important for understanding of the
final results. It follows from the previous paradigmatic principles that to
initiate a research process a theoretical framework has to be established
(Bryman and Cramer, 1997). A recent theoretical framework, the means-
end chain analysis and its laddering method" are one of the mostpromising
developments in consumer research within the last decade" (Grunert et al.,
1995a: 1).
The MEC Theory (Gutman, 1982; Olson and Reynolds, 1983) presents a
model to assess consumers' product knowledge and meaning structures.
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Previous research using the MEC approach, seems to indicate that this
micro-psychological theoretical framework offers a practical metaphor to
assess the way consumption-relevant knowledge is stored and organised in
human memory: "means-end models can be more broadly viewed as representing
the relationship between self and products, where the means represent aspects of
product knowledge, and the ends represent aspects of consumer self-knowledge"
(Walker and Olson, 1991: 112). This practical metaphor is able to link the
product and self by capturing the representation of cognitive structures in
memory (Claeys et al, 1995). Thus, the central tenet of MEC theory is that
product, service or behaviour meaning structures stored in memory consist
of a chain of hierarchically-related elements (Gutman, 1982). This linear,
hierarchical structure and network context forms a "means-end chain" in
that attributes are the means by which the product, service or behaviour
provides the desired consequences or values, i.e. the ends. As a result,
values (which derive from a specific culture, society, or personality) are
the ultimate source of choice criteria that drive buying behaviour (Clayes
et aI., 1995).
Consumers translate product attributes into the benefits (termed
consequences) they produce, and benefits are ultimately translated into the
consumer's driving value orientation. These values are consumers' mental
representations of the important end states they are trying to achieve in
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their lives. Durgee et al. (1996) pointed out that values impact attitudes,
which in turn impact behaviour. Two types of values were identified:
instrumental and terminal values (Walker and Olson, 1991: 113). The
former represents a "preferred mode of conduct ... a preferred pattern of
behaviour", while the latter "represent preferred end states of being" (Peter and
Olson, 1987: 112). By definition, instrumental values represent the less
abstract knowledge which affect the consumer's cognitions and behaviours
in accordance to "self-schema that may be activated in different situations"
(Walker and Olson, 1991: 113).
The intimate connection between products and self that has been
established within the MEC framework determines the two fundamental
assumptions about consumer behaviour that are advanced in the means-end
chain model:
I. "that values, defined here as desirable end-states of existence, play a
dominant role in guiding choice patterns; and
2. that people cope with the tremendous diversity of products that are
potential satisfiers of their values by grouping them into sets or classes
so as to reduce the complexity of choice" (Gutman's 1982: 60).
What seems to emerge from these fundamental assumptions is that in
addition to the product-class type of product categories, consumers have
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the capacity to organise categories based on product functions, in order to
organise "the linkages between the product and the personally relevant role it has
in the life of the consumer" (Reynolds and Gutman, 1988: 11). That is,
because of the multiplicity of a product's attributes, consumers are
selective about which attributes are most meaningful to them. The reason
for such selection is the limited capacity of the human cognitive
processing" system (Alba and Hutchinson, 1987). Hence, the meaning of a
product to a consumer is based on selected product attributes, which are
important for organising categories based on product functions. Two other
general assumptions complement the previous ones:
1. consumer actions have consequences; and
2. consumers learn to associate particular consequences with particular
actions.
Consistent with these considerations, product meanmg becomes a
consumer's cognitive and affective representation of a product (Valette-
Florence and Rapachi, 1991). The product in turn has attributes that are
important for obtaining the desired benefits (consequences), through
which certain ends or valued states of being are satisfied. Therefore, the
4Cognitive processes are the processes by which the cognitive structures are changed due to new
information from the environment, and by which information is retrieved from the cognitive
structures and used to direct behaviour.
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first element of the chain subsumes the product knowledge component.
Attributes in turn determine a set of consequences and benefits", that are
evaluated by consumer personal values. This sequence of links from the
product attributes to consumer values, forms a "means-end chain" in that
attributes can be faced as the means by which the product provides the
desired consequences and values, the ends.
The interest in cognitive structure approaches to determine the linear
hierarchical structure and network context" that links means to ends, has
given researchers the opportunity to study motivational issues in general
(Sorensen et aI., 1996; Claeys et al, 1995; Olson, 1995; Grunert and
Grunert, 1995a;b; Celsi and Olson, 1988) or consumers' goals and their
hierarchical structure in particular (Bagozzi and Edwards, 1998; Olson,
1995; Pieters and aI., 1995; Bagozzi and Dabholkar, 1994; Huffman and
Houston, 1993). For example, Bagozzi and Dabholkar (1994), in an
attempt to improve the Theory of Reasoned Action (Ajzen and Fishbein,
1980) to explain recycling behaviour, have used a means-end approach
and its laddering procedure to capture excerpts from cognitive structure
that could explain recycling goals.
sBenefitsdiffer from attributes in that people receive benefits whereas products have attributes.
~e literature on cognitive psychology is replete with models of cognitive structure. Most of them are
variants of a basic network model. However, there are alternatives to network models: schemas,
frames and scripts are some of the non-network constructs that have been used to model cognitive
structures.
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Typically, these researchers have tended to represent mental models that
derive from content analysis in a range of areas which vary from, for
example, the regulation of body weight and recycling (Bagozzi and
Edwards, 1998; Bagozzi and Dabholkar, 1994 respectively), to fish
consumption (Sorensen et aI., 1996).
In looking at differences between means and ends to achieve goal-directed
consumer behaviour in terms of a Means-End hierarchical structure,
researchers are able to determine the product functions (i.e., main
attributes of a product-class type of product categories), the direct
consequences that their use implies, and the values attached to consumer
behaviour: "More recent work links values and products together via "means-
ends" chains. Most of these begin by asking about important product attributes as
perceived by respondents, then probing until the researcher identifieS more general
motives or values regarding the producl' (Durgee et aI., 1996: 91). Consistent
with this reasoning, it seems reasonable to expect that the MEC model
(Gutman, 1982) gives researchers the opportunity to understand deeply the
values-consequences-attributes linkages derived from a product-use
situation. To summarise, the model may be conceptualised as shown in
Figure 4.1.
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Figure 4.1: The values-consequences-attributes Linkages
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It IS the associational aspects of the Means-End model that provides a
unique perspective on consumers' personally relevant meaning, because its
framework is able to encompass all three levels of consumers' decision-
making. That is, attributes, consequences and values are the linear
hierarchical structure and network context to link means to ends.
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The Means-End-Chain model presents three main parts: the means-end
chain, matrices and inputs and outputs. According to the Figure 4.2, the
means-end chain subsumes three different levels of distinctions - values,
consequences and grouping. Higher hierarchical concepts focus on what
products are supposed to do for the consumer, while the grouping level
concentrates on distinctions that can be made according to the product
attributes. The "Inputs" to the framework are mainly consumption
situations and products; "Outputs" are products chosen for fmal
consideration. The matrices are the structure within the system through
which situations and products are categorised according to the hierarchical
levels represented in the means-end chain.
Figure 4.2: The Means-End Chain Model (MEC)
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A Means-End Chain Model Based on Consumer Categorization Processes
Source: Adapted from Gutman (1982)
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4.5 The MEC Theory and its Epistemological Location
The last decade has seen an increasing interest in cognitive structure 7
approaches for studying consumer motivation and choice behaviour.
Means-End Chain (MEC) Theory (Reynolds and Gutman, 1984; Olson
and Reynolds, 1983; Gutman, 1982) has been the basis of much of this
work. This theoretical framework and its laddering technique have been
considered useful tools for understanding personal relevance and consumer
decision-making. As such, use of MEe theory and its laddering technique
in consumer research have been viewed as "one of the most promising
developments in consumer research within the last decade" (Grunert et al 1995a:
I).
A discussion of any theory is only possible when its epistemological
location has already been defined. For some researchers, this is not the
case with MEC:
"A discussion of means-end chain theory is 1IUlde diffICult by the fact that the
epistemological status of means-end chains (MEe) is not completely clear"
(Grunert et aI., 1995a: 1).
7A cognitive structure is the organization of experience and other types of information in human
memory. "In consumer research, cognitive structure has generally referred to factual knowledge (i.e.,
beliefs) that consumers have about products and the ways in which that knowledge is organized. The
principal function of cognitive structure is to differentiate various products and services in ways that
are useful for decision-making" (Alba and Hutchinson, 1987: 414).
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The epistemological location of MEe theory is controversial. Various
research traditions, "ranging from an interpretivist phenomenological view to a
neo-positivist nomological view" (Grunert et al 1995a: 1) claim its interest.
Two basic views are identified: the motivational and the cognitive as
important sources of reflection for the development of MEC. Not only
these roots, but also the contribution of MEe theory to other theoretical
approaches on consumer behaviour, have generated some misinterpretation
about its epistemological location. Having said this, it should be added that
there is also evidence that this misinterpretation is only possible if one
forgets that the hierarchical value map derived from laddering data is an
aggregate map of cognitive structure (Olson and Reynolds, 1983). Any
other scientific explanation of the use of MEC theory in consumer research
that "adopts a phenomenological view that all measurements are context-
dependent, the notion of measuring a situation-invariant cognitive structure does
not 11IIlke much sense" (Grunert and Grunert, 1995: 210). As a result, a
discussion of the epistemological location of MEC Theory has to be
organised. This discussion illustrates further the relevance of an
understanding of the epistemological location of MEe Theory in terms of
its roots and contribution to other theoretical approaches to consumer
behaviour.
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4.5.1 The Roots
Gengler et al. (1995a) argued that the roots of Means-End Chain Theory
and its Laddering methodology is derived from Kelly's (1955) original
Personal Construct Psychology. That is, the representation of cognitive
structures in memory advocated by the MEC theory are identical to the
Personal Construct Psychology of Kelly (1955) in the sense that both are
based on the acknowledgement that product, service or behaviour may be
linked to self What seems to emerge is that the roots of MEC theory are
closed related to the "person-as-scientist" metaphor: "Like Personal
Construct Psychology, Means-End Theory assumes that the meaning is both in the
'WOrdsthat consumers use to describe their world; and in the connections between
different concepts" (Gengler et at, 1995a: 254).
Through personal experimentation, individuals develop personal
constructs'', Following this assumption, it can be seen that each individual
is assumed to develop a final behaviour which is function of his or her
view of the "world", which in turn is guided by "rules" or "theories" to
organise their lives within the physical world (Gengler et aI., 1995a).
•A construct can be defined as "a property attributed to several events, by means of which they can be
differentiated into homogeneous groups" (Kelly, 1955: 20).
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4.5.2 A Micro-Psychological Perspective
Also a link between the MEC model and the value" research has been
established (Reynolds and Gutman, 1988). During the last decade, the new
applications of value theory to marketing problems have taken two
theoretically-grounded perspectives (Reynolds, 1985):
1. the macro-sociological approach, quantitative m essence, usmg
standard survey research methodology, aimed at clustering individuals
into groups defined by a priory specified value orientations.
2. the micro-psychological perspective, qualitative in nature, which uses
in-depth qualitative methods to understand consumer motivations. This
approach does not adopt apriory any assumptions.
The macro-sociological approach, though strong on face validity, fails to
provide an understanding of how consumers link the attributes that exist in
products, the consequences provided by these attributes, and the personal
values the consequences reinforce (Valette-Florence and Rapachi, 1991).
Consistent with current distinctions in cognitive psychology, micro-
psychological researchers argue that all elements of the means-end chain
are available (Reynolds and Gutman, 1988).
9"A value is defined as an enduring prescriptive or proscriptive belief that a specific end state of
existence or specific mode of conduct is preferred to an opposite end state or mode of conduct
(Rokeach 1968, 1973). These values are considered the important principles guiding one's behaviour
throughout life" (Bearden et al., 1993: 83).
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Within the value research framework, micro-psychological researchers
persuasively argued that personal values are a source of attitude and
preference (Rosenberg, 1956; Vinson, Scott, and Lamont, 1977; Howard,
1977). Particularly relevant to attitude theory was the Expectancy-Value
Theory (Rosenberg, 1956), which has provided evidence showing that
individuals learn how to associate particular product attributes with
specific consequences. However, it is important to distinguish between
consumers' perceptions of these attributes and the objective reality of the
attributes themselves:
"It is essentilll to distinguish between the attributes per se and the consumers'
perceptions of these attributes, because consumers differ in their perceptions. It is
the perception that affects behaviour, not the attribute itself. "Attribute" is often
used to mean choice criteria, but this leads to confusion. To use "attribute" when
you mean not the attribute itself but the consumer's mental image of it, is to reify
what is in the consumer's mind" (Howard, 1977: 28)
Howard's (1977) model is one of the earliest comprehensive models of
consumer choice that attaches paramount significance to the influence of
consumer values on purchase outcomes. The model assumes that the
choice of products or services is ultimately a means by which consumers
achieve important personal values.
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4.5.3Assessing Consumers' Cognitive Structure
During the 1990' s, marketing research on personal values received
substantial attention from both academics and practitioners (see for
example Botschen, 1999; Claeys et al., 1995). Adopting this more micro-
psychological perspective of the market place, recent studies have shown
the interest of the MEC theory in developing and assessing communication
strategies and advertising practices (Reynolds and Whitlark, 1995;
Reynolds and Gengler, 1991; Reynolds and Craddock, 1988). In line with
these studies, MEC is also concerned with obtaining insight into
consumers' buying motives: "consumers ...learn to choose products that have
certain attributes as an instrument to obtain the desired consequences, which means
the combination of two aspects: motivation and the cognitive structure (Reis, 1997:
163). Therefore, MEC theoretical framework can simultaneously be faced
as a modem variety of Dichter's (1960) motivation research, in the sense
that it tries to identify insights regarding the motives involved in a certain
consumption. The previous assumptions reinforce one of the most
important differences between the MEC framework and the Expectancy-
Value Theory (Rosenberg, 1956) in terms of the focus of analysis:
"It is the person that is the focus of study, not the product" (Reynolds
and Gutman, 1988: 16).
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It is possible to argue, however, that MEC Theory was also inspired by the
Expectancy-Value Theory (Rosenberg, 1956), which reinforces the
importance of the linkages between the product attributes and the
consequences of their use for consumers' choice. That is, MEC explains
how the perceptions of attributes, not the concrete aspects of the product,
are linked to consequences, "which in turn move consumers toward valued end
states" (Gutman, 1982: 62).
Analysis of MEC roots and sources of inspiration suggests that
understanding the differences between the MEC theory and other
explanations of consumer behaviour derives from recognising the various
alternative cognitive and motivational frameworks which underpin them
(Grunert and Grunert, 1995; Grunert et aI., 1995). The various roots of and
sources of inspiration for MEC Theory development (Gutman, 1982) do
not preclude a clear teleological identification with the "cognitive
behaviourism". That is, the MEC model organises the laddering procedure
in order to retrieve an excerpt of the consumers' cognitive structure,
contingent upon the situation and the motivational state of the individual.
As situations play a critically important role in any cognitive structure
theory of self by determining which self-knowledge is activated from
memory, it is possible to use MEC theoretical framework for connecting
product knowledge to self-knowledge (Walker and Olson, 1991).
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4.5.4 The Contribution of MEC Theory to Goal Structures Research
Recent research on consumer behaviour has highlighted a degree of
polarisation over goal structures associated with the motivation research
tradition (Pieters et aI., 1995). It should be noted that the MEe approach
to consumer goal structures represents an important theoretical link
between psychological theories concerning the self-regulation of behaviour
and action identification and the work in marketing on MEe structures of
consumer product knowledge (pieters et aI., 1995; Bagozzi and
Dabholkar, 1994; Huffinan and Houst, 1993). This intimate connection
between cognitive and motivational theoretical frameworks is particularly
evident within the cognitive schemes approach proposed by Bagozzi and
Dabholkar (1994). With the rigour of this study as a notable example, it
can be said that the importance of goals and their hierarchical structures
has given researchers the opportunity to link MEe theoretically to
consumer behaviour through expectancy-value models. These researchers
have provided evidence showing that it is possible to use MEe theory and
its laddering methodology to derive the goals structures relevant to
consumers for recycling. That is, using the MEe framework, the
Laddering approach investigates how situational factors lead to the
activation of subsets of cognitive structures. According to this version of
the basis for goal setting, the consumption of products is ultimately a
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means for achieving important values in the domain of goal-oriented
behaviour, which is a promising approach for modelling consumer goal
structures:
"The hierarchical structure of superordinate goals constitutes a fundamentally
different representation of the consequences of goal pursuit and goal achievement
than expectancy-valuemodels. Unlike thepoint-form summation of products of beliefs
and evaluations, the hierarchical goal structure models the pattern and
interdependence amongst goals" (Bagozzi and Edwards, 1998: 617). These
hierarchical goal structures are cognitive schemas (Austin and Vancouver,
1996) that influence goal intention:
"We attempted to show that the cognitive and motivationalfoundation for goal setting
is more complex than currently depicted in leading theories. The motivation for a
goal intention was found to be dependent on cognitive schemas people hold with
respect to superordinate goals that a focal goal fulfils (Bagozzi and Edwards,
1998: 619).
Both the Bagozzi and Edwards' (1998) and Bagozzi and Dabholkar's
(1994) studies suggest that their line of investigation is more concerned
with overcoming the problems presented by the expectancy-value
approaches than with having any influence on the MEe' s theoretical
framework:
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"One drawbackwith expectancy-value representations is that they fail to capture the
underlying structure, if any, amongst cognitions or beliefs" (Bagozzi and
Edwards, 1998: 606).
These studies, while adapting schema theory (i.e., information already
stored in memory that is important to organise consumers' self-knowledge
of a particular domain), regard the principles derived from network
analysis not as measures of cognitive structure, but as a "reconstruction"
of relevant information in terms of self-regulation, which constitute the
ultimate goals or standards for behaviour. Given this perspective, it is
possible to view the previous studies as a new theoretical effort to develop
a conceptual and methodological framework for investigating consumer
goal structures. The same studies may also indicate "that motivational
research may be experiencing a renaissance in marketing and consumer behaviour"
(pieters et at, 1995: 227).
The contribution of MEe theory to motivational studies reflects not only
its capacity in "measuring" consumers' consumption-relevant cognitive
structures (micro-psychological perspective), but also its flexibility to
complement or substitute other theoretical personal values approaches. It
is important to stress again that MEe theory's capacity and flexibility do
not preclude or diminish its epistemological status.
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4.5.5 The Objectives
The motivational and the cognitive paradigms have different objectives
when explaining consumer behaviour. While the former tries to understand
the consumer's basic motives that are present in herlhis daily shopping
behaviour, the latter is concerned with two different topics (Reynolds and
Gutman, 1988):
1. the way consumers obtain and analyse information from the
environment; and
2. the way they relate this consumption-relevant knowledge to information
already stored in their minds in order to understand its influence to
consumers' behaviour.
According to this cognitive perspective, MEe (and its laddering technique)
is a procedure that tries to identify the process through which consumption
relevant information is organised within cognitive structures, which in turn
guide consumers' choices (Gengler et aI., 1995a). Therefore, MEC is
supposed to obtain the precise verbal information to develop the links
between attributes, consequences and values (Gutman, 1982; Olson and
Reynolds, 1983; Reynolds and Gutman, 1988; Gutman, 1991; Gengler and
Reynolds, 1995). This is fundamentally different from previous
approaches:
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"Most marketing research has focused on only one level of consumers' product
knowledge - typically the attribute level, occasionally the benefit! consequence level.
Unfortunately, as we noted earlier, attention to a single level of meaning gives
marketers only a partial understanding of consumers' product knowledge" (Peter
and Olson, 1987: 116-117).
The information already stored in memory is a vital cognitive asset that
consumers use to direct their behaviour towards the attainment of desired
personally-relevant values. It follows, then, that MEe would be a
theoretical framework whose objective is to understand how consumption
of that vital information is stored and organised in memory in different
category structures (Gutman, 1982).
At the most basic level, the objective is to distinguish and examine the
content and structure of consumer knowledge in order to organise it in
means-end chains. The former identifies the specific means-end concepts
mentioned by respondents, while the latter refers to the pattern of
relationships between concepts. These concepts can be classified
according to their level of abstraction (i.e., attributes, consequences and
values). For example, women who are concerned about osteoporosis may
look for information that enables them to identify high-calcium foods
which include not only milk, cheese and fresh fish, but also certain
vegetables and other products. All these different products are organised in
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different cognitive categories according to the consumer's knowledge of
the topic. As knowledge is not a uniform asset among people, these
cognitive structures 10 represent deep structure differences (i.e., patterns of
relationships between concepts) that are related to nutritional mechanisms.
Understanding these differences, would be important for connecting the
product attributes, their consequences and the values (i.e., the concepts)
that guide the choice. That is, it would be necessary to have insight into
women's life style and subjective product meanings with regard to those
high-calcium foods. More specifically, the objective ofMEC theory and its
laddering approach would be to give insight into how women mentally link
the purchase and consumption of high-calcium foods to the attainment of
life values, and into which possible demotivating factors (product
attributes-consequences) prevent women from buying and consuming some
of these products. These salient reasons for purchase may, possibly, be
derived from more important goals and values, and we will look at the
contribution of the laddering technique in providing guidance about this
motivational process (e.g., how to identify these goals and values).
10 "The marketing constructs of product class, benefit segment, usage situation, and evoked set all
entail some type of category structure for competing brands" (Alba and Hutchinson, 1987: 415).
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4.6 LADDERING TECHNIQUE
In order to retrieve the attribute-consequence-value chain, a one-to-one in-
depth interview technique called "Laddering" has been the method most
advocated and used to understand the relevant excerpts of consumers'
cognitive structures (Reynolds and Gutman, 1988).
4.6.1 Elicitation Techniques
In its structure, the Laddering technique is considered an extension of the
Repertory Grid technique (Kelly, 1955): "The means-end chain model used by
the authors in extending the Repertory Grid procedure follows the scheme presented
by Gutman (1982)" (Reynolds and Gutman 1984: 157). However, the
Laddering technique, in contrast with the Repertory Grid technique, does
not "oblige" the respondent to perform a series of triadic 11 sorts to defme
the way in which certain physical attributes of products are linked to his or
her personal values during product consumption. Complex methods like
triadic sorting have been found to be more time consuming than other
methods without providing better results: "Thus, in general there seems to be
little reason to apply complicated sorting procedures like triadic sorting, when
eliciting attributes/or low involvement products" (Bech-Larsen et aI., 1997: 20).
II Triadic sorting is a technique developed by Kelly (1955) with the purpose of mapping cognitive
structures. The sorting procedure starts by the respondent being shown triple combinations of the
product concerned. For each triple combination, the respondent is repeatedly asked for an important
attribute on which two of the products are alike and at same time different from the third.
244
The intimate connection between the laddering technique and the
hierarchical structure of attributes, consequences, and values, that has been
established within the MEC theoretical framework, provides the
theoretical and conceptual structure to link consumers' values to their
behaviour. To elicit the connections between these hierarchical structures,
other techniques of eliciting distinctions rather than triadic sorting have
been found to be relevant (Reynolds and Gutman, 1988). Particularly
important has been the method known as 'differences by occasion', which
evokes a product-use situation familiar to the respondent in order to create
a personally meaningful context within which is easier to elicit the
distinctions: "Attention to the context of consumer behaviour provides a more
meaningful context for laddering to proceed People do not use or consume products
in general; they do so inparticular contexts" (Reynolds and Gutman, 1988: 15).
The evocation of a product-use situation provides a meaningful semantic
structure within which the respondent is able to move from attributes to
consequences and from this to personal values. Using specific interviewing
approaches like 'evoking the situational context' to reinforce the
consumer's familiarity with the consumption act, facilitates content
analysis. Furthermore, these verbatim transcriptions are more realistic
because they represent the "real" world of the respondent's product
consumption. As a result, evoking the situational context facilitates the
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laddering procedure and respondents are able to develop better
associations between means and ends, because
"it is the person that is the focus of study, not the product. Therefore, it is essential
to elicitfrom respondents the most relevant occasions for product consumption and
to use these as the focus of the interview" (Reynolds and Gutman, 1988: 16).
The purpose of the discussion on Laddering elicitation techniques is to
illustrate further the relevance of understanding means and ends that can
be obtained when the interviewer keeps the focus of the discussion on the
consumer rather than on the product or service. What seems to emerge is
that the technique to elicit the hierarchical attribute-consequence-value
chain is only effective when the researcher embraces the conviction that it
is only possible to understand groups of respondents after a complete
understanding of the individual respondent. Given this perspective
(Gutman, 1982), it is possible to argue that attention to the context of
consumer behaviour is of paramount importance for achieving the full
"understllnding of how consumers derive personally relevant meaning about
products" (Gengler and Reynolds, 1995: 19). However, one point should be
kept clearly in mind when choosing the best technique to develop the
laddering approach:
"the choice of elicitation technique should depend on the purpose of the particular
study" (Bech-Larsen et aI., 1997: 20).
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4.6.2 Objectives
The laddering procedure, following the MEC theoretical framework, seeks
to explain how products or services, as means, are linked to ends, which
are a person's values. That is, the objective of laddering is to elicit
meaningful differences between products in order to understand "how a
product or service selection facilitates the achievement of desired end states"
(Gutman, 1982: 60). As a result, laddering methodology is the process
through which it is possible to elicit the way consumption-relevant
knowledge is stored and organised in human memory. According to this
cognitive view, the laddering procedure is able to analyse information that
consumers obtain from the environment, which in tum is connected to
information already stored in memory (i.e., cognitive category structure on
Alba and Hutchinson (1987) terminology).
Assuming that "means-end chains are hierarchical cognitive structures that model
the basis for personal relevance by relating consumers' product knowledge to their
self-knowledge" (Olson, 1995: 189), the laddering technique has as its
supreme objective, the identification of criteria consumers use in their
decision-making process. Such information permits marketers to design
products that are more likely to be adopted and to promote their products
more effectively.
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4.6.3 Interview Environment
Reynolds and Gutman (1988) have suggested that the interview
environment is an important factor for obtaining an in-depth understanding
of the consumer's decision-making. Two rules were advanced:
1. the interview environment must avoid any "fear" for the respondent in
terms of quality of responses; and
2. the respondent has to feel that he or she is the real expert in the matter.
To overcome the respondent's initial suspicion about the interview
objectives, the interviewer must explain in the introductory comments the
reasons of the study, as well as to be explicit about the lack of any kind of
evaluation in terms of write or wrong answers.
To reinforce the initial process of relaxing the respondent, the sequence of
the conversation should be guided by an introduction to the focus of
interview in such a way that the individual understands that he or she has
the ability to think critically about the connections between product/service
choice and personal motivations. This introspective effort must be
supported by the idea that the interviewer is there only to understand how
"expert" people organise their everyday commonplace behaviours. That is,
interviewers must be friendly and interested trained facilitators of a
discovery adventure, rather than investigators who are completely aware of
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the code of good practice on any type of consumption decision-making
process. This creates an interview environment in which the respondent
has total "control" of the discourse, while the interviewer assumes a low
profile, in order to "create a slight sense of vulnerability on the part of the
interviewer" (Reynolds and Gutman, 1988: 13). In line with this interview
environment, the initial questions must reinforce the respondent's "expert"
status. Without loosing the control of the interview, the "why is that
important to you" format of the interviewer questions must be assumed by
the respondent as natural in the context of the discourse, and in line with
certain specific guidelines that the interviewer has to follow. Furthermore,
the interviewer's questions reinforce the respondent's perception of how
important it is to dig deeply into his or her mind to prove their "expert"
status. Subsequently, it is possible to make the respondent feel that the
interviewer has a real but not vested interest in the topic.
The laddering procedure, as with all qualitative research, is based on a
natural flow of speech of the respondent. In this context, the interviewer's
role is minimal and directional (i.e., soft laddering), to avoid respondents
retrieving episodic, instead of semantic, information (Grunert and Grunert,
1995). However, this task requires considerable cognitive processing effort
from the interviewer in order to develop a deep understanding of how
consumers translate the attributes of products into meaningful associations
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with respect to self, following Means-End Theory (Gutman, 1982). The
interviewer's capacity to translate respondent's "chunks" of information
into means-ends chains it is vital for the accuracy of data. This is only
possible if the respondent feels comfortable and encouraged to reveal why
each reason for the consumption behaviour is important to him or her
personally. Finally, the respondent is "invited" to reflect on deeper motives
behind the answers to the questions about the original reasons. This
laddering procedure only finishes when a set of means-end chains reveals
the self-knowledge structures containing interconnected meanings about
goals or values for that concrete consumption behaviour.
4.6.4 The Soft Laddering Interview
Laddering is based on a tailored interviewing format using, primarily, a
series of directed probes, typified by the "Why is that important to you?"
question. This tailored interviewing format is developed in a face-to-face
context wherein an interviewer asks a sequence of in-depth probes
designed to force the consumer up the ladder of abstraction, in order to
retrieve deeply into his/her motives in decision-making (Reynolds and
Gutman, 1988).
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The laddering approach is based on a two-step interviewing process
(Reynolds and Gutman 1988; Claeys et aI., 1995):
1. Elicitation of salient criteria used to discriminate between products; and
2. The salient attributes will be used for further questioning in order to
obtain the product consequences and personal values.
Initially, respondents are given a simple categorisation or sorting task,
which is designed to elicit basic concepts or distinctions consumers use to
differentiate between the stimuli (e.g., products or brands) within the
domain of interest. Thus, laddering "consists of a series of directed probes based
on mentioned distinctions initially obtained from perceived differences between and
among specific brands of products or services" (Reynolds and Gutman, 1988:
13). These basic distinctions are typically made at the relatively concrete
product attribute level, although distinctions at the other higher-order
consequence and value levels are also possible.
The categorisation process takes place at each level of the means-end
chain in order to understand which components the consumers emphasise
most. The emphasis of the laddering approach is different from that of
more traditional multi-attribute models of choice, particularly those that
follow the triadic sorting (Kelly, 1955) through the Repertory Grid
procedure. The laddering procedure focuses mainly on why and how
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product attributes are important in terms of consequences and personal
values, while the Repertory Grid concentrates on determining if and to
what degree particular product attributes are important. The why
procedure uses an open-ended questioning format to encourage the
respondent to give an answer specific to their own particular thoughts, and
in their own words. Specifically, the subject is presented with one of the
distinctions elicited from the categorisation task and asked "why is (this
distinction) important to you?". His or her response is then used as the
focus of the next "why is that important ...?" question. With such an
approach it is possible 'to force' the respondent up or down the 'ladder of
abstraction', bridging relatively concrete product meanings at the attribute
level to more abstract meanings at the consequence and personal-values
levels. This is the reason why this procedure is called "laddering"
(Reynolds and Gutman, 1988; KIenosky et aI., 1993). The questioning
process will be finished only when the attribute-consequence-value chain
of the individual is defined. That is, the soft laddering interview will be
developed until the retrieved information from the respondent constitutes a
"ladder". What seems to emerge is that the MEC approach, as a model of
personal relevance, uses the laddering technique as a sort of repetitive
questioning process through which it is possible "to force the subject up the
ladder of abstraction until the value level is reached" (Claeys et aI., 1995: 194).
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In the consumer context, knowledge and prior experience in the product
category gives a greater ability for solving consumption problems in terms
of a solution strategy (Alba and Hutchinson, 1987; Johnson and Russo,
1984; Bettman and Park, 1980). As a result, the number of ladders elicited
from each individual respondent varies according to his or her knowledge,
prior experience, or involvement in the product category (Bech-Larsen et
aI., 1997; Grunert and Grunert, 1995; Gengler and Reynolds, 1995;
Reynolds and Gutman, 1988). It follows from these assumptions that the
number of multiple ladders across respondents is expected to vary.
Furthermore, during the soft laddering procedure, the respondent may use
the same adjacent concepts several times when verbalising different
ladders. When this occurs "the association is only counted once per respondent
when constructing the implication matrix in order to prevent bias in the aggregate
results" (Gengler and Reynolds, 1995: 24-25). Resulting hierarchical maps
(which summarise the most frequently evoked means-end paths) are then
interpreted within an associative-memory framework: "The attribute --+
consequence --+ value linkages elicited from consumers through a laddering
technique lead to the development of a hierarchical value map (HVM)" (Valette-
Florence and Rapachi, 1991: 40). It follows, then, that the purpose of the
soft laddering procedure is to elicit distinctions at higher levels of
abstraction.
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4.6.5 The Hard Laddering Interview
The classic method for implementing the laddering technique is a face-to-
face interview (Reynolds and Gutman, 1988). More recently, this one-to-
one in-depth interview technique (soft ladderingt has been substituted by a
"paper-and-pencil" version of the laddering procedure, known as hard
ladderlng (Botchen et aI., 1999; Frauman et aI., 1998; Grunert and
Grunert, 1995; Pieters et aI., 1995; Bagozzi and Dabholkar, 1994; Walker
and Olson, 1991). In these studies, a questionnaire was administered
simultaneously to a group of respondents, in contrast with the open-ended
format of the laddering interviews. Although this approach represents an
attempt to find more cost-effective and efficient methods of data
collection, it is limited the insightful probing characteristic to laddering
(Gengler and Reynolds, 1995). This paper-and-pencil operationalization
of laddering "refers to interviews and data collection techniques where the
respondent is forced to produce ladders one by one, and to give answers in such a
way that the sequence of the answers reflects increasing levels of abstraction"
(Grunert and Grunert, 1995: 216).
While Botchen et aI. (1999) and Walker and Olson (1991) used only self-
administered questionnaires as their data collection method to obtain
ladders, Bagozzi and Dabholkar (1994) began with a paper-and-pencil
version of the laddering procedure. This was modified to fit the telephone
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interview context that was used to elicit the personal motives or goals of
respondents for recycling.
Other researchers used both soft and hard laddering in similar studies (see
for example Frauman et aI., 1998). The questionnaire contained a paper-
and-pencil laddering interview with three sets of questions which were
designed to assess the means-end relationships that park visitors perceived
as relevant when selecting interpretive service offerings. The classic
approach (i.e., soft laddering), based on a preference-oriented sorting task
(Reynolds and Gutman, 1988), was applied to elicit the basic distinctions
that these park visitors used to choose among different interpretive
services. The authors drew particular attention to the problems that can
occur during data collection when engaged in both the soft and hard
laddering interview process (Grunert et aI., 1995; Grunert and Grunert,
1995).
The soft approach has been found particularly suitable for respondents
whose cognitive structure with regard to the product or context in analysis
is either especially weak or especially sophisticated. The former has been
found to be linked to low involvement and/or little experience with the
product, while the latter embraces very elaborated cognitive structures
"due to high involvement and much experience, such as when the respondent is an
expert in the respective area" (Grunert and Grunert, 1995: 217).
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The hard approach has been proposed in cases of average involvement
and experience, or whenever the classic laddering interview may produce
artificially abstract hierarchical levels derived from respondents' cognitive
efforts to fmd arguments for their buying behaviour. Some researchers
argued that hard laddering reduces the influence of cognitive processing
on the interviewer side, and subsequent bias on the data collection that can
be found with soft laddering (Botschen et aI., 1999).
4.6.6 The Predictive Validity of Lad dering
Consumers have the faculty to use automatic or strategic cognitive
processes to retrieve information from cognitive categories stored in
memory (Grunert and Grunet, 1995). The former is unconscious, not
subject to capacity limitations, and quite invariant with regard to different
task requirements. By contrast, the latter is conscious, subject to capacity
limitations, and easily adapted to task requirements. In this case, an
intentional, problem-solving mental activity, like trying to fmd meaning in
unfamiliar stimuli, may be activated:
"One way to understand a means-end framework is to think of consumer decision-
making as a problem-solving process" (Reynolds and Whitlark, 1995: 9).
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Consumers use the interaction between cognitive structures and cognitive
processes to develop their decision-making in different contexts.
Consumer behaviour in a data collection situation, such as the laddering
task, is not an exception to this cognitive capacity. In line with this
reasoning, it is possible to argue that there is no capacity to retrieve a real
and pure representation of cognitive structure, because the behaviour of
any respondent in a data collection situation is the result of automatic or
strategic cognitive processes to retrieve information from cognitive
categories stored in memory. Implications for the evaluation of the validity
of the results from laddering are obvious (see next page - Figure 4.3):
• Firstly, it is inevitable that coded data include not only the
respondent's "impure" cognitive structure, but also the researcher's
cognitive structure and processes, who, because of the nature of the
process, has an impact on data collection.
• Secondly, the algorithm for data reduction, may also influence the
predictive validity of the data collected with regard to the target
situation (Grunert and Grunert, 1995).
257
Figure 4.3: A general cognitive model for data collection, analysis and prediction
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Nevertheless, it is possible to improve the predictive validity of soft
laddering and a number of criteria for doing so have recently been
advanced (Grunert and Grunert, 1995):
1. The raw data should be the result more of the respondent's cognitive structures
and processes that of the researcher's cognitive structures and processes.
• The typical example of violation of this first criteria are Fishbein-
type rating scales, because the cognitive categories are specified in
advance, without any intervention from the respondent. As a result,
the output of this methodology, which is supposed to measure the
respondent's cognitive structure, is influenced by the researcher's
cognitive structures and processes.
2. The dais collection should not involve strategic processes not typical of the tIlrget
sitlllltion.
• The context within which the behaviour is to be predicted (i.e., the
target situation) must be reproduced in the context of the laddering
interview, in order to improve the correlation between the former
and the latter.
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3. Coding should preferably be based on cognitive categories widely shared among
both consumers, researchers, and users of research results, and not on the
researcher's idiosyncratic cognitive categories.
• In order to avoid interviewer influence on the coding scheme,
secondary data, or any other formal information attached to
respondents behaviour, particularly previous studies on the topic,
are helpful for developing a common understanding of the cognitive
categories widely shared among both consumers, researchers, and
users of research results.
4. The algorithm used/or dota reduction (aggregation) should be based on theory
about cognitive structure and processes.
• The aggregation process is supposed to be derived from the
theoretical framework from which the language of the concepts is
translated into cognitive categories, representing the aggregate of
the respondents ladders. This summarisation of the means-end study
results should not be influenced by wrong technical decisions that
are important for determining which connections should be
represented on a Hierarchical Value Map. To accomplish this, an
implication matrix has to be developed.
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4.6. 7 The Implication M 'atrix
After collecting a significant number of ladders, the researcher is able to
shift from the individual level to the group level (Gutman, 1991). When
individual data are combined, what emerges are the relations that occur
most frequently across respondents. This first movement generates data of
an aggregate cognitive structure of a group of interviewees. That is, the
implication matrix that derives from laddering data does not address the
issue at the individual level. The process of creating an overall element by
element matrix in which all direct and/or indirect relations are counted is
the basis for this approach. To perform such a movement, the researcher
encapsulates each laddering response within the correspondent level of
abstraction (i.e., attribute, consequence, or value). That is, after performing
the content analysis, the researcher is able to determine the number of
direct and indirect relationships between attributes, consequences and
values. This second movement in the procedure involves the definition of
an Implication Matrix. In its goals' version, "It is a square matrix Z whose
elements (Zi:J reflect how often goal i leads to goal j, where this is based on an
aggregation across respondents and linkages" (Bagozzi and Dabholkar, 1994:
326). The implication matrix subsumes "the number of times two adjacent levels
in the ladder were connected by some respondents" (Claeys et al., 1995: 194).
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In accordance with previous considerations, the implication matrix
displays the number of times each attribute leads to each consequence, or
the number of times each consequence leads to each value. However, the
implication matrix encapsulates two types of relations:
1. direct relations; and
2. indirect relations.
The former represent adjacent levels, which are the normal sequential
order within the ladder, while the latter has a more indirect sequence. In
filling in the implication matrix, individual respondents' ladders are
decomposed into their direct and indirect components in order to construct
a hierarchical value map.
What seems to emerge is that there are many ways to study the linkages
between consequences stemming from consumer choice and the personal
values that may be related to that choice. Nevertheless, "one goal of values
research is to specify the content and sequence (or structure) of outcomes stemming
from choice behaviour that extends from attributes possessed by the choice object
through consequences to "end benefits" orpersonal values" (Gutman, 1991: 143).
This is the particular goal of the laddering approach and its implication
matrix.
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4.6.8 The Hierarchical Value Map (HVM)
Laddering and MEe are concerned with obtaining insight into consumers'
buying motives, within a specific consumption context. As a result, the
data obtained from a laddering interview will represent consumers'
cognitive excerpts with situationally constructed meanings (Grunert and
Grunert, 1995). That is, a common output of a means-end study is a tree-
like network diagram called a Hierarchical Value Map, or HVM (Gutman,
1982; Reynolds and Gutman, 1988). This graphical representation of the
aggregated cognitive structure of respondents, reflects their perceptions in
terms of products' physical attributes, the benefits provided by their use,
and the values they satisfy (Olson and Reynolds, 1983). Therefore, it can
be said that an HVM presents a graphical representation of a set of means-
end chains which can be thought of as an aggregate (e.g., market-level)
cognitive structure map (Grunert and Grunert, 1995).
An HVM consists of nodes and lines which connect these nodes. The
nodes of the HVM represent the most important conceptual meanings
(typically classified as attributes, consequences, and values) derived from
data collection and analysis. The line segments connecting these nodes
represent the associations between these concepts, which can be used to
define marketing and promotion practices (Frauman et aI., 1998; Klenosky
et al., 1993).
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Just a quick glance at these figures representing HVMs show that different
pathways can be identified within each ladder. It follows, then, that" each
unique pathway from an attribute to a value in the HVM represents a potential
perceptual orientation or positioning for the product or service in question"
(Frauman et aI., 1998: 164). In Gengler and Reynolds' (1995) words, "the
HVM represents thepatterns of meaning by which individuals give personal relevance
to product distinctions" (ibidem: 27). However, until a couple of years ago,
building a coherent HVM was not an easy task:
"The manual compilation of the association chains in itself represent an
extraordinaryworA;and makes the use of samples a little more than thirty interviews
totally impracttcal" (Reis, 1997: 165).
Due in part to the difficulty of drawing an HVM with a minimum of
crossing lines, Reynolds and Gutman (1988) point out that considerable
ingenuity is required when building a coherent map. Researchers who were
seriously analysing laddering data needed to develop their own software to
implement Reynolds and Gutman's (1988) approach or needed to develop
their own analytic approaches to obtain HVM maps. However, in 1995
LadderMap became available. It was the first commercially available,
personal computer-based software for analysing laddering data in order to
produce HVM maps (Gengler and Reynolds, 1995).
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4.7 LADDERMAP: The Algorithm for Data Reduction
Some researchers developed an inventory of problems which were related
to MEC's epistemological status, as well as its approach to data collecting,
coding, and analysis and the validation of results from a laddering study
(Grunert et aI., 1995; Grunert and Grunert, 1995). Nevertheless, despite
criticism, several aspects of Means-End Theory and Laddering have
received increased attention because they open space to the adoption of
different strategies on the part of the companies and the communication
devisers (Reis, 1997). For example, some researchers addressed the
application of the MEC theory and and its laddering technique to
marketing strategy (Frauman et aI., 1998; Reis, 1997; Klenosky et aI.,
1993, Reynolds and Craddock, 1988; Reynolds and Gutman, 1984; Olson
and Reynolds, 1983). While others apply Means-End Theory as a
conceptual framework for the strategic assessment of advertising
(Reynolds and Gengler, 1991; Reynolds and Rochon, 1991). Still others
addressed research methodology (Valete-Florence and Rapacchi, 1991;
Reynolds and Gutman, 1988), or even adaptive selling behaviour (Gengler
et at, 1995b). In summary, MEC and its laddering approach should be
viewed as a method for developing insights about potential means-end
chains that underlie purchase decisions. However, three major practical
problems emerge in the use ofMEC and its laddering technique:
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1. the significant time and cost of gathering individual in-depth data;
2. the time and effort required to perform the content analysis of the
qualitative responses (steps in the ladders) and the quantitative
summaries of the dominant pathways; and
3. the lack of any detailed framework or system to translate strategic
options as represented in the summary HVM into a working format for
researchers and marketing strategists.
Most of these practical problems, particularly the time and effort to
perform the content analysis, have been solved through a new algorithm
for data reduction: LadderMap software (Gengler and Reynolds, 1995).
Although LadderMap is not an automated interviewing protocol for
collecting laddering data through a computer-driven interview, three main
tasks can be performed with laddering interview data in hand (Gengler and
Reynolds, 1995). The software does the following.
• Provides a data entry and content analysis system for qualitative
laddering data;
• Tabulates an implication matrix, portraying the degree of connection
between the various attributes, consequences, and values; and
• Creates a HVM map from the implication matrix and enables the user to
edit the HVM or otherwise make it easier to use and understand.
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4.7.1 Data Entry and Content Analysis
The study of cognitive structure has recently examined techniques for
collecting means and ends (Aurifeille and Valette-Florence, 1992; Valette
- Florence and Rapachi, 1991; Walker and Celsi, 1989; Reynolds and
Gutman, 1988), as well as methodological improvements for analysing
means-end data once it has been collected (Klenosky et aI., 1993; Valette-
Florence and Rapachi, 1991. Recently, personal computer-based software
has become available for implementing Reynolds and Gutman's (1988)
laddering approach to developing HVM maps. An academic research
version of LadderMap (Version 5.3), from Chuck Gengler's Means-End
Software (Lastovicka, 1995), was used in this study (see Appendix Five).
The LadderMap program can handle up to 3000 different ladders.
However, meticulous care must be taken when coding the interview results
into the LadderMap software. At this stage, two important decisions must
be made by the researcher in order to avoid adulterating the data.
First of all, due to the conversional nature of laddering, the analyst must be
able to distinguish relevant meaning from conversation extraneous to the
topic at hand. As the laddering procedure is based on open-ended, in-depth
interviews, the conversional nature of raw data that are obtained, forces
the researcher to desegregate the ladder responses of each respondent into
"chunks" of meaning.
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Secondly, the analyst must separate each individual ladder into "chunks"
of meaning corresponding to the different levels of abstraction. Each chunk
represents a separate concept communicated in the interview, which is the
fmal result of a "purification" process according to what are, and are not,
the relevant "chunks" to include from the verbatim responses. Specifying
what composes a chunk of meaning is extremely important since these
units correspond to the hierarchical structure of attributes-consequences-
values that are present in any ladder, and which are thus the basis of all
stages of analysis. The classification of responses must therefore be
divided according to their capacity to be included in the means-end chain
network. That is, LadderMap accepts data concerning the attributes,
consequences and values mentioned by respondents, following the
measurement model proposed by the MEC approach (Gutman, 1982).
As ladders are entered for each respondent, and as respondents are able to
define a different number of ladders, an interactive data entry feature is
provided which allows the researcher to enter multiple ladders per
interview subject and up to ten "chunks" of meaning per ladder. In this
way, ladders are entered for each respondent, and the first stage of content
analysis is started (LadderMap, 1998).
An example of the ladder entry screen is shown in Figure 4.4 - Ladder
Entry Screen, with an hypothetical ladder from patient typology data.
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Figure 4.4 - Ladder Entry Screen from LADDERMAP Software
LADDER EDIT SCREEN data name = typology
Subject ID = 001 Ladder# = 6
» hypertensive woman in perimenopausic period
VALUE Synonym: age/gender
» less development of target-organ damage
CONSEQUENCE Synonym: to reduce morbidity and mortality
» greater protection against the risk of cardiovascular problems
CONSEQUENCE Synonym: cardiovascular protection
» improve compliance with drug regimen
CONSEQUENCE Synonym: compliance with drug regimen
»Ace inhibitors (capoten) are effective
ATTRIBUTE Synonym: effectiveness
» Ace inhibitors (capoten) have low incidence of side-effects
ATTRIBUTE Synonym: low side-effects
»Ace inhibitors (capoten)/good profile in concomitant diseases/problems
ATTRIBUTE Synonym: safety
Screen ID = LE-2 Enter FlO to exit, Ft for belp
Next, "chunks" of meaning are content analysed in order to aggregate and
generalise across subjects. That is, each "chunk" is classified according to
pre-defined attribute, consequence, and value categories. This process
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involves two steps. The first step aims to obtain a dictionary of content
codes into which classifications of "chunks" of meaning can be made.
Once data have been entered and coded, the software generates a lexical
listing file that contains all these attributes, consequences, and values
content codes, as well as the verbatim qualitative data that correspond to
each content code. This second step is a deeper level of analysis in the
sense that this vast verbatim data have to be assigned to the hierarchical
codes, which form a ladder.
Developing content codes is a critical stage of the analysis, which requires
several judgement-based decisions. The researcher must be able to
determine the optimal level of classification. The general rule of thumb is
that the codes must be broad enough to obtain replications of more than
one respondent saying one element leads to another. A paradox arises if
the categorisation codes become too broad, as meaning is lost through
excessive aggregation. In accordance with the means-end perspective, the
key here is to aim for consistency and reliability across multiple coders.
This enables the analysts "to split, combine, or redefine categories quic/clyand
easily on line. The content analysis task is truly the heart of laddering analysis. It is
the step where qualitative data (the raw, verbatim responses from the laddering
interviews) are converted into nominal codes which can be quamified" (Gengler
and Reynolds, 1995: 24).
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Researchers must be careful when developing content codes, and should
follow two specific guidelines (Reynolds and Gutman, 1988):
1. The analysis of laddering data across respondents involves summarising
the key elements to identify the concepts which are mentioned most
frequently; and
2. When the researcher is unsure of what is meant by a specific statement,
it may be useful to examine it in the context of the whole ladder. This will
serve to reduce the risk of misclassification due to interpretation error.
It should be noted that "where analysts typically have strong insights into
consumers' perceptions and motivations, many of the category codes may be defined
a priory" (Gengler and Reynolds, 1995: 23). Otherwise, the classification
procedure, which is an highly labour-intensive and recursive task, evolves
into an interaction between "chunks" of meaning from verbatim responses
and codes.
The LadderMap software allows content analysis to be performed
interactively, in order to facilitate the researcher's intensive judgement and
decision-making. This is useful when checking and correcting any
mistakes which arise because concepts have been assigned incorrectly, or
when evaluating the initial coding scheme: "If,upon inspection, it isfound that
some concepts are assigned incorrectiy, they can be easily corrected and assigned to
theproper content code" (ibidem: 23).
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Also, if the initial coding scheme is very specific, many content codes may
have relatively few actual concepts assigned to each (see Figure 4.5).
Similar codes can then be easily grouped hierarchically under a larger
code, making reassignment an easy task.
Figure 4.5 - Performing Content Analysis Interactively
» comorbidity
hypertensive patients with left ventricular hypertrophy
hypertensive patients with gout
hypertensive patients with obesity
hypertensive patients with diabetes
hypertensive patients with anxiety/depression
» age
young-adult hypertensive patients
middle-aged hypertensive patients
elderly hypertensive patients
n=6
n=2
n=4
n=7
n=1
n= 19
n=76
n=93
F2-EDIT SYN F4 - Track Code FlO ExitF3 - Change AVC
Any further analysis of the data is only as good as the content analysis.
Hence, this task should not be underrated in importance.
272
4.7.2 Generating the Implication Matrix
The definition of connections between codes is only possible after an
aggregate implication matrix has been generated. The implication matrix
serves as a method of bridging the gap between the qualitative aspects of
laddering to the quantitative analysis of the relations between concepts.
Before an implication matrix can be generated, the number of content
codes should be reduced to 120 or less. LadderMap determines the
strength of association between concepts and produces a square matrix.
This matrix consists of the sums of all the instances when concepts were
associated during the laddering interviews. In filling in the implication
matrix, individual respondent's ladders are decomposed into their direct
and indirect components which represent the degree of connection
between the various attributes, consequences, and values. Quite often in
laddering studies, more than one ladder is collected from each subject. The
number of ladders elicited from the subject is dependent on a number of
factors including the subject's knowledge of the product category and the
subject's ability to communicate their knowledge. A subject may repeat
associations between concepts in the different ladders obtained. This
matrix is constructed such that, though a given respondent may repeat the
associations between the same cognitions several times in several ladders,
the association between cognitions is tabulated only once per subject.
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4.7.3 Generating the Hierarchical Value Map (HVM)
From the implication matrix, LadderMap is able to generate different
percentages of the associations in the data that it would be possible to
represent in a HVM map. This gives the researcher the opportunity to
select the most appropriate percentage of association in the data that
would be represented in a HVM constructed using different cut-off values
(where the cut-off values refer to the minimum degree of association in the
data required to support a chain in a map). Although there are no
theoretical or statistical criteria to guide the selection of this powerful
device for reducing the complexity of the map, two criteria have been put
forward by Reynolds and Gutman (1988) for use when selecting a cut-off
value:
1. To tty multiple cut-off levels and choosing the one that gives the most
informative solution; and
2. To inspect the number of active /inkllges as a proportion of al/linkages and
selecting the cuJ-off that achieves maximum completeness combined with ease
of interpretability.
Other researchers, based on their experience in conducting this kind of
study, suggest that at least 70 percent of the relationships on the map
should be represented:
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"From experience in conducting over 100 studies, the minimum threshold value
should never be less than 70percent with an average number typically in the 75 to 85
percent range" (Gengler and Reynolds, 1995: 25).
Any cut-off point smaller than 70 percent may not represent important
respondent's information and some valuable insights on consumer
behaviour may be lost. However, it is important to bear in mind that a
percentage cut-off point is different from a numerical cut-off point. The
former represents the total percentage of direct links represented by each
numerical cut-off point, while the latter, based on the implication matrix,
determines what connections/associations between the hierarchical chain
attributes-consequences-values should be represented on the HVM. It
follows, then, the higher the chosen numeric cut-off level, the more
parsimonious the representation of the HVM. Again, this stage involves
important qualitative judgements made by the researcher "to produce an
HVM which is both accurate and aesthetically pleasing, hence a trade-off between
validity and parsimony" (Gengler and Reynolds, 1995: 25). Parsimonious
representations, however, have a price. With high numerical cut-off points,
fewer relations between the hierarchical chain attributes-consequences-
values are considered. As a result, a smaller percentage of all connections
between these hierarchical structures made by respondents is accounted
for.
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Efforts to come to a better understanding of the cut-off point decisions
were made in recent research where two additional heuristics for choosing
a cut-off were proposed (Pieters et aI., 1995; Bagozzi and Dabholkar,
1994):
1. To graph the number (or percentage) of connections accounted for at a given
cut-off against different cut-off levels and choosing those occurring before an
elbow results; and
2. To compare the proportion of active cells in the implication matrix to the
proportion of total linkages accounted for at a given cut-off level.
A final point to note here is that the LadderMap software is an heuristic-
based algorithm which quickly and easily generates several HVMs based
upon different cut-off points. As such, the researcher has his task
facilitated in terms of cut-off point decision. Once an appropriate cut-off
level has been chosen, the heuristic-based algorithm produces the HVM
map. Subsequently, the HVM map can be edited in several useful ways to
generate an easier-to-understand, or more aesthetically pleasing, map.
Two requirements must be observed when constructing a HVM:
1. the fmal HVM must encapsulate a signifICant number of the associations, which
must be representative of the raw laddering data;
2. the fmal HVM must be a rich representation of the reality in order to be easily
interpretable by those people that have to use it as a viable tool.
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4.8 The Use of MEC Theory and Laddering Technique in Marketing
The dramatic increase in the number of competing brands in most product
categories forces marketers to look for segmentation, positioning, and
differentiation strategies that are more directly relevant to the decision-
making criteria of the consumer (Botschen et aI., 1999). As a result, "The
means-end chain approach has much to offer the scholar interested in developing
theoretical explanations of consumer behaviour, as well as the business person
interested in developing strategic solutions to marketing problems" (Olson, 1995:
190). That is, understanding the personally relevant meanings that
consumers hold for a product, and the new marketing strategies which may
stem from these meanings, is invaluable to marketing strategists.
During the 1990' s, a substantial amount of attention both from marketing
academics and practitioners has been devoted to the means-end chain
theoretical framework and the laddering technique (see for example
Botschen, 1999; Mattila, 1999; Frauman et aI., 1998; Reis, 1997; Sorensen
et aI., 1996; Gengler et aI., 1995; Pieters et aI., 1995; Reynolds and
Whitlark, 1995; van Rekom, 1994; Bagozzi and Dabholkar, 1994;
Klenosky et al., 1993; Doucette and Wiederholt, 1992; Pieters et al., 1992;
Walker and Olson, 1991; Gutman 1991). Meanwhile, special issues on
means-end chains have been advanced in prestigious publications (i.e.,
IJRM - International Journal of Research in Marketing), where several
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researchers have made important contributions for the improvement of the
Means-End Chain Theory and Laddering procedure (Olson, 1995; Clayes
et al., 1995; Grunert and Grunert, 1995; Pieters et. aI., 1995; Gengler et.
aI., 1995; Reynolds et aI., 1995, Aurifeille and Vallette-Florence, 1995).
Other special editions on Means-End Chain Theory and Laddering
technique were put forward, particularly by Danish researchers (Bech-
Larsen et aI., 1997; Sorensen et al., 1996; Grunert, et aI., 1995). An
unanimous conclusion derived from these studies reveal that Means-End
Chain approach and Laddering technique are important to understand what
energise and directs consumer decision making. One reason for means-end
chain advocates' enthusiasm about the use of the approach to represent
cognitive structures seems to be the face validity of a relatively
unstructured elicitation task rather than the use of pre-specified cognitive
categories. As a result, academic researchers were "invited" to be more
familiar with this theoretical framework: "The major goals of this special issue
are to generate greater awareness of the means-end approach and to stimulate
academic researchers to conduct research on means-end issues. Although many
business firms are using means-end chains and laddering methods, relatively few
academic researchers have incorporated the means-end approach into their
research" (Olson, 1995: 190). Recent studies using means-end chains and
laddering methods suggested that the goal proposed by Olson (1995) was
obtained:
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• segmentation (Botschen, 1999; Roehrich and Vallett-Florence, 1991);
• positioning (Reis, 1997);
• differentiation strategies (Doucette and Wiederholt, 1992); and
• consumer behaviour decision-making (Sorensen et al., 1996; Klenosky
et aI., 1993).
• adaptive behaviours of salespeople (Gengler et aI., 1995b).
For example, Reis (1997) concluded that MEC model and its laddering
technique were able to define a hierarchical sequence of values-
consequences-attributes which were used to define the "positioning of
products and brands, and 000 ways of communication" (Reis 1997: 162). In
positioning a product, the marketing strategist has the opportunity to link a
particular attribute, or a set of attributes, to consequences and values
which have been found relevant to a selected or particular market segment
of consumers. Inherent in this strategy is the notion that the emphasised
means-end chain has a specific and desirable meaning to the market
segment of interest. That is, translating knowledge of consumers' cognitive
structures into the development of advertising strategic operations is one of
the results that it is possible to obtain with a means-end chain approach
(Reynolds et aI., 1995; Reynolds and Gutman, 1988; 1984; Gutman, 1984;
Olson and Reynolds, 1983).
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Reynolds and Whitlark (1995) also argued that: "The means-end framework
for viewing consumer decision-making leads to a means-end theory of
communications strategy" (Reynolds and Whitlark, 1995: 9).
In an application to lingerie retail, Roehrich and Vallett-Florence (1991)
developed a weighted cluster-basis analysis using direct and indirect
connections present in a means-ends chains approach as the basis for
clustering. While these researchers have used ladders to develop their
segmentation strategy, Botschen et al. (1999) using a modified laddering
technique, based on MEC theory, were able to define benefit segments.
In looking at disadvantages of the standard benefit segmentation approach,
the researchers concluded that the MEC theoretical framework was a
powerful tool for effective market segmentation: "Means-end chains seem
ideally suited to segment markets according to different levels. benefits or values. and
on the linkages between the meanings" (Botschen et aI., 1999: 54),
Using the means-end chain approach, the researchers have precluded the
two most important disadvantages presented by the classic approach:
1. aU identified at/ributeslbeneflls have to be rated by respondents, even when they
are not relevant for the respondent; and
2. respondents tend to rate most of the items as important which makes it more
diffICult to develop signiflCll1lt different segments.
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In a recent study on consumer behaviour, Sorensen et al. (1996)
interviewed 90 respondents in Copenhagen about meat types and found
out that both individual and social values were related to health and
physical well-being while product attributes and consequences were linked
to difficulties in buying, preparing and eating fish.
Using the LadderMap software (Gengler and Reynolds, 1995) to construct
hierarchical value maps, Sorensen et al. (1996) concluded that the MEC
approach and its laddering methodology were important for understanding
how consumers perceive self-relevant consequences of products like fish.
In a similar vein, Klenosky et al. (1993) examined a variety of factors
(ranging from the relatively tangible attributes of products, to the
intangible benefits, needs, and personal values of people) to understand
and explain sky destination choice. They concluded that the "Means-end
theoryprovides a logical framework and methodology for relating these tangible and
intangible elements" (ibidem, 1993: 362).
Laddering technique was also found important for eliciting salespeople's
knowledge structures about the characteristics of sales situations: "Of
interest, then, is to gain insight into the characteristics of customers and sales
situations that sales people use as cues, to uncover how these cues are linked to
adaptive behaviours of salespeople, and to demonstrate the relevance and validity of
these results by linking them to an external variable, such as experience lever'
(Gengler et al., 1995: 288).
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4.9 The Use of MEC Theory and its Laddering Technique in
Pharmaceutical Marketing
The MEe model (Gutman, 1982) has been also found an important tool "to
help identify important dimensions of consumers' product meaning for a particular
drug product or therapeutic category of drug products" (Doucette and
Wiederholt, 1992: 345), in order to develop differentiation strategies.
Based on a sample of 550 consumers of pharmaceutical products (i.e.,
patients), these researchers were able to identify five product dimensions
and three consequence dimensions. However, rather than using the means-
end chain theory and the laddering methodology to derive the attributes
and consequences relevant for those patients, the authors used a 29-item
semantic differential prescription product meaning scale (i.e., paper and
pencil version of laddering) to evaluate their own four hypothesised
dimensions of consumers' meaning for prescribed medications. Such an
approach was developed "because of a scarcity of research in this area, a
domain of attributes and consequences based on professional experience and the
pha17tUlcyliterature was hypothesisetf' (Doucette and Wiederholt, 1992: 49).
This statement is a clear violation of at least, two important assumptions
concerning the predictive validity of laddering results (Grunert and
Grunert, 1995):
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• The raw data should be a result more of the respondent's cognitive structures
and processes than of the researcher's cognitive structures and processes.
• Coding should be preferably based on cognitive categories widely shared among
consumers, researchers, and users of research results, and not on the
researcher's idiosyncratic cognitive categories.
As has been noted, critical to the validity of any hierarchical value map
derived from laddering data is the ability of the interviewer to obtain the
real sequence of an aggregate map of cognitive structure despite the
influence of the interviewer on the interview process: "Understanding the
respondent involves putting aside all internal references and biases while putting
oneself in the respondent's place" (Reynolds and Gutman, 1988: 14). This
violation of the basic foundations of MEC theory and the laddering
approach diminishes the credibility of the Doucette and Wiederholt's
(1992) study. Nevertheless, their study presents some interesting fmdings
relating to the dimensions that consumers of pharmaceutical products (i.e.,
patients) use to evaluate their prescribed medication. Doucette and
Wiederholt (1992) argued that "such information could be used in
advertisements and promotions to prescribers and to consumers as long as that
information meets Food and Drug Administration regulations" (Doucette and
Wiederholt, 1992: 53).
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4.10 The Concept of "Clinical Value"
The purpose of this section is to justify and outline the role of the concept
of clinical value and its influence in the research design of this thesis. In
doing so, it is intended that the overall configuration of the research and
its presentation will clarify the relationships between the conceptual
basis/theoretical literature review, as well as the development of
methodologies in this thesis (see flowchart/Chapter Two-Figure 2.2: Study
Overview).
Due to the general lack of empirical investigation into the clinical cognitive
apparatus of GPs' prescribing behaviour, the first phase of research is
inductive in nature and aimed at an in-depth understanding of respondents
'real lived clinical experience' (see Decision Box 4.1). That is, a two-
stage qualitative-quantitative research design was followed and responds
to calls for methodological pluralism in understanding the consumer
behaviour (see flowchart/Chapter Two-Figure 2.2: Study Overview).
4.10.1 The Nature of Values
Despite their importance and prominent place in the scientific and public
discourse at a number of levels, there is a lack of consensus on the nature
of values (Meglino, 1998; Feather, 1995; Rokeach and Ball-Rokeach,
1989). Thus, in this section we will attempt to provide some coherence on
the nature of values by:
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(a) discussing what type of values we are talking about;
(b) describing what influences a person's value system;
(c) reinforcing the stability of values; and
(d) questioning whether values are changeable.
What Type of Values Are We Talking About?
Recent research indicates a lack of consensus on the nature of values:
"Among other things, values have been considered as needs, personality types,
motivations, goals, utilities, attitudes, interests, and nonexistent mental entities"
(Meglino and Ravlin, 1998: 351).
Thus, the first step towards understanding the nature of values is to clarify
what type of values we are talking about.
At the most basic level, Rokeach (1973) discriminates between two types
of values. One type is the value that an individual places on an object or
outcome. Feather (1995) assumes this type of value as valences which
refer to the subjective attractiveness or aversiveness of specific objects and
events within the immediate situation. As with the valence term used in
expectancy models of motivation (e. g., Vroom, 1964), these objects or
outcomes acquire value through their instrumental relationship with other
objects or outcomes, which, in turn, are instrumental to still other objects
or outcomes.
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Feather emphasises the goal properties of potential actions and outcomes
as perceived by the person at a given moment. Thus, this approach
suggests that valences are linked to a specific context and to a present time
frame.
A second type of value is more likely to be used to describe a person as
opposed to SUbjective attractiveness or aversiveness of specific objects.
These two types of values are often identified using terms such as the
value "inherent in an object" and the values "possessed by a person" (see
Rokeach, 1973). That is, "values are properties of persons, they are more
abstract and general, and they maintain some stability across a wider time frame"
(Feather, 1995: 1135). Thus, the origin of both types of values (i.e., the
value "inherent in an object" and the values "possessed by a person") is
within the individual. This cognitive view is in line with recent research
which indicates a strong correlation between these two types of values
such that the values held by a person are assumed to influence the value
(s)he places on certain objects or outcomes (Meglino and Ravlin, 1998).
The analysis of behaviour in terms of the subjective value of expected
outcomes and their consequences has a long history in social behaviour
(Bagozzi, 1992; 1982). Behavioural intentions directed at outcomes have
sometimes been studied with the theory of reasoned action, but as the
authors of this well known approach have emphasized, "it is not applicable to
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outcome or end-state values" (Ajzen and Fishbein, 1980: 29-30; Ill). This
assumption reinforces the importance of end-state values held by
individuals, particularly those that are important for maintaining and
enhancing self-esteem: "All behavior is not guided by values, only that behavior
that is related to maintaining and enhancing self-esteem" (Rokeach, 1973: 14).
That is, we will focus on values applied to individuals, as opposed to the
values placed on objects or behavioural intentions directed at outcomes
described by the theory of reasoned action (see Chapter III). Therefore, a
deeper understanding of the values held by individuals may provide a
better understanding of the value placed on objects or outcomes (Meglino
and Ravlin, 1998; Feather, 1995).
Rokeach has provided much of the impetus for research on values
possessed by a person, which are modelled by "culture, society, and its
institutions, and personality" (Rokeach, 1973: 3). However, the researcher's
conceptualisation of value "as an enduring belief that a specific mode of conduct
or end-state of existence is personally or socially preferable to an opposite or
converse mode of conduct or end-state of existence" (ibidem: 5) suggests that
values held by individuals can be further subdivided into:
1. terminal values; and
2. instrumental values.
287
The former are concerned with preferred end-states of existence (e.g., an
exciting life; a comfortable life; a world of peace; national security), while
the latter are related to modes of behaviour (e.g., independent; ambitious;
cheerful) which are instrumental in achieving the desired end-states.
The Rokeach's (1973) Value Survey (RVS) was designed to measure
these two sets of personal values. This functional relationship between
instrumental values (i.e., means) and terminal values (i.e., ends) is referred
to as a value system.
What Influences a Person's Value System?
Having limited our attention to the nature of values, we next consider the
influence of both social and culture aspects on a person's value system
defmition. In this respect, we reflect the views of Rokeach (1973) who
maintained that values are also influenced by society and its institutions.
Rokeach (1973) accepts that the most frequently evoked reason for
similarities and differences in a value system is that they are influenced by
personal experiences and exposure to more formal socialization forces.
Other researchers also suggest that "values can be conceived as abstract
structures that involve the beliefs that people hold about desirable ways of behaving
or about desirable end states. These beliefs transcend specific objects and situations,
and they have a normative, or oughtness, quality about them. They have their source
in basic human needs and in societal demands" (Feather, 1995: 1135).
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Once developed, a system of values can be defmed "as a person's
internalized belief about how he or she should or ought to behave" (Ravlin, 1995:
598). That is, a person's instrumental values do not necessarily reflect how
(s)he wants or desires to behave, but rather, they describe hislher
internalised interpretations about socially desirable ways to fulfill hislher
needs. This distinction derives from values being partially influenced by
culture, as Rokeach (I973) and other researchers also pointed out: "This is
not surprising given that most theorists see values as products of a culture or social
system" (Meglino and Ravlin, 1998: 354). For example, Triandis (1989)
suggests that a person's dispositions and behaviours are affected not only
by his or her own makeup, but also by the norms and beliefs derived from
the cultural environment.
Both in consumer behaviour literature and in psychology more generally,
researchers have primarily conceptualised acculturation as imparting a set
of general, stable tendencies, akin to personality dispositions. However,
this cultural knowledge that drives these tendencies has to be activated:
"Cultural knowledge comprises many specific knowledge structures - categories,
beliefs, decision principles - that exert an influence only when they have been
activated or brought to thefore of the mind" (Briley et aI., 2000: 158).
In studies of decision making, a way to evaluate whether cultural
knowledge is activated and influences a person's values is by asking
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decision makers to provide reasons for their decisions. In this regard,
Vinson et al (1977) "suggest the influence of the socio-cultural, economic, and
familial environment on the formation and development of the individual's value
system" (ibidem: 45). Given the abstract nature of human values (Grunert
and Muller, 1996), some variance in a person's value system may be
explained by differences in individuals' receptivity to these sources of
influence.
Are Values More Stable than Attitudes?
Values have been viewed as a "relatively permanent perceptual framework that
shapes and influences the general nature of an individual's behaviour. Values are
similar to attitudes, but are more ingrained, permanent, and stable in nature.
(Values are) closer to ideology or philosophy" (England, 1967: 54).
Like attitudes, values are social cognitions that facilitate adaptation to
one's environment (Kahle, 1983). Values and attitudes differ, however, in
that attitudes represent organizations of beliefs around a specific object or
situation, whereas values are more abstract in nature (Grunert and Muller,
1996). Furthermore, values were found to be deeper and broader than
attitudes and are determinants, rather than components, of those attitudes
(McCarty and Shrum, 2000; Homer and Kahle, 1988). After an extensive
review of the current attitude-change literature, Olson and Zanna (1993)
also concluded that values are potential determinants of attitudes and
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preferences. That is, personal values have long been considered by social
scientists to be relevant determinants of attitudes and behaviours
(Rokeach, 1973).
Feather (1995) suggested that values "are not only fewer in number than the
many specific beliefs and attitudes that people possess" (ibidem: 1135), but also
more stable than attitudes. In a similar vein, Durgee et al. (1996) assume
that values are not only more stable than attitudes, but also more important
than attitudes in terms of influencing behaviour:
"Although a person's attitudes and opinions might vary and conflict from time to time
and situation to situation, values are felt to be relatively enduring and have stronger
effects on behavior" (ibidem: 91).
Recent efforts to gain a better understanding of helping behaviour and to
provide insight into the factors influencing charitable giving also
emphasize the stability of values across different cultures:
"Schwartz (1992) has conducted empirical tests in 20 countries examining values and
identifies 10 value types that are consistent across cultures. Two of these value types
represent pro-social values of a self-transcending nature: benevolence and
universalism" (Webb et aI., 2000: 305).
Using Rokeach's Value Survey, they measured six of the nrne values
identified by Schwartz (1992) as comprising universalism. Webb and
colleagues found a positive relationship between these six values and
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attitudes toward helping others. The fmdings indicate that personalised
norms and internalised values are the main sources to donation behaviour,
which "is consistent with the long-standing idea that attitudes are embedded in
cognitive structures including beliefs, values, and other attitudes (Scott 1968)"
(ibidem: 301). In addition to understanding the relationship between
attitudes and charitable behaviour Webb et al. (2000) also recognise that
values are potential determinants of attitudes and preferences.
The previous assumptions not only give values to the capacity for
determining attitudes and preferences, but also reaffmn the nature of
values as very stable elements with a strong influence on behaviour. This
assumption was observed by Lubinski, Schmidt, and Benbow (1996) who
studied a sample of gifted adolescents and found that values were
remarkably stable over a 20 year time frame. Dominant value orientation
either remained unchanged, or moved to an adjacent value. This finding
confirms values stability and reinforces the conviction of values as
enduring elements tending to form early in life.
Describing goal-content taxonomies, Austin and Vancouver (1996)
reinforce the nature of values as consistency elements to guide an
individual's behaviour:
"Higher order goals (e.g., system concepts and values) act in a top-down fashion to
drive a certain level 0/ consistency" (ibidem: 360).
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Because values are socially desirable people are "forced" to publicly
express and validate these values whether or not they are held internally.
Thus, values are commonly regarded as:
"the link between the individual and society because values help one to know and
comprehend the interpersonal world and guide the individual's adaptation to
surrounding conditions. That is, values are cognitive representations of various
human needs, tempered by societal demands" (Grunert and Muller, 1996: 170).
In line with this reasoning, values are assumed to be relatively permanent
and, consequently, are believed to have substantial influence on the
affective and behavioural responses of individuals (see Burgess (1992) for
a review).
There is also some indirect evidence in the literature to suggest that the
difficulty in changing prior beliefs and preferences derives from values'
stability:
"our findings document the difficulty in changing prior beliefs, even of the pencil-
and-paper kind manipulated in our experimental setting. Thefact that more than 50
percent of the respondents in experiment 2 did not switch from X-Tel to Crown even
after being exposed to strongly argued (preference-inconsistent) information indicates
that the resistance to changing one's preferences may be more entrenched than
sometimes assumed" (Jain and Maheswaran, 2000: 169).
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Are Values Changeable?
A system of values affects an individual's perceptual processes in that
external stimuli are perceived in ways that are consistent with the value
structure itself. Thus, this structure reduces social desirability bias because
it directly affects behaviour in that it encourages individuals to act in
accordance with their system of values (Feather, 1995). A system of values
should, therefore, have its greatest impact on the absence of task and
situational variables (e.g., incentives, limitations) that affect behaviour in
other ways. However, the value structure includes some values that are
more important than others:
"People typically internalize a system of personal values, within which individual
values have been prioritized or assigned a relative importance. It is a person's
hierarchy of values that determines what activities, interests, and material goods are
worth identifying with, cherishing, protecting, acquiring, or consuming. Indirectly,
value priorities drive consumption behavior in the marketplace" (Grunert and
Muller, 1996: 170).
That is, individuals learn, through both formal and informal means, to
establish a hierarchy of remarkably stable values that guide their product
and brand choice. While acknowledging that major longitudinal studies of
values have in general showed their remarkable stability, Rokeach and
Ball-Rokeach (1989) were able to demonstrate that adult socialisation,
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such as that which occurs through the media, or through organizational
processes, can in fact change this hierarchy of values in a meaningfulway.
Feather (1995) also suggests that "they (i.e., values) are relatively stable but not
unchanging across the life span" (ibid: 1135). The same opinion was
expressed by Meglino and Ravlin (1998) who reported that "unlike
constructs that are more peripheral to an individual (e.g., attitudes, opinions), values
are relatively permanent, although capable of being changed under certain
conditions" (ibid: 354). These assumptions suggest that although
remarkably stable, values are not permanent and can be changed under
certain conditions.
In line with the reasoning that has been advanced, it is possible to make
three main assumptions about the nature of human values:
1. values drive almost every aspect of human behaviour (Rokeach,
1973) and "values are the ultimate source of choice criteria that
drive bUYing behaviour" (Claeys et aI., 1995: 193);
2. the antecedents of human values can be traced to culture, society
and its institutions, and personality (Rokeach, 1973); and
3. Althought the total number of values that any person holds is
relatively small, they have a strong endurance and stability.
Nevertheless, values can be changed under certain conditions
(Feather, 1995; Rokeach and Ball-Rokeach, 1989; Rokeach, 1973).
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4.10.2 Value Theory and Doctors' Prescribing Behaviour
In recent years, personal values have gained acceptance as elements of
influence in consumer behaviour, psychology and marketing (Grunert and
Muller, 1996). With the growing application of the value concept in
marketing strategy, "especially in segmentation efforts, ever increasing numbers of
marketers are keen to collect data on their target consumers' values and to apply this
information to advertising, product design, and positioning decisions" (ibid: 169).
In a consumer behaviour context, personal values have been researched
extensively and cross-nationally for about two decades and found to be
relevant for a number of consumption related behaviours - though often in
an indirect way. Examples are product ownership (Cheron and Muller,
1993), environmental concerns (Grunert and Juhl, 1991), touristic
preferences (Muller, 1991), gift-giving behaviour (Grunert and Wagner,
1989), criteria used for brand choice (Pitts and Woodside, 1983), media
usage (Becker and Conner, 1981), and choice of leisure activities
(Jackson, 1974). While a great deal of research has examined how values
held by individuals affect their behavioural orientations (Schwartz, 1992),
value research has not been extrapolated to the area of drug choice.
Phannaceutical manufacturers have long acknowledged the importance of
attitudes and attitude change in the study of doctors' prescribing
behaviour. However, personal values are prototypes from which attitudes,
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as well as behaviours, are derived. Even though the marketing literature
reflects an emerging interest in the topic (Steenkamp et aI., 1999; Grunert
and Muller, 1996; Olson, 1995), personal values have not been used to
investigate the underlying dimensions of doctors' prescribing behaviour.
This is surprising considering the importance typically assigned to the
strong relationship between personal values and consumption behaviour
(Carlson, 2000; Webb et al., 2000).
4.10.3 Doctors' Clinical Values and Drug Choice
While it seems that personal values of male and female doctors have
important implications for medical careers (Neittaanmaki et aI., 1999),
research on clinical values and the ways in which they influence the
prescribing behaviour of GPs who look at and choose therapeutic classes
for treating patients is not available. Despite good reasons to expect that
this might be the case, no empirical evidence exists to support this idea.
Thus, it is necessary to operationally define the nature and content of
clinical values in order to understand drug choice. As a result, the purpose
of this section is to address these issues. Specially, attention will be
focused on:
1. A discussion of the influence of medical training on clinical values
and their relationship to prescribing behaviour.
2. To distinguish doctors' personal values from clinical values.
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4.10.3.1 Medical Training: A Source of Clinical Values
In the case of values that are relevant to specific social institutions such as
medical schools, these primarily occur during the educational process
(Satterwhite et aI., 2000). Although a detailed description of medical
students' socialization is beyond the scope of this research, two main
characteristics of this evolutionary process have important implications for
understanding the nature of doctors' clinical values:
a) medical students' training
b) medical typologies
At medical school the GP is trained in clinical skills to interpret patient
complaints (Ridsdale, 1995). During the doctor-patient encounter a
medical routine is developed to clarify the disease. Thus, the doctor-
patient dialogue is based on clinical skills which are useful for identifying
focal points (i.e., attributes or characteristics of the patient) which predict
the development of a specific clinical syndrome:
"The doctor could decide whether or not a clinical syndrome belongs to a particular
category by judging the similarity between the attributes of the patient and the
attributes of the category represented in the prototypes" (Bordage and Zacks,
1984: 416).
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From the perspective of the prototype theory, it could be argued that
patient attributes/characteristics such as age, sex, and disease are relevant
criteria encapsulated within doctors' long-term memory that mould drug
choice. That is, the GP's prescribing behaviour must be understood as an
individual, clinical, reasoning process through which doctors translate a
clinical syndrome into a patient typology in order to develop the
therapeutic approach:
"Shared meanings and assumptions about that which is categorized and various
aspects of its environment are embedded in the typology itself. Typologies are used to
define experience and may be used as a basis for action toward that and subsequent
similar experience. Typologies are more then verbal or mental "boxes" with which to
categorize people and events. They consist of meanings and agendas for action"
(Schneider and Conrad, 1981: 211).
One of the chief merits of a typology is parsimony (Bailey, 1994). The
doctor who is overwhelmed by tens of clinical focal points can work
comfortably with them when they are grouped into a few main types. A
related merit is the emphasis on bringing simplicity and order out of
complexity and chaos. As a clinical reasoning process, it has its roots in
medical training which advocates a coherent and rational sequence of
clinical information processing activities to construct the therapeutic
decision (Morrell, 1993).
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4.10.3.2 From Doctors' Personal Values to Clinical Values
Personal values were found to be important for understanding the
foundation of attitudes and behaviours of individuals in organizations and
often serve as a way in which individuals integrate personality and regulate
behaviour (Carlson, 2000). Furthermore, exposure to the clinical
environment may cause medical students to change their values, perhaps
without their recognition of that change (Satterwhite et al., 2000).
Nevertheless, it is important to distinguish those values that pertain to
desirable end states of existence (i.e., private life) from values that guide
doctors' prescribing behaviour (i.e., clinical life). This distinction is
partially supported by recent research on private life values which shed
light on the life situation, career and future plans of young doctors and
their views on medical education (Neittaanmaki et aI., 1999) as well as
the ethical development of medical students (Satterwhite et aI., 2000). For
example, Satterwhite et al. 's study emphasises that medical students have
two separate codes of ethics when they are exposed to unethical situations:
"students' exposure to unethical situations within the clinical environment may
motivate them to maintain separate codes of ethics, one personal and one as a
physician" (Satterwhite et aI., 2000: 464).
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According to Hunt and Vitell (1986), ethical decision making is influenced
by two major moral philosophies - deontology and teleology. The former
focus on the specific actions or behaviours of an individual, whereas the
latter focus on the consequences of the actions or behaviours.
With this distinction in mind, we are only interested in pharmacological
codes of ethics that derive from medical students' training and/or clinical
experience. A pharmacological code of ethics is based on deontological
norms or guidelines that represent personal values or rules of behaviour:
"one's deontological evaluation is a process wherein one evaluates the inherent
rightness or wrongness of an evoked set of alternatives that he/she views as possible
courses of action; this evaluation process involves comparing possible behaviors with
a set of predetermined deontological norms or guidelines that represent personal
values or rules of behavior" (ibid: 6).
Medical students become doctors only if they acquire the personal values
that represent the conscientious, explicit and judicious use of current best
evidence in making decisions about the care of individuals patients:
"Doctors acquire norms and values, not only from their family and social
background, but also from their training. An individual entering medical school, or
indeed general practice, is sensitive to the particular values and norms that exist in a
new setting and gradually adapts so that he comes to think as, act as, and indeed 'is a
doctor' " (pendleton et aI., 1996: 6).
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Ridsdale (1995) believes that doctors have a pharmacological code of
ethics that enable them to defme the best therapeutic approach for their
patients. A pharmacological code of ethics embraces an evoked set of
therapeutic alternatives which are important for GPs who have "to
question their clinical practice systematically and, where shortcomings
are identified, change that practice in line with scientifically valid
evidence" (Tomlin, 1999: 2). This evaluation process involves comparing
possible therapeutic solutions with a set of medical guidelines that
represent criteria for drug choice. Surprisingly, little attention has been
focused on the clinical values or criteria which represent the scientific
aspects of drug choice.
4.10.4 The Nature of Clinical Values
A long shared medical training ensures medical students and doctors will,
to a large extent, share the same clinical criteria in dealing with specific
diseases (Norton and Smith, 1994). Unfortunately, prescribing behaviour,
the fmal and visible part of this clinical criteria, has been found to vary
widely (McInnes, 2000). This reality has "stimulated the publication of
guidelines to assist practitioners in the management of hypertension" (McInnes,
2000: 28). As a pharmacological code of ethics, these medical guidelines
embrace homogeneous clinical values that may provide a powerful basis
for understanding drug choice.
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Medical care in general, and prescribing in particular, is an extensive
problem solving activity that requires special clinical skills (Pendelton et
aI., 1996).
As we shall repeatedly see in the sections that follow, medical problem
solving proceeds by selecting clinical values as a vehicle by which drug
choice becomes easier. In line with this reasoning, we move from
organizational values (i.e., medical school or health authorities) to
individual clinical values (i.e., GPs' therapeutic decisions). This approach
represents how a GP gradually adapts so that he or she comes to think as
and act as a doctor in terms of prescribing behaviour. In other words, a
pharmacological code of ethics is a medically created reality that makes
GPs understand the degree to which they are "prisoners" of the medical
ideology in which they were brought up.
The previous assumptions confirm Rokeach' s (1973) conviction that the
adoption of value systems derives from culture, society, and its
institutions. Thus, the medical culture, derived from the medical society
and its institutions, is assumed to be an important source of clinical values.
Values provide guidelines for individuals' behaviour. While psychology
and consumer research have used 'values' in terms of preferential
judgements in their applications of the expectancy-value or multi-attribute
models, in this research we use Rokeach's (1973) defmition of 'values'
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that refer to the "criteria" by which such preferential judgements are
made. This is consistent with Rokeach's work which found that values-as-
criterion are stable entities that are highly resistant to change because they
represent terminal values.
Ifwe have stable criteria for the choice of a therapeutic category, we also
have stable and highly resistant to change choices in terms of therapeutic
classes.
The advantages of studying values-as-criterion, Rokeach (1973) argues:
"we would be dealing with a concept that is more central, more dynamic, more
economical, a concept that would invite more enthusiastic interdisciplinary
collaboration" (ibidem: 5). For these reasons, Rokeach's (1973) vision of
values-as-criterion will shape the conceptualisation of clinical values:
clinical values are general criteria that are developed bv GPs. through
the medical educational process. which influence the selection of a
therapeutic class, with specific therapeutic attributes. which in turn are
instrumental in helping them achieve their desired clinical consequences.
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The hierarchical nature of clinical values and clinical consequences that
can be linked to product attributes, is based on five fundamental
assumptions:
1. clinical values are doctors' enduring beliefs or general criteria;
2. about desirable selection of specific therapeutic classes in order to
improve the therapeutic benefitsfor the patient;
3. that transcend specific clinical situations;
4. the antecedents of clinical values can be traced to medical
education and general practice (i.e., clinical experience); and
5. although the relationship between clinical values and the selection
of specific therapeutic classes can be changed under certain
conditions, it is highly resistant to change because this relationship
derives from medical students' training and/or clinical experience.
The influence of clinical values on prescribing decision-making has not
been analysed by the theoretical works in the drug choice literature.
However, clinical values approach needs an infusion of theory to give it a
broader perspective in linking product choice to clinical values. As a
result, the most representative value models have to guide this reflection.
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4.11 Personal Values Research
4.11.1 Rokeach's (1973) Value Survey (RVS)
Although it is sometimes difficult to identify one scholarly piece of work
as the seminal work for an area of inquiry, it is relatively easy to do this
with individual values. As Feather (1995) noted, most research on personal
values derives from the seminal contributions of Rokeach (1968; 1973;
1979). Milton Rokeach's work from the late 1960s and early 1970s holds
the distinction of being the work most used by later research. Subsequent
research uses the work of Rokeach to defme the conditions and meaning of
values, to provide insight into the empirical examination of values, and as a
way of measuring values. That is, one of the most commonly researched
value inventories is the Rokeach Value Survey. Thus, in discussing the
values measuring instruments reported herein, we follow mostly the social-
psychological conceptualisation of the term "value", and in particular
Rokeach's view. Furthermore, the most important general value scales that
have been used in the last decade (e.g., Schwartz, 1992; Feather, 1995)
were derived scales that were based on the Rokeach Value Survey (RVS).
The RVS uses ordinal scales to measure 18 terminal and 18 instrumental
values, which are alphabetically listed on two separate pages. Then,
respondents are invited to rank order each value as to its importance as a
guiding principle in living their life. A "1" indicates the most important
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value and a "18" the least important. But, of course, the problem with
Rokeach's scale is that it asks participants to rank-order their values, as
argued earlier, that results not only in statistical difficulties, but also in
respondent difficulties. That is, the Rokeach's original ranking procedure
presents difficulties both for researchers and respondents. Furthermore,
Rokeach's interest in values has not led to his developing mechanisms for
translating instrumental values into choices of objects to satisfy those
values.
4.11.2 Schwartz's (1992) ValueSurvey
Probably the most important programmatic stream of research on personal
values in the past decade has been conducted by Schwartz and colleagues
(e.g., Schwartz, 1992; Schwartz and Sagiv, 1995). Building on and
extending Rokeach's (1973) work, values have been defmed as "desirable
trans-situational goals, varying in importance, that serve as guiding
principles in the life of a person or other social entity" (Schwartz, 1994:
21). Values, then, are responsible for the selection and maintenance of the
ends or goals towards which human beings strive and, at the same time,
regulate the methods and manner in which this striving takes place. As
such, the measurement of personal values provides an indication of the
motivating factors in a person's life.
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Schwartz (1992) developed a new value measurement instrument which
derives from previous research on the content and structure of values
initially presented by Schwartz and Bilsky (1987; 1990).
Schwartz and Bilsky encapsulated many of the features mentioned by
Rokeach (1973) into their definition of values; in addition, they developed
new ideas about the structure and content of values, deriving them from a
theoretical consideration of the three basic requirements that were assumed
to preexist in all individuals - namely, "to satisfy biological needs, to achieve
coordinated social interaction, and to meet social institutional demands for group
welfare and survival" (Schwartz and Bilsky 1987; 1990).
They proposed that there were eight motivational types of values that
could be derived from the three universal human requirements. The crucial
aspect that distinguishes among values is the type of motivational goals
they express.
Schwartz and Bilsky also specified sets of dynamic relations between the
values types on the assumption that the actions taken in pursuit of different
value types may come into conflict, or be compatible, with each other. For
example, actions expressing conformity values may be in conflict with
actions that expressed self-direction values, but they may be compatible
with actions that expressed security values. Schwartz and Bilsky (1987;
1990) found support for their ideas in cross-cultural studies that used the
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RVS to investigate the structure of relations. Subsequently, Schwartz
(1992) developed this analysis further by expanding the number of value
types, by sharpening some of the definitions of these values types, and by
specifying the content of the larger classification of value types in terms of
the sets of values that comprised them.
The new Schwartz Value Survey, which has been used in crosscultural
studies of work values (Ralston et aI., 1997; Schwartz, 1994; Schwartz
and Bilsky, 1990), embraces 10 value types, which enclose 56 values
covering a wide range of content. These items were measured with a nine-
point scale, ranging from "opposed to my values (-1)" to "of supreme
importance (7)" . The ten value types emerged from smallest-space
analysis (Gutman, 1968) applied to ratings obtained for the 56 values in
the Schwartz Value Survey from student and teacher samples in 20
different countries (Schwartz, 1992).
The value types proposed by Schwartz (1992) were power, achievement,
hedonism, stimulation, self-direction, universalism, benevolence, conformity, tradition
and security. These personal value types were discussed in relation not only
to the three universal human requirements that are assumed to preexist in
all individuals, but also to the motivational goals that they express. Thus,
the ten motivationally distinct types of values described above reflect a
continuum of related motivations. It gives rise to a circular structure that
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captures the notion that the pursuit of different value types can be
compatible or in conflict, depending on how close the value types are. For
example, stimulation and self-direction are situated next to each other. The
simultaneous pursuit of these value types is compatible because both
involve intrinsic motivation for mastery and openness to change.
Conversely, stimulation is located opposite conformity and tradition, as the
former emphasizes challenge, risk, and change, whereas the latter favours
self-restriction and preservation of the status quo.
As Schwartz (1992) noted, simultaneous pursuit of both groups of value
types would give rise to psychological and social conflict. That is, the
analysis yielded a circular structure of wedges in which some value types
were adjacent to each other in the circle (e.g., power and achievement),
whereas others were on opposite sides of the circular map (e.g., self-
direction and security). For example, the motivational goal of power was
assumed to involve social status and prestige and control or dominance
over people and resources; the motivational goal of security was assumed
to involve safety, harmony and stability of society, of relationships, and of
self.
Schwartz pointed out that the ten value types are organised in four higher
order value domains that form two basic bipolar dimensions: openness to
change versusconservation and self-transcendence versus self-enhancement.
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These two bipolar dimensions constitute the most fundamental aspect of
the Schwartz value system (Schwartz and Sagiv, 1995). The former arrays
"values in terms of the extent to which they motivate people to follow their own
intellectual and emotional interests in unpredictable and uncertain directions versus
to preserve the status quo and the certainty it provides in relationships with close
others, institutions, and traditions" (Schwartz, 1992: 43).
An index of the importance of a value domain was obtained by computing
the mean importance for each value type separately, and subsequently
averaging the importance attributed to the value types within each domain.
This procedure ensures equal weighting of all value types in the
construction of a particular value domain (Schwartz, 1992).
4.11.3 Feather's (1995) Values Types
The structure and content of Schwartz's value system has received
impressive empirical support in research, particularly from other
researchers who have tested his model. For example, Feather's (1995)
study on the influence of values on the perceived attractiveness and choice
of alternatives contrasts the use of circumplex models (Johnson and
Ostendorf, 1993) adopted the circular value structure presented by
Schwartz (1992). Feather (1995) suggested that the former is particularly
important in describing the structure of personality traits which are distinct
from, but related to, values (see Blisky and Schwartz, 1994). That is,
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circumplex models are closer to Rokeach's instrumental values, while the
circular value structure is mainly concerned with terminal values:
"Some of the trait-descriptive terms used in these analysis are similar to the specific
value terms involved in the Rokeach Value Survey (Rokeach, 1973) and the Schwartz
Value Survey (Schwartz, 1992), but more so in relation to values that relate to the
importance of instrumental behaviors, such as being ambitious, forgiving,
responsible, and obedient, than for abstract terminal values that refer to general
goals" (ibidem: 1137).
The response measures for the circular value approach (Schwartz, 1992)
also differ from those used in the measurement of personality traits in that
the emphasis in value measurement is on the importance of each value for
the self as a guiding principle in a person's life rather than on self-
descriptions that refer to consistent modes of behaviour. Thus, the circular
value approach is assumed to have an explicit motivational basis, given
that values express motivational goals that are more similar for adjacent
value types. In contrast, the circumplex structures of personality traits that
have been proposed are not usually related to motivational concerns.
Furthermore, the circular value structure captures the notion that the
pursuit of different value types can be compatible or in conflict depending
on how close together the values types are on the circular map. Feather
pointed out that circumplex models of personality traits do not consider
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compatibilities and conflicts in trait-related behaviours. Furthermore,
Feather (1995) does not limit the effect of values to cognitive choices in
structured ego-involving situations: "Values also have long-term effects on a
person's behavior, functioning to influence both the short-term and long-term goals
that become salient for a person and the selection of plans and actions that relate to
these goals. In that sense they have a motivational role...They influence a person's
cognitive-affective appraisal of a situation in relation to both means and ends"
(ibidem: 1136). Thus, behaviours and their possible outcomes become
linked to the cognitive-affective system via a person's dominant values.
Thus, the person's perception of the attractiveness or aversiveness of
alternative behaviours or potential outcomes would depend in part on the
values that the person deems to be important for self. In line with this
reasoning, these value-induced valences would be expected to influence
the choices that a person makes between alternatives in a given situation.
Consistent with the general framework of expectancy-value theory,
Feather (1995) assumes that a person's choice between alternatives would
be influenced by his or her valences or subjective values and by
expectations that the person holds: "The assumption that values may induce
valences onpotential actions and their possible outcomes has important consequences
for motivational theory because it enables one to bridge the gap between values and
actions by using the general framework of expectancy-value theory" (ibidem:
1148).
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The participants in Feather's study were 239 university students who
answered a questionnaire that contained the Schwartz Value Survey'S,
different hypothetical scenarios and standard demographic items such as
age and gender. For each scenario (ten hypothetical scenarios were
designed that described situations that could be assumed to engage
particular sets of values), participants provided ratings of valence or
attractiveness for each alternative and then indicated which alternative they
would choose if they were in that situation. These measures were related
to participants' scores on the value types and higher order dimensions that
were based on their responses to the Schwartz Value Survey (Schwartz,
1992).
Feather's (1995) research and Schwartz's (1992) study have influenced
recent reflection in the context of consumer innovativeness. Based on
these theoretical frameworks, Steenkamp et aI. (1999) developed a new
conceptual scheme to evaluate the effects of personal values, consumer-
context-specific dispositions, and national culture in 11 European Union
countries. Both value orientations and secondary, consumer-context-
specific dispositions exerted significant effects on consumer
12 This survey consists of 56 values. Each value is accompained by a short descriptive phrase, and
participants used a 9-point rating scale numbered from -1 to 7 to rate how important each value was
as "a guiding principle in your life". The rating scale was labeled as follows: -I (opposed to my
values), 0 (not important), 3 (important), 6 (very important), and 7 (of supreme importance).
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innovativeness. These researchers also found that national cultural
variables were relevant in explaining systematic differences ID
innovativeness between countries. Steenkamp et al.' s (1999) findings are
important because they "demonstrate that innovation orientation differs not only
among consumers, but also among countries" (ibidem: 64). If a company
decides to introduce a new product in countries whose national culture is
less conducive to fostering innovativeness in its citizens, the marketing
strategy has to be modified in several aspects to increase its effectiveness.
Webb et al. (2000) also suggested that personal and cultural values have
commonly been associated with the differential behaviour of individuals.
Steenkamp et al. 's (1999) study is one of several attempts that have been
made in the last two decades to provide a theoretical and conceptual
structure connecting consumers' values to their behaviour.
4.11.4 Kahle's (1983) List of Values (LDV)
Kahle's (1983) list of values (LOV) is another interesting example of a
survey approach that establishs a relationship between general values and
behaviour. The LOV scale consists of nine parsimonious Rokeach-like
terminal values: excitement, warm relationship with others, being wellrespected,
security, sense of belonging, fun and enjoyment in life, self fulfillment, a sense of
accomplishment, and self-respect. Each of these values can be scored in a
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number of ways. Each value can be rank ordered from most to least
important, or the values can be evaluated on 9 or 10 point scales, ranging
from very unimportant to very important. A combination of the two
methods is also possible where each value is rated on 9 or 10 point scales
and then individuals are asked to circle the one or two values that are most
important to them in living their daily lives. This value-based survey
methodology is important not only for understanding, measuring, and
presenting the importance of interpersonal relations in value fulfillment,
but also for defining personal factors (i.e., self respect, self-fulfillment),
and other factors such as fun, security and excitement in value fulfillment.
In focusing primarily on the product and values related to it, LOV
measures those values that are central to people in living their lives,
particularly work, leisure and daily consumption.
Exploring the meaning of LOV, Kamakura and Novak's (1992) study
suggests that the LOV approach is related to, and predictive of, consumer
behaviour and related activities. Using a value system segmentation,
Kamakura and Novak identified two segments. The first segment valued
security and the second valued warm relationships and fun. The former
was relatively risk averse and correspondingly tried fewer new products,
while the latter liked outdoor activities, leisure products, and preferred
television sitcoms over religious and news programs.
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4.11.5 Mitchel/'s (1983) Values and Lifestyle Typology (VALS)
The values and lifestyle typology (VALS 13) (Mitchell, 1983) method
essentially created a priori categories based on Maslow's (1954) hierarchy
of needs and the concept of social character and then developed a set of
statements (and a scoring system) that permitted classification of
respondents into those categories. The original VALS survey encapsulates
a set of 40 attitude statements scored on a 6-point "disagree strongly"
"agree strongly" basis, and 15 more questions assessing different
perspectives on politics, finances, job satisfaction and the like.
In addition, the VALS program presents a number of demographic, media
habits, activities, financial issues, household inventory, and product usage
questions that permitted the classification of American adults into nine
typologies. Some researchers suggest that VALS and LOV models "are
silent about how information is processed and organized Related to this is their
neglect of the underlying structure of information and whether beliefs or values are
related in hierarchical, functional, or inferential manners" (Bagozzi and
Dholakia, 1999: 22). Identical opinion was expressed by Durgee et al.
(1996) who developed a new methodology to identify core life values and
their influence on consumer behaviour.
13 Though several well known value-based survey methodologies were reported, the prototypical
example of this approach on a total population basis is the VALS Program developed and marketed by
Stanford Research Institute (SRI) (Bearden et al., 1993).
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4.11.6 Durgee et al. 's (J996) List of Values
Durgee et al. (1996) believe that a classification scheme such as VALS
may be useful for developing marketing strategy and predicting consumer
behaviour. However, VALS and other value-based survey methodologies
such as Kamakura and Novak's (1992) research "identify associations
between values and products which may or may not be causal. They are merely
associations" (ibid: 91). To overcome this problem, a new methodology was
described for identifying core life values and tracing their direct impact on
consumption. Durgee et al. 's (1996) list of values represents a combination
of values from the Rokeach and LOV value surveys. In the first step,
respondents were presented with a combination of values from the
Rokeach and other value surveys such as Kahle's (1983) list of 9 values
(LOV) and asked individually to indicate which five values were most
important in his/her life. In the next step, five products from many different
categories were selected to make each of the five selected values possible.
Finally, respondents were invited to explain the intermediate reasons or
"means" between end values and products. The nature of this approach is
a "means-ends" product value chain which begins with core target values
(i.e., ends) and causally relates them to actual product use (i.e., means). In
other words, Durgee et al. 's (1996) means-end chain seeks to explain how
a product selection links values to behaviour.
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4.11.7 Vinson et al. 's (1977) Means-End Chain Model
Vinson et al.' s (1977) model is another means-end chain model that
assumes values as "centrally held cognitive elements which stimulate motivation
for behavioral response" (ibidem: 49). Their vision to the consumer's value-
attitude system derives from Rokeach's (1973) Value Survey. That is,
based on the difficulty respondents have had in ranking all Rokeach's 18
terminal and 18 instrumental values, Vinson et al. (1977) have attempted
to create three levels of abstraction, arranged in a hierarchical network.
The model begins with global values (a redefinition of terminal values) at
the most central level (closest to a person's self-concept) and causally
relates them to domain-specific values. With this cognitive view, they were
able to establish an hierarchy that links global values to domain-specific
values. This intermediate level bridges the contact with evaluative beliefs
about product attributes (e.g., beliefs used in expectancy-value research),
the least central level. As a result, values "exist in an interconnected
hierarchical structure in which global values are related and connected to
generalized consumption-related values, which are, in turn, similarly associated with
product attributes" (ibidem: 49):
~ Global or generalised personal values: centrally held and enduring
beliefs which guide actions and judgements across specific
situations.
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)0> Domain-specific values: individuals acquire values through
experiences in specific situations. As a result, behaviour can only be
understood or efficiently predicted in the context of a specific
environment.
)0> Evaluation of product attributes: descriptive and evaluative beliefs
such as the desirable attributes of product classes. It is this less
centrally held level of values that most of the expectancy-value
research has used in predicting brand appeal.
This work suggests that "value acquisition represents a socio-cultural process
and that differential value orientations will lead to variations in preferences for
products and brands" (ibidem: 46). In order to test the proposition that values
are culturally and socially learned, an exploratory study was undertaken to
investigate whether subjects from two culturally distinct regions of the
United States would manifest different value orientations; and, if so, the
extent to which these value differences may be related to attitudes toward
automobiles and the importance of automobile attributes.
Subjects used in the research were selected from a sample of
undergraduate marketing students at two different state universities (liberal
and traditional universities). Each group was administered an identical
questionnaire, which included a number of seven point Likert-type scales
designed to measure the importance of the Rokeach global values and
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specific consumption-related values. In addition, data were also collected
on the importance of 20 automobile attributes, and the appeal of 10
consumer products and services. Attitudes toward a number of current
social issues were also collected to further explore attitudinal differences
between the two groups. The results indicated that the two groups of
marketing students were significantly different with respect to their basic
value orientations. These differences were consistent with preference for
the consumer products or services as well as for the perceived importance
of the selected social issues.
Gutman (1982) noted that Vinson et al.'s (1977) model has fallen short of
meeting the criteria of specifying the links in their means-end chain:
"although various levels of a means-end chain are articulated, no means are
provided by which values at global and domain-specific levels are related to each
other nor how either level of values is tied to evaluations of product attributes"
(ibidem: 64).
4.11.8 Howard's (1989) Consumer Value Model (CVM)
Howard (1989) incorporated many of the features mentioned by Rokeach
(1973) into his definition of values. This applies to Rokeach's (1973)
battery of 18 "terminal" and 18 "instrumental" values.
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These individual values, which have been found to be important criteria for
influencing evaluations or choices regarding persons, objects, and ideas,
were used in marketing/consumer research (Bearden et aI., 1993). One of
the most important examples is Howard's (1989) consumer value model
(CVM).
The CVM, in its "extensive problem-solving" version is a theoretical and
conceptual structure connecting consumers' value systems to their
behaviour. This model suggests a hierarchical evaluative structure having
two different levels, one headed by terminal values and one headed by
instrumental values:
Terminal choice criteria for belief about attitude toward
Values product class product class product class
Instrumental choice criteria belief about attitude toward
Values for brand brand brand
Terminal and instrumental values are defined m the same way that
Rokeach defmes them:
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"terminal values are the more general personal values referring to end-states of
existence, for example, a comfortable life, an exciting life" (Howard, 1989: 56),
while "instrumental values that are less general, more specific personal values
referring to modes of behavior such as ambitious, loving, and so on" (ibidem: 56).
In his model "choice criteria" refer to benefits, and "belief' "refers to where
the consumer "believes" a brand is located on those respective benefits" (ibid: 56).
After considering the benefits, consumers form attitudes, and their
attitudes lead to decisions of whether or not to purchase a particular
product category or class (i.e., first level of choice). In other words, the
choice of a product category is believed to be initiated by general personal
values, which provide choice criteria for a product category. Beliefs about
each of a set of product classes lead to a decision to make a purchase from
a particular product class. From this product category, and following the
same reasoning, a specific brand is chosen (i.e., second level of choice).
Such reasoning strengthens the argument that
"terminal values determine choice at the product class level but instrumental values
at the brand choice lever' (ibidem: 58).
Howard pointed out that the major reason for this two-level choice
structure is that consumers are making choices across categories of
products. For example, a successful pharmaceutical manufacturer should
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help the doctor to group a new brand into the appropriate category and to
distinguish it from other brands in that category. Unless the doctor can put
the new pharmaceutical brand into a category in hislher mind, s(he) is less
likely to prescribe it. If the manufacturer's information is not clear enough,
the company could lose a prospective prescriber who is too busy to use the
time and effort required to learn about the product category. Thus,
Howard's two-level choice model implies that the analysis across products
are the most important step "to understand those fundamental consumer changes
that open opportunities for product innovations that are so crucial to marketing
success in industrially advanced countries" (ibid: 58).
Despite featuring terminal values as initial motivations for product choice
Howard does not specify whether these general personal values are stable
in different situational contexts. There are reasons to believe, however,
that only a limited number of general values will be activated in any
particular choice situation, and that which and how many terminal values
will become salient depends on the nature of the problem. Furthemore,
"Howard (1989) does not specify how these values are organized and how they
function to influence attitudes, decisions, and choice" (Bagozzi, 1999: 22).
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4. 12 Problems with Measuring Instruments
There have been many values instruments developed over the years. There
are also many views on how values can best be measured (McCarty and
Shrum, 2000; Finegan, 2000; Rallapalli et al, 2000; Meglino and Ravlin,
1998; Oliver, 1999; Agle and Caldwell, 1999; Grunert and Muller, 1996;
Feather, 1995; Howard (1977; 1989); Kahle, 1983; Mitchell, 1983;
Rokeach, 1973). One of the main problems recognised by many
researchers, but rarely dealt with in practice, is the question of whether
and how values and their influence on behaviour can be verbalised and
thus made accessible for measurement. In addition to this main problem,
values have been conceptualized in different ways (Meglino and Ravlin,
1998; Rokeach and Ball-Rokeach, 1989), ranging from personality types
to needs, attitudes or even higher order goals to life role values (Carlson,
2000; Austin and Vancouver, 1996; Feather, 1995). For example, Carlson
argues that life role values are the system of values an individual holds
because he or she believes them to be important to, central to, or a priority
in his or her life. Thus, values are a desirable state of existence, not
necessarily a reality. This remains an open empirical question: "How are
consumers prioritizing their values when asked to do so by value researchers? Are
they thinking "ideal" life or are they thinking "real" life, i.e., subject to the realities
and demands of everyday life? Hence, this distinction between "real" and "ideal"
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values presents a methodological problem for any consumer researcher using the
concept of values" (Grunert and Muller, 1996: 171). Furthermore, the
respondent's hierarchy of values has to be determined to know whether is
possible to assume some of them as main causes of consumption behaviour
in the market place. Unfortunately, researchers have advanced two distinct
values measuring instruments (McCarty and Shrum, 2000). This may help
to explain why some studies have generally shown modest relationships
between personal values and the behaviours of interest: "Although it may be
that the paucity of strong and consistent findings is simply because the relationship
between values and behavior is tenuous, it may just well be that the relatively weak
findings are attributable to problems with the measurement of values" (McCarty
and Shrum, 2000: 272). This debate centres on whether a respondent who
is presented with a set of values should be obliged to rank them from most
to least important, or to rate a set of items, or statements describing a value
or a set of values, on an importance scale. In summary, it would be
possible to argue that:
1. there is a lack of consensus on the nature of values themselves; and
2. value measuring instruments may cause a bias in the fmding. As a
result, "value researchers are divided on the appropriate way to
measure values" (Meglino and Ravlin, 1998: 358). Some of them
prefer to use ipsative measuring techniques, while others suggest the
use of normative measuring techniques.
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4.12.1 Ipsative Measuring Techniques
As pointed out earlier, the tricky issue of how survey respondents
understand and evaluate the value rating or ranking task has not been
properly resolved. The main explanation for this derives from how these
researchers conceptualise the nature of values themselves: "obtaining
unambiguous value priority data from consumer surveys is a tricky task, given the
abstract nature of human values" (Grunert and Muller, 1996: 171). Because
personal values are relatively abstract concepts, measuring them has
proven to be a difficult task. Those who believe that values are less than
totally conscious, somewhat below an individual's level of complete
awareness (Meglino and Ravlin, 1998; Rokeach, 1985; 1973), prefer to
use methods that oblige respondents to rank order a set of values. As a
result, this method assumes that accurate value measurement requires
assessments made in choice situations. Therefore, ipsative scores are
believed to more closely represent an individual's true values, rather than
his or her public endorsements of socially desirable statements.
Furthermore, many researchers maintain that values are hierarchically
structured based on their relative importance to an individual. Because
ipsative methodologies ultimately yield a rank ordering of values based on
importance, they are believed to duplicate the way values are cognitively
held by individuals (Meglino and Ravlin, 1998).
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4.12.2 Normative Measuring Techniques
Value researchers from the Stanford Research Institute (SRI) and others
(Grunert and Muller, 1996; Feather, 1995; Schwartz, 1992) prefer to
measure values independently of each other using values scores. As a
result, they argue that "normative" techniques are able to defme a
respondent's value profile in accordance with the way (s)he rates a set of
items or statements describing a value or a set of values (Feather, 1995).
This is impossible using ipsative procedures because each value must be
assigned a different rank. Furthermore, the SRI method and its VALS
Program assumes that when values are rated independently, it is possible
to capture absolute differences between values. Therefore, researchers are
able to compare the strength of various values across individuals. This
information is unavailable when values are ranked. Similarly, normative
procedures also allow for values to be rated as equal in strength, which is
not possible with ipsative measures: "ranking procedures mayforce distinctions
between values when none exist, whereas ratings allow for ties" (McCarty and
Shrum, 2000: 272). Furthermore, a ranking procedure is more difficult to
administer than a rating task because it requires a great deal of time and
energy for respondents to complete, particularly when the number of items
to be ranked is more than four or five (Reynolds and Jolly, 1980).
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This set of advantages of nonnative techniques over ipsative methods also
permits the use of more sophisticated statistical analysis. Normative
proponents also note that ratings are less cumbersome than rankings,
making a normative format more convenient to administer. They argue that
ranking procedures are extremely difficult to administer using telephone
survey methods. Moreover, the ordinal nature of ranked data imposes the
use of nonparametric statistics. Rokeach and Ball-Rokeach (1989) stressed
that some researchers prefer to use normative measurement techniques
simply because these techniques are more convenient from a statistical
point of view. However, measurement problems with ipsative and
normative techniques can not be reduced only to statistical problems. In
this respect, we agree with researchers who maintain that allowing
statistical issues to dictate methods of value measurement amounts to
"putting the methodological 'cart' before the theoretical 'horse' "
(Rokeach and Ball-Rokeach, 1989: 775). Thus, we believe that the
theoretical relevance that derives from different paradigms should take
precedence over statistical convenience in such studies. This means that
the problem has to be analysed according to two different theoretically-
grounded perspectives:
1. the Macro Approach; and
2. the Micro Approach.
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4.13 Macro VS. Micro Value Research Methodologies
Personal values research in marketing and consumer behaviour has
received a substantial amount of attention from both academics and
practitioners (Durgee et aI., 1996; Walker and Olson, 1991; Howard,
1989; Reynolds and Gutman, 1988; Reynolds, 1985; Gutman, 1984;
1982). However, the application of value theory and research to marketing
problems has taken two theoretically-grounded perspectives:
1. The "macro" approach, grounded in sociology and survey research
methodology, has been able to develop a classification scheme to
categorize respondents into predetermined groups defmed by value
orientation.
"Macro" value approaches such as RVA, VALS, LOV models and their
derivatives provide interesting representations of a "means-end" product
value chain. As a result, it is possible to argue that the value items on these
inventories are, themselves, well grounded in theory. Furthermore, the
empirical work indicates that their advantages lie in their simplicity, ease
of operationalisation, and usefulness in prediction. That is, not only value
survey approaches present a robust theoretical framework, but also their
empirical research brought new blocks of knowledge to consumer
behaviour and marketing action. These empirical generalizations may be
seen as important contributions for science:
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"Science is a process in which data and theory interact leading to generalized
explanations of disparate types of phenomena. Thus, empirical generalizations are
the building blocks of science" (Bass and Wind, 1995: G 1). Nevertheless, the
"macro" survey approach presents some problems that should be
highlighted.
Reynolds (1985) argued that the "macro" methodological approach is
based on several key assumptions, "the most important being that respondents
can, in fact, deal with value orientations and the statements that reflect such highly
personal meanings" (ibidem: 298). The different value surveys described
earlier assume that values being measured represent the dimensions upon
which individuals actually base their assessment. As Grunert and Muller
(1996) noted, the relationship between "real" and "ideal" life value
measures and other aspects of consumption behaviour that are driven by
value priorities indicate the possibility of wrong connections between
values and some predicted behaviour: "Our finding tentatively signals that the
measurement problem in value surveys can lead to faulty conclusions by marketing
managers who wish to apply value data to marketing decisions such as product
design, segmentation, and the refinement of marketing communications. And we
believe that our finding is just the tip of a methodological iceberg" (ibidem: 179).
As a result, their primary disadvantage rests in the limited way they
accomplish an explanation and understanding of consumer behaviour.
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Two other implicit assumptions derive from the central and explicit
assumptions:
» respondents are engaged with these personal motivations;
» respondents are assumed to respond accurately.
From experience, researchers are aware that is extremely difficult m a
survey context to test assumptions such as these; hence, they are "taken on
faith" (Bagozzi, 1999). Furthermore, McCarty and Shrum (2000) pointed
out that "cognitively sophisticated respondents are more motivated than those with
less sophistication, and this motivation influences differention regardless of the rating
instructions with which they are presentee!' (ibid: 275). In other words,
unmotivated respondents tend not to make distinctions and thus do not
differentiate greatly among the items they evaluate.
In terms of statistical problems that derives from this positivist approach,
three other problems should be listed:
» Whether the instrument should have individuals rate or rank values.
The type of data acquired from rankings is ipsative in nature,
meaning that the information gathered is the relative judgement of
one value against another. For this reason, items cannot be
eliminated or added without substantially altering the integrity of
the scale. This is a problem because the information gathered on the
value is only relative, and the knowledge about the absolute
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strength of the value is not gathered (Braithwaite and Scott, 1991).
This also makes the statistical analysis awkward. However,
absolute ratings are also problematic. Because values are often
perceived as socially acceptable and desirable, individuals may
tend to use the extreme positive categories on a rating scale. This
leads to a skewed distribution, which also creates statistical
analysis problems.
~ Whether a value should be measured by one item or multiple items.
Rokeach (1973) pointed out that one item, that is well-defmed, is
enough and that multiple items would lengthen and complicate the
measurement procedure. Others argue that a value should be
measured by multi items to increase the reliability and validity of
the scale (Meglino and Ravlino, 1998). Single item measures also
are particularly problematic when making cross cultural
comparisons (Braithwaite and Scott, 1991).
~ Whether values should be evaluated alone or in comparison to
others. This third problem is related to the first two. As previously
noted, a system of values encapsulates a hierarchy of values and
some of them have a high importance. However, what happens
when individuals have to make a choice between two values that
are extremely important?
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All these problems usmg the "macro theoretical framework" to value
. d 1"measurement were recognise recent y: Despite decades of research on values,
and numerous studies comparing normative and ipsative measurement techniques,
there appears to be no clear resolution to the value measurement controversy. We
believe that this conflict, and perhaps its resolution, is linked to differences in the way
individuals process information under various circumstances. Specifically, there
appear to be times when an individual's cognitive processes are naturally focused on
creating a rank ordering...On the other hand, there appear to be occasions when an
individual's cognitive processes are primarily focused on making absolute
discriminations on independent dimensions" (Meglino and Ravlin, 1998: 360).
This contingency approach suggests a phenomenological measurement
methodology which appears to be more correct because it closely mirrors
the actual cognitive process engaged in by respondents.
Regardless of which method represents the better approach to measuring
personal values, it is possible to argue that most attempts that have been
made to provide a theoretical and conceptual structure connecting
consumers' values to their behaviour have their origin in the Rokeach' s
(1973) Value Survey. However, Jones et al.'s (1978) study has shown that
only one-third of Rokeach's Values are among the spontaneously
mentioned values. This clearly suggests that respondents should be
allowed to express their own values rather than scoring (or ranking)
predetermined values.
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2. The "micro" methodology, based on cognitive psychology, prefers
to ask consumers to describe their feelings about products in such a
way that ultimate values come out.
The "micro" methodology recognises that subjects should be allowed to
express their own values because "values provide the overall direction,
consequences select specific behaviors in specific situations, and attributes are what
is in the actual products that produce the consequences" (Gutman, 1984: 25). Gutman
uses "a model that seeks to explain how a product or service selection facilitates the
achievement of desired end states. Such a model consists of elements that represent
the major consumerprocesses that link values to behavior" (ibid: 60).
As Gutman (1982) noted, "the nature of the various means-end chain appearing
in the literature is a function of the perspectives of their authors" (ibidem: 64).
Gutman's means-end approach differ from Howard's (1977; 1989) two-
level choice structure in that the concept of instrumental values is not
used:
"there is only one chain as opposed to hypothesizing parallel semantic and evaluative
chains. Value and consequence level categories subsume grouping level categories,
creating a single hierarchy of categories across all levels of the means-end chain"
(ibid: 64).
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This single hierarchy of categories across all levels of the means-end chain
is a system whose inputs "are products and situations; outputs are products
chosen for final consideration" (ibid: 65). That is, "products can also be
interpreted as value satisfiers. These personal values are therefore important life
goals that consumers are trying to achieve (e.g., happiness, security, wisdom) which
may, in certain instances, be linked to the products or services consumed by the
individual" (Baker, 1992: 662). Thus, the "micro" approach "especially
focuses on the linkages between the attributes that exist in products, the consequences
for the consumer provided by the attributes, and thepersonal values the consequences
reinforce" (Valette-Florence and Rapacchi, 1991: 30).
In line with the reasoning that has been advanced, the "micro" approach
suggests that establishing the personal relevance of a product should be a
primary objective of marketing managers: "To develop effective marketing
strategies that build personal relevance, marketing managers need to understand the
factors that underlie consumers' perceptions of importance and self-relevance"
(Olson, 1995: 189). From the consumers' perspective, products are
important or self-relevant only when their attributes (the means) lead to
important, useful consequences and values (the ends). These "consequences
and values in the means-end chain are more self-related, personal, and emotional
and, therefore, are a major source of the motivation that energizes and directs
consumer decision-making" (ibid: 190). As a result, the nature of the "micro"
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methodology has stayed closest to the Rokeach's conceptualisation of
terminal values rather than instrumental values:
"Quite frequently respondents reach a level where they are talking about terminal
values such as those indicated by Rokeach (Gutman, 1982: 66). However,
"Rokeach's interest in values has not led to his developing mechanismsfor translating
instrumental values into choices of objects to satisfy those values. Therefore, from a
marketing perspective more needs to be done to demonstrate howpreferred end-states
of existence are translated into specific choices in specific situations" (ibid: 63).
Thus, a "micro" methodology should be used. It indicates a greater focus
on values as end-states of existence or criteria (terminal values) as
opposed to modes of behaviour (instrumental values). Also, in contrast to
modes of behaviour, criteria have more in common with terminal values
as they are used by researchers and practitioners to describe the
relationship between product/service consumption and self. This approach
suggests a new means-end chain theoretical framework:
"More recent work links values and products together via "means-ends" chains. Most
of these begin by asking about important product attributes as perceived by
respondents, then probing until the researcher identifies more general motives or
values regarding that product" (Durgee et aI., 1996: 91).
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4.14 A Micro Means-End Chain Approach to Doctors' Drug Choice
Doctors learn about a product by categorizing it, by placing it in their
minds - memorizing it - in a category of equivalent brands called a
"product category", for example, diuretics for hypertension treatment.
Important for the purpose here is that the theoretical framework explains
the role of clinical values or criteria when a doctor is developing a
therapeutic class choice. The major reason for this cross-therapeutic class
analysis is that doctors are making choices across categories of products.
This requires that our approach to measuring clinical values has to be
based on two fundamental assumptions about prescribing behaviour:
1. that clinical values, defined here as desirable clinical criteria, playa
dominant role in guiding therapeutic choice patterns; and
2. that doctors cope with the tremendous diversity of products that are
potential satisfiers of their clinical values by grouping them into
therapeutic classes so as to reduce the complexity of choice.
In addition to these two assumptions about prescribing behaviour that are
essential to the particular form of the model and its most appropriate
measures of clinical values, there are two other assumptions of a more
general nature. These assumptions are that all therapeutic choices have
consequences for the patient, and that GPs learn to associate particular
consequenceswith particular therapeutic choices.
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The central aspect of the model is that doctors choose therapeutic classes
that produce desired clinical consequences and minimize undesired
consequences. It is suggested that values provide consequences with
positive or negative valences. Therefore, the clinical values-therapeutic
consequence linkage is one of the critical linkages in the model.
As previously noted, Rokeach (1973) suggests that values are ordered in
importance. This assumption also give clinical consequences importance,
in that consequences leading to important clinical values should be more
important to a doctor than those leading to less important clinical values.
In terms of product choice, there is a major difference between ordinary
consumers and doctors. The former have no specific skills to choose the
products they buy, while the latter have a long medical training. All
doctors are taught to take a medical history and to make initial decisions
about the aetiology of the patient problem. Similarly, all doctors are
instructed in the use of drugs and are familiar with other therapies. Thus, a
choice among alternative therapeutic solutions is based on the attributes of
the therapeutic classes that they have learned that will produce the desired
consequences. Therefore, the second important linkage in the model is
that between consequencesibenefits and product attributes.
The Means-End Chain Model (MEC) embraces these two relevant
linkages.
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While research in prescribing behaviour has often focused on doctors and
their consensus in terms of product attributes rather than clinical values,
the current study opens up a different, complementary micro approach.
This view rests on the idea that medical know ledge is often latent but
arises to influence cognition under certain conditions, such as when
doctors search for clinical values to support their prescribing behaviour.
Our view can be called a new means-end approach to therapeutic decision
making. It emphasises that clinical values from medical education and
clinical practice are continuously present and become operative as a
function of the patient characteristics. This new approach reveals a way to
understand some inconsistencies in the fmdings of previous research on
drug choice and suggests a research agenda that derives from the means-
end chain theoretical and conceptual structure that assumes that clinical
value or criteria acquisition represents a medical cultural process which
determines drug choice: "Culture is the source of any group's collective memory
and provides a basis for consciousness. The values that people hold dear, their
collective sense of self and their aspirations are rooted in cultural learning.
Moreover, the material components of culture - the tools and trappings used in daily
life - have deep roots in these ideational aspects. In this way culture comes to play an
important role in product choice, usage and resistance. Deciding to use, and picking
a particular brand of children's cough syrup, are rooted in culturally-based ideas and
values about health, child rearing and causality" (Mariampolski, 1999: 78).
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This medical cultural process enables us to hypothesize that GPs create
arrays of therapeutic classes that will be instrumental in helping them
achieve their desired clinical consequences, which in turn move doctors
toward valued clinical criteria:
"To enable a person to achieve his/her values, groups or categories of products
(product classes) have to be related systematically to the higher level ends if the chain
is to serve its instrumentalpurpose" (Gutman, 1982: 62).
In the psychological literature, problem-solving, judgment and decision-
making typically refer to different research paradigms and models.
However,
"In complex real task environments such as are encountered in medicine, the
processes of problem solving, judgment, and decision-making relate to one another
very closely" (Elstein et al., 1978: 10).
It is, therefore, not surprising that a means-end approach to problem
solving, judgment, and decision-making is the dominant theoretical
perspective of this research project. Reynolds and Whitlark (1995) also
claims that:
"0ne way to understand a means-end framework is to think of consumer decision-
making as a problem-solving process" (ibid: 9).
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4.15 Research Goals
Newell and Simon's (1972) information processing theory emphasizes that
rational human problem solving is characterised by the adaptation to the
problem to be solved. Since it is adaptive, "a theory of problem solving must
be, first, a description of how different kinds of problems are solved, and, second, a
taxonomic or logical analysis of the interrelations among problem types" (Elstein et
al., 1978: 22). In line with this reasoning, two objectives were defmed:
First, to describe how different kinds of clinical problems are solved,
means-end chain researchers need to be able to obtain cognitive material
that represents GPs' prescribing-relevant knowledge.
Second, an analysis of the interrelations among clinical problem types
requires the selection of dimensions and fmding cases for classifications:
"a well-constructed typology can be very effective in bringing order out of chaos. It
can transform the complexity of apparently eclectic congeries of diverse cases into
well-ordered sets of afew important dimensions" (Bailey, 1994: 33).
With a well-constructed typology, means-end chain researchers are able to
develop realistic representations of GPs' daily clinical work. That is,
patient typologies can be useful as heuristics devices to highlight:
(a) the relevant theoretical features or dimensions of the type;
(b) exhibited extreme clarity on all dimensions.
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This is generally true for taxonomic techniques that are based on
qualitative, conceptual typologies: "The monothetic typologies ...are formed
conceptually and deductively. Any empirical data, if utilized at all, enters theprocess
relatively late, after the conceptual types have beenformed" (ibid: 34).
The patient typology, as a conceptual type derived from relevant clinical
values, embraces a heuristic search process for prescribing decision-
making. As the diagnostic process is taught to medical students and
reinforced by medical guidelines, doctors are assumed to use similar
medical typologies to select different drug treatments. These patient
typologies are consensual and used by the medical community to identify
the major clinical criteria of both practical and intellectual interest and
offer possible drug treatment solutions. However, a consensual typology
does not mean a similar drug therapeutic approach, even when medical
guidelines are available for first-line drug treatment.
In a book about hypertension, born at the Department of Medicine and
Therapeutics, University of Glasgow, Western Infirmary in Glasgow,
McInnes (2000) recognised that "unfortunately, the standards of care are
extremely variable, ranging from total neglect to over-intensive use of drugs in
individuals who stand to gain little if anything from treatment...Earlier guidelines
differed in their views of the optimal threshold for treatment, the choice of first-line
drugs and the goals of treatment" (ibidem: 27).
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As a consensual patient typology does not mean a similar drug treatment,
we have to distinguish two different steps in terms of research design:
~ the patient typology definition (i.e., the link between the diagnostic
process and the therapeutic approach); and
~ the therapeutic approach (i.e., drug choice).
The first step is attached to "clinical criteria or clinical values" in terms
of patient typology definition, while the second step uses the patient
typology for therapeutic decision-making. The latter step is relevant
because it opens the opportunity for categorising Portuguese GPs' first-line
drug treatment. This means that for this means-end chain approach,
understanding and explanation take precedence over prediction as the
scientific contribution of the theory. In line with this reasoning, this study
has two goals:
1. to identify the links between product attributes and therapeutic
consequences and from these to clinical values employed by GPs
as they choose among therapeutic classes for patients with
hypertension;
2. to use these clinical values (i.e., patient typologies) for
categorising Portuguese GPs according to their first-line drug
therapy.
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4.16 Research Focus and Research Methods
In this phase of the research process, we believe that each patient typology
will be "designed" by the GP to simulate certain aspect of the doctor-
patient encounter, notably the fmal part of the diagnosis process and
management. The interpersonal skills of the GP, the degree to which a
patient feels satisfied with the encounter are not assessed at all. Our aim is
not to provide an explanation of GP thought by use of more elementary
processes, operations, or capabilities. This rationale is characteristic of
process-tracing studies as a whole. Our focus, rather, is on GPs'
prescribing-relevant knowledge stored and organised within the GPs'
memory which is used for connecting self related clinical values with
specific product attributes that satisfy them in terms of desired clinical
consequences (see Chapter Two: Figure 2.2: Study Ovel'View).
One reason for means-end chain advocates' enthusiasm about the use of
qualitative, in-depth interviews, is its links across different levels of
abstraction: "unlike those output from traditional factor analysis or
multidimensional scaling methods, is structural in nature and represents the linkages
or associations across levels of abstraction (attributes-consequences-values) without
reference to specific brands...lnterpretation of this type of qualitative, in-depth
in/ormation permits an understanding of consumers' underlying personal motivations
with respect to a given product class" (Reynolds and Gutman, 1988: 12).
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4.17 Levels of Abstraction: Attributes, Consequences and Values
In analysing laddering data (see Chapter Five), each category is usually
characterized as being either an attribute, or a consequence, or a value.
The distinction between cognitive categories should, of course, be based
on a conceptual definition of these terms. However, "The laddering literature
is surprisingly void of such definitions" (Grunert and Grunert, 1995: 217). It is
obvious that coding is a complicated process that gives a lot of latitude to
the researcher. Thus, special attention should be paid to it in terms of
methodological discussion than has been done up till now.
At the time of writing, we are not aware of any study on doctors'
prescribing behaviour that has used the means-end chain theory and its
laddering technique for the definition of an hierarchical cognitive structure
that links attributes, consequences, and personal values. Because of a
scarcity of research in this area, the concepts of attributes, consequences
and values were defmed in accordance with both the review of the
literature (see Chapter III), medical guidelines and medical books for the
management of hypertension (see Chapter Two). Based on these aids, this
iterative coding" was revised with the help of one cardiologist and one
GP.
14 Iterative coding means that a first coding is performed, and the implications of this coding are made
transparent by aids like doctors, medical books and medical guidelines.
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This procedure continued until the coding appeared to be in line not only
with prescribing-relevant cognitive categories widely shared by the
medical community, but also with previous research on drug choice.
The review of the literature, which describes the influence of product
attributes on drug choice, along with medical guidelines and medical
books for the management of hypertension, were used to clarify the
author's definition of the concept included in the lower level of the means-
end chain model (i.e., attributes).
Most research into the prescribing behaviour of GPs examined the relative
importance placed on product attributes such as efficacy or effectiveness,
side effects, compliance with the therapeutic regimen, cost, dosage
schedule, drug interactions, risk of dependency, overdose toxicity, speed
in reducing symptoms, and contraindications of the drug (Freeman et aI.,
1993; Chinburapa and Larson, 1992; 1988; Chinburapa et al., 1987; Segal
and Hepler, 1985; 1982; Epstein et aI., 1984; Zelnio, 1982 Lilja, 1976).
For example, Chinburapa and Larson (1988) asked 98 GPs and
cardiologists to indicate the importance of several attributes in the
treatment of patients with essential hypertension. Although patient
characteristics were not evaluated in their model, results revealed that the
incidence of side effects and drug product efficacy were the two most
important attributes.
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Zelnio (1982) also identified side effects, efficacy, and contra indications
as the most important drug attributes rated by American doctors.
Segal and Hepler (1985) found that outcomes such as disease control,
patient compliance with the therapeutic regimen, and low side-effects
were valued alike for both antihypertensive and antidiabetic therapies,
whereas cost was less important, suggesting that doctors may value
outcomes similarly from disease to disease. In this study, patient
compliance with the therapeutic regimen was classified as an attribute.
However, medical books related to the practical management of
hypertension and medical guidelines stress that the patient compliance
with the therapeutic regimen depends on drug attributes such as efficacy
or effectiveness, side effects, cost, dosage schedule, and drug interactions.
In line with this reasoning, patient compliance with the therapeutic
regimen is a consequence of specific drug attributes, not an attribute.
Adverse drug events, efficacy, and patient characteristics were found to
be important considerations when GPs prescribe medication. Freeman et
a1. (1993) found that patient characteristics such as the patient's age, the
patient's sex and general patient factors were important dimensions on
drug choice. Unfortunately, these researchers did not clarify the concept of
general patient factors. Nevertheless, Freeman and colleagues pointed out
that patient characteristics (i.e., patient's age and sex, as well as general
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patient factors) influence GPs' prescribing decisions for patients with
panic disorder. This reinforces the researcher's conviction that "patient
characteristics" may be a major contribution to GPs' drug prescribing
behaviour.
Most prescribing studies described in Chapter Three sought to establish
whether general measures of doctor attitudes, subjective norms, and
intentions (i.e., measures that did not specify patient characteristics)
could predict a general measure of prescribing behaviour. This method was
developed because "General measures of attitude and prescribing behavior are
easier to collect than patient-specifIC measures, especially given the current state of
most prescription drug information systems" (Lambert et aI., 1997: 1769). As a
result, it is not possible to use previous studies on doctors' prescribing
behaviour for developing the coding process of concepts such as clinical
values and consequences. As these concepts are not available, we decided
to use medical guidelines and medical books for the management of
hypertension as important sources for coding development. That is, the
cognitive concepts of clinical values and consequences, along with
product attributes, particularly those that were listed in the literature
review, were encapsulated within a coding procedure that derived mainly
from medical guidelines and medical books for the management of
hypertension.
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This approach improves the face validity of verbalizations of cognitive
processes because it reduces the subjective judgement of the researcher
(Grunert and Grunert, 1995).
Different medical books related to the practical management of
hypertension (Birkennhager, 1996; Beevers and MacGregor, 1995,
Houston, 1992) subdivide product attributes on 3 dimensions:
1. pharmacological characteristics of the drug;
2. economy of the drug; and
3. mechanism of action.
According to different medical guidelines (WHO-ISO, 1999; 1993; INC
VI, 1997; WHO, 1996), the pharmacological characteristics of the drug
embrace therapeutic properties such as effectiveness, low side-effects,
neutral metabolism, smooth action, tolerability, trough-peak ratio and
safety.
The economy of the drug includes the cost of the treatment: "The cost of
therapy may be a barrier to controlling high blood pressure and should
be an important consideration in selecting antihypertensive medication"
ONC VI, 1997: 2427). Furthermore, the cost of therapy has been a main
concern for health authorities:
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"Various bodies in different countries have pontificated about advising doctors how
treat high blood pressure. This plethora of guidelines has been partly brought about
by the financial pressures related to the cost of treatment and a genuine desire to
improve patients' blood pressure control and their quality of life" (Beevers and
MacGregor, 1995: 171).
Since therapeutic classes have different mechanisms of action, their
proper use should become clear when the patient populations suitable for
each therapeutic class are specified and the usefulness of combination
therapy is establish. Thus, the mechanism of action is also a product
attribute's dimension, particularly for doctors who disagree with a
stepped-care protocol'P:
"The basic concept behind step-care programmes is that what really matters in
antihypertensive treatment is blood pressure reduction per se, not the means or
mechanisms by which bloodpressure is reduced' (Birkennbager, 1996: 155).
Doctors would be aware of product attributes because they receive
information about the physiological effects of therapeutic classes from
their patients who experience such effects of drugs during consumption. In
line with this reasoning, drug experience is also an important attribute on
drug choice because the doctor becomes aware not only of its mechanism
of action, but also its cost and pharmacological properties.
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Moving up the means-end chain from attributes to consequences, we
assume that doctors prescribe drugs for avoiding or reducing patients'
cardiovascular problems: "The primary goal of treatment of the patient with high
blood pressure is to achieve the maximum reduction in the total risk of cardiovascular
morbidity and mortality" (WHO-ISH, 1999: 164).
As a result, the consequence level encapsulates not only cardiovascular
risk reduction for the improvement of the patient's quality of life, but also
less morbidity and mortality. However, it is only possible to obtain these
therapeutic goals, if the patient's compliance with the therapeutic regimen
is a reality:
"Poor adherence to antihypertensive therapy remains a major therapeutic challenge
contributing to the lack of adequate control in more than two thirds of patients with
hypertension" (JNC VI, 1997: 2430).
Patients were found to improve their compliance with the therapeutic
regimen when a therapeutic class has less side effects than other drugs or
when drugs from the main classes available are used as monotherapy. If
this is possible, and no orthostatic hypotension will occur, the patient's
compliance with the therapeutic regimen is a reality.
15 In a stepped-care protocol. therapy should be simple. starting generally with a single diuretic. at low
dose (in an effort to reduce adverse effects). and only later if necessary progressing to more elaborated
therapeutic regimens.
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In line with the reasoning that has been advanced, it is possible to argue
that the consequence level embraces not only doctors' therapeutic goals,
but also strategies for improving patients' compliance with the therapeutic
regimen. Means-end theory (Reynolds and Gutman, 1988) simply suggests
that the way in which the physical attributes of products are linked to
personal values of individuals is the manner by which products gain
personal relevance, essentially, the manner in which meaning is
established. Thus, a physical attribute is important only to the extent to
which this attribute delivers a benefit or consequence to the consumer
through the perception of product usage. The perceived consequence of
product usage, then, is important only to the extent that this consequence
is linked to another higher level, ultimately, to an individual's personal
value orientation.
For the reasons discussed above, a connected hierarchy of translations of
meaning, from the product attributes to how, ultimately, they are
personally meaningful to the prescriber, would seem a logical way of
storing therapeutic information and thus serve as the perceptual lens
through which doctors see and process clinical information. Although this
last point clearly is conjecture, particularly given the early stage of
research in this domain, there is mounting evidence that personal clinical
values should be taken into account in defining and managing drug choice:
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"the model allows the physician's personal values and assessments of clinical
information to be integrated. Thus, the art of making a therapeutic decision has
embedded within it many small judgments, from those based on clinical science to
those based onpersonal values" (Mancuso and Rose, 1987: 1284).
The concept of clinical value is similar to the Mancuso and Rose's
concept of focal point: The clinical criterion is an element of clinical information
in a case that the GP considers to be critical in the assessment of the case and
around which is built the therapeutic approach.
Clinical values or clinical criteria such as patients' demographic
characteristics and concomitant disorders are critical clinical
information on antihypertensive drug choice. That IS, our
conceptualisation of clinical values follows medical guidelines on the
management of hypertension: "Special considerations in the selection of initial
therapy include demographic characteristics and concomitant diseases that may be
beneficially or adversely affected by the antihypertensive agent chosen (INC VI,
1997: 2426). "All available drug classes suitable for the initiation and maintenance
of antihypertensive therapy, but the choice of drugs will be influenced by many
factors:
• the cardiovascular riskfactor profile of the individual patient;
• thepresence of target-organ damage, of clinical cardiovascular disease, renal
disease and diabetes;
• the presence of other co-existing disorders that may either favour or limit the
use of particular classes of antihypertensive drugs" (WHO-ISH, 1999:
167/168).
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As pointed out earlier, medical guidelines suggest 3 main dimensions in
terms of critical clinical values or clinical criteria:
~ blood pressure levels (BP);
» demographic characteristics; and
» concomitant diseases.
Blood pressure levels, both systolic (SBP) and diastolic (DBP), have
been shown to be an important criterion for selecting drug therapy.
However, "Decisions about the management of patients with hypertension should
not be based on the level of blood pressure alone, but also on the presence of other
risk factors, concomitant diseases such as diabetes, target-organ damage, and
cardiovascular or renal disease, as well as other aspects of the patient's personal,
medical and social situation" (WHO-ISH, 1999: 162).
Demographic characteristics such as age, gender and socio-economic
status are critical values on drug choice. In a similar vein, racial and
ethnic minority populations are growing segments of our society. Thus,
race or ethnicity are clinical values that may influence antihypertensive
therapy. All these clinical values may coexist with various other
concomitant diseases such as left ventricular hypertrophy,
cerebrovascular disease, angina, renal disease and others. In other
words, comorbidity is also a critical clinical value for the management of
hypertension.
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4.18 Summary
The wide variety of patients seen in general practice (as a result of the
general accessibility of primary health care) inhibits a strong focus on one
particular antihypertensive guideline. Nevertheless, these guidelines can be
thought of as 'philosophies of prescribing' that guide the therapeutic
approach. This perspective, which is based upon the realisation that
therapeutic products go beyond functional pharmacological properties and
are actually integral to doctors' clinical lives, has resulted in research that
focuses on doctors' "philosophies of prescribing" and on how therapeutic
classes fit into their clinical world, particularly on the relationship between
therapeutic categories and patient typologies. In line with this reasoning,
we focused on drugs prescribed for newly diagnosed cases of
hypertension because of our interest in the initial choice of therapy rather
than switching patterns among the various antihypertensive drugs.
Therefore, the direction of this research - in both theory and empirical
work - will be towards developing an understanding of the GPs' clinical
values that guide first-line antihypertensive drug therapy. As a result, the
research design embraces both qualitative and quantitative approaches.
The former uses the MEC model (Gutman, 1982) and its Laddering
technique (Reynolds and Gutman, 1988) for understanding the relationship
between patient typologies and drug choice.
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The MEe model (Gutman, 1982) and its Laddering technique (Reynolds
and Gutman, 1988) have been discussed in detail. Rather than focus on a
particular level of meanings, the MEe theoretical framework incorporates
all levels into a conceptual model that additionally focuses on the
associations (or derived meanings) between these levels.
The central tenet of the MEe theory is that product, service or behaviour
meaning structures stored in memory, consist of a chain of hierarchically-
related elements. The chain starts with the product, service or behaviour
components (attributes) and establishes a sequence of links with the self
concept (personal values) through the perceived consequences or benefits
produced by certain attributes of the product, service or behaviour. This
forms a means-end chain in that attributes are the means by which the
product, service or behaviour provides the desired consequences or values,
i.e. the ends. As a model of personal relevance, the MEC approach implies
that marketing strategists should create and/or reinforce connections
between product attributes (the means) and self-relevant consequences and
values (the ends). That is, values have a powerful force in governing the
behaviour of individuals in all aspects of their lives. Their use in marketing
planning and strategy could be improved if the behaviour of consumers
could be related to their values. This is the MEC's objective.
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The most common method of measuring means-end chains has been the
Laddering interview technique. This semi-qualitative approach is open to
the respondent's own answers without flooding the interviewer with data,
as other qualitative techniques do. Once means-end data have been
collected, the analysis follows a three-stage process. First, the results from
the laddering interviews are coded in order to develop an implication
matrix. Second, in filling in the implication matrix, individual respondent's
ladders are decomposed into their direct and indirect components, which
are usually presented in a so-called Hierarchical Value Map (HVM).
Third, in order to develop specific marketing strategies, some means-end
chains are selected from the HVM. To obtain the HVM, an new algorithm
was presented. By describing this newly available software (LadderMap)
(Gengler and Reynolds, 1995) the stages of computer analysis of means-
end data were clarified.
This chapter presented a general discussion about the nature of values. As
values are inherently complex, clinical values classification can thus be
approached from many angles. Based on the work of researchers such as
Gutman (1982) and Reynolds and Gutman (1988), we suggested that the
theoretical framework providing the greatest potential for illuminating a
systematic approach to drug choice is the one that links values and
products via "means-end" chains. Thus, clinical values were theoretically
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and methodologically encapsulated within the micro means-end chain
view. By focusing on means-end chain (MEe) theoretical framework,
clinical values research approach represents a long-neglected opportunity
for pharmaceutical marketers. The underlying assumption of this approach
is that values play an important role in guiding GPs' therapeutic choice.
Thus, a "micro" approach using a laddering technique "forces" GPs to
think about the clinical values (i.e., clinical criteria or focal points) they
use to select the therapeutic classes. If this connection can be made,
marketing managers will be in better position to understand how clinical
values or criteria influence drug choice.
To the best of our knowledge. there is no research on doctors'
prescribing behaviour that has used Means-End Theory and the
Laddering approach as the basis for defining patient tvpologies and
subsequent therapeutic approaches (see Appendix Four: Letter from
Richard Bagozzi).
In summary, the author's definitions of the concepts included in the
means-end chain analysis are GPs' real prescribing-relevant cognitive
categories (see Appendix Five: Laddering Interviews and Verbatim
Example).
359
S CHAPTER FIVE Eliciting Portuguese GPs' Prescribing-Relevant
Cognitive Categories: Attributes, Consequences and Clinical Values
s.i Introduction
As indicated on Chapter Three, most of the research on doctors'
prescribing behaviour has placed great emphasis on brand attributes. GPs'
clinical values, in terms of different patient characteristics used to
organise a therapeutic approach, have however been neglected, or have
received scant attention in these studies. Patient characteristics are, by
definition, the centre of clinical reflection (WHO-ISO, 1999; 1993; WHO,
1996; Veterans Health Administration, 1996). Therefore, it does not make
sense to analyse GPs' prescribing behaviour without precisely identify
how doctors organise and retrieve the clinical information that they use to
develop their therapeutic approach. For that reason, Chapter Five examines
the effect of clinical values on GPs' therapeutic approach in primary care.
After defming the substantive and methodological objectives, the purpose
of Chapter Five is to introduce the reader to the data collection methods
used for gaining insights into GPs' therapeutic approach. This Chapter also
includes the preliminary interviews that were organised to support this
exploratory phase of the present research. Finally, Chapter Five presents
Portuguese GPs' prescribing-relevant cognitive categories in terms of
drug attributes, therapeutic consequences and clinical values.
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5.2 The Importance of Laddering Data for Obtaining Substantive and
Methodological Objectives
In this exploratory phase of the research, only two objectives were
considered: a substantive objective and a methodological objective.
Substantively, the research consisted in applying the means-end chain
theory and the laddering technique with the aim of retrieving an excerpt
from doctors' cognitive categories/structures with regard to their
prescribing behaviour. The results obtained from this approach will be
relevant for pharmaceutical marketers interested in drug choice. With this
information, marketers have a better basis for product development and the
design of marketing strategies, particularly segmentation, positioning,
differentiation, and communication strategies.
Methodologically, we are interested in investigating how helpful the
laddering technique is in eliciting excerpts from doctors' cognitive
categories/structures concerning the link between patient characteristics
and antihypertensive therapeutic categories. Specifically, we want to
investigate an important application proposed by Reynolds and Gutman
(1988) who argued that it is possible to segment/categorise "consumers with
respect to their values orientation for a product class or brand" because "the value
orientations in a person's ladder 1IUIJ' serve as the basis for classification"
(Reynolds and Gutman, 1988: 25).
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5.3 Data Collection Methods for Gaining Insights into Portuguese
GPs' Therapeutic Approach: Purposes and Procedures
To accomplish the substantive and methodological objectives mentioned
earlier, a review of previous research was augmented by an exploratory
investigation of the means-ends chain theory and the laddering
approach in the product category of cardiovascular drugs.
Up to this point we have talked for the most part as though research
design decisions in drug choice are based solely on theoretical and
methodological criteria. This is of course highly relevant. However, issues
of practicability play a major role in this kind of research. The medical
field we might wish to select (i.e., primary care) may not be open to study,
for one reason or another; and even if it is (only with a special
authorisation), effective strategies for gaining access to the necessary data
will need to be developed. Similarly, not all the people we wish to talk to,
nor all the contexts we wish to sample, may be accessible; certainly not at
the times we want them to be. The problem of gaining access to data is
particularly serious in therapeutic decision making since one is operating in
settings where the researcher generally has little power, and people have
pressing concerns of their own that often give them little reason to co-
operate. This is true for gaining access to prescribing data both from the
pharmaceutical industry and health authorities (see Chapter ill).
362
Thus, co-operation was obtained both from an international pharmaceutical
company and from Portuguese health authorities. The former provided the
sampling frame of Portuguese GPs, as well as fmancial support to visit
different Portuguese health centres all over the country, while the latter
gave the researcher special authorisation to visit and to be supported by
the local health authorities in connection with the interviewing process.
With their support, not only pharmaceutical company interviews, but also
focus groups, and in-depth interviews were conducted to gain insights into
GPs' prescribing-relevant cognitive categories/structures.
Clearly, pharmaceutical managers and GPs questioning are likely to
provide different kinds of data, and thus will be useful at different stages of
the inquiry. The same applies to the various methods available for gaining
access to prescribing data (patton, 1990). That is, methods were selected
according to different purposes:
5.3.1 Pharmaceutical company interviews
These interviews were conducted because pharmaceutical managers
represent the naturally reflective and objective persons in the prescribing
field. That is, they are respondents who are especially sensitive to the area
of concern. As a result, they are particularly important for understanding
which level(s) of the means-end chain theoretical framework is/are
represented in their approach to the pharmaceutical market.
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5.3.2 Focus Groups
The focus group interview is one of the most frequently used data-
collectionmethods in marketing research (Chisnall, 1992).
As Morgan (1997) suggested, focus group interview is typically used to
explore highly specific issues. In line with this reasoning, focus group
discussion was used to get an initial sense of the dimensions that are of
particular relevance to Portuguese GPs' prescribing decision-making.
An informal setting within different health centres were used to explore a
limited number of "focus questions" on GPs' prescribing behaviour (see
Section 5.4.2). Our approach to focus group discussion focused more on
the meanings embedded either in therapeutic language or, in some
moments, in construction of a patient typology. GPs "got caught up" in the
spirit of group discussion and revealed more than they would in the more
formal interview setting. Concerns are often expressed about whether the
presence of the researcher influences the interaction between members
group that the interaction is no longer authentic (Morgan, 1997).
Nevertheless, as doctors asked questions of each other, it was possible to
come to a consensus that no one GP would have articulated on their own.
Furthermore, the purpose of the focus group method was to evaluate
whether GPs were used to develop a relationship between patient
characteristics and therapeutic approach, particularly drug choice.
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5.3.3 In-Depth Interviews
In-depth interviews, as well as in focus groups interviews, the interview
environment necessary for conversation to take place was given special
attention. Basically, the interview environment was created such that the
GPs were "willing to be introspective and look inside themselves for the underlying
motivations behind their perceptions of a given product class" (Reynolds and
Gutman, 1988: 13). That is, an interview environment was developed to
assist GPs in critically examining the therapeutic assumptions underlying
their drug choice. In other words, we created an interview environment
where GPs were not threatened and thus willing to be introspective in
terms of therapeutic decision-making. We want them to feel as if on a
voyage of therapeutic self-discovery and that the object of the trip was to
revisit daily clinical activity in terms of prescribing behaviour.
Most of the time, these in-depth interviews, as well as focus group
interviews, were developed in the GPs' library room at the health centre.
This is a special room were GPs are able to read a medical article or a
medical book, or simply to rest for a while during a break. In some cases,
the health centre had not a library room. When this happened, GPs were
led into a room especially arranged (easy chairs, dimmed lights) to create
an informal, cosy atmosphere. When this was not possible, the in-depth
interview took place at GPs' clinical office.
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In all cases, the purpose was to make the interviewee feel comfortable and
at ease in order to induce a positive mood state towards talking freely
during the interview.
As with all qualitative research, the interviewer must maintain control of
the in-depth interview. This is not easy because laddering technique is
supposed to elicit attribute-consequence-value associations, which are abstract
concepts. Nevertheless, the reason why an in-depth interviewing technique
was used is quite clear: to help Portuguese GPs think critically about the linkages
between patient characteristics and prescribing behaviour that were found to exist
during the focus group interviews. This was accomplished by "minimizing the
responses options, in essence being as direct as possible with the questioning, while
still following what appears to be an "unstructured" format" (Reynolds and
Gutman, 1988: 13). GPs were forced up the ladder of abstraction mainly
by using probes of the form "why is this important for you?". A ladder was
considered to be at its terminal level when:
» GPs started giving circular answers; and
» GPs were unable or unwilling to answer (a GP question such as "do
you have more questions?" would be assumed as the end of the interview).
In conclusion, to identify Portuguese GPs' cognitive linkages between
patient characteristics and prescribing behaviour we used focus groups
and individual interviews.
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5.4 THE EXPLORATORY STUDY
5.4.1 Pharmaceutical Company Interviews
The pharmaceutical company that supported the fmancial costs of the
exploratory study markets three different therapeutic categories for
hypertension treatment (ace inhibitor, beta blocker, and diuretic) and was
about to lunch a fourth one (angiotensin II antagonist). Interviews were
held individually with the strategic business unit (SBU) director, the senior
product manager for cardiovascular diseases, and in a subsequent phase,
with the senior product manager and the doctor in charge of cardiovascular
diseases within the medical department of the company.
Informal open-ended questions were used for issues such as:
• the recent research on GPs' prescribing behaviour on hypertension;
• GPs' perceptions about the interest of WorId Health Organisation -
International Society of Hypertension (WHO-ISO) or others medical
guidelines for the management of hypertension;
• the cardiovascular market research and other sources of information to
support marketing strategy; and
• the implementation of the communication strategy of the company's
antihypertensive drugs.
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The mam conclusion of these interviews was that the communication
strategyhad been focused on brand attributes only.
The main source of information on doctors' prescribing behaviour has
been the Portuguese subsidiary of International Marketing Service (lMS).
A substantial amount of internal research had been done locally and
internationally by this pharmaceutical company to support the marketing
strategy of the new therapeutic category of angiotensin II antagonist. With
regard to the marketing strategy of this therapeutic category, this private
study reinforces the conviction that an "attribute" approach to brand
position would be more appropriate. An international marketing and
communication programme developed by the international product
manager for the new drug, suggested a strong emphasis should be placed
on brand attributes, particularly tolerability and dosage regimen (i.e.,
once-daily dosing), as well as the new mechanism of action of this
therapeutic category. The last attribute would be used to differentiate the
new angiotensin II brand from other frrst-line, antihypertensive therapies.
From the previous positioning attributes, the company planned to develop
a brand image based on the simplification of antihypertensive therapy
and patient management. Combined with the brand image, the
international marketing strategists of the company planned to develop a
meaningful brand character to obtain a special place in the minds of
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doctors. The following slogan was therefore used to add significant
communication value to the brand:
"The power you need with the tolerabilityyour patients deserve"
(Pharmaceutical Company's International Product Manager, August 1997).
Expectations in terms of the future importance of angiotensin II antagonists
in the cardiovascular market are significant. Despite the tremendous
success of ace inhibitors and calcium antagonists on world-wide
antihypertensive therapy (with 75% of market share), primary and
secondary international market research indicates that there are important
needs that remain unmet in the marketplace, as well as a wealth of
opportunities for new agents. Although there are many effective drugs
currently available for the treatment of hypertension, the medical need for
safe and well-tolerated therapies for a wide range of patients is still not
fully met as indicated in a recent, European, qualitative market research
study. According to the main conclusions of this study, doctors in four
developed European countries revealed the following limitations of
antihypertensive drugs:
• sub-optnnalefficacy;
• interactions with concomitant medications;
• lack of tolerability and negative side effect profile; and
• efficacy vs. side-effects trade-off.
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5.4.2 Focus Group Interviews with General Practitioners (GPs)
Based upon the assumption that doctors' perceptions of antihypertensive
therapy are related to clinical knowledge structures that link drug choice to
patient characteristics, focus group interviews were organised in the south
(Lisbon), and north (OPorto) of the country to test some of the
assumptions derived from the European, qualitative market research study.
The focus group was formed in accordance with guidelines traditionally
followed in the marketing research field (Chisnall, 1992; Kinnear and
Taylor, 1991; Sampson, 1986). Participants were selected locally after an
invitation made by the health centre director, who was contacted in
advance by fax or phone, following rules imposed by local health
authorities. Participants were recruited to fit the demographic profile of
prescribers of cardiovascular drugs in primary care (i.e., GPs).
It has been suggested that ',/or nonconsumer goods research (pertaining to
architects, doctors, industrial purchasers, engineers, investors, contactors, etc.), 6
or 7people may be best for 11IIlXimuminteraction among participants" (Kinnear
and Taylor, 1991: 311). Although the researcher had pointed out to the
local health authorities the importance to have between six and eight
doctors in every focus groups' discussion, only five GPs were present in
the focus group discussion in Lisbon and Oporto. Nevertheless, five focus
group participants are enough when respondents have strong skills on the
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discussion topic:
"There is no correct size for any group. The number of participants may vary
according to the type of participant, the subject matter for discussion and the group
leader's preference. For example, with highly articulate and fluent professional
people, the ideal size is perhaps five or six participants (Sampson, 1986: 33).
In Coimbra, were there is also a prestigious medical school, the number of
GPs was insufficient for a focus group discussion. Nevertheless, the three
GPs that were present had an interesting conversation on drug therapeutic
approach to hypertension and some insightful data were obtained. These
GPs had been practising in the medical profession for between 10 and 20
years. In Lisbon and OPorto, the clinical experience was the same for three
of the five members of the focus groups discussion. In relation to the other
two peers, they were selected to represent one younger and one older
doctor. In other words, it was noticed that the younger had between 5 and
10 years of clinical experience, while the older enjoyed considerable
experience of more than twenty years of medical practice.
All participants were practising medicine in the health centre where the
focus group took place, and our sessions were held towards the end of the
afternoon. The support or identity of the participating pharmaceutical
company was not revealed in the interview.
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The focus-group discussion was initiated after a short presentation of the
research project, its main goals and time-schedule. GPs were previously
informed by the health centre director that the focus-group discussion
would last between forty-five and sixty minutes, and this was emphasised
by the researcher at the very beginning of the conversation. This
introduction was followed by the researcher's invitation to initiate an
informal discussion about hypertension, specifically in relation to the
treatment problems doctors faced in their daily clinical activity. The
discussion was not restricted and GPs started to exchange ideas about
different patients and different therapeutic approaches, including patients'
lifestylemodification and other non-pharmacological decision-making.
Discussion about the therapeutic approach to hypertension in general, and
the drug treatment in particular, centred on doctors' perceptions of the
therapeutic classes used to treat hypertension, attribute differences
between them and indications in terms of thepatient demographic profile.
The researcher's intervention as a moderator covered such topics as
patients' age, gender, lifestyle, cardiovascular risk factors and
comorbidity, plus their influence on drug choice. This approach was in
accordance the figurine described on previous guidelines for the
managementof mild hypertension.
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Emphasis was also placed on the clinical heuristics I that doctors had to
devise in order to manage hypertensive patients.
When a therapeutic class was cited, the attributes used to evaluate clinical
values were discussed, and differences in terms of the drug therapeutic
approach were explored.
The main fmdings of the focus group approach can be summarised into
four vectors:
• The hypertensive patient's demographic profile;
• The concomitant diseases and factors of risk (i.e., comorbidity);
• The therapeutic approach; and
• The GP's demographic profile.
Vectors can be described together as a means of matching the drug's
properties to the individual hypertensive patient according to a supreme
clinical value that: 'there are no diseases, there are patients' .
As mentioned at the beginning of this section, medical guidelines for the
management of mild hypertension were found to influence this individual
patient centred therapeutic approach. Several non-pharmacological
interventions were put forward for the primary prevention of hypertension.
'Basically, heuristics are simple "if ... , then ..." propositions that connect an event with an action.
"Heuristics may be stored in memory like mini decisions plans or scripts that are applied fairly
automatically to information encountered in the environment" (peter and Olson, 1987: 250).
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However, participants recognised that lifestyle modifications were often
difficult to encourage at large, and compliance to such recommendations
was frequently poor over the long term. Consequently, GPs stressed that in
most cases a combination of non-pharmacological interventions and a drug
therapeutic approach was necessary.
Once the diagnosis of essential or primary hypertension was reached,
several different risk factors for patient cardiovascular disease were
analysed to defme the therapeutic approach:
• Age"
• Gender"
• Family history of premature cardiovascular disease"
• Previous cardiovascular events"
• Previous cerebrovascular events"
• Left ventricular hypertrophy
• Systolic blood pressure
• Diastolic blood pressure
• Lifestyle (i.e., nutritional factors; sedentary lifestyle; smoking; alcohol)
• Dyslipidaemia (i.e., high total and low-density lipoprotein-cholesterol
and low high-density lipoprotein-cholesterol)
• Obesity
• Diabetes
• Renal disease
• Micro-albuminuria
GPs were unanimous in stressing that some of these factors (i.e., with the
sign .) cannot be modified, but are relevant for drug choice.
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Ace inhibitors and diuretics were found the two most important
therapeutic categories for most hypertensive patients. The former were
mentioned more often in relation to hypertensive patients with
obesity/diabetes/renal disease, while the latter were preferred in the case
of elderly hypertensive patients. The use of diuretics was, however, a
controversial subject as was opinion concerning the best therapeutic
approach depending on the patient's age and gender.
Beta blockers were attached mostly to young hypertensive patients, while
calcium antagonists were only mentioned in the case of elderly
hypertensive patients with angina. However, ace inhibitors were also
referred to as a possible antihypertensive solution for middle-aged and
elderly patients with dyslipidaemia (Le., subjects with either isolated
elevated triglycerides, low HDL cholesterol or elevated LDL cholesterol,
or a combination of the above that are associated with an increased
incidence of coronary heart disease). In this case, diuretics proved to be
inappropriate. The association in a fixed dose of ace inhibitor and
diuretic was a controversial therapeutic solution in the case of elderly
patients with high blood pressure, unless congestive heart failure was
noticed. In this case, some GPs suggested the use of ace inhibitors in
monotherapy, followed, if necessary, by the association in a fixed dose of
ace inhibitor and diuretic.
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5.4.3 Doctors Individual Interviews
A convenience sample of seven doctors was defined to test the concepts
obtained from the focus group approach, in accordance with the laddering
approach. After these interviews, the main phase of the field work was
initiated. This second phase started in April 1997, one week after the focus
group interview. The main phase of these interviews was developed
between May 1997 and the middle December 1997, with an interruption in
August 1997, required by the Algarve Health Region Administration. The
strong increase in the number of tourists during summer time keeps doctors
very busy in the third quarter of the year. A new opportunity for
developing laddering interviews in the Algarve in the last quarter of 1997,
was also cancelled because of the stormy weather.
Several health centres were randomly selected from a framework made
available by local health authorities. Participant doctors were then
recruited with the help of the health centre directors who invited their
peers to collaborate in a study. To stimulate and encourage doctors'
participation, health centre directors had to mention to their peers that the
study was authorised previously by central and regional health authorities.
The special authorisation, as well as the explanation of the goals of the
study, were described by the health centre director to GPs who were still
free to reject any type of collaboration.
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In total, 317 doctors from different health region administrations agreed to
talk with the researcher. Lisbon and Tagus Valley Health Region, which is
the most important one in terms of patients and number of doctors,
contributed 173 interviews. In the North Health Region 86 interviews were
carried out, while the Centre Health Region only offered 58. However, of
these 317 interviews, only 113 (35%), actually took place under the
appropriate conditions needed in order to obtain the desired hierarchical
levels proposed by the Means-End Chain Theory (Gutman, 1982) (see
Table 5.1).
TABLE 5.1: Formal and Laddering Interviews
REALm FORMAL LADDERING TOTAL
REGION INTERVIEW INTERVIEW
Lisbon and 127 (73%) 46 (27%) 173
Tag"s VaHey
(62%) _(4I%) (55%)
North 52 (61%) 34 (39%) 86
(26%) (30%) (27%)
Centre 25 (43%) 33 (57%) 58
(12%) (29%) (18%)
TOTAL 204 (64%) 113 (36%) 317
(100%) (100%) (100%)
The other 204 were considered formal interviews, and could be
characterised as a friendly informal conversation about hypertension in
general, mainly focus on patient characteristics according to the GPs'
annual report in hypertension.
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5.4.4 Formal Interviews
As pointed out earlier, the formal interviews were found inappropriate for
the development of an hierarchical structure of attributes, consequences
and values. The 'symptoms' of this interviewing reality were noticed when
most doctors produced superficial responses to avoid introspection about
the real reasons underlying their prescribing behaviour.
In Lisbon and Tagus Valley Health Region, 127 of the 173 (73%) GPs
were not very keen to discuss their prescribing behaviour deeply. In the
North Health Region this figure was a little bit lower (61%) than in the
Lisbon and Tagus Valley Health Region, while in the Centre Health
Region the laddering rejection was only 43%.
It is our belief that these low figures are a consequence of an investigation
that was launched by the police in the second quarter of 1997, when
sought to detect any relationships between prescribing and unauthorised
gifts, financial rewards or other incentives given by the pharmaceutical
companies. As a result, the topic of the conversation was not the most
convenient because some doctors were suspicious about the real aims of
the research project.
As pointed out earlier, the focus of both the formal interview and laddering
interview were patient centred according to the GP annual report in
hypertension (see Table 5.2).
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TABLE 5.2: Hypertensive Patients Report
• Centre Health Region - Aveiro Health Sub-Region
• Ovar Health Centre - 1996Report
AGE MALE FEMALE MALE FEMALE
< 45 0 0 0 0
15 - 44 170 204 121 156
45 -64 827 1254 622 999
>=65 939 1501 717 1177
SUB-TOTAL 1936 2959 1460 2332
TOTAL 4895 3792
In accordance to Table 5.2 - Hypertensive Patients Report, GPs argued that
male hypertension appears to be frequently under-treated. Two main
heuristics were used to organise the therapeutic approach: age and gender.
These heuristics were used to 'force' doctors to identify the higher-ordered
concepts. This laddering approach was found to be centred on patient
typologies according to the GPs' annual report on hypertension.
The annual report was used in subsequent interviews as the introductory
topic of conversation, in order to create an interview environment familiar
to GPs. This personally meaningful clinical context provided a more
suitable approach for laddering to proceed: "...the best answer to the level of
focus seems to lie in evoking a relevant situation into which the respondent can
project him- or herself. This gives the best assurance that wherever laddering starts,
meaningful connections between elements will be obtained" (Gutman, 1991:
147).
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Doctors were aware that because the researcher was not an expert in
hypertension, the interviewing process would include some questions that
would seem somewhat obvious and possible even naive. This tendency to
create a slight sense of vulnerability on the part of the interviewer was well
accepted and led to a conducive environment for the interview. However,
this effort was not enough to produce substantive information in terms of
the means-end chain approach.
The attempt to use the heuristics age and gender in order to establish
means-end chains proved unsuccessful. When faced with the question
"Why are age and gender important to pharmacological decision?"
Doctors pointed out that these two factors and others like concomitant
disease (i.e., comorbidity) guide drug choice. When the researcher probed
as to "Why are all these factors important to the pharmacological
decision?", doctors argued that therapeutic classes had different
mechanisms of action which determine contraindications for their use in
some patients. From this point on, we tried to establish a hierarchical
means-end chain by asking again "Why are contraindications of
therapeutic classes important for your pharmacological decision ?". Most
doctors responded that a cautious approach to drug is required because a
significant number of elderly hypertensive patients present other
cardiovascular problems.
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To push the respondent up or down in the means-end ladder, the following
question was applied: "Why do you use different therapeutic classes for
elderly hypertensive patients with cardiovascular problems ?". If the GP
was unable to link to adjacent concepts between a specific hypertensive
patient and a drug class, the subsequent question would be more direct:
"Why do you, or do you not, prescribe diuretics for hypertensive
patients?" In this case, neither the positive nor the negative laddering
approach produced satisfactory "chunks/" of information. The common
answer was that the use of diuretics or other therapeutic categories in the
treatment of hypertension depends on patient characteristics. Different
free-elicitation strategies were performed to obtain information about the
cognitive structures of doctors, changing from differences by occasion to
triadic sorting. In the former, an age-regression contrast probe was
advanced for encouraging doctors to think critically about, and be able to
verbalise, their prescribing behaviour. Moving respondents backwards in
time was also found not suitable for these doctors. The same result was
obtained with the third-person probe approach, citing national or local
opinion leaders with opposite views on hypertension treatment.
2Individual concepts that are perceived to be similar in some relevant way are grouped or cbunked
together by consumers' cognitive processing systems. "A chunk is an abstract meaning with
"psychological significance" to the person" (peter and Olson, 1987: 82).
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In the triadic sorts, each GP was asked to think back to the three most
recent hypertensive patients in order to know "Why, and which, would you
treat most differently than the other two?". However, no important feed-
back was obtained in terms of the means-end chain approach.
5.4.5Differences Between Formal and Laddering Interviews
The looped conversation described above was a clear indication that the
majority of doctors were not interested on prescribing introspection.
Though doctor ladder productivity was not a success in 650/0 of all the
interviews, the same techniques described earlier produced a very
significant contribution to the laddering process in most of the remaining
respondents. This difference includes not only the substance of the elicited
information but also the time that was spend in each interview. Formal
interviews lasted for 15 up to 30 minutes, while faddering interviews have
varied between 40 minutes up to 90 minutes. In most cases, the time of a
faddering interview may be included in a interval of 50 up to 60 minutes.
Doctors who were interviewed after the end of their daily activity,
particularly those who finished in the afternoon period, were found to
spend more time with the researcher. By contrast, GPs who were
interviewed before their daily clinical work started, particularly in the
morning, were less generous in their time allocation. In a normal day of
work, three up to five formal and faddering interviews were obtained.
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5.4.6 Ladder Characteristics
The 113 respondents whose interviews have developed clear links
between the hierarchical adjacent levels of attributes, consequences, and
values provided between 3 and 7 ladders each, and a total of 548 ladders,
which represents an average of 4.85 ladders per respondent (Table 5.3).
Table 5.3: Number of Elicited Ladders
W/)~lil~~'1I~~'~~"';1~'f-\'JI'{lJ:.1tI':§~tW':'~'~~~~0?*~~~~r.~~41\;iII'lttf.:;;~·~'ri'?t.\{j'<f"it';:;;r\·.!I&"'I"I1~l:;:t~fi"9fX7n!'''''~D
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3 3
4 29
5 65
6 14
7 2
TOTAL NUMBER OF RESPONDENTS: 113
TOTAL NUMBER OF LADDERS: 3*3 + 4*29 + 5*65 + 6*14 + 7*2=548
AVERAGE NUMBER of LADDERS per RESPONDENT: 548/113=4.85
The average number of ladders per respondent was almost the double that
found in recent research where the same algorithm was used (e.g.,
Frauman et aI., 1998; Klenosky et aI., 1993). The number of ladders per
respondent corresponds directly with the number of different therapeutic
classes that GPs usually prescribe for hypertension. In other words, ace
inhibitors, diuretics, beta blockers, calcium antagonists, and association
in fixed dose of ace inhibitors and diuretics are the most cornmon
therapeutic classes prescribed by GPs to treat hypertension. However,
some innovative doctors may have a larger set of drugs that includes not
only the previous therapeutic categories but also the new therapeutic
383
category of angiotensin II antagonists. In contrast to these larger sets of
therapeutic categories, some doctors were found not particularly interested
in all possible solutions. The intention to prescribe all the therapeutic
categories is, therefore, not a homogeneous reality, since doctors have
different pharmacological approaches to the same patient characteristics.
Furthermore, hypertensive patients present not only different demographic
characteristics, but also different associated diseases or risk factors. As a
result, it is possible to argue that the number of ladders per respondent is a
function of the number of therapeutic categories attached to those patient
characteristics elicited during the interview. In most cases, the number of
hypertensive patients described by doctors in each ladder is greater than
three. Therefore, each respondent was able to describe an average of
fifteen different hypertensive patients during all the interview.
5.4.7 Coding Laddering Interviews
The laddering interviews confirmed that the General Practitioners'
therapeutic approach of hypertension is based on patients' demographic
profile, particularly age, gender, race/ethnicity, and socio-economic
status. Some risk factors, such as heredity, genetic factors, body weight,
central and portal obesity and metabolic balance (i.e., cholesterol levels),
and nutritional factors, were also found relevant in drug choice.
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Furthermore, patients with hypertension and other coexisting diseases
(e.g., comorbidity) were also clinical clues to the therapeutic approach.
Faced with this complexity, we decided to simply use the coding process
in accordance with the medical guidelines for the management of
hypertension and prevention of associated cardiovascular disorders.
Therefore, the process of coding the laddering interviews, in terms of the
separation between clinical values, attributes of products, and
consequences of their use was made less complex. Nevertheless, the
coding process was discussed with a Portuguese opinion leader in the
treatment of hypertension, Dr. Pedro Marques da Silva, who is in charge
of hypertension and dyslipidaemia consultation at St. Marta Hospital in
Lisbon.
Categories were found to follow several different medical protocols in
terms of diagnosis and therapeutic approach (WHO-ISH, 1999; 1993;
Silva 1997;Veterans Health Administration, 1996;WHO, 1996).
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5.4.8 Laddering Results: The GP's Hierarchical Means-End Chain
The GPs' therapeutic approach follows a logical sequence of steps In
which doctors identify the patient's demographic and pathological
characteristics before any prescribing decision is made.
Drug choice follows the hierarchical sequence of clinical values-attribute-
consequence. As a result, coding laddering data will be presented In
accordance to the GPs' hierarchical means-end chain (Table 5.4).
TABLE 5.4: The GP's Hierarchical Means-End Chain
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CLINICAL VALUES 12
PRODUCT ATTRIBUTES 11
CONSEQUENCES 8
TOTAL 31
Based on Table 5.4, it is possible to argue that clinical values have a
critical importance for the GP's hierarchical means-end chain in terms of
the number of categories. It is also important to point out that most of
these categories represent patient typologies. The other two hierarchical
levels have also a significant number of categories.
In order to facilitate the understanding of the Hierarchical Value Map
(HVM), all these 31 categories will be described.
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5.4.8.1 Clinical Values
Twelve categories were created within the clinical value dimension.
Table 5.5: The Value Dimension
~~!"b~"1)"m~'Jf l~'i"ll!:r01'ifi~\~n~r~~~af:;~it1wmT~ljff:ri;1\~~;~'i", •.• ,'" Jam _1,&~ ~",,,,,~,_"",;~~"':''r>,,t;t".b,:w,~,_,~.Ji~,;.Jl,,b.,' '-..'''''~ ~ ~~,~!lI •.,jo.;' ,~"', ~,.;,.;.... "","\" _,,:,J. "
Age (314) 3
Age and Comorbidity (482) 5
Age and Drug Combination Therapy (90) 1
Age and Gender (107) 3
Age and Level of Blood Pressure (46) 1
Age and Preventive Effect (8) 1
Age and Socio-Economic Status (27) 1
Age and Treatment (24) 1
Age and Type of Blood Pressure (63) 1
Age/Gender/Comorbidity (145) 2
Comorbidity (207) 10
RacelEthnicity (6) 1
The concepts of age, gender, and comorbidity when isolated or in
association, were the main demographic and clinical values used by GPs.
The demographic profile of hypertensive patients, particularly age and
gender were found to be relevant clinical values. However, age turned to
be the most important heuristic in terms of prescribing behaviour.
Table 5.6: The Age Dimension
~rl :;l·r}).{:.)?J~':~:.:'~~'l:','~~.:} ~'5;'(~t,'~"'~;'#i r,~I,~~gt1~{'1(~;;,~~;~.~}~~1;.i$~~~:~~~Jjft'1:,~''''t i.;';)';'::.' J/" i~Yv~ 14;'\ ':: ~:,rf~~~j;~.,~, ~:!~:k- ;~,~~.J;'~.' .I)~:~ ~~~\1
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YOUNG-ADULT 104
MIDDLE-AGED 108
ELDERLY 102
TOTAL 314
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Doctors referred to three levels of hypertensive patients in terms of age:
• Young-Adult (less than 45 years old)
• Middle-Aged (45 - 64 years old)
• Elderly (65 or more years old)
These three levels of age are important descriptors in terms of prescribing
behaviour. The importance of the category indicates the number of times
these levels of age were cited by respondents during the ladder
development.
The concept of age combined with comorbidity is the most important one
in terms of value presence within the different ladders. In this case all the
diseases associated with hypertension are most common in elderly
patients.
Table 5.7: The Age and Comorbidity (Elderly Patients) Dimensions
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ANGINA 114
CEREBROVASCULAR DISEASE 112
PERIPHERAL VASCULAR DISEASE 39
RENAL INSUFFICIENCY 106
CONGESTIVE HEART FAILURE 111
TOTAL 482
Four out of five represent elderly patients with hypertension and other
common coexisting diseases: angina, cerebrovascular disease, congestive
heartfailure, and renal insufficiency.
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If an elderly hypertensive patient has no comorbidity associated with
hypertension, doctors usually prescribe diuretics or ace inhibitors.
However, if the same patient has angina combined with hypertension,
calcium antagonists will be prescribed instead.
Gender is another important descriptor in terms of prescribing behaviour,
particularly in middle-aged (i.e., age) hypertensive woman (i.e., gender) in
perimenopausic' period as Table 5.8 suggests.
Table 5.8: The Age and Gender Dimensions
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HYPERTENSIVE WOMAN IN 92
PERIMENOPAUSIC PERIOD
YOUNG-ADULT WOMAN 6
YOUNG-ADULT MAN 9
TOTAL , 107
GPs differentiated the hypertensive woman in perimenopausic period
from other middle-aged patients with hypertension because their
prescribing behaviour may change according to this sensitive and crucial
period in a woman's life. GPs pointed out the fact that, before menopause,
most women are at a 50% lower risk of cardiovascular disease than men.
However, when the woman reaches menopause, the risk of cardiac disease
or depression becomes very high. Therefore, psychological problems such
as anxiety or depression, (i.e., comorbidity) are not rare.
3Current medical knowledge holds that the average age for peri menopause, a period of changing
ovarian function, although a discrete point in time, is about 51 years.
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Obesity also is sometimes noticed.
Table 5.9: The Age/Gender/Comorbidity Dimensions
TOTAL
47
ANXIETY!DEPRESSION 98
OBESITY
145
Comorbidity alone encapsulates several independent patient factors of
risk, diseases and characteristics that are, of themselves, important
discriminators in terms of prescribing behaviour. This is a crucial step,
since all the subsequent procedures used to defme the therapeutic
approach depend on these clinical conditions that still present risk of
cardiovascular disease. Table 5.10 identifies the most important of these
discriminators.
Table 5.10: Hypertensive Patients with Comorbidity
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DIABETESIDYSLIPIDAEMIA 95
LEFT VENTRICULAR HYPERTROPHY 29
CENTRAL OR PORTAL OBESITY 26
GOUT 6
INTELECTUAL ACTMTY 2
TACHIARRHYTHMIAS 18
DRY COUGH 8
DYSLIPIDAEMIA 12
PROST ATISM PROBLEMS 1
DIABETES 10
TOTAL 207
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Comorbidity alone has ten different sub-categories. However, intellectual
activity is not a clinical problem. Its inclusion into comorbidity is based on
the assumption that therapy should be tailored to individual characteristics
of the hypertensive patient (reported only by two GPs).
Diabetes and dyslipidaemia associated with hypertension are by far the
most important discriminators of drug choice. All the other concepts
presented in Table 5.10 are attached to hypertension in elderly patients.
From all these clinical values, it is possible to reinforce the importance of
different characteristics that influence drug treatment in elderly
hypertensive patients. For example, age and drug combination therapy
encapsulates elderly hypertensive patients whose blood pressure (BP)
requires more than just one therapeutic class to normalise the BP values.
In elderly patients, age and type of BP and age and level of BP were also
found important discriminators in terms of drug therapeutic approach. The
former distinguishes systolic BP from other types of hypertension, while
the latter assumes the treatment of borderline hypertension in a different
way from mild or moderate hypertension.
Elderly hypertensive patients with low income (i.e., age and SOCIO-
economic) may also be treated with less expensive therapeutic categories.
Other drug treatments for non-cardiovascular diseases that elderly
hypertensive patients require was also identified as a clinical value.
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Although the Portuguese population is almost all Caucasian, a very small
percentage of African citizens from former Portuguese colonies have been
working in Portugal. As a result, a few doctors reported race as another
clinical value that influences their prescribing behaviour. For example,
these GPs suggested that the ethnicity factor is important in defming the
anti-hypertensive treatment because black patients were found "to
respond" better to calcium antagonists rather than to ace inhibitors.
It has already been pointed out that the clinical value dimension
encapsulates several patient typologies whose configuration derives from
all the clinical values that have been described. This complexity has been
recognised by specialised institutions on the management of hypertension:
"In preparing these guidelines, the World Health OrganizlltionlInternational
Society of Hypertension (WHOnSH) Sub-Committee was keenly aware that there
are marked differences between individual patients with similar levels of
hypertension, which have important implications for decisions concerning
treatment Hypertensive patients differ with respect to age, blood pressure
elevation, organ damage and concomitant risk factors and diseases, and
they live in societies in which cardiovascularrisk and economic resources also
differ widely"(WHO-ISO, 1993: 905).
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5.4.8.2 Pharmaceutical Product Attributes
Eleven different pharmaceutical product attributes were mentioned to
justify the intention to prescribe six different therapeutic categories, which
were found relevant in terms of attributes such as effectiveness, low side-
effects and tolerability (Table 5.11).
Table 5.11: The Attribute Dimension
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Additive Hypotensive Effect (92) Association between Diuretic and Ace
Inhibitor (ADAn
Drug Experience (78) Diuretics and Beta Blockers
Effectiveness (546) Diuretics; Beta Blockers; Ace
Inhibitors; Calcium Antagonists; and
ADAI
Low Cost (193) Diuretics and Beta Blockers
Low Side-Effects (189) Diuretics; Beta Blockers; Ace
Inhibitors; Calcium Anta_gonists
Neutral Metabolism (27) Beta Blockers; Ace Inhibitors; Calcium
Antagonists
New Mechanism of Action (8) Angiotensin II Antagonists
Safety (95) Ace Inhibitors; Calcium Antagonists
Smooth Action (40) Diuretics; Ace Inhibitors; Calcium
Ant~onists
Tolerability (146) Diuretics; Beta Blockers; Ace
Inhibitors; Calcium Antagonists
Trough-Peak Ratio (48) Ace Inhibitors
By just taking a quick glance at the above Table, one can see that some
figures are very high. For example, the effectiveness attribute has a value
of 546 attached to it. This value is an indication of redundant hierarchical
connections. That is, GPs mentioned an association between effectiveness
and the adjacent concept several times in multiple different ladders
gathered in the course of the interview. This is also true for the
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consequence elicitation. However, a different reality was obtained from
the clinical value dimension. That is, the multiple ladders that were
gathered from each respondent have no redundant clinical values. and
they represent different patient categories.
Effectiveness is by far the most important attribute that GPs reported.
The value of 546 indicates that effectiveness was almost always present
in any ladder developed by the 113 respondents. This finding suggests that
all the therapeutic categories are considered effective in the treatment of
hypertension. Otherwise it would not make sense to use them. This
indicates that the attribute effectiveness is not appropriate for
distinguishingbetween the therapeutic classes.
The second most important attribute is low cost (193) which is associated
exclusively to diuretics and beta blockers. The same reality can be found
with drug experience (78), which is the seventh most important attribute.
The intimate connection between low cost and drug experience that has
been established with diuretics and beta blockers indicates that doctors are
aware not only that these two therapeutic classes are have been used for
decades, but also they are not expensive. However, it does not mean that
these attributes have discriminant power. Itmeans only that for specific
patients characteristics (i.e., clinical values) doctors prescribe these
therapeutic categories because they have the appropriate pharmacological
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characteristics. When asked "Why", doctors referred to different attributes
that diuretics and beta blockers contain, including effectiveness, low cost,
and drug experience in the cardiovascular market, among others.
The third most important attribute is low side-effects (189), which have
been attached to Diuretics, Beta Blockers, Ace Inhibitors, and Calcium
Antagonists. However, with a closer inspection of ladders, it is possible to
detect that both antagonists of angiotensin II and association of diuretic
with ace inhibitor have a lower incidence of side-effects than the
previous therapeutic categories. The former, given its new mechanism of
action, is considered an alternative treatment (consequence) when ace
inhibitors cause side-effects such as dry cough (i.e., side-effect). The
latter, has been presented in several ladders as an important therapeutic
class to reduce the adverse effects (consequence) of both therapeutic
categories.
The fourth most important attribute is tolerability (146). Conceptually, it
is possible to distinguish tolerability from low side-effects because the
former includes not only the latter, but also a low interaction with other
drug treatment that patients have to take. Again, diuretics, beta blockers,
ace inhibitors, and calcium antagonists are well tolerated. The same is true
for angiotensin II antagonists and for the association between the diuretic
and ace inhibitor ifwe analyse the consequences of their use.
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The 1lI!l! most important attribute is safety (95). However, this attribute is
only mentioned by some doctors when ace inhibitors and calcium
antagonists are analysed. It is reasonable to speculate that some doctors
have the perception that these therapeutic categories are less risky in terms
of contraindications than diuretics and beta blockers. If this assumption is
true, it would be possible to say that some doctors prefer to use ace
inhibitors and calcium antagonists rather than diuretics and beta blockers.
The sixth most important attribute is the additive hypotensive effect (92),
which is only attached to the association between the diuretic and ace
inhibitor. In short, it appears that doctors prefer to use the association in
fixed dose of diuretic and ace inhibitor when just one of the components is
not enough to reduce blood pressure values. This indicates that doctors
consider monotherapy and compliance with the drug regimen as
important consequences to be obtained with the use of some therapeutic
classes to treat hypertensive patients, as explained later in this section.
According to the respondents, the reason is easy to understand: poor
adherence to antihypertensive therapy remains a major therapeutic
challenge, contributing to the lack of adequate blood pressure control in a
significant number of patients with hypertension.
The seventh most important attribute, which is the drug experience, has
already been mentioned.
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The eighth most important attribute, trough-peak rati04 (48), reinforces
the importance of monotherapy and compliance, in this case with the use
of more recent ace inhibitors.
The ninth most important attribute, the smooth action (40), is attached to
more recent diuretics, ace inhibitors, and calcium antagonists, particularly
the last two therapeutic classes.
The tenth most important attribute, neutral metabolism (27), although a
pharmacological characteristic present in some calcium antagonists and
beta blockers, is almost exclusive to ace inhibitors. Diuretics were not
mentioned. As with the safety attribute, it appears that some doctors prefer
to prescribe ace inhibitors rather than diuretics to reduce blood pressure.
The final attribute, the new mechanism of action (8), is only mentioned
by innovative GPs, who have been prescribing the new therapeutic
category of antagonists of the angiotensin II.
4 "Recently, the American Food Drug Administration (F&D) has claimed that a new drug in order to
be registered for once-a-day dosing must satisfy a new criterion: the trough/peak ratio. According to
this new criterion, the blood pressure reduction at the moment of the administration of the drug at the
end of the intervals between the doses (trough) must be at least 50% of the maximum blood pressure
preduction (peak)" (Birkenhager, 1996: 157).
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5.4.8.3 Pharmaceutical Product Consequences
The 113 GPs who were interviewed reported eight different consequences.
Four of these categories are particularly relevant to the context of the
consequence dimension (1) cardiovascular risk reduction (2) less morbidity
and mortality; (3) compliance; (4) quality of life. The redundancy noticed
in these four categories means that there is a strong homogeneity across
respondents in terms of consequences. Table 5.12 presents the listing of
the eight consequences.
Table 5.12: CONSEQUENCES
ALTERNATIVE TREATMENT (1)
COMPLIANCE (498)
1
CARDIOVASCULAR RISK REDUCfION (556) 3
1
LESS MORBIDITY and MORTALITY (547) 1
LESS SIDE-EFFECfS (56) 1
MONOTHERAPY (71) 1
NO ORTHOSTATIC HYPOTENSION (42) 1
QUALITY OF LIFE (386) 1
Only the consequence concept of cardiovascular risk reduction, which is the
most important consequence concept, with a permanent presence in all
ladders, has more than one category. As a result, the figure of 556 attached
to cardiovascular risk reduction is bigger than the number of ladders (548).
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The results mean that some doctors presented a larger ladder in terms of
consequences that include not only the sub-category "greater protection",
but also "24 Hours BP Control" and "do not aggravate co-existing cardiovascular
problems", to reinforce the importance of cardiovascular risk reduction, as
represented in Table 5.13.
Table 5.13: Cardiovascular Risk Reduction
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DO NOT AGGRAVATE CO-EXISTING 25
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TOTAL 556
It should be noted that only the consequence dimension, and not the
categories, are represented in the fmal hierarchical value map (HVM).
That is, redundant "chunks of meaning" that are elicited from the ladders,
are "absorbed" by the specific concept. Repeated associations between
adjacent concepts in the different ladders obtained from the same
respondent, are not included into the implication matrix. When
constructing the matrix, LadderMap counts the redundant association only
once per respondent in order to guarantee that the fmal HVM is not
influenced by sub-categories that encapsulate redundant information.
The most representative category within the concept of cardiovascular risk
reduction is that of "greater protection". This category, as well as the
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other two, reinforce the importance of the anti-hypertensive therapeutic
categories as a means by which GPs improve cardiovascular protection
against the risk that high blood pressure represents for different patients.
Along with cardiovascular risk reduction, consequence concepts like less
morbidity, less mortality and compliance play an important role in high
blood pressure treatment. The former is, by itself, a sub-consequence of
cardiovascular risk reduction, while the latter is of great importance in
obtaining the others. All of them are important for improving the quality of
life of the hypertensive patient.
Other consequence concepts are not as important as those described
above. However, what seems to emerge from a closer analysis of all them,
from monotherapy to less side effects and no orthostatic hypotension, is
the importance of improving patient compliance with the prescribed
treatment. The same is true for the least important consequence concept,
alternative treatment. In this case, GPs who intend to prescribe the new
therapeutic category of antagonists of angiotensin II try to avoid or
reduce side-effects (e.g., dry cough), derived from the use of ace inhibitors
in certain hypertensive patients. Having said that, it should be added that
this reasoning reinforces the intimate connection between compliance, less
morbidity and mortality and cardiovascular risk reduction, described
above.
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5.4.9 From the Implication Matrix to the Hierarchical Value Map
The goal at content code level of analysis was to focus on meanings
central to the purpose of the research, in order to obtain strong reliability in
terms of relationships between the categories. However, these ladders
were "purified" in order to avoid respondents naming an association
between two hierarchical concepts several times in the different ladders
that were elicited. To obtain a meaningful, uncluttered hierarchical value
map (HVM), all the redundant connections between adjacent attribute,
consequence and value (ACV) hierarchical concepts were eliminated from
the aggregate implicationmatrix.
Once these master codes were established as an initial process to embrace
the importante distinctions that respondents have used to discriminate
among products, numbers were assigned to these categories. These
numbers were then used to score each element in each ladder, thereby
producing an aggregate implication matrix with rows representing an
individual respondent's ladder (doctors have multiple ladders and thus
multiple rows) and the hierarchical categories within the ladder
corresponding to the consecutive column designations. Thus, the number
of columns in the square matrix corresponds to the 31 content codes that
were established.
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As mentioned earlier, the movement from the aggregate implication matrix
to the HVM is based on 31 content codes previously defmed:
Attributes (35%) *
(AI) Effectiveness
(A2) Low Cost
(A3) Low Side-Effects
(A4) Tolerability
(AS) Safety
(A6) Additive Hypotensive Effect
(A7) Drug Experience
(A8) Through-Peak Ratio
(A9) Smooth Action
(AIO)Neutral Metabolism
(All) New Mechanism of Action
Consequences/Benefiu (26%) *
(CI2) Cardiovascular Risk reduction
(CI3) Less Morbidity and Mortality
(CI4) Compliance
(CIS) Quality of Life
(CI6) Monotherapy
(CI7) Less Side-Effects
(CIS) No Orthostatic Hypotension
(CI9) Alternative Treatment
Values (39%)*
(V20) Age and Comorbidity
(V21) Age
(V22) Comorbidity
(V23) Age/Gender/Comorbidity
(V24) Age and Gender
(V2S) Age and Drug Combination Therapy
(V26) Age and Type of BP
(V27) Age and Level of BP
(V28) Age and Socio-Economic
(V29) Age and Treatment
(V30) Age and Preventive Effect
(V31) RacelEthnicity
• The symbol * refers to the percentage represented by the number of
each ACV hierarchical concept to the total number of concepts.
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In order to provide a clear picture of the dominant relationships among the
31 content codes, the implication matrix was splitted into five sub-tables:
Table 5.14a - Implication Matrix for Therapeutic Category Approach
To Attributes
From Al A2 A3 A4 A5 A6 A7 A8 A9 AIO All
Attributes
Al 104.107 59.40 56.81 35.72 90.90 10.63 34.47 19.35 17.25 7.7
A2 6.8 24.47 17.46 57.57 3.3 1.1
A3 5.5 11.11 25.26 5.6 3.3 1.3
A4 1.1 1.1 30.31 . 23.24 1.1 1.2 5.6 2.2
A5 25.27 8.8 2.2 1.1 2.2
A6
A7 2.2 5.6 24.26 32.33
A8 6.6 1.2
A9 5.5 1.1
AIO 1.1 .3 2.2
A11 7.7 1.113 .113 3.113 .106 .70 2.56 .37 .7 .1
Table S.14b - Implication Matrix for the Therapeutic Category Approacb
To Consequences
From C12 Cl3 Cl4 Cl5 Cl6 Cl7 Cl8 Cl9
Attributes
Al 1.113 .113 3.113 .106 .70 2.56 .37 .7
A2 .107 .107 55.106 .82 .3
A3 .90 .90 78.89 .67 .3
A4 1.81 .81 53.80 .65 .6
A5 1.72 .71 42.69 .53 .1
A6 .88 .90 1. 87 .65 68.70 22.54 .1
A7 2.63 .63 8.61 .43
A8 39.48 .48 1.20 .35 1.12
A9 .34 .35 .32 .21 30.33
AIO 22.26 .26 1.8 .22 .1
All .8 .8 .8 .4 8.8
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Table 5.14c - Implication Matrix for the Therapeutic Category Approach
To Consequences
From Cl2 Cl3 Cl4 Cl5 CI6 Cl7 CI8 Cl9
Consequences
CI2 72.113 13.22 105.105 6.6
Cl3 12.12
Cl4 113.113 7.113 13.105 .3
CI5 5.6 105.106 3.3
CI6 2.68 .70 37.67 .52 32.32
Cl7 1.55 .56 52.55 .39 2.2 1.1
CI8 2.32 .37 36.36 .23
CI9 1.8 .8 7.8 .4
Table 5.14d - Implication Matrix for the Therapeutic Category Approach
To Values
From V20 V21 V22 V23 V24 V25 V26 V27 V28 V29 V30 V31
Attributes
Al .113 .113 .108 .103 .92 .89 .62 .45 .27 .24 .8 .6
A2 .31 .97 .37 .87 .38 .31 .36 .18 .1 .2 .3
A3 .73 .78 .56 .32 .37 .25 .17 .15 .1 .1 .4
A4 .57 .59 .38 .32 .21 .20 .8 .3 .4 .1
A5 .58 .35 .43 .13 .14 .17 .3
A6 .85 .20 .1 .1 .87 .2 .1 .8 .23 .1
A7 .15 .54 .16 .35 .8 .11 .9 .6 .1 .1
A8 .15 .42 .39 .13 .24 .1 .5 .3
A9 .18 .21 .14 .2 .5 .5 .3
AIO .11 .15 .22 .7 .6 .3 .1
All .3 .2 .8 .1 .6
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Table 5.14e - Implication Matrix for the Therapeutic Category Approach
To Values
From V20 V21 V22 V23 V24 V25 V26 V27 V28 V29 V30 V31
Consequences
Cl2 .112 .113 .108 .104 .93 .87 .61 .45 .26 .24 .8 .6
Cl3 96.113 106.113 55.108 17.103 13.93 32.89 10.61 16.45 7.27 2.24 2.8 1.5
Cl4 .112 .113 .88 .96 .78 .86 .59 .41 .27 .24 .5 .6
Cl5 5.97 5.96 6.82 2.79 .70 1.65 .39 1.30 .19 .17 .4 .5
Cl6 .66 .15 .1 .1 .67 .2 .1 .7 .15
Cl7 .54 .12 .55 .2 .10 .1
Cl8 .20 .22 .14 .2 .5 .1 .5 .4
Cl9 .3 .2 .8 .1 .6
Table 5.14f - Implication Matrix for the Therapeutic Category Approach
To Values
From V20 V21 V22 V23 V24 V25 V26 V27 V28 V29 V30 V31
Consequences
V20 25.38 15.17 3.7 10.11 52.53 20.25 8.8 2.5 5.13 3.3 2.2
V21 35.49 47.63 72.84 34.64 2.7 14.16 5.12 2.5 .4 1.2
V22 32.35 31.35 23.34 23.43 2.4 1.2 .3
V23 8.8 11.14 17.17 16.19 2.3 2.4 2.3
V24 4.5 8.12 15.16 1.1 .1 .1
V25 31.37 7.11 1.1 1.1 2.6 16.20
V26 14.15 3.4 1.1 1.3 9.10 4.4 2.2 1.1
V27 3.4 4.7 .1 1.1 3.7 12.13 6.8 1.1
V28 3.3 1.2 .1 1.1 1.1 .2 1.2 1.1 1.1
V29 6.7 2.3 1.1 2.2
V30 2.4 .1 1.2 1.1 1.2
V31 1.1 .1 1.1 1.1
The entries in the implication matrix identify the number of times each pair
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of concepts was associated together across respondents' ladders. Two
types of relations were represented in this matrix: direct relations and
indirect relations. Table 5.14, from "a" to ''J' presents the row-column
frequency implication matrices indicating the number of times in which all
the row elements directly and indirectly led to all column elements. The
numbers are expressed in fractional form with direct relations to the left of
the decimal and indirect relations to the right of the decimal. Here it should
be emphasised that this interaction from qualitative in-depth interviews to
quantification, representing an individual respondent's ladder, is the
"pedigree" of the LadderMap algorithm:
"It is this "crossing over" from the qualitative nature of the interviews to the
quantitative way of dealing with the information obtained that is one of the unique
aspects of laddering and clearly the one that sets apart from other qualitative
methods" (Reynolds and Gutman, 1988: 19).
In filling in the implication matrix of aggregate relations, the LadderMap
algorithm transforms individual respondent's ladders into sums of all the
instances where concepts were linked in the laddering interviews.
As these associations can be counted in two ways - only the direct
associations are included, or direct and indirect components between
adjacent hierarchical concepts are counted, the bar chart derived from the
implication matrix was analysed and a cut-off level decision was made.
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After determining how much variance would be explained by different
levels of cut-off values (see Figure 5.1), it was decided to choose a cut-off
value that represents 76% of all the associations. This decision
encapsulates a significant number of the associations derived from the raw
laddering data. Furthermore, the cut-off level was chosen in accordance
with Gengler and Reynolds' (1995) advice that at least 70 percent of
associations must be represented. but that the 75 to 85 percent range
would be the best solution.
Figure 5.1: Percentage of Direct Links Represented by Each Cut-Off Point
94%
91%
76%
71% 58%
D 43%D D 31% 16%0% D 0%c:::::=J
12 24 36 48 60 72 84 96 108 120
As outlined earlier, 76% o[_all associations were obtained with a cut-off
value of 36, which means that a link is drawn between two concepts if at
least 36 doctors have mentioned the concept as a direct or indirect
consequence of another concept. Although this figure is higher than the
value reported in previous studies (Reynolds and Gutman, 1988), it is
important to bear in mind the specificity of the structure of medical
knowledge:
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"There are indications that doctors' categorization of a physical illness may play a
central role in the reasoning processes used by them in arriving at diagnostic and
treatment decisions" (Bordage and Zacks, 1984:406).
As a result, it should be noted that the cut-off value of 36 is a normal
figure if we assume that medical practice derives from a common medical,
problem-based learning in which simulated patients and feed-back on
prescribing have been used in undergraduate teaching and have become
increasingly popular in postgraduate teaching and assessment (Maxwell
and Howie, 1995; Roberts et aI, 1995; Baerheim and Malterud, 1995;
Norman, 1988; Gerritsma and Smal, 1988; Elstein and al., 1978).
Furthermore, choosing a cut-off value of 36 associations or connecting
linkages reduces the complexity and thereby increases the transparency of
the resultingHierarchical Value Map (HVM). That is, only those dominant
relations among concepts that were mentioned most often by doctors have
the opportunity to be fully represented in the HVM. This choice is
somewhat arbitrary, but is supported by the fact that this cut-off decision
is similar to an eigenvalue in factor analysis, which has the capacity to
defme which relations should be represented in the HVM and which
should not.
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The HVM was analysed in order to obtain a deeper understanding of how
the cut-off decision had captured the most important patterns of meaning
between attributes, consequences, and values.
Twenty-three of the thirty one content codes/concepts were selected to
represent the common pathways of meaning, representing how product
attributes are related to clinical values. The number of content
codes/concepts that were selected suggests a stable HVM, without loosing
the most important "chunks" of information:
"When elements are too na"owly specified, there is not enough redundancy to
build up frequencies across respondents. Without repetition, aggregate maps tend to
be too unstable. When elements are too broadly specified, too much meaning is lost
when interpreting maps 01' ladders" (Gutman, 1991: 146).
It is the relationships between these pathways of meaning that are the
focus of interest, not the elements themselves. However, in order to
simplify the explanation of the HVM, Table 5.15 presents the number of
GPs who reported the 23 content codes, which represent the most
important pathways of meaning.
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Table 5.15: Content Codes/Concepts Included in the HVM
Al Effectiveness 113
A2 Low Cost 107
A3 Low Side-Effects 90
A4 Tolerability 81
AS Safety 72
A6 Additive Hypotensive Effect 90
A7 Drug Experience 63
A8 Through-Peak Ratio 48
C9 Cardiovascular Risk Reduction 113
CIO Less Morbidity and Mortality 113
Cll Compliance 113
CI2 Quality of Life 106
CI3 Monotherapy 70
CI4 Less Side-Effects 56
CIS No Orthostatic Hypotension 37
VI6 Age and Comorbidity 113
VI7 Age 113
VI8 Comorbidity 108
VI9 Age/Gender/Comorbidity 101
V20 Age and Gender 93
V2I Age-Drug Combination Therapy 89
V22 Age and Type of BP 62
V23 Age and Level of BP 45
The twenty-three dimensions were organised according to eight attributes,
seven consequencesibenefits and eight clinical values.
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5.4.10 Findings Obtained/rom the Hierarchical Value Map (HVM)
The relationships between the twenty-three pathways of meaning within
the HVM suggested some interesting findings:
1. The upper part of the HVM suggests that GPs have a strong perception
that it is essential to develop an individual patient approach for treating
hypertension, according to clinical values such as patient's age,
gender, comorbidity, and level and type 0/ blood pressure. As major
risk factors for cardiovascular diseases, these clinical value dimensions
include several different cognitive categories that strongly discriminate
GPs according to their preference for different therapeutic categories.
The attributes attached to these therapeutic categories, represented in
the lower part of the HVM, and the consequences of their use, placed in
the centre part of the HVM, may not be as relevant as clinical values
for discrimination amongst the GPs therapeutic approach.
2. The profile of the HVM suggests that doctors assume that the risk of
developing cardiovascular disease can be reduced if the choice of
antihypertensive therapeutic categories takes into account the
characteristics of the individual patient, particularly the level 0/ risk for
cardiovascular disease, the presence of target organ damage (i.e.,
consequence level), the occurrence of side-effects (Le., attribute level)
and coexisting disorders (i.e., value level).
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3. As hypertension is more common in people aged 65 years or more, in
whom target organ damage and concomitant disease (i.e.,
comorbidity) are more frequent, most dimensions in the upper part of
the HVM encapsulate cognitive categories that represent elderly
hypertensive patients. These clinical values were found to be linked to
attributes placed on the bottom right comer of the HVM. This
configuration suggests that some therapeutic categories were chosen by
GPs according to their effectiveness, tolerability and safety. Two
therapeutic categories have been found particularly suitable for
improving tolerability and safety in the treatment of elderly
hypertensive patients: ace inhibitors and calcium antagonists: the
former in elderly hypertensive patients with diabetes and dyslipidaemia,
as well as in renal inSUfficiency, and the latter in elderly hypertensive
patients with angina (i.e., age and comorbidity). Furthermore, ace
inhibitors and calcium antagonists, along with diuretics in
monotherapy, and the association in fixed dose between ace inhibitors
and diuretics were found to avoid sudden drops in blood pressure and
other side-effects, particularly in elderly patients. GPs argued that the
attributes described earlier have an important impact on patients'
compliance with the drug regimen, which in turn bridges, in the "north",
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the three consequences represented in the centre part of the HVM,
(a) greater cardiovascular protection; (b) better quality of life; (c) less
morbidity and mortality, to clinical values, and in the "south", to
attributes.
4. The centre bottom part of the HVM indicates that the patient's socio-
economic status will cause the GPs to think carefully about the cost-
effectiveness of alternative drugs. Although doctors recognised that
diuretics and beta blockers are the less expensive antihypertensive
therapeutic categories available to GPs (i.e., low cost), their intention to
prescribe these products is attached to specific hypertensive patients
who represent only a low percentage of the cardiovascular market.
Nevertheless, low cost, along with effectiveness, are two of the most
important attributes placed on the centre bottom part of the HVM. This
"positioning" suggests that some GPs recognise an important role
attached to the benefits of the use of diuretics and beta blockers on
hypertensive patients with low incomes. Furthermore, the attribute drug
experience, placed in the bottom centre position of the HVM, reinforces
the conclusion that some doctors believe that diuretics and beta-
blockers are two important therapeutic categories which serve as a
first-line therapeutic approach for hypertensive patients. Respondents
have provided evidence that drug experience (i.e., product attribute)
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with diuretics and beta-blockers has been reported in medical journals
for decades and is supported by long-term clinical trials. Some GPs
argued that these studies have pointed out not only the importance of
these therapeutic categories for the improvement of cardiovascular
protection and the quality of life of hypertensive patients, but also for a
reduction of morbidity and mortality (i.e., consequences/benefits) on
elderly and middle-aged hypertensive patients (l.e., age dimension -
clinical value).
5. The disaggregation of the upper left clinical values' dimension placed
on the upper right comer of the HVM may indicate that GPs are not
uniform in their opinion towards the use of beta blockers and diuretics.
Although the success of certain beta blockers in reducing high blood
pressure with a low cost and supported by decades of drug experience,
their prescription is associated particularly with young-adult
hypertensive patients (i.e., age) and middle-aged hypertensive women
with anxiety or depression (i.e., age-gender-comorbidity). The same
reasoning is valid for diuretics which are particularly attached to elderly
hypertensive patients, particularly those with borderline or systolic
hypertension (i.e., age and level of BP and age and type of BP). In these
cases, ace inhibitors were found to be great competitors of diuretics.
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6. The ladders suggested and the HVM confirmed that elderly
hypertensive patients with concomitant diseases (i.e., age and
comorbidity - or comorbidity alone) have been treated with ace
inhibitors, because this therapeutic category is safer (i.e., safe), as well
as better tolerated (i.e., tolerability) and respects the trough-peak ratio
(i.e., clinical values therapeutic category attributes). This
pharmacological characteristic has generally been associated with a low
incidence of side-effects and with an easy-to-use once-daily therapy,
which are important attributes for obtaining compliance with the drug
regime. However, other therapeutic categories were also described as
once-daily therapies.
7. The HVM, in its age and comorbidity dimension, also encapsulates
elderly hypertensive patients with congestive heart failure (i.e., clinical
value), who have been treated mainlywith a fixed dose of ace inhibitor
and a diuretic. This association was described by doctors as effective
and with an additive hypotensive effect (i.e., product attributes).
However, some respondents have suggested that they prefer to use each
component in monotherapy. That is, the analysis of the ladders
suggested, and the links between the hierarchical chain of the HVM
confirm, that some GPs have a therapeutic approach to elderly
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hypertensive patients with congestive heart failure which is based on
ace inhibitors, while others doctors reinforced the interest of diuretics
for the same clinical situation. However, the attributes attached to these
therapeutic categories, and the consequences of their use are almost the
same. These findings derived from the disaggregation of the clinical
values dimension of the HVM attached to age and comorbidity suggest
that most doctors prefer associating a fixed dose of ace inhibitors with
diuretics. However, this option is not uniform and other GPs have
preferred diuretics and some ace inhibitors to treat elderly hypertensive
patients with congestive heart failure (i.e., age and comorbidity).
Having said this, it should be added that diuretics and ace inhibitors, in
monotherapy or in association, playa central role in almost all twenty-
tree dimensions encapsulated within the HVM.
8. Ifwe analyse the clinical value dimension which has been placed in the
middle of the upper left part of the HVM, age and drug combination
therapy, it is possible to identify an important hierarchical value chain.
Doctors have argued that combinations of two or more drugs from
different therapeutic categories, particularly the association in fixed
dose between ace inhibitor and diuretic, are particularly relevant to the
treatment of elderly hypertensive patients who have been taking other
drugs not related with hypertension (i.e., age and drug combination
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therapy). Respondents argued that the association in fixed dose
between ace inhibitor and diuretic not only reinforces the addictive
hypotensive effect of both components (i.e., product attribute - additive
effect), but also reinforces the patient compliance (i.e., consequence)
because it can be used in monotherapy once a day. As mentioned
earlier, drugs with an easy-to-use once-daily therapy (i.e., consequence-
monotherapy) improve compliance with the drug regime. Furthermore,
GPs have pointed out that the association in fixed dose of diuretics and
ace inhibitors diminishes the level of side effects (i.e., consequence -
less side effects) that eventually derive from both components (i.e.,
clinical value - attribute - consequence).
9. The HVM also suggests that the dimensions age and comorbidity,
particularly the cognitive category of elderly hypertensive patients with
renal insufficiency, are linked to product attributes such as low side-
effects, tolerability, safety, in the case of doctors who prefer ace
inhibitors or calcium antagonists. GPs who prefer diuretics reinforce
the low cost and the huge amount of clinical trials (i.e., drug experience)
that have been supporting the interest of this therapeutic category on the
treatment of elderly hypertensive patients. The association in fixed dose
of ace inhibitor and diuretic has also been found to be suitable for the
treatment elderly hypertensive patients with renal insufficiency. Again,
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the dispersion of respondents' intentions to prescribe those therapeutic
categories is not only based on product attributes themselves, but also
on specific patient characteristics, particularly demographic profile and
concomitant diseases. However, the representation of these networks,
or ladders, in the HVM, shows that the GPs' therapeutic approach to
elderly hypertensive patients with renal insufficiency or other
concomitant diseases is partially identical in terms of attributes and
consequences of all therapeutic categories, although heterogeneous in
terms of therapeutic approach when clinical values are defmed.
10. The far upper left corner of the HVM embraces an excerpt of doctors'
cognitive structure which has been defmed as age-gender-comorbidity,
This dimension is by far one of the most relevant fmdings elicited from
the laddering interviews. This conviction derives from the fact that the
cognitive category of age-gender-comorbidity has not been described
by the different hypertension guidelines that have been advanced by
prestigious, expert medical committees. Therefore, the perimenopause
period, a time of changing ovarian function, may represent a strong
clinical value for GPs, who have reported causal associations between
the menopause and several symptoms and diseases. Cardiovascular
diseases and hypertension are the other side of the coin. Again, the
GPs' drug choice was found non-homogeneous when categories from
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the age-gender-comorbidity dimension are used. This dimension is
centred on the hypertensive middle-aged woman. This cognitive
category has been structured in doctors' memory around key patient
typologies", These hypertensive prototypes, which capture the core
meaning of the age-gender-comorbidity dimension, encapsulate
hypertensive woman (i.e., gender) in perimenopausic period (i.e., age)
with one important factor of risk, obesity, associated with diabetes,
dyslipidaemia, and anxiety or depression (i.e., comorbidity). Three
different patient typologies derive from this excerpt of the cognitive
structure: (a) Obese hypertensive woman in perimenopauslc period
with diabetes; (b) Obese hypertensive woman in perimenopausic
period with dyslipidaemia; and (c) Obese hypertensive woman in
perimenopausic period with anxiety or depression. These three
typologies were found particularly relevant in discriminating between
the GPs' drug choice. Again, ace inhibitors play an important role in all
them, particularly the first two, while beta blockers are relevant for the
last one. However, if we define the same woman in perimenopausic
period (i.e., age and gender dimension) neither with obesity nor with
other factor of risk, the reality changes in terms of drug therapy.
SPatient typologies represent prototypical abstractions induced from past clinical experience with
specific instances of the phenomenon and provide the basis for identification of features through
which the phenomenon is categorised. Patient typologies are, then, the result of cognitive processes
and, in turn, shape subsequent cognitive processes.
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11.The upper-centred dimension of age and gender (i.e., clinical value),
which are placed on the far right bottom of the HVM, encapsulates the
category of woman in perimenopausic period, in which diuretics and
ace inhibitors are again the two main competitors in discriminating
doctors' prescribing behaviour. That is, a dichotic reality emerges from
respondents' pharmacological decision-making, which appears to be
centred on diuretics and ace inhibitors. This dichotomy varies
according to a symmetric relationship between the existence or
absence of comorbidity. If any type of comorbidity exists, ace
inhibitors have been found to be safer (i.e., safety attribute), better
tolerated (i.e., tolerability attribute), and with lower side-effects (i.e.,
low side-effects attribute). By contrast, if there is a total absence of
comorbidity, as represented by those dimensions of clinical values in
the upper centre and right comer of the HVM (i.e., age and gender -
hypertensive woman in perimenopausic period; age and level of BP
and age and type of BP - elderly hypertensive patients), diuretics and
ace inhibitors discriminate amongst doctors into two different groups
of respondents in terms of therapeutic approach. Particularly important
in this discrimination between GPs, is the category hypertensive
woman in perimenopausic period, which belongs to the dimension of
age and gender. The same reality can be found within the dimension
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age alone, which has been placed in the upper left part of the HVM. In
this dimension, the categories of middle-aged and elderly
hypertensive patients, were found to be important descriptors of GPs'
drug choice in terms of diuretics and ace inhibitors.
12. The HVM also shows that comorbidity alone IS an important
dimension. Placed at the upper-centre of the HVM, just above the last
consequence dimension, comorbidity embraces all the concomitant
diseases or factors of risk that may be attached to hypertensive patients,
independent of their age. Some of these cognitive categories reinforce
the importance of the ladders established within the age and
comorbidity dimension. In short, it appears that diabetes/dys/ipidaemia
or obesity, two of the most important categories encapsulated within this
dimension, are neither factors of risk attached exclusively to elderly
hypertensive patients, nor less important in terms of discriminant power
than other cardiovascular factors of risk. The analysis of ladders
represented within the HVM suggests a strong link between these
factors of risk and the attributes attached to ace inhibitors.
13.As described earlier, the HVM reinforces the conclusion that the link
between therapeutic categories' attributes and clinical values that is
established by consequence dimensions has not distinguished the
respondents. That is, Portuguese GPs who were interviewed are
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strongly homogeneous in terms of consequences/benefits they have
been looking for when they decide to prescribe the different therapeutic
categories available to treat hypertensive patients. At the "midlands" of
the HVM it is possible to identify several consequences/benefits that
link the two antipodes levels of clinical values and attributes:
cardiovascular protection to reduce the morbidity and mortality and to
improve the quality of life of hypertensive patients, if compliance with
the therapeutic regime is obtained.
14. Three other consequences/benefits, which have been placed on the
bottom left corner, are also mentioned in the HVM: monotherapy, less
side effects, and no orthostatic hypotension. As pointed out earlier,
these consequences/benefits are particularly important for improving
patients' compliance with the therapeutic regime. In the terminology
developed earlier, these consequenceslbeneflts are principally linked to
the attribute addictive hypotensive effect, which exclusively belongs to
the association in fixed dose between the ace inhibitor and diuretic. In
this case, the HVM has placed the consequences/benefits of
monotherapy, less side effects, and no orthostatic hypotension on the
opposite bottom corner of the other consequence/benefit of compliance,
and close to its origin (i.e., the attribute addictive hypotensive effect).
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This hierarchical pathway is closely related to two different clinical values
represented by the dimensions (a) age and drug combination therapy; and
(b) age and comorbidity. Both of them are attached to elderly
hypertensive patients. The former is designed to absorb the ladders
developed by respondents who have placed great emphasis on the use of
the fixed dose of the ace inhibitor and diuretic to treat elderly
hypertensive patients who were prescribed other drugs for non-
cardiovascular diseases, while the latter is particularly attached to elderly
hypertensive patients with congestive heart failure.
A fmal issue we wish to comment upon and reinforce, is the role that GPs
have attached to attributes to characterise the five major therapeutic
categories for treating hypertensive patients. In looking at differences
between these therapeutic categories in terms of attributes, the results
suggest that GPs use these attributes to characterise the therapeutic
categories rather than for drug decision-making. To understand this
surprising fmding, it is important to bear in mind that the medical-
pharmaceutical market has a number of special characteristics, which were
described in Chapter II. One of most important of these special
characteristics is that the person (i.e., the doctor) who chooses the ethical
product(s) and to whom most promotional effort is addressed, is not the
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purchaser. In consumer decision making, the perceptions of product
attributes are often important discriminators when organising choice
criteria, because consumers use these products in their daily life. In
doctors' decision making, the product is absent from their daily clinical
activity. It follows then, that the importance of product attributes for
consumer decision making is different from the importance that product
attributes have for GPs therapeutic approach. That is, therapeutic
categories attributes have a characterisation function rather than a
decision making function. This characterisation function is important to
link therapeutic category attributes to patient typologies. For example, as
has been noted, there is evidence that the clinical value comorbidity in its
diabetesldyslipidaemia category, makes GPs prescribe ace inhibitors
rather than diuretics in elderly and middle-aged hypertensive patients.
That is, with few exceptions, ace inhibitors have no undesirable metabolic
effects, which may be not the case for diuretics. However, if the same
elderly and middle-aged hypertensive patients have no commorbidity,
particularly diabetes or dyslipidaemia, some GPs prefer diuretics while
others are more keen to use ace inhibitors. Subsequently, it is the patient
typology that guides drug choice as a function of the characteristics
attached to the therapeutic categories rather than product attributes by
themselves. Nevertheless, some of these attributes are important in
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understanding how GPs organise their therapeutic approach to different
patient typologies. Ace inhibitors and calcium antagonists are more
linked to safety attributes. Some doctors have presented ladders which
reinforce the importance of ace inhibitors in terms of attributes such as
throug-peak ratio and neutral metabolism. In a similar vein, diuretics
and beta blockers were considered less expensive and with a longer
experience in the treatment of hypertension than the other therapeutic
classes. However, this perception was common across all the respondents,
and some of them were found not to prescribe diuretics in most cases. It is
therefore not surprising that for the same hypertensive patient typology
derived from the combination of clinical values such as age, gender or
comorbidity, some GPs prefer ace inhibitors while others choose
diuretics as the best therapeutic approach. These findings suggest that GPs
may be categorised according to whether they are "in favour of',
"indifferent to", or "opposed to" the use of diuretics, and ace inhibitors,
or the association of both components, with regard to important patient
typologies.
In short, it appears that hypertensive patient typologies, based on clinical
values such as age, gender, and comorbidity, alone or in association, has
a strong discriminant power to categorise GPs according to their first-line
antihypertensive therapy.
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5.5 Methodological Limitations
Before discussing the results and their implications, two limitations of the
methodology should be noted:
First, is the uncertainty about whether the GPs' ladders represent their
real prescribing behaviour or just their knowledge about the national
guidelines for the management of hypertension issued by health authorities.
This problem has been addressed in recent research: "We cannot exclude that
some answers were given just to demonstrate that respondents were in line with
pharmacological criteria" (Himmel et aI., 1997: 169).
Second, although the medical language used by GPs during the interviews
was familiar to the researcher", the differentiation of specific pathologies
within the same coexisting diseases was not an easy task. That is, some
medical vocabulary used by a small number of GPs was too technical for
a clear understanding of their importance in the context of the ladders.
For example, a few GPs suggested that hypertensive patients with renal
parenchymal disease' and hypertensive patients with renovascular
diseases would require a special categorisation in terms of pathology.
However, this technical vocabulary was content-analysed by the
researcher and then by two independent judges (one cardiologist and one
6 given the past experience in the marketing and sales department of the international pharmaceutical
company that supported the financial costs of this exploratory study.
'Renal disease that reduces the number of functioning nephrons, leading to sodium and water
retention, which increases blood pressure.
BRenal artery stenosis that may be associated with all stages of hypertension. particularly resistant
hypertension. When bilateral. can lead to reduced kidney function (ischemic nephropathy).
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GP) who confIrmed that both situations may be included within the
comorbidity value dimension as renal insufficiency. Their agreement
supported the view that this small number of GPs was deliberately
skipping certain "Why" questions concerning their therapeutic approach
rather than approaching new clinical values.
Finally, the percentage of the Laddering interviews (35%) in relation to the
total number of interviews indicates that a significant number of GPs
addressed were suspicious about the researcher's work because it was
overlapping a special police investigation to determine the veracity of
bribes given by some international pharmaceutical companies to GPsfor
influencing their therapeutic approach. Having said that, it should be
added that it seems reasonable to expect that this "suspicious
environment" may have contributed to a selection bias in an unknown
direction.
Despite these limitations, several conclusions arise from the Laddering in-
depth interviews developed during the exploratory phase of the research.
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5.6 Conclusions
This exploratory study attempted to demonstrate how Means-End Theory
(Gutman, 1982) and the Laddering Technique (Reynolds and Gutman,
1988), through the algorithm LadderMap (Gengler and Reynolds, 1995),
could bring a useful perspective to the study of GPs' prescribing
behaviour. Essentially, we are building an understanding of how doctors
organise their perceptions and make sense of the heterogeneous
complexity of different clinical values such as age, gender, and
comorbidity for the therapeutic management of hypertensive patients.
Such an understanding is of interest to academics for further study of GPs'
therapeutic approach, and has a managerial relevance for the particular
domain of pharmaceutical marketing strategy.
Substantively, the fmdings suggest that Means-End Theory and the
Laddering technique can be regarded as a strong theoretical and
methodological tool to specify GPs' cognitive processes determining how
clinical values lead to the activation of subsets of cognitive structure in
terms of patient typologies. Furthermore, the Means-End Theory and the
Laddering technique have shown how these patient typologies then guide
the formation of doctors' behavioural intentions in terms of the chosen
therapeutic category and consequences of its use.
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The laddering results have shown that there is several different patient
typologies that influence drug choice. As a result, to use a hypothetical
hypertensive patient is to encourage doctors to produce only a very small
portion of their complex clinical reality in terms of patient typologies.
According to the laddering results, the hypertensive patient with diabetes
mellitus is but one of several patient typologies that doctors have to defme
their therapeutic approach. In this case, neither the age of the patient is
defmed, nor the gender is indicated. That is, comorbidity is the only
clinical value that was assumed to explore the drug selection. It is
therefore not surprising, that Segal and Hepler's (1985; 1982) model was
found an accurate predictor of drug choice. However, product attributes
such as cost of the treatment and side-effects, as well as consequences
such as control of disease and patient compliance, are very similar
across doctors. Consequently, the accuracy of the model results from the
selection of a hypothetical hypertensive patient whose variance in terms of
therapeutic approach is very low. That is, the defmition of a hypothetical
case of a patient with diabetes mellitus and hypertension tends to
reinforce the model's accuracy in terms of drug choice because it restricts
the range of available therapeutic options. This helps to explain the reason
why, in contrast to their 1982 study, the Segal and Hepler (1985) results
indicated that the value placed by doctors on the various outcomes made
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little difference to the predictive value of the model. In this instance, the
doctors' perceived probabilities of outcomes was found to be enough to
alone predict their intended drug choices.
Our exploratory study approach represents another research strategy trying
to fmd out the real hypertensive patients that influence GPs in their
therapeutic approach. The results suggest that the most important
implication derived from this real hypertensive patients research strategy
is that the drug choice is patient oriented rather than attribute oriented.
That is, "For many product categories or subclasses of categories, respondents are
much more likely to make preference judgements at the consequence and values
levels than at the attribute level' (Reynolds and Gutman, 1988: 26).
Methodologically, the results from the Laddering procedure indicate that
Reynolds and Gutman's (1988) assumption that would be possible to
categorise "consumers with respect to their values orientation for a product class
or brand" because "the value orientations in a person's ladder may serve as the
basis for classifICation" (Reynolds and Gutman, 1988: 25) appears to be
correct and therefore deserves further investigation. As a result, it is our
belief that it is possible to extend, methodologically, the importance of
these clinical values, in terms of patient typologies, as explanatory
variables to categorise Portuguese GPs according to their first-line drug
therapy.
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5.7 Summary
The purpose of this chapter was two-fold:
1. to use the Means-End Theory and the Laddering technique to elicit
excerpts from the GPs' cognitive structure that were relevant for the
therapeutic approach; and
2. to analyse the interest of this cognitive information on subsequent
model development to categorise Portuguese GPs according to their
first-line therapeutic approach.
In the exploratory phase of this research, only clinical values were found
to have discriminant power in terms of the therapeutic approach.
Clinical values such as age, gender and comorbidity, are the main
heuristics used to organise different patient typologies. These GPs' mental
schemas are relevant for organising their drug therapeutic approach.
As is typical in exploratory studies using means-end chains (e.g., Olson
and Reynolds, 1983), the data generated were not numerical. Instead, the
data were in the form of protocols and means-end maps for individual
consumers. Patterns of responses and observed similarities across
respondents form the results of this exploratory phase of the research:
• The number of ladders per GP are more than the double the numbers
reported in some recent studies on consumer behaviour using Gengler
and Reynolds' (1995) algorithm (Frauman et al., 1998; Klenosky et aI.,
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1993), but are not atypical when compared with other studies that have
used the same algorithm (Sorensen et al., 1996);
• A great homogeneity on GPs' ladders in terms of clinical values;
• The clinical values dimensions are particularly relevant in terms of the
discriminant power to differentiate doctors according to their drug
therapeutic approach;
• A clear differentiation of the GPs' drug therapeutic approach in function
of the patient's age, gender, and comorbidity, which represent the
main heuristics to organise hypertensive patient typologies;
• Although the patient typologies are constructed within the constraints of
a medical culture which defines the appropriate therapeutic approach to
be used, non-homogeneous first-line drug therapeutic approaches by
the GPs on the same hypertensive patient typologies have been found;
• A fmal point to note here is that the fmdings from the laddering
approach support the view that the disagreement among Portuguese GPs
about the best antihypertensive therapeutic approach may reflect the
reality that Beevers and MacGregor (1995) have described: "it is not
surprising, therefore, that there is some disagreement even between
experts about which drugs or combinations of drugs are best for the
individual patients" (Beevers and MacGregor, 1995: 169).
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